



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

**Draft TSCA Screening Level Approach for Assessing Ambient  
Air and Water Exposures to Fenceline Communities  
Version 1.0**

*January 2022*

37 **TABLE OF CONTENTS**

---

38 **TABLE OF CONTENTS** ..... 2

39 **LIST OF EXECUTIVE SUMMARY TABLES** ..... 5

40 **LIST OF TABLES** ..... 5

41 **LIST OF FIGURES** ..... 7

42 **LIST OF APPENDIX TABLES** ..... 7

43 **ACKNOWLEDGEMENTS** ..... 8

44 **EXECUTIVE SUMMARY** ..... 9

45 **1 INTRODUCTION**..... 16

46 **2 SCREENING METHODOLOGIES** ..... 21

47 2.1 Ambient Air Pathway ..... 21

48 2.1.1 Environmental Air Releases ..... 22

49 2.1.1.1 Step 1: Obtain 2019 TRI Data ..... 22

50 2.1.1.2 Step 2: Map 2019 TRI to Occupational Exposure Scenarios ..... 23

51 2.1.1.3 Step 3: Estimate Number of Release Days for Each OES ..... 24

52 2.1.1.4 Step 4: Estimate Air Emissions for OES with No 2019 TRI Data ..... 24

53 2.1.1.5 Step 5: Prepare Air Emission Summary for Ambient Air Exposure Modeling ..... 25

54 2.1.2 Ambient Air Concentrations and Exposures ..... 27

55 2.1.2.1 Ambient Air Pre-screening Methodology ..... 28

56 2.1.2.2 Ambient Air Full-Screening Methodology ..... 30

57 2.1.2.3 Ambient Air Co-resident Screening Methodology ..... 40

58 2.2 Ambient Water Pathway ..... 44

59 2.2.1 Environmental Water Releases ..... 44

60 2.2.1.1 Step 1: Obtain TRI and DMR Data ..... 45

61 2.2.1.2 Step 2: Map TRI and DMR to Occupational Exposure Scenarios ..... 45

62 2.2.1.3 Step 3: Estimate Number of Release Days for Each OES ..... 45

63 2.2.1.4 Step 4: Estimate Water Releases for OES with No TRI or DMR Data ..... 46

64 2.2.1.5 Step 5: Prepare Water Release Summary for Ambient Water Exposure Modeling ..... 46

65 2.2.2 Ambient Water Concentrations and Exposures ..... 46

66 2.2.2.1 Step 1: Obtain Measured Drinking Water Concentrations ..... 46

67 2.2.2.2 Step 2: Model Surface Water Concentrations from Facility Releases ..... 47

68 2.2.2.3 Step 3: Estimate Drinking Water Exposure ..... 48

69 2.2.2.4 Step 4: Estimate Incidental Oral Exposures from Swimming ..... 49

70 2.2.2.5 Step 5: Estimate Incidental Dermal Exposure from Swimming ..... 51

71 2.3 Risk Estimation Approach ..... 53

72 2.3.1 Characterization of Non-cancer Risks ..... 53

73 2.3.2 Characterization of Cancer Risks ..... 54

74 2.4 Key Assumptions and Uncertainties ..... 54

75 2.4.1 Assumptions and Uncertainties in Release Estimation ..... 54

76 2.4.2 Assumptions and Uncertainties in Air Pathway Exposure Modeling ..... 57

77 2.4.3 Assumption and Uncertainties in Drinking Water Monitoring Results ..... 59

78 2.4.4 Assumptions and Uncertainties in Water Pathway Exposure Modeling ..... 60

79 2.4.5 Assumptions and Uncertainties in Risk Characterization ..... 61

80 **3 CASE STUDY RESULTS** ..... 62

81	3.1	1-Bromopropane (Air Pathway)	62
82	3.1.1	Background for 1-BP	62
83	3.1.2	Human Health Hazard Endpoints for 1-BP	62
84	3.1.2.1	Assumptions and Uncertainties for 1-BP Human Health Hazard	63
85	3.1.3	Environmental Releases for 1-BP	63
86	3.1.3.1	Step 1: Obtain 2019 TRI Data	63
87	3.1.3.2	Step 2: Map 2019 TRI to OES	63
88	3.1.3.3	Step 3: Estimate Number of Release Days for Each OES	64
89	3.1.3.4	Step 4: Estimate Air Emissions for OES with No TRI Data	65
90	3.1.3.5	Step 5: Prepare Air Emission Summary for Ambient Air Exposure Modeling	69
91	3.1.4	Exposures for 1-BP	69
92	3.1.5	Risk Characterization for 1-BP	82
93	3.1.5.1	Fenceline Inhalation Risk for 1-BP	82
94	3.1.5.1.1	Land Use Considerations	88
95	3.1.5.2	Co-resident Inhalation Risk	88
96	3.1.6	Confidence and Risk Conclusions for 1-BP Case Study Results	89
97	3.2	Methylene Chloride – Air and Water Pathways	89
98	3.2.1	Background for MC	89
99	3.2.2	Human Health Hazard Endpoints for MC	90
100	3.2.2.1	Assumptions and Uncertainties for MC Human Health Hazard	91
101	3.2.3	Environmental Releases for MC	91
102	3.2.3.1	Step 1: Obtain TRI Data and DMR	91
103	3.2.3.2	Step 2: Map TRI and DMR to OES	91
104	3.2.3.3	Step 3: Estimate Number of Release Days for Each OES	92
105	3.2.3.4	Step 4: Estimate Air Emissions for OES with No 2019 TRI Data and Water Releases for OES with No TRI or DMR Data	93
106	3.2.3.5	Step 5: Prepare Air Emission and Water Release Summary for Ambient Air and Water Exposure Modeling	98
107	3.2.4	Exposures for MC	99
108	3.2.4.1	Air Pathway	99
109	3.2.4.2	Water Pathway	111
110	3.2.4.2.1	Ambient Water Monitoring Results	111
111	3.2.4.2.2	Drinking Water Monitoring Results	111
112	3.2.4.2.3	Modeled Drinking Water	116
113	3.2.4.2.4	Incidental Oral for MC	119
114	3.2.4.2.5	Incidental Dermal for MC	122
115	3.2.5	Risk Characterization for MC	125
116	3.2.5.1	Risk Characterization for the Air Pathway	125
117	3.2.5.1.1	Land Use Considerations	132
118	3.2.5.2	Risk Characterization for the Water Pathway	133
119	3.2.5.2.1	Drinking Water Risk for MC	133
120	3.2.5.2.2	Incidental Swimming Risk for MC	136
121	3.2.5.2.3	Ambient and Drinking Water Monitoring Information for MC	140
122	3.2.6	Confidence and Risk Conclusions for MC Case Study Results	141
123	3.3	n-Methylpyrrolidone (Water Pathway)	141
124	3.3.1	Background for NMP	141
125	3.3.2	Human Health Hazard Endpoints for NMP	141
126	3.3.2.1	Assumptions and Uncertainties for NMP Human Health Hazard	142
127	3.3.3	Environmental Releases for NMP	143
128			
129			

130	3.3.4 Exposures for NMP .....	145
131	3.3.4.1 Drinking Water for NMP.....	145
132	3.3.4.2 Incidental Oral for NMP.....	148
133	3.3.4.3 Incidental Dermal for NMP.....	151
134	3.3.5 Risk Characterization for NMP .....	154
135	3.3.5.1 Drinking Water Risk for NMP .....	154
136	3.3.5.2 Incidental Swimming Risk for NMP .....	155
137	3.3.5.2.1 Incidental Oral for NMP .....	155
138	3.3.5.2.2 Incidental Dermal for NMP .....	157
139	3.3.6 Confidence and Risk Conclusions for NMP Case Study Results.....	159
140	<b>REFERENCES.....</b>	<b>160</b>
141	<b>Appendix A ABBREVIATIONS AND PHYSICAL-CHEMICAL PROPERTIES.....</b>	<b>164</b>
142	A.1 Abbreviations .....	164
143	A.2 Select Physical-Chemical Properties of Case Study Chemicals.....	166
144	<b>Appendix B LIST OF SUPPLEMENTAL FILES.....</b>	<b>168</b>
145	<b>Appendix C TRI-CDR CROSSWALK.....</b>	<b>169</b>
146	<b>Appendix D EXPOSURE – PRE-SCREENING ANALYSIS.....</b>	<b>188</b>
147	<b>Appendix E 1-BP, MC, AND NMP RISK EVALUATION COU TO OES MAPPING.....</b>	<b>192</b>
148		
149		

150 **LIST OF EXECUTIVE SUMMARY TABLES**

---

151	Table_ES 1. EPA’s Overall Approach for Assessing Exposures and Associated Risks for Fenceline	
152	Communities.....	12
153	Table_ES 2. Seven of the First 10 Chemicals, and Associated Pathways, for Which EPA Intends to	
154	Conduct Screening Level Analyses .....	13
155	Table_ES 3. Summary of Additional Risks Identified for the 1-BP Air Pathway .....	13
156	Table_ES 4. Summary of Additional Risks Identified for the MC Air Pathway .....	14
157	Table_ES 5. Summary of Additional Risks Identified for the MC Water Pathway .....	14
158	Table_ES 6. Summary of Additional Risks Identified for the NMP Water Pathway.....	15

160 **LIST OF TABLES**

---

161	Table 1-1. Seven of the First 10 Chemicals Undergoing Risk Evaluation and Associated Pathways for	
162	Which Supplemental Screening Level Analysis for Fenceline Communities Will Be Conducted .....	17
163	Table 2-1. Summary of Air Release Data Elements .....	27
164	Table 2-2. Assumptions for Intraday Emission-Release Duration .....	34
165	Table 2-3. Assumptions for Inter-day Emission-Release Pattern.....	35
166	Table 2-4. Description of Daily or Period Average and Air Concentration Statistics.....	39
167	Table 2-5. Summary of Two Building Configurations and Methods to Estimate Interzonal Flow Rate .	42
168	Table 2-6. Incidental Oral Exposure Factors for MC and NMP.....	50
169	Table 2-7. Incidental Dermal Exposure Factors for MC and NMP.....	53
170	Table 3-1. Hazard Values Used for Risk Estimation in the 1-BP Risk Evaluation .....	62
171	Table 3-2. Hazard Values for 1-BP Used in this Fenceline Analysis.....	63
172	Table 3-3. Number of Release Days for Each 1-BP OES.....	64
173	Table 3-4. Summary of Air Release Estimation Approaches for Each 1-BP OES.....	66
174	Table 3-5. Fenceline Community Exposure Scenarios for 1-BP.....	69
175	Table 3-6. 95th Percentile Exposure Concentration Summary across Facilities within Each OES for 1-	
176	BP.....	72
177	Table 3-7. Simulation Matrix for Evaluating Co-resident Exposures from Dry-Cleaning Operations	
178	(IECCU) for 1-BP.....	80
179	Table 3-8. Predicted 1-BP Concentrations for Co-resident Apartment .....	82
180	Table 3-9. 1-BP Inhalation Risk across OES at Various Distances from Releasing Facility (Based on	
181	95th Percentile Exposure Concentrations) .....	83
182	Table 3-10. Summary of Fenceline Community Exposures Expected near Facilities Where Modeled Air	
183	Concentrations Indicated Risk for 1-BP .....	88
184	Table 3-11. 1-BP Inhalation Risk for Co-residents of Dry Cleaning Facilities.....	89
185	Table 3-12. Hazard Values Used for Risk Estimation in the Methylene Chloride Risk Evaluation .....	90
186	Table 3-13. Hazard Values for MC Used in this Fenceline Analysis.....	91
187	Table 3-14. Number of Release Days for Each MC OES.....	92
188	Table 3-15. Summary of Air Release Estimation Approaches for Each MC OES.....	94
189	Table 3-16. Summary of Water Release Estimation Approaches for Each Methylene Chloride OES ....	96
190	Table 3-17. Fenceline Community Exposure Scenarios for MC.....	99
191	Table 3-18. 95th Percentile Exposure Concentration Summary across Facilities within Each OES for	
192	MC .....	102
193	Table 3-19. Measured Concentrations of MC in Drinking Water Obtained from the Six-Year Review	
194	Data (2006–2011) <sup>a</sup> .....	113
195	Table 3-20. Summary of MC Drinking Water Exposure by OES for 20 Days of Release Scenarios ....	117
196	Table 3-21. Summary of MC Drinking Water Exposure by OES for Maximum Days of Release	
197	Scenarios.....	118

198 Table 3-22. Summary of MC Incidental Oral Ingestion Exposure by OES for 20 Days of Release  
199 Scenarios ..... 120  
200 Table 3-23. Summary of MC Incidental Oral Ingestion Exposure by OES for Maximum Days of Release  
201 Scenarios ..... 121  
202 Table 3-24. Summary of MC Incidental Dermal Exposure by OES for 20 Days of Release Scenarios 123  
203 Table 3-25. Summary of Methylene Chloride Incidental Dermal Exposure by OES for Maximum Days  
204 of Release Scenarios ..... 124  
205 Table 3-26. MC Inhalation Risk across OES at Various Distances from Releasing Facility (Based on  
206 95th percentile exposure Concentrations)..... 126  
207 Table 3-27. Summary of Fenceline Community Exposures Expected near Facilities Where Modeled Air  
208 Concentrations Indicated Risk for MC ..... 132  
209 Table 3-28. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES under 20  
210 Days of Release Scenarios for MC ..... 133  
211 Table 3-29. Summary of Cancer Risk Estimates from Drinking Water Exposure by OES under 20 Days  
212 of Release Scenarios for MC ..... 134  
213 Table 3-30. Summary of Risk Estimates for Drinking Water Exposures by OES under Maximum Days  
214 of Release Scenarios for MC ..... 135  
215 Table 3-31. Summary of Cancer Risk Estimates from Drinking Water Exposure by OES under  
216 Maximum Days of Release Scenarios for MC ..... 136  
217 Table 3-32. Summary of Non-cancer Risk Estimates for Incidental Oral Ingestion Exposures by OES  
218 under 20 Days of Release Scenarios for MC ..... 137  
219 Table 3-33. Summary of Non-cancer Risk Estimates for Incidental Oral Ingestion Exposures by OES  
220 under Maximum Days of Release Scenarios for MC ..... 138  
221 Table 3-34. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposures by OES under 20  
222 Days of Release Scenarios for MC ..... 139  
223 Table 3-35. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposures by OES under  
224 Maximum Days of Release Scenarios for MC ..... 140  
225 Table 3-36. Hazard Values Used for Risk Estimation in the n-Methylpyrrolidone Risk Evaluation..... 142  
226 Table 3-37. Hazard Values for NMP Used in this Fenceline Analysis ..... 142  
227 Table 3-38. Summary of Water Release Estimation Approaches for Each NMP OES..... 143  
228 Table 3-39. Summary of NMP Drinking Water Exposure by OES for 12 Days of Release Scenarios . 146  
229 Table 3-40. Summary of NMP Drinking Water Exposure by OES for Maximum Days of Release  
230 Scenarios ..... 147  
231 Table 3-41. Summary of NMP Incidental Oral Ingestion Exposure by OES for 12 Days of Release  
232 Scenarios ..... 149  
233 Table 3-42. Summary of NMP Incidental Oral Ingestion Exposure by OES for Maximum Days of  
234 Release Scenarios..... 150  
235 Table 3-43. Summary of NMP Incidental Dermal Exposure by OES for 12 Days of Release Scenarios  
236 ..... 152  
237 Table 3-44. Summary of NMP Incidental Dermal Exposure by OES for Maximum Days of Release  
238 Scenarios ..... 153  
239 Table 3-45. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES for Various  
240 Lifestages under 12 Days of Release Scenarios for NMP ..... 154  
241 Table 3-46. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES for Various  
242 Lifestages under Maximum Days of Release Scenarios for NMP ..... 155  
243 Table 3-47. Summary of Non-cancer Incidental Oral Ingestion Risk by OES for Various Lifestages  
244 under 12 Days of Release Scenario for NMP ..... 156  
245 Table 3-48. Summary of Non-cancer Incidental Oral Ingestion Risk by OES for Various Lifestages  
246 under Maximum Days of Release Scenario for NMP ..... 157

247 Table 3-49. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposure by OES for  
248 Various Lifestages under 12 Days of Release Scenario for NMP ..... 158  
249 Table 3-50. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposure by OES for  
250 Various Lifestages under Maximum Days of Release Scenario for NMP ..... 159  
251

252 **LIST OF FIGURES**

---

253 Figure 2-1. Overview of EPA’s Screening Level Ambient Air Pathway Methodology ..... 22  
254 Figure 2-2. General Methodology for Estimating Air Emissions..... 22  
255 Figure 2-3. Decision Tree for Estimating Air Releases..... 25  
256 Figure 2-4. Brief Description of Methodologies Used to Estimate Ambient Air Concentrations and  
257 Exposures..... 28  
258 Figure 2-5. Pre-screen Exposure Scenarios Modeled for Max and Mean Release Using IIOAC Model. 29  
259 Figure 2-6. Receptor Locations around Each Distance Ring..... 36  
260 Figure 2-7. Modeled Distances from Facility ..... 37  
261 Figure 2-8. Receptor Locations between 100 and 1,000 m ..... 38  
262 Figure 2-9. Schematic Representation of the Two-Zone Model for Co-resident Exposure ..... 41  
263 Figure 2-10. Overview of EPA’s Screening Level Ambient Water Pathway Methodology ..... 44  
264 Figure 2-11. General Methodology for Estimating Water Releases..... 44  
265 Figure 2-12. General Methodology for Estimating Ambient Water Exposures ..... 46  
266

267 **LIST OF APPENDIX TABLES**

---

268 Table\_Apx A-1. Select Physical-Chemical Properties of Case Study Chemicals..... 167  
269 Table\_Apx C-1. TRI-CDR Use Code Crosswalk..... 169  
270 Table\_Apx D-1. Parameters Used for Point and Fugitive Source Type..... 188  
271 Table\_Apx D-2. Average Air Concentrations and Particle Deposition for 14 IIOAC Climate Regions 188  
272 Table\_Apx D-3. Maximum and Mean Releases by Chemical for Pre-screening Analysis..... 189  
273 Table\_Apx D-4. Exposure Concentrations and Risk Calculations..... 191  
274 Table\_Apx E-1. 1-BP Risk Evaluation Conditions of Use to OES Mapping..... 192  
275 Table\_Apx E-2. MC Risk Evaluation Conditions of Use to OES Mapping..... 195  
276 Table\_Apx E-3. NMP Risk Evaluation Conditions of Use to OES Mapping ..... 201  
277  
278

279 **ACKNOWLEDGEMENTS**

280 This report was developed by the United States Environmental Protection Agency (U.S. EPA), Office of  
281 Chemical Safety and Pollution Prevention (OCSPP), Office of Pollution Prevention and Toxics (OPPT).

282  
283 **Acknowledgements**

284 The OPPT Assessment Team acknowledges assistance from the following EPA contractors: Eastern  
285 Research Group, Inc (ERG; Contract No. 68HERD20A0002), ICF (Contract No. EP-W-12-010), and  
286 Versar (Contract No. EP-W-17-006)

287  
288 **Docket**

289 Supporting information can be found in public docket: [https://www.regulations.gov/docket/EPA-HQ-  
290 OPPT-2021-0415](https://www.regulations.gov/docket/EPA-HQ-OPPT-2021-0415).

291  
292 **Disclaimer**

293 Any mention of trade names or commercial products should not be interpreted as an endorsement by  
294 EPA.

295



296 **EXECUTIVE SUMMARY**

---

297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312

**Background**

The United States Environmental Protection Agency (EPA) published 10 final risk evaluations between 2020 and 2021 under the Toxic Substances Control Act (TSCA) as amended by the Frank R. Lautenberg Chemical Safety for the 21st Century Act in June 2016. TSCA section 6(b)(4)(A) requires the Agency to “conduct risk evaluations...to determine whether a chemical substance presents an unreasonable risk of injury to health or the environment, without consideration of costs or other non-risk factors, including an unreasonable risk to a potentially exposed or susceptible subpopulation identified as relevant to the risk evaluation by the Administrator, under the conditions of use.” However, during the course of finalizing many of these first 10 risk evaluations, a policy decision was made, at that time, for EPA’s Office of Chemical Safety and Pollution Prevention (OCSPP) to not assess certain exposure pathways (including, but not limited to, ambient air, ambient water, and drinking water) that fall under the jurisdiction of other EPA-administered laws. As a result, there are instances where EPA did not evaluate potential exposures and associated potential risks to the general population or certain subsets of the general population.

313 **What Is EPA Doing in This Work?**

314 EPA developed a proposed screening level methodology to evaluate potential exposures and associated  
315 potential risks to human receptors in proximity to (1) facilities releasing chemicals undergoing risk  
316 evaluation under TSCA section 6 to the ambient air, and (2) waterbodies receiving facility releases  
317 (direct or indirect) of chemicals undergoing risk evaluation under TSCA section 6. EPA considers these  
318 receptors a subset of the general population and categorizes them as “fenceline communities”  
319 throughout this work. Additionally, one or more receptors comprising fenceline communities can be of  
320 any age, including reproductive age, health status, or other factors like chemical sensitivity and therefore  
321 may also be considered potentially exposed or susceptible subpopulations (PESS).<sup>1</sup>

322  
323 For purposes of the proposed screening level methodology, EPA limits the proximity of receptors  
324 evaluated to those less than or equal to 10,000 meters from a facility releasing chemicals undergoing  
325 risk evaluation under TSCA section 6 to the ambient air. For evaluated aquatic exposure routes,  
326 proximity is limited to the extent of the identified waterbody receiving a facility discharge and therefore  
327 does not have a specific distance associated with the human receptor. Therefore, for purposes of this  
328 report, EPA is defining “fenceline communities” as follows:

329  
330 *Members of the general population that are in proximity to air emitting facilities or a*  
331 *receiving waterbody, and who therefore may be disproportionately exposed to a chemical*  
332 *undergoing risk evaluation under TSCA section (6). For the air pathway, proximity goes*  
333 *out to 10,000 meters from an air emitting source. For the water pathway, proximity does*  
334 *not refer to a specific distance measured form a receiving waterbody, but rather to those*  
335 *members of the general population that may interact with the receiving waterbody and*  
336 *thus may be exposed.*

337  
338 The proposed screening level methodology, as presented in this work, will go through public and peer  
339 review (including review by the Scientific Advisory Committee on Chemicals [SACC]) for comments

---

<sup>1</sup> TSCA section 3(12) states that “the term ‘potentially exposed or susceptible subpopulation’ means a group of individuals within the general population identified by the Administrator who, due to either greater susceptibility or greater exposure, may be at greater risk than the general population of adverse health effects from exposure to a chemical substance or mixture, such as infants, children, pregnant women, workers, or the elderly.” (15 U.S.C. §2602).

340 on the proposed methodology as well as recommended revisions or improvements to the methodology.  
341 Following public and peer review, EPA will review comments, recommendations, and improvements;  
342 modify the proposed screening level methodology, as appropriate, and utilize the resulting final  
343 screening level methodology as a framework to conduct screening level analyses for seven of the first 10  
344 chemicals for which EPA published risk evaluations between 2020 and 2021, and listed in Table\_ES 2,  
345 to help determine if there are potential risks to fenceline communities from the air and water pathways  
346 that were previously not assessed. Although the focus of this work is screening level analyses for seven  
347 of the first 10 chemicals for which EPA published risk evaluations between 2020 and 2021, the final  
348 screening level methodology framework can also be applied to future chemicals undergoing risk  
349 evaluation under TSCA section 6.

350  
351 EPA also provides three case study chemicals in this work to illustrate the application of the proposed  
352 screening level methodology described in this document. Two case studies are provided for the air  
353 pathway screening level methodology (1-bromopropane [1-BP] and methylene chloride [MC]) and two  
354 case studies are provided for the water pathway screening level methodology (MC and n-methyl-2-  
355 pyrrolidone [NMP]). The three case studies are carried through the processes of the environmental  
356 release assessment, exposure assessment, risk calculations, and associated risk characterizations based  
357 on the proposed screening level methodologies. While all three case study chemicals are chemicals for  
358 which EPA published risk evaluations between 2020 and 2021, the results as presented in this work are  
359 not final agency actions and will not be used as presented to support risk management actions or  
360 associated rulemaking activities resulting from the published risk evaluations at this time.

361  
362 Finally, EPA provides a brief description of how results from the screening level analysis may further  
363 inform or support the Agency’s risk management actions and associated rulemaking outcomes under  
364 TSCA resulting from published risk evaluations for chemicals undergoing risk evaluation. The  
365 descriptions are presented as hypothetical examples in the Introduction (Section 1) only to provide  
366 insight into the next steps following completion of a screening level analysis. Although these examples  
367 describe potential risk management actions/rulemaking outcomes, neither the outcomes described in the  
368 examples, nor the results from screening level analysis, are final agency actions as presented in this  
369 work. All proposed risk management actions/rulemaking activities and supporting documentation for  
370 such actions, including any screening level analyses conducted, will go through public comment prior to  
371 finalization.

### 372 373 **What Is EPA Not Doing in This Work?**

374 EPA is not providing any risk conclusions related to fenceline communities for any chemical substance  
375 in this work. Similarly, EPA is not providing any risk management actions or rulemaking activities for  
376 any chemical substance in this work.

377  
378 This work is intended to present a proposed methodology for conducting screening level analyses for  
379 chemicals undergoing risk evaluation under TSCA section 6. All case study chemicals included in this  
380 work are presented for illustrative purposes only to demonstrate the applicability and efficacy of the  
381 proposed methodology and do not represent final agency actions in relation to environmental release  
382 assessments, exposure assessments, or risk characterizations.

383  
384 The proposed methodology presented in this work is limited to certain air and water pathways  
385 previously not assessed in published risk evaluations. This work does not include proposed methodology  
386 for other pathways previously not assessed (*e.g.*, disposal, land use, groundwater-derived drinking water  
387 sources like wells, fish consumption) in published risk evaluations. Other components of published risk  
388 evaluations including, but not limited to, hazard identification, development of hazard endpoints, and

389 assessment of occupational exposure, ecological exposure, and consumer exposure will not be revisited  
390 as part of supplemental screening level analyses for fenceline communities.

391  
392 EPA is not providing a proposed methodology for conducting screening level analyses for  
393 aggregate/cumulative exposures in this work. However, EPA believes the design of the proposed  
394 methodology presented in this work is sufficiently flexible to allow addition of expanded capacities to  
395 evaluate concepts like aggregate/cumulative exposures. Additionally, the Agency invites suggestions as  
396 part of the charge for the SACC on what such expanded capacities could look like for future risk  
397 evaluations.

398  
399 EPA is not providing a proposed methodology for conducting screening level analyses to address  
400 potential environmental justice concerns in this work. Although the Agency is not conducting an  
401 environmental justice analysis of fenceline communities as part of this work, the Agency anticipates the  
402 proposed screening level methodology can serve as a baseline analysis which can identify potential  
403 environmental justice concerns and inform future environmental justice analyses that assess racial and  
404 economic disparities in risk exposure under baseline and policy scenarios. Additionally, EPA invites  
405 suggestions as part of the charge for the SACC on what such expanded capacities could look like for  
406 future risk evaluations.

#### 407 408 **Overall Approach Summary**

409 The proposed screening level methodology presented in this work uses reasonably available data,  
410 information, and models to quantify environmental releases, evaluate exposures to fenceline  
411 communities and characterize risks associated with such releases and exposures for certain air and water  
412 pathways previously not evaluated in published risk evaluations. The overall approach for the screening  
413 level methodology is summarized in Table\_ES 1 and is intended to be applied to 7 of the first 10  
414 chemicals undergoing risk evaluation under TSCA section 6, as summarized in Table\_ES 2, as well as  
415 future chemicals undergoing risk evaluation under TSCA section 6, across the conditions of use  
416 considered in the associated risk evaluations.

417  
418 When assessing exposures for industrial/commercial conditions of use (COUs), EPA generally defines  
419 an occupational exposure scenario or scenarios (OES for both) to capture the basic, underlying source of  
420 exposure for a given COU. Although the proposed screening level methodology does not involve  
421 evaluation of occupational exposures, EPA carries the OES label through this work to allow  
422 categorization of multiple facilities which may be involved with a single COU. A mapping of OES to  
423 the conditions of use (COU) in published risk evaluations for the three case study chemicals is provided  
424 in Appendix E.

#### 425 426 **Overall Results Summary**

427 EPA provides three case study chemicals (1-BP, MC, and NMP) in this work to illustrate the application  
428 of the proposed screening level methodology described in this document. The three case studies are  
429 carried through the processes of the environmental release assessment, exposure assessment, risk  
430 calculations, and associated risk characterizations based on the proposed screening level methodology.  
431 While all three case study chemicals are chemicals for which EPA published risk evaluations between  
432 2020 and 2021, the results, as presented in this work, are not final agency actions and will not be used as  
433 presented to support risk management actions or associated rulemaking activities resulting from the  
434 published risk evaluations at this time.

435  
436

437 The 1-BP case study presented in this work includes evaluation of 15 air pathway OES. Additional  
 438 risks<sup>2</sup> were identified for 14 of the 15 OES and are summarized in Table\_ES 3. An analysis of the water  
 439 pathway for 1-BP was conducted in the published problem formulation and discussed in the published  
 440 risk evaluation. To summarize, the analysis found that exposure to 1-BP via the water pathway is not  
 441 expected for 1-BP due to physical-chemical and fate properties of 1-BP, along with low reported  
 442 releases to water (5 lbs total in a year for all facilities). Since exposure via the water pathway is not  
 443 expected for 1-BP, EPA does not intend to conduct screening level analysis of the water pathway for  
 444 fenceline communities.

445  
 446 The MC case study presented in this work includes evaluation of 17 air pathway OES. Additional risks  
 447 were identified for 8 of the 17 OES and are summarized in Table\_ES 4. EPA also evaluated 13 water  
 448 pathway OES for MC. Additional risk was identified for one of the 13 OES evaluated for the drinking  
 449 water pathway but none for the incidental oral/dermal pathways as summarized in Table\_ES 5.

450  
 451 The NMP case study presented in this work includes evaluation of six water pathway OES. There were  
 452 no additional risks identified for any of these OES as summarized in Table\_ES 6. Although this work  
 453 currently does not include evaluation of the air pathway for NMP, as shown in Table\_ES 2, NMP is  
 454 included among the seven of the first 10 chemicals undergoing risk evaluation for which EPA will  
 455 conduct a screening level analysis using the final screening level analysis framework for the air  
 456 pathway.

457  
 458 **Table\_ES 1. EPA’s Overall Approach for Assessing Exposures and Associated Risks for Fenceline**  
 459 **Communities**

Assessment Step	Air Pathway	Water Pathway
Release Assessment	<ul style="list-style-type: none"> <li>• Use 2019 Toxics Release Inventory (TRI) Data.</li> <li>• Where no 2019 TRI data are available, estimate releases based on past TRI data, estimation methods used in final risk evaluations, and TRI surrogate data (TRI data from other OES).</li> </ul>	<ul style="list-style-type: none"> <li>• Use release scenarios from final risk evaluations, which incorporate direct and indirect release data from both TRI and Discharge Monitoring Report (DMR) information depending on chemical.</li> </ul>
Exposure Assessment	<ul style="list-style-type: none"> <li>• Use the American Meteorology Society/Environmental Protection Agency Regulatory Model (AERMOD) to estimate ambient air exposure concentrations for receptors at eight finite distances and one area distance out to 10,000 meters from a facility releasing the chemical evaluated to the ambient air.</li> <li>• When applicable, use the Indoor Environmental Concentrations in Buildings with Conditioned and</li> </ul>	<ul style="list-style-type: none"> <li>• Use modeled surface water concentrations from final risk evaluations to evaluate drinking water and incidental oral/dermal exposure; surface water concentrations were estimated using the Exposure and Fate Assessment Tool (E-FAST) 2014.</li> </ul>

<sup>2</sup> Additional risks are indicated when the calculated margin of exposure (MOE) is less than the benchmark MOE for non-cancer effects or when calculated inhalation unit risks (IUR) are greater than the benchmark IUR of  $1 \times 10^{-06}$  for cancer effects.

Assessment Step	Air Pathway	Water Pathway
	Unconditioned Zones (IECCU) to estimate indoor air exposure concentrations for residents that live above or adjacent to a releasing facility.	
Risk Characterization	<ul style="list-style-type: none"> <li>Use human health hazard endpoints from the final risk evaluations applied to the above scenarios for a continuous-exposure basis.</li> </ul>	

460

461

462

**Table\_ES 2. Seven of the First 10 Chemicals, and Associated Pathways, for Which EPA Intends to Conduct Screening Level Analyses**

Assessment Step	Air Pathway	Water Pathway
Case study chemicals	<ul style="list-style-type: none"> <li>1-Bromopropane (1-BP)</li> <li>Methylene chloride (MC)</li> </ul>	<ul style="list-style-type: none"> <li>n-Methylpyrrolidone (NMP)</li> <li>Methylene chloride (MC)</li> </ul>
Additional chemicals subject to screening level analyses	<ul style="list-style-type: none"> <li>n-Methylpyrrolidone (NMP)</li> <li>Trichloroethylene (TCE)</li> <li>Perchloroethylene (PCE)</li> <li>Carbon tetrachloride (CTC)</li> <li>1,4-Dioxane (1,4D)</li> </ul>	<ul style="list-style-type: none"> <li>Trichloroethylene (TCE)</li> <li>Tetrachloroethylene (PCE)</li> <li>Carbon tetrachloride (CTC)</li> <li>(1,4-Dioxane water pathways will be examined via a separate Supplement to the published Risk Evaluation)</li> </ul>

463

464

**Table\_ES 3. Summary of Additional Risks Identified for the 1-BP Air Pathway**

1-BP Air Pathway OESs	Additional Risk Identified?
Manufacturing	Yes
Import	Yes
Processing-Formulation	Yes
Processing-Incorporate into Articles	Yes
Processing as Reactant	Yes
Repackaging	Yes
Degreasing	Yes
Aerosol Spray Degreaser/Cleaner	Yes
Dry-Cleaning	Yes
Spot-Cleaning/Stain Remover	Yes
Spray Adhesives	No
Other Uses – Cutting Oil	Yes
Asphalt Extraction	Yes

1-BP Air Pathway OESs	Additional Risk Identified?
Recycling and Disposal	Yes
Co-Resident Receptors (Dry-Cleaning)	Yes

465

466

**Table\_ES 4. Summary of Additional Risks Identified for the MC Air Pathway**

MC Air Pathway OESs	Additional Risk Identified?
Manufacturing	No
Processing-Reactant	Yes
Processing-Incorporate into Formulation, Mixture, or Reaction Product	Yes
Repackaging	No
Batch Open-Top Degreasing	No
Cleaner/Degreaser-Unknown	Yes
Commercial Aerosol Products	No
Fabric Finishing	No
Spot Cleaning	No
Cellulose Triacetate Film Production	Yes
Flexible Polyurethane Foam Production	Yes
Laboratory Use	No
Plastic Product Manufacturing	Yes
Lithographic Printing Plate Cleaning	No
Miscellaneous Non-aerosol Industrial and Commercial Use	Yes
Waste Handling, Disposal, Treatment, Recycling	No
Paint Remover	Yes

467

468

**Table\_ES 5. Summary of Additional Risks Identified for the MC Water Pathway**

MC Water Pathway OESs	Additional Risk Identified?		
	Drinking Water	Incidental Oral	Incidental Dermal
Manufacturing	No	No	No
Import and Repackaging	No	No	No

MC Water Pathway OESs	Additional Risk Identified?		
	Drinking Water	Incidental Oral	Incidental Dermal
Processing as a Reactant	No	No	No
Processing: Formulation	No	No	No
Polyurethane Foam	No	No	No
Plastics Manufacturing	No	No	No
CTA Film Manufacturing	No	No	No
Lithographic Printer Cleaner	No	No	No
Spot Cleaner	No	No	No
Recycling and Disposal	Yes	No	No
Other	No	No	No
DOD	No	No	No
WWTP	No	No	No

469

470

**Table ES 6. Summary of Additional Risks Identified for the NMP Water Pathway**

NMP Water Pathway OESs	Additional Risk Identified?		
	Drinking Water	Incidental Oral	Incidental Dermal
Chemical Processing, Excluding Formulation	No	No	No
Electronics Manufacturing	No	No	No
Formulation	No	No	No
Metal Finishing	No	No	No
Disposal and Recycling	No	No	No
Cleaning	No	No	No

471

472

# 1 INTRODUCTION

The United States Environmental Protection Agency (EPA) published 10 risk evaluations between 2020 and 2021 under the Frank R. Lautenberg Chemical Safety for the 21st Century Act (Lautenberg Act). The Lautenberg Act amended the Toxic Substances Control Act (TSCA) in June 2016. Each of these TSCA section 6(b) risk evaluations underwent public comment and peer review (including review by the Scientific Advisory Committee on Chemicals, SACC) prior to publication. The published risk evaluations can be accessed online at [Chemicals Undergoing Risk Evaluation under TSCA](#).

During the course of finalizing many of these first 10 risk evaluations, a policy decision was made, at that time, for EPA’s Office of Chemical Safety and Pollution Prevention (OCSPP) to not assess certain exposure pathways (including, but not limited to, ambient air, ambient water, and drinking water) that fall under the jurisdiction of other EPA-administered laws. As a result, there are instances where EPA did not evaluate potential exposures and associated potential risks to the general population or certain subsets of the general population.

To examine whether the policy decision to exclude certain exposure pathways from the published risk evaluations may have caused EPA to miss potential exposures and associated potential risks from the air or water pathways, EPA developed this proposed screening level methodology to evaluate potential exposures and associated potential risks to human receptors in proximity to (1) facilities releasing chemicals undergoing risk evaluation under TSCA section 6 to the ambient air, and (2) waterbodies receiving facility releases (direct or indirect) of chemicals undergoing risk evaluation under TSCA section 6. EPA considers these receptors a subset of the general population and categorizes them as “fenceline communities” throughout this work. Additionally, one or more receptors making up fenceline communities can be of any age—including reproductive age, health status, or other factors like chemical sensitivity—therefore, they may also be considered potentially exposed or susceptible subpopulations (PESS).<sup>3</sup>

For purposes of the proposed screening level methodology, EPA limits the proximity of human receptors evaluated to those less than or equal to 10,000 meters from a facility releasing chemicals undergoing risk evaluation to the ambient air. This distance of 10,000 meters was selected to capture receptors nearer to releasing facilities than may otherwise be evaluated under other EPA administered laws. Additionally, professional knowledge and experience regarding exposures associated with the ambient air pathway found that typical risks frequently occur out to approximately 1,000 meters from a releasing facility and quickly decrease farther out. Although 10,000 meters is an order of magnitude farther out than where risks are expected to decrease, it provides an opportunity to verify expectations and also characterize how quickly risks decrease. For evaluated aquatic exposure routes, proximity is limited to the extent of the identified waterbody receiving a facility discharge and therefore does not have a specific distance associated with the human receptor. Therefore, for purposes of this report, EPA is defining “fenceline communities” as follows:

*Members of the general population that are in proximity to air emitting facilities or a receiving waterbody, and who therefore may be disproportionately exposed to a chemical undergoing risk evaluation under TSCA section (6). For the air pathway, proximity goes out to 10,000 meters from an air emitting source. For the water pathway, proximity does*

---

<sup>3</sup> TSCA section 3(12) states that “the term ‘potentially exposed or susceptible subpopulation’ means a group of individuals within the general population identified by the Administrator who, due to either greater susceptibility or greater exposure, may be at greater risk than the general population of adverse health effects from exposure to a chemical substance or mixture, such as infants, children, pregnant women, workers, or the elderly.” (15 U.S.C. §2602).



45 *not refer to a specific distance measured from a receiving waterbody, but rather to those*  
 46 *members of the general population that may interact with the receiving waterbody and*  
 47 *thus may be exposed.*

48  
 49 The Agency believes the screening level methodology presented in this work can be used to ensure  
 50 potential risks to fenceline communities will not go unidentified and unaddressed for the first chemicals  
 51 that underwent risk evaluations under TSCA. The Agency also believes, given the extensive  
 52 unreasonable risks already identified for all of these first substances, that it is imperative the Agency  
 53 address these risks via protective and expeditiously promulgated risk management rules. It is for these  
 54 reasons that the Agency quickly moved to develop and release this proposed screening level  
 55 methodology for public comment and peer review—the Agency believes that the law requires, and the  
 56 public is entitled to, protections from the identified risks as quickly as those protections can be finalized  
 57 and implemented.

58  
 59 The proposed screening level methodology, as presented in this work, will go through public and peer  
 60 review (including review by the SACC) for comments on the proposed methodology as well as  
 61 recommended revisions or improvements to the methodology. Following public and peer review, EPA  
 62 will review comments, recommendations, and improvements; modify the proposed screening level  
 63 methodology, as appropriate, and finalize the screening level methodology as a framework to conduct  
 64 screening level analyses. The final screening level analysis methodology framework will be used to  
 65 conduct screening level analyses for seven of the first 10 chemicals for which EPA published risk  
 66 evaluations between 2020 and 2021, as listed in Table 1-1, to help determine if there are potential  
 67 exposures and associated potential risks to fenceline communities from the air and water pathways that  
 68 were previously not assessed. The final screening level analysis methodology framework can also be  
 69 used for future chemicals undergoing risk evaluation under TSCA section 6.

70  
 71 **Table 1-1. Seven of the First 10 Chemicals Undergoing Risk Evaluation and Associated Pathways**  
 72 **for Which Supplemental Screening Level Analysis for Fenceline Communities Will Be Conducted**

Chemical	Air Pathway	Water Pathway
1-Bromopropane (1-BP)	Yes	No
Methylene chloride (MC)	Yes	Yes
n-Methyl-2-pyrrolidone (NMP)	Yes	Yes
Carbon tetrachloride (CTC)	Yes	Yes
Trichloroethylene (TCE)	Yes	Yes
Tetrachloroethylene (PCE)	Yes	Yes
1,4-Dioxane (1,4D)	[Yes] <sup>a</sup>	[Yes] <sup>a</sup>
<sup>a</sup> EPA is currently pursuing a full supplemental risk evaluation for 1,4-dioxane and the components of the screening level analysis for fenceline communities may be considered for part of that full supplemental risk evaluation.		

73  
 74 Other components of published risk evaluations including, but not limited to, hazard identification,  
 75 development of hazard endpoints, and assessment of occupational exposure, ecological exposure, and  
 76 consumer exposure will not be revisited as part of screening level analyses for fenceline communities. A

77 screening level analysis for fenceline communities via the water pathway will not be conducted for 1-BP  
78 since analysis conducted during Problem Formulation indicated that exposures via drinking water and  
79 surface water are unlikely to cause human or ecological risk. This was based on a combination of 1-BP's  
80 physical-chemical and fate properties (relatively high volatility and biodegradability), minimal releases  
81 to water or wastewater treatment plants according to Toxics Release Inventory data, and a lack of  
82 reported detections in drinking water ([U.S. EPA, 2020b](#)). Lastly, this work does not include proposed  
83 methodology for other pathways previously not assessed in published risk evaluations (*e.g.*, disposal,  
84 land use, groundwater derived drinking water sources like wells, or fish consumption),  
85 aggregate/cumulative exposures, or potential environmental justice concerns to inform future  
86 environmental justice analyses that assess racial and economic disparities in exposure and associated  
87 risks. However, EPA believes the design of the proposed methodology presented in this work is flexible  
88 enough to allow addition of expanded capacities to evaluate all three of these concepts and invites  
89 suggestions as part of the charge for the SACC on what such expanded capacities could look like for  
90 future risk evaluations.

91  
92 In this report, EPA proposes a screening level methodology for assessing chemical exposures to  
93 fenceline communities via the ambient air and water pathways. These methodologies are described in  
94 Section 2 and include developing release assessments, exposure assessments, risk calculations, and risk  
95 characterizations. EPA then presents three case study chemicals as illustrative examples of applying the  
96 screening level methodology. These are presented in Section 3. EPA presents two case study chemicals  
97 for the air pathway (1-BP and MC) and two case study chemicals for the water pathway (MC and NMP).  
98 While all three case study chemicals are chemicals for which EPA published risk evaluations between  
99 2020 and 2021, the results as presented in this work are not final agency actions and will not be used as  
100 presented to support risk management actions or associated rulemaking activities resulting from the  
101 published risk evaluations at this time. The purpose of these case study chemicals is to show the  
102 application and efficacy of the proposed screening level methodology and not to support risk  
103 management actions or rulemaking.

#### 104 105 Looking Ahead

106 In this sub-section, EPA provides a brief description of how results from the screening level analysis  
107 may be used to further inform or support the Agency's risk management actions and associated  
108 rulemaking outcomes under TSCA resulting from published risk evaluations for chemicals undergoing  
109 risk evaluation. The descriptions are presented as simplified hypothetical examples only to provide  
110 insight into the next steps following completion of a screening level analysis. Although these examples  
111 describe potential risk management actions/rulemaking outcomes, neither the outcomes described in  
112 these examples nor the results from screening level analysis are final agency actions as presented in this  
113 work. All proposed risk management actions/rulemaking activities and supporting documentation for  
114 such actions, including any screening level analyses conducted, will go through public comment prior to  
115 finalization.

116  
117 *Setting Up the Example:* EPA finalizes the screening level methodology and uses the framework to  
118 conduct a screening level analysis for chemical XYZ, which is a chemical undergoing risk evaluation  
119 under TSCA. The published risk evaluation for Chemical XYZ includes four conditions of use (COU1,  
120 COU2, COU3, and COU4) but as published did not include the ambient air pathway or ambient water  
121 pathways in the evaluation. Preliminary risk findings indicate there is unreasonable risk for COU1  
122 (worker exposure) and COU3 (worker and consumer exposure), but not for COU2 or COU4. Risk  
123 management actions are considering an existing chemical exposure limit for COU1 and a ban on use of  
124 chemical XYZ for COU3. Since no unreasonable risk was identified for COU2 or COU4, there is no risk  
125 management action proposed for COU2 or COU4.

126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172

*Actions Taken:* Since the published risk evaluation for Chemical XYZ did not include the ambient air or ambient water pathways, EPA conducts a screening level analysis for fenceline communities using the final screening level methodology framework and preliminary risk findings indicate there is additional unreasonable risk to fenceline communities for three of the four COUs. Unreasonable risk for COU1 occurs via the ambient air pathway only (primarily fugitive releases), unreasonable risk for COU2 occurs via the ambient water pathway only with some additional uncertainties requiring consideration, unreasonable risk for COU3 occurs via the air and water pathways based on the screening level analysis results. COU4 still has no unreasonable risk identified.

*How the Screening Level Analysis Results May Be Used to Further Inform Risk Management Actions:* Combining the risk findings from the published risk evaluation and screening level analysis findings the Agency has identified unreasonable risks for three of the four COUs, the Agency now has a statutory obligation to craft risk management rules to address those identified risks. Considering the risks identified for the three COUs, and the information supporting such risk findings, EPA may develop and pursue one or more of the following outcomes:

- **OUTCOME ONE:** No unreasonable risk was identified for COU4 in the published risk evaluation and the additional screening level analysis did not identify any unreasonable risk to fenceline communities for COU4. The Agency expeditiously proposes no restrictions on the chemical being used for COU4 as no unreasonable risk is identified or expected. The published risk evaluation and associated screening level analysis results and documentation demonstrating the findings are placed in the docket and the Agency publishes a proposed rule which will undergo public comment prior to finalization.
- **OUTCOME TWO:** Unreasonable risk was identified for COU3 in the published risk evaluation and the additional screening level analysis for COU3. The Agency considers the additional unreasonable risks found to fenceline communities through the screening level analysis and determines the initial thought to ban use of chemical XYZ for COU3 is further substantiated by these additional risks to fenceline communities. The Agency expeditiously proposes a ban on the chemical from use with COU3 since the proposed prohibition(s) would be expected to address all identified risks. The published risk evaluation and associated screening level analysis results and documentation demonstrating the findings are placed in the docket and the Agency publishes a proposed rule which will undergo public comment prior to finalization.
- **OUTCOME THREE:** Unreasonable risk was identified for COU1 (worker exposure) in the published risk evaluation and the additional screening level analysis for COU1 (fenceline communities primarily as a result of uncontrolled fugitive emissions within a workplace which may enter the ambient air through uncontrolled roof vents, open windows, or similar exit points). The Agency considers the additional unreasonable risks found through the screening level analysis as well as the fugitive nature of those releases and determines the initial thought to propose an existing chemical exposure limit within the workplace to protect the workers from the unreasonable risk may also reduce the amount of fugitive emissions available for escaping into the ambient air. The Agency expeditiously proposes a risk management rule which establishes an existing chemical exposure limit which can be met by utilizing local controls to capture releases and direct them away from the worker. This risk management rule is also expected to reduce fugitive releases to levels below which an unreasonable risk is expected. The published risk evaluation and associated screening level analysis results and documentation demonstrating the findings are placed in the docket and the Agency publishes a proposed rule which will undergo public comment prior to finalization.

173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201

- **OUTCOME FOUR:** As an alternative to outcome three, if the Agency concludes that the unreasonable risks identified for COU1 would be more effectively addressed by another EPA administered Federal law (the Clean Air Act [CAA] in this case), the Agency may comply with the requirements of section 9 of TSCA, which sets forth a process for referring such risk findings to be managed under another EPA administered Federal law. In the example described for outcome three, this may be a more effective outcome to pursue if COU1 tends to involve area sources (non-major sources) where the CAA has expertise with area source regulations which requires specific localized controls on certain emission sources within a source category as best management practices to minimize emissions released to the ambient air. Although such standards are not set up to address worker exposures directly, requirements like total enclosures or high capture and control efficiency requirements can reduce both worker exposures as well as total fugitive emissions released to the ambient air and therefore directly reduce both worker exposures and fenceline community exposures to levels below which unreasonable risk is expected.
- **OUTCOME FIVE:** Unreasonable risk was not identified for COU2 in the published risk evaluation, however, the additional screening level analysis for fenceline communities for COU2 did identify unreasonable risk to fenceline communities. The Agency recognizes the additional screening level analysis has some COU2-specific uncertainties which should be considered prior to proposing a risk management rule. The Agency determines that rather than expeditiously propose and risk management rule, additional analysis beyond the screening level analysis for fenceline communities is warranted to further substantiate the unreasonable risk finding for COU2. The Agency then undertakes additional analysis beyond the screening level analysis for fenceline communities, supplements the published risk evaluation and, depending on the outcome of the additional analysis, either retains the no unreasonable risk determination or revises the determination to unreasonable risk and then proposes a risk management rule appropriate for the final risk determination that will undergo public comment prior to finalization.

## 202 **2 SCREENING METHODOLOGIES**

---


### 203 **2.1 Ambient Air Pathway**

---

204 Figure 2-1 provides an overview of EPA’s screening level methodology for the ambient air pathway.  
205 Where reasonably available, fugitive and stack air release data from the 2019 Toxic Release Inventory  
206 (TRI) are used to quantify environmental releases. The 2019 TRI dataset is used for the proposed  
207 screening level analysis because it is not limited to criteria pollutants or chemicals listed as Hazardous  
208 Air Pollutants like the National Emissions Inventory (NEI) and is a more recent dataset than the latest  
209 NEI (2017). While the 2019 TRI dataset is used for the proposed screening level analysis, there are  
210 uncertainties associated with the 2019 TRI dataset which may warrant use of other, or additional,  
211 datasets for more detailed analyses under TSCA or other statutory programs administered by EPA.  
212 These are discussed in the assumptions and uncertainties section for environmental releases (Section  
213 2.4.1) and include not capturing smaller releasing facilities, location coordinates of source specific  
214 release points, or source specific stack parameters/plume characteristics. Lastly, although the 2019 TRI  
215 dataset is used for the proposed screening level analysis in this work, the proposed methodology can use  
216 one or more datasets, like TRI and NEI, or multiple years of one or more datasets, if there is added  
217 benefit to the intended outcome of the screening level analysis.

218  
219 AERMOD (EPA’s regulatory model for air dispersion modeling) is used to estimate ambient air  
220 concentrations and exposures to receptors at various distances from the emission source. Distances of up  
221 to 10,000 meters are evaluated to capture potential exposures and associated risks to fenceline  
222 communities. A distance of 10,000 meters is used for this screening level analysis methodology to  
223 capture receptors nearer to releasing facilities than may otherwise be evaluated under other EPA  
224 administered laws. Additionally, professional knowledge and experience regarding exposures associated  
225 with the ambient air pathway find risks frequently occur out to approximately 1,000 meters from a  
226 releasing facility and quickly decrease farther out. Although 10,000 meters is an order of magnitude  
227 farther out than where risks are expected to occur, 10,000 meters provides an opportunity to capture  
228 other factors related to potential exposure and associated potential risks via the ambient air pathway  
229 (like multiple facilities impacting a single receptor) providing flexibility for screening level analyses for  
230 future risk evaluations. Although 10,000 meters is used for the outer distance in the screening level  
231 analysis, the methodology is not limited to 10,000 meters. If risks are identified out to 10,000 meters,  
232 then additional analysis using the screening level methodology can be extended to farther distances for  
233 purposes of identifying where risks may fall below levels of concern.

234




235  
236  
237

**Figure 2-1. Overview of EPA’s Screening Level Ambient Air Pathway Methodology**

**2.1.1 Environmental Air Releases**

238  
239  
240  
241

This section describes the general methodology (Figure 2-2) that was used to develop estimates of air emissions from facilities as part of EPA’s screening level ambient air pathway methodology. The results of applying this methodology to 1-BP and MC are presented in Section 3 (Case Study Results).



242  
243

**Figure 2-2. General Methodology for Estimating Air Emissions**

**2.1.1.1 Step 1: Obtain 2019 TRI Data**

244  
245  
246  
247  
248  
249  
250  
251  
252  
253

The first step in the methodology for estimating air emissions was to obtain 2019 TRI data for the chemical from EPA’s [Basic Plus Data Files \(U.S. EPA, 2021\)](#). EPA included both TRI reporting Form R and TRI reporting Form A submissions in the fenceline analysis. Facilities may submit a Form A instead of a Form R if the amount of chemical manufactured, processed, or otherwise used does not exceed 1,000,000 pounds per year (lb/year) and the total annual reportable releases do not exceed 500 lb/year. Facilities do not need to report release quantities or uses/sub-uses on Form A. For Form A, the methodology to estimate emissions differs slightly from what is described below. Specifically, in Step 2, EPA does not have use/sub-use information for Form A submissions, so instead relies on North American Industry Classification System (NAICS) codes and facility information from internet searches

254 to map these facilities to an OES. Additionally, for Step 5, EPA used the Form A threshold of 500  
255 lb/year for total releases for sites that reported using a Form A. These differences are highlighted in the  
256 sections below.

### 257 **2.1.1.2 Step 2: Map 2019 TRI to Occupational Exposure Scenarios**

258 In the next step of fenceline analysis development, EPA mapped the chemical’s 2019 TRI data to the  
259 OES that were in the published risk evaluation for the chemical. EPA used the following procedure to  
260 map 2019 TRI data to OES:

- 261 1. Compile TRI uses/sub-uses: EPA first compiled all the reported TRI uses/sub-uses for each  
262 facility into one column.
- 263 2. Map TRI uses/sub-uses to *Chemical Data Reporting* (CDR) IFC codes: EPA then mapped the  
264 TRI uses/sub-uses for each facility to one or more 2016 CDR Industrial Function Category (IFC)  
265 codes using the TRI-to-CDR Use Mapping crosswalk (see Appendix C).
- 266 3. Map OES to CDR IFC codes: EPA then mapped each Condition of Use (COU)/OES  
267 combination from the published risk evaluation to a 2016 CDR IFC code and description. The  
268 basis for this mapping was generally the COU category and subcategory from the published risk  
269 evaluation.
- 270 4. Map TRI facilities to an OES: Using the CDR IFC codes from Step 2 and the COU-CDR  
271 Mapping from Step 3, EPA mapped each TRI facility to an OES. EPA’s rationale for the OES  
272 determination is generally described below.
  - 273 ○ In some cases, the facility mapped to only one OES and the mapping appeared to be  
274 correct given the facility name and NAICS code. For these, the OES as mapped from  
275 Steps 2 and 3 was used without adjustment.
  - 276 ○ In many cases, the facility mapped to multiple OES, and EPA decided which was the  
277 primary OES. To make this determination, EPA considered
    - 278 ● Industry and NAICS codes;
    - 279 ● Internet research of the types of products made at the facility;
    - 280 ● Which OES was most likely to result in releases (*e.g.*, for a facility that reported  
281 both importation and formulation, EPA assigned the formulation COU because, in  
282 such cases, importation itself is likely to have lower releases; and
    - 283 ● Grouping of like OES (*e.g.*, for facilities that reported the sub-use of cleaner or  
284 degreaser, EPA may assign the facility a grouped OES that covers both cleaning  
285 and degreasing because the specific cleaning/degreasing operation cannot be  
286 determined from the TRI data).
  - 287 ○ In some cases, EPA determined that the OES mapping from the TRI use/sub-use – CDR  
288 IFC code was incorrect. This incorrect mapping is a result of limitations of the TRI-to-  
289 CDR Use Mapping crosswalk. For example, the crosswalk maps the TRI use/sub-use of  
290 “Otherwise Use as Manufacturing Aid (Other)” to only CDR IFC codes U013 (closed-  
291 system functional fluids) and U023 (plating agents and surface treating agents); however,  
292 this TRI use/sub-use may encompass multiple other uses that are not captured in these  
293 CDR IFC codes. In these cases, EPA reviewed the reported NAICS codes and researched  
294 the facility to determine the likely OES.
  - 295 ○ Additionally, EPA reviewed 2016 CDR ([U.S. EPA, 2016b](#)) for sites that reported  
296 manufacturing (including importing) of the chemical. If the sites that reported to 2016  
297 CDR also reported in 2019 TRI, EPA assigned the OES according to 2016 CDR.
- 298 5. Form A’s: For Form A submissions, there were no reported TRI uses/sub-uses. To determine the  
299 COU for these facilities, EPA used 2016 CDR as described above, the NAICS codes, and  
300 internet searches to determine the type of products and operations at the facility.

301 The specific rationale for the OES mapping for each facility is broadly described in the supplemental  
302 fenceline analysis spreadsheets, *SF\_FLA\_Environmental Releases to Ambient Air for 1-BP* and  
303 *SF\_FLA\_Environmental Releases to Ambient Air for MC* (See Appendix B).

### 304 **2.1.1.3 Step 3: Estimate Number of Release Days for Each OES**

305 TRI air emissions data are provided on an annual basis, in pounds of chemical released per year via  
306 fugitive or stack emissions. However, for the exposure modeling described in Section 2.1.2, releases are  
307 needed on a daily basis. To estimate daily releases, EPA needs the number of release days for each  
308 facility. Because the number of release days is not reported in TRI, EPA used the general approach from  
309 the number of operating days in the published risk evaluations for the first 10 chemicals that were based  
310 on the following logic:

- 311 • Manufacture of solvents: 350 days/year (assumes the plant runs 7 days/week and 50 weeks/year,  
312 with two weeks down for turnaround, and assumes that the plant is always producing the  
313 chemical).
- 314 • Processing as reactant: 350 days/year (assumes chemical plant setting like manufacture of  
315 solvents and that the chemical of interest is used consistently throughout the year).
- 316 • Other Chemical Plant Scenarios: 300 days/year (based on a European Solvents Industry Group  
317 Specific Environmental Release Category factsheet that uses a default of 300 days/year for  
318 release frequency for the chemical industry, since it is unreasonable to assume the chemical of  
319 interest is always in use at the facility) ([European Solvents Industry Group, 2012](#)).
- 320 • All Other Scenarios: 250 days/year or the value cited in any relevant generic scenarios (GS) or  
321 emission scenario documents (ESD) (e.g., a risk evaluation may use 260 days/year for  
322 degreasing operations per the Vapor Degreasing ESD ([Organization for Economic and  
323 Development, 2017](#))).

324  
325 This approach assumes the number of release days for a facility is equal to the estimated number of  
326 operating days for its assigned OES.


### 327 **2.1.1.4 Step 4: Estimate Air Emissions for OES with No 2019 TRI Data**

328 2019 TRI data were not available for every OES for 1-BP or MC. The hierarchy that was followed to  
329 estimate air emissions for facilities with no 2019 TRI data is presented in the decision tree diagram in  
330 Figure 2-3. As shown in the hierarchy, the first alternative approach considered was using TRI data from  
331 prior reporting years that map to the OES (only prior reporting years 2016 through 2018 were  
332 considered for this Version 1.0 screening-level approach). If no past years' TRI data were available, the  
333 next approach considered was modeling, including using any modeling already completed in the  
334 published risk evaluation or performing modeling with existing models. No new models were developed  
335 or researched for this screening-level fenceline analysis. After modeling, existing literature sources used  
336 in the published risk evaluation were considered. For example, the 1-BP fenceline analysis uses a Trinity  
337 Consultants report containing air emissions data for dry cleaning and spray adhesives, which is  
338 referenced in the systematic review supplemental file for releases and occupational exposures ([Trinity  
339 Consultants, 2015](#)).

340  
341 If the published risk evaluation did not contain any literature sources with air release data, the use of  
342 2019 TRI data for a different OES was considered as surrogate for the OES being assessed. For  
343 example, the MC fenceline analysis uses 2019 TRI data for Miscellaneous Non-aerosol Industrial and  
344 Commercial Uses as surrogate for the Adhesives and Sealants OES because these OES are expected to  
345 be similar and potentially overlap (see Section 3.2.3). Where none of the above approaches were  
346 sufficient to develop an air release assessment for an OES, additional approaches or refinements were



347 considered, such as the use of Generic Scenarios and Emission Scenario Documents. The specific  
 348 approaches used to estimate releases for each chemical’s OES are discussed in the chemical-specific  
 349 case studies in Section 3.  
 350



351 **Figure 2-3. Decision Tree for Estimating Air Releases**

352

### 353 **2.1.1.5 Step 5: Prepare Air Emission Summary for Ambient Air Exposure Modeling**

354 The final step was to prepare a summary of the fugitive and stack releases. See the supplemental files  
 355 *SF\_FLA\_Environmental Releases to Ambient Air for 1-BP* and *SF\_FLA\_Environmental Releases to*  
 356 *Ambient Air for MC* (See Appendix B) for the summaries developed for 1-BP and MC. The content of  
 357 the summaries was developed to connect with the next stage of the analysis, which was the exposure  
 358 modeling described in Section 2.1.2. The parameters included were selected with this next step in mind.  
 359 Key parameters and their description and purpose for the exposure modeling are provided below and  
 360 summarized in Table 2-1.

361

362 For each OES, EPA summarized air releases in a table containing the data elements shown in Table 2-1,  
 363 with one row per site. EPA summarized site information, including site identity, city, state, zip code,  
 364 TRI facility ID, and Facility Registry Service (FRS) ID because the exposure modeling is site and  
 365 location specific. The summary includes the NAICS code and description and comparison to the  
 366 assigned OES for the site. Next, the summary includes annual releases to stack and fugitive air. These  
 367 annual releases are from 2019 TRI or from the alternative approaches discussed in Section 2.1.1.4. For  
 368 these alternative approaches, where sufficient data (modeled or otherwise) were available, EPA  
 369 presented the 50th and 95th percentile air emissions. Additionally, where sites reported to 2019 TRI  
 370 with a Form A, EPA used the Form A threshold for total releases of 500 lb/year. EPA used the entire  
 371 500 lb/year for both the fugitive and stack air release estimates; however, since this threshold is for total

372 site releases, these 500 lb/year are attributed either to fugitive air or stack air for this analysis, not both  
373 (since that would double count the releases and exceed the total release threshold for Form A).

374  
375 As discussed in Section 2.1.1.3, the exposure modeling requires daily releases. Therefore, the summary  
376 for each site includes the estimated number of release days according to the methodology in Section  
377 2.1.1.3 and the calculated daily fugitive and stack air releases. These daily releases were calculated by  
378 dividing the annual releases by the number of release days.

379  
380 To accompany the summary table for each OES, EPA also provided any reasonably available  
381 information on the release duration and pattern, which are needed for the exposure modeling. Release  
382 duration is the expected amount of time per day during which the air releases may occur. Release pattern  
383 is the temporal variation of the air release, such as over consecutive days throughout the year, over  
384 cycles that occur intermittently throughout the year, or in a puff/instantaneous release that occurs over a  
385 short duration. The TRI dataset does not include release pattern or duration, so EPA used information  
386 from models or literature. For example, EPA presented the mean release duration from the Open-Top  
387 Vapor Degreasing Near-Field/Far-Field Inhalation Exposure Model for the cleaning/degreasing OES for  
388 both 1-BP ([U.S. EPA, 2020b](#)) and MC ([U.S. EPA, 2020c](#)). For release pattern, EPA provided the  
389 number of release days with the associated basis as described in Step 3. However, for most OES, no  
390 information was found on release duration and pattern and EPA listed these as “unknown.”


391  
392

393 **Table 2-1. Summary of Air Release Data Elements**

Data Element	Data Element Description
Site Identity	Name of the facility where release occurred
City	Name of the city where the facility is located
State	State abbreviation for the state where the facility is located
Zip	Zip code for the location of the facility
TRIFID	TRI facility identification number
NAICS/SIC	Primary NAICS code for the facility
NAICS/SIC Description	Description of the industry associated with the reported primary NAICS code
Annual Fugitive Air Release (kg/site-year)	Reported or estimated annual fugitive air release from the facility
Annual Stack Air Release (kg/site-year)	Reported or estimated annual stack air release from the facility
Annual Release Days (day/year)	Estimated number of days per year the fugitive and/or stack air release occurs.
Daily Fugitive Air Release (kg/site-day)	Estimated average daily fugitive air release from the facility
Daily Stack Air Release (kg/site-day)	Estimated average daily stack air release from the facility
FRS	Facility Registry Service identification number for the facility
Sources & Notes	Identifies source of air release estimates and other key notes related to the estimates

394 **2.1.2 Ambient Air Concentrations and Exposures**

395 This section describes the tiered methodologies utilized to estimate ambient air concentrations and  
396 exposures for members of the general population that are in proximity (between 5 to 10,000 meters) to  
397 emissions sources emitting the chemicals being evaluated to the ambient air. All exposures were  
398 assessed for the inhalation route only. These methodologies are briefly described in Figure 2-4.  
399



400  
401  
402

**Figure 2-4. Brief Description of Methodologies Used to Estimate Ambient Air Concentrations and Exposures**

403

#### **2.1.2.1 Ambient Air Pre-screening Methodology**

404  
405  
406  
407  
408  
409  
410  
411  
412

The pre-screening analysis methodology was developed to identify, at a high level, if there are inhalation exposures to select receptors from a chemical undergoing risk evaluation which indicates a potential risk. Findings from the pre-screening analysis are intended to inform the need for a full-screening level analysis. If findings from the pre-screening analysis suggest there is any indication of risk (acute non-cancer, chronic non-cancer, or cancer) for a given chemical, EPA conducts a full-screening level analysis of exposures and associated risks for that chemical. If findings from the pre-screening analysis suggest there is no indication of risk for a given chemical, EPA does not expect to identify risks from a full-screening level analysis and therefore does not conduct further analysis for that chemical.

413

414

#### **Model**

415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426

The pre-screening methodology utilizes EPA’s Integrated Indoor/Outdoor Air Calculator (IIOAC) model<sup>4</sup> to estimate high-end and central tendency (mean) exposures to select receptors at three pre-defined distances from a facility releasing a chemical to the ambient air (100, 100 to 1,000, and 1,000 meters). IIOAC is an Excel-based tool that estimates indoor and outdoor air concentrations using pre-run results from a suite of dispersion scenarios run in a variety of meteorological and land-use settings within EPA’s American Meteorological Society/Environmental Protection Agency Regulatory Model (AERMOD). As such, IIOAC is limited by the parameterizations utilized for the pre-run scenarios within AERMOD (meteorologic data, stack heights, distances, receptors, etc.) and any additional or new parameterization would require revisions to the model itself. Readers can learn more about the IIOAC model, equations within the model, detailed input and output parameters, pre-defined scenarios, default values used, and supporting documentation by reviewing the IIOAC users guide ([U.S. EPA, 2019c](https://www.epa.gov/tsca-screening-tools/iioac-integrated-indoor-outdoor-air-calculator)).

<sup>4</sup> IIOAC page: <https://www.epa.gov/tsca-screening-tools/iioac-integrated-indoor-outdoor-air-calculator>.

427 **Releases**


428 EPA modeled exposures from two categorical release values for each chemical undergoing risk  
 429 evaluation under TSCA section (6). These values were extracted from 2019 TRI<sup>5</sup> data as follows:

- 430 1. The maximum individual facility release value for the chemical of concern among all facilities  
 431 reporting to TRI.  
 432 2. The average (mean) release value for the chemical of concern across all facilities reporting to  
 433 TRI.

434 **Exposure Scenarios**

435 EPA developed and evaluated a series of exposure scenarios for each categorical release value (max and  
 436 mean) designed to capture a variety of release types, topography, meteorological conditions, and release  
 437 scenarios as presented in Figure 2-5. Figure 2-5 includes a total of 16 different exposure scenarios, each  
 438 of which is applied to both the maximum and mean release data resulting in a total of 32 exposure  
 439 scenarios modeled for each chemical.

440  
 441  
 442



443  
 444  
 445  
 446

**Figure 2-5. Pre-screen Exposure Scenarios Modeled for Max and Mean Release Using IIOAC Model**

447 EPA modeled pre-screening exposure scenarios for two source types: stack (point source) and fugitive  
 448 (area source) releases. These source types have different plume and dispersion characteristics accounted  
 449 for differently within the IIOAC model. The topography represents an urban or rural population density  
 450 and certain boundary layer effects (like heat islands in an urban setting) that can affect turbulence and  
 451 resulting concentration estimates at certain times of the day.

452

<sup>5</sup> TRI page: <https://www.epa.gov/toxics-releasE-inventory-tri-program>.

453 IIOAC includes 14 pre-defined climate regions (each with a surface station and upper-air station). Since  
454 release data used for the pre-screening analysis was not facility location specific, EPA selected 2 of the  
455 14 climate regions to represent a central tendency (West North Central) and high-end (South [Coastal])  
456 climate region based on a sensitivity analysis of the average concentration and deposition predictions  
457 (further described in Appendix D). The meteorological stations associated with these two climate  
458 regions represent meteorological data sets that tended to provide high-end and central tendency  
459 concentration estimates relative to the other stations within IIOAC. Use of these two stations, therefore,  
460 provides high end and central tendency exposure concentrations utilized for risk calculation purposes to  
461 identify potential risks. The meteorological data within the IIOAC model are from years 2011 to 2015 as  
462 that is the meteorological data utilized in the suite of pre-run exposure scenarios during development of  
463 the IIOAC model (see IIOAC users guide ([U.S. EPA, 2019c](#))). While this is older meteorological data,  
464 sensitivity analyses related to different years of meteorological data found that although the data does  
465 vary, the variation is minimal across years so the impacts to the model outcomes remain relatively  
466 unaffected.

467  
468 The release scenarios consider two potential facility operating conditions. The first represents a facility  
469 that operates year-round (365 days per year), 24/7. The second represents a facility that operates  
470 generally on a Monday through Friday schedule (260 days per year) for 8 hours per day, 5 days per  
471 week. The difference between the two release scenarios is the resulting total daily release, frequency of  
472 release, and duration of release. These conditions result in a different exposure pattern that is captured  
473 by modeling both release scenarios. As an example, if a facility has a total annual release of 10,000  
474 lb/year, then the daily release from a facility operating 365 days/year, 7 days per week, and 24 hours per  
475 day would be 27.4 lb per day for every day of the year over a 24-hour period. If the facility operates 260  
476 days per year, 5 days per week, for 8 hours per day, the daily release would be 38.5 lb per day, but only  
477 Monday through Friday and over an 8-hour period.

#### 478 479 ***Exposure Results and Risks***

480 Modeled exposure concentration results from the pre-screening modeling effort were reviewed and  
481 summarized for each scenario modeled. To ensure potential risks were not missed, EPA maintained a  
482 conservative approach for the pre-screening analysis by selecting the highest estimated exposure  
483 concentrations from the 32 scenarios modeled for each chemical. These values were used for the risk  
484 calculations to estimate the Margin of Exposure (MOE) and excess cancer risk for comparison to the  
485 equivalent human health endpoints and benchmark values within the respective published final risk  
486 evaluations. The calculated risks were then compared to the benchmark values for the respective  
487 chemical to identify if there was an indication of potential added risk for either or both acute and chronic  
488 non-cancer effects (calculated MOE below the benchmark MOE for the specific chemical) or if there  
489 was an indication of potential excess risk for cancer (calculated values greater than the benchmark of  
490  $1 \times 10^6$  for general population).

491  
492 Chemical specific details and associated results of the pre-screening effort are provided in Appendix D.

#### 493 **2.1.2.2 Ambient Air Full-Screening Methodology**

494 The full-screening methodology was developed to allow EPA to conduct a full-screening level analysis  
495 of releases, exposures, and associated risks to fence-line communities for chemicals undergoing risk  
496 evaluation when the pre-screening analysis identifies potential exposure and associated risk(s) to the  
497 select receptors. The full-screening methodology can be performed independent of the pre-screening  
498 analysis, provides a more thorough analysis, and allows EPA to fully characterize identified risks for  
499 chemicals undergoing risk evaluation.

500

501 **Model**

502 The full-screening methodology utilizes AERMOD<sup>6</sup> to estimate exposures to fence-line communities at  
503 user defined distances from a facility releasing a chemical undergoing risk evaluation. AERMOD is a  
504 steady-state Gaussian plume dispersion model that incorporates air dispersion based on planetary  
505 boundary layer turbulence structure and scaling concepts, including treatment of both surface and  
506 elevated sources and both simple and complex terrain. AERMOD can incorporate a variety of emission  
507 source characteristics, chemical deposition properties, complex terrain, and site-specific hourly  
508 meteorology to estimate air concentrations and deposition amounts at user-specified receptor distances  
509 and at a variety of averaging times. Readers can learn more about AERMOD, equations within the  
510 model, detailed input and output parameters, and supporting documentation by reviewing the AERMOD  
511 users guide ([U.S. EPA, 2018](#)).

512  
513 **Releases**

514 EPA modeled exposures using the release data developed as described in Section 2.1.1 and summarized  
515 below. Release data was provided (and modeled) on a facility-by-facility basis:

- 516 1. Facility specific chemical releases (fugitive and stack releases) as reported to the 2019 TRI,  
517 where available.
- 518 2. Alternative release estimates as described in the decision tree for estimating air releases (Figure  
519 2-3), where facility specific 2019 TRI data were not available. Alternative release estimates may  
520 include facility specific releases reported in previous TRI reporting years (2016 to 2018) or  
521 modeled release estimates using existing EPA models or other surrogate data.

522 **Exposure Scenarios**

523 EPA modeled exposure concentrations on a facility-by-facility basis, building out a series of facility  
524 specific exposure scenarios based on the release data provided as described in Section 2.1.1. EPA  
525 modeled exposure concentrations at 8 finite distances from a releasing facility (5, 10, 30, 60, 100, 2,500,  
526 5,000 and 10,000 meters) and one area distance from a releasing facility (100-1,000 meters) in a series  
527 of concentric rings around the facility. Since these are radial distances from a releasing facility, the  
528 resulting diameter of distances evaluated is two times the distances evaluated.

529  
530 For TRI reporting facilities, EPA used facility specific information extracted from TRI or provided as  
531 part of the release assessment to inform the exposure scenario(s) for a given facility including, but not  
532 limited to: facility names, locations, identifier codes, annual air releases (stratified by fugitive and  
533 stack), and descriptions of intraday and inter-day air-release patterns. Where surrogate data or estimated  
534 releases were provided, EPA followed a similar scenario development scheme as used for the pre-screen  
535 work described in Section 2.1.2.1. One difference, however, is EPA modeled a single facility specific  
536 operating condition, based on assumptions used in the release assessment, to estimate exposures in the  
537 full-screening level analysis rather than the two operating conditions presented in Section 2.1.2.1 (24/7  
538 and 8/5).

539  
540 Facility coordinates, in the form of latitude/longitude coordinates, were used to match the facility to the  
541 closest available meteorological station. For facilities reporting to the 2019 TRI, latitude/longitude  
542 coordinates were provided as part of the release assessment as extracted from TRI. For a limited number  
543 of facilities where earlier TRI reporting years were used to estimate releases, the TRI system<sup>7</sup> was  
544 queried to obtain latitude/longitude coordinates for the surrogate data. Where data were not in the TRI,  
545 but EPA estimated releases from a surrogate facility with a city location, the latitude/longitude  
546 coordinates were set near the center of the city in which the facility was located. Where data were not in

---

<sup>6</sup> See [AERMOD](#) for further information.

<sup>7</sup> Toxics Release Inventory search page: <https://www.epa.gov/enviro/tri-search>.

547 TRI or based on a city location, EPA was unable to identify and apply latitude/longitude coordinates and  
548 instead used the meteorological data applied for the pre-screen work (West North Central and South  
549 (Coastal) regional meteorologic stations from IIOAC) and described in Section 2.1.2.1.

550

551 Meteorological data for TRI reporting facilities was obtained using the same AERMOD-ready  
552 meteorological data that EPA’s Risk and Technology Review (RTR) program uses for multimedia,  
553 multipathway-risk modeling in review of National Emission Standards for Hazardous Air Pollutants  
554 (NESHAP).<sup>8</sup> These data cover 824 hourly stations in the 50 states, District of Columbia, and Puerto  
555 Rico. The data are for year 2016. While this is older meteorologic data, sensitivity analyses related to  
556 different years of meteorological data found that although the data does vary, the variation is minimal  
557 across years so the impacts to the model outcomes remain relatively unaffected.

558

559 All meteorologic data was processed with version 16216 of AERMOD’s meteorological preprocessor  
560 (AERMET).<sup>9</sup> <sup>10</sup> Following EPA guidance,<sup>11</sup> all processing utilized sub-hourly wind measurements (to  
561 calculate hourly-averaged wind speed and wind direction; see Section 8.4.2 of that guidance). The  
562 processing for the 2016 data also used the “ADJ\_U\*” option for mitigating modeling issues during light-  
563 wind, stable conditions. All processing also used automatic substitutions for small gaps in data for cloud  
564 cover and temperature.

565

566 Meteorological data for EPA estimated releases (where TRI or city data were not available) were  
567 modeled with the two meteorological stations utilized in the pre-screen methodology (Sioux Falls, SD,  
568 and Lake Charles, LA). These two meteorological stations represent meteorological data sets that tended  
569 to provide high-end and central tendency concentration estimates relative to the other stations within  
570 IIOAC based on a sensitivity analysis of the average concentration and deposition predictions (further  
571 described in Appendix D) conducted in support of IIOAC development. Use of these two stations,  
572 therefore, provides high end and central tendency exposure concentrations utilized for risk calculation  
573 purposes to identify potential risks. The “ADJ\_U\*” option was not used for the 2011 to 2015 data,  
574 which could lead to model overpredictions of ambient concentrations during those particular conditions.

575

576 Urban/rural designations of the area around a facility are relevant when considering possible boundary  
577 layer effects on concentrations. Air emissions taking place in an urbanized area are subject to the effects  
578 of urban heat islands, particularly at night. When sources are set as urban in AERMOD, the model will  
579 modify the boundary layer to enhance nighttime turbulence, often leading to higher nighttime air  
580 concentrations. AERMOD uses urban-area population as a proxy for the intensity of this effect.

581

582 EPA utilized a population density analysis to identify facilities warranting an urban designation for the  
583 AERMOD runs. Specifically, EPA considered a facility to be in an urban area if it had a population  
584 density greater than 750 people per square kilometer (km<sup>2</sup>) within a 3-km radius of the facility (see  
585 Section 7.2.1.1 of the guidance referenced in footnote 11) and set the relevant inputs to urban within  
586 AERMOD. However, as noted in the EPA guidance referenced in footnote 11, the population-density  
587 analysis can be misleading for facilities in an industrial park within a city, facilities that border a water  
588 body or some other unpopulated area, etc. Recognizing this limitation can result in situations where the

---

<sup>8</sup> RTR page: <https://www.epa.gov/stationary-sources-air-pollution/risk-and-technology-review-national-emissions-standards-hazardous>.

<sup>9</sup> See [AERMET](#) for further information.

<sup>10</sup> Note: The RTR program’s inhalation-risk modeling now uses data mostly from year 2019 and a more updated version of AERMET (see the [HEM4 User’s Guide](#)). However, EPA does not anticipate the modeling used here to be sensitive to these differences.

<sup>11</sup> See [EPA Guideline on Air Quality Models](#).



589 facility site likely is influenced by urban heat island effects but the population density within 3 km is  
590 below 750 people per km<sup>2</sup>, EPA conducted a brief visual examination of the region around the facility,  
591 using aerial imagery, to identify any facility within or on the edge of an urban domain but where a  
592 substantial portion of the 3-km radius around the facility had low population counts. Facilities meeting  
593 these visual conditions were also given an urban designation for modeling purposes.

594  
595 For facilities set for urban modeling, AERMOD requires an estimate of the urban population count. EPA  
596 estimated the urban-area population by identifying a proxy for the area of urbanization. The urban-area  
597 proxy was the largest radius around the facility (out to a limit of 15 km) having a population density  
598 greater than 750 people per km<sup>2</sup> and identified the population within that radius and applied it for  
599 modeling purposes. EPA used U.S. Census data at the level of block groups for these analyses (with  
600 geographies from the 2019 census TIGER/Line shapefiles<sup>12</sup> and population counts from the American  
601 Community Survey<sup>13</sup> 2015 to 2019 5-year estimates-detailed tables (table B01003)).

602  
603 Where TRI or city data were not available for a facility requiring modeling, there was no way for EPA  
604 to determine an appropriate urban or rural designation. Instead, EPA modeled each such facility once as  
605 urban and once as not urban.<sup>14</sup> There is no recommended default urban population for AERMOD  
606 modeling, so for these facilities EPA assumed an urban population of 1 million people, which is  
607 consistent with the estimated populations used with IIOAC. Although slightly higher, the assumed urban  
608 population is close to the average of all the urban populations used for the TRI reporting facilities  
609 (which was 847,906 people).

610  
611 Source-specific physical characteristics like actual release location, stack height, exit gas temperature,  
612 etc. are generally not reported as part of the TRI dataset but can affect the plume characteristics and  
613 associated dispersion of the plume. For the release location, EPA used a local-coordinate system. EPA  
614 centered a facility's emissions on one location which was assigned the local coordinate of (0,0) and  
615 concentrations were estimated at modeled distances in concentric rings from that one location.

616  
617 EPA used physical stack parameters and plume characteristics consistent with those used in IIOAC,  
618 including, but not limited to: stack emissions released from a point source at 10 meters above ground  
619 from a 2-m inside diameter stack, with an exit gas temperature of 300 °Kelvin and an exit gas velocity of  
620 5 m per second (see Table 6 of the IIOAC User Guide). EPA acknowledges these stack parameters  
621 represent conservative plume characteristics which resemble a slow-moving, low-to-the-ground plume  
622 with limited dispersion but believe are appropriate for screening level purposes.

623  
624 Fugitive emissions were modeled using a release height of 3.05 m above ground from a square area  
625 source 10 m on a side (see Table 7 of the IIOAC User Guide). These parameters are also conservative in  
626 that they represent fugitive sources relatively low to the ground with no buoyancy or momentum to the  
627 emissions. Additionally, because we modeled fugitive sources centered at (0,0) and 10 m on a side (*i.e.*,  
628 extending out 5 m to the north, south, east, and west from the facility center point, and extending out  
629 about 7.1 m to the northeast, southeast, southwest, and northwest), all of the modeled exposure  
630 concentrations at the 5-m ring distance will be either directly on the edge of the fugitive source or “on

---

<sup>12</sup> 2019 census TIGER/Line shapefiles page: <https://www.census.gov/geographies/mapping-files/timE-series/geo/tiger-linE-file.2019.html>.

<sup>13</sup> American Community Survey page: <https://www.census.gov/programs-surveys/acs>.

<sup>14</sup> While this may be viewed as a potential double counting of these releases, EPA only utilized the highest estimated releases from a single exposure scenario from the suite of exposure scenarios modeled for surrogate/estimated facility releases as exposure estimates and for associated risk calculations.

631 top of’ the fugitive source. All other modeled concentrations for fugitive sources will be well outside the  
632 fugitive source.

633  
634 Temporal emission patterns are another factor that can affect the overall modeled concentration  
635 estimates. The release assessments for this work included information on temporal emission patterns—  
636 release duration (across the hours of a day, or intraday) and release pattern (across the days of a year, or  
637 inter-day)—stratified by OES. When release duration was “unknown,” EPA assumed releases occurred  
638 each hour of the day. When release duration or release pattern was described as a distribution, EPA used  
639 the stated mean of that distribution, and when they were fractional values EPA rounded to the nearest  
640 integer.

641  
642 EPA’s assumptions for intraday release duration are provided in Table 2-2. The hours shown conform to  
643 AERMOD’s notation scheme of using hours 1 to 24, where hour 1 is the hour ending at 1 a.m. and hour  
644 24 is the final hour of the same day ending at midnight.

645  
646 **Table 2-2. Assumptions for Intraday Emission-Release Duration**

Hours per Day of Emissions	Assumed Hours of the Day Emitting (Inclusive)
Unknown	All (hours 1–24)
1	Hour 13 (hour ending at 1 p.m.; <i>i.e.</i> , 12 to 1 p.m.)
3	Hours 13–15 (hour ending at 1 p.m. through hour ending at 3 p.m.; <i>i.e.</i> , 12 to 3 p.m.)
4	Hours 13–16 (hour ending at 1 p.m. through hour ending at 4 p.m.; <i>i.e.</i> , 12 to 4 p.m.)
8	Hours 9–16 (hour ending at 9 a.m. through hour ending at 4 p.m.; <i>i.e.</i> , 8 a.m. to 4 p.m.)
12	Hours 9–20 (hour ending at 9 a.m. through hour ending at 8 p.m.; <i>i.e.</i> , 8 a.m. to 8 p.m.)
14	Hours 7–20 (hour ending at 7 a.m. through hour ending at 8 p.m.; <i>i.e.</i> , 6 a.m. to 8 p.m.)

647  
648 EPA’s assumptions for inter-day release pattern are provided in Table 2-3. EPA started with the  
649 assumption that emissions took place every day of the year. Next, EPA turned emissions off for certain  
650 days of the year as needed to achieve the desired number of emission days: assumptions such as no  
651 emissions on Saturday and Sunday, no emissions on the days around New Year’s Day, no emissions at  
652 regular patterns like the first Monday of every month, and so on. EPA developed these patterns for the  
653 TRI reporting facilities, and then adjusted the patterns as needed for facilities where no TRI or city data  
654 were available (years 2011 to 2015), since the number of Mondays, Saturdays, etc., in the year varies  
655 year-by-year.

656

1 **Table 2-3. Assumptions for Inter-day Emission-Release Pattern**

Provided Language for Release Pattern	Implemented Release Pattern: Days When Emissions Are on (Format of Month Number/Day Number)	
	Real Facilities (Year 2016)	Generic Facilities (Years 2011–2015)
<u>Release pattern:</u> unknown; <b>350 days/yr</b> is based on the assumption of operations over <b>7 days/wk and 50 wk/yr</b> .	All days except 1/1–1/5 and 12/21–12/31	Not applicable
<u>Release pattern:</u> unknown; <b>300 days/yr</b> is based on the assumption of operations over <b>7 days/wk over some portion of the year</b> since the chemical may not be processed throughout the entire year.	All days except 12/26–12/31 and the first 5 days of each month	Not applicable
<u>Release pattern:</u> unknown; The Brake Servicing Model estimates 260 to 364 days/yr with a mean of <b>291 days/yr</b> ; Use of aerosol degreasers is expected to be intermittent throughout the year; Aerosol degreasing is expected to be <b>intermittent throughout the day, week, and year</b> .	Not applicable	All Mon.–Sat. except 1/1–1/5, 12/21–12/31, the first Mon. of Feb.–Sep. (and Oct. but only for 2012 and 2014)
<u>Release pattern:</u> unknown; The Dry Cleaning Model calculates a mean of <b>287 days/yr</b> using a triangular distribution of low-end 250 days/yr (5 day/wk and 50 wk/yr), high-end 312 days/yr (6 day/wk and 52 wk/yr), and mode 300 days/yr (6 day/wk and 50 wk/yr)	All Mon.–Sat. except 1/1–1/5, 12/21–12/31, the first Mon. of Feb.–Dec., and the first Tue. of Feb.–Mar.	All Mon.–Sat. except 1/1–1/5, 12/21–12/31, the first Mon. of Feb.–Dec., and the first Tue. of Feb. (and Mar. but only for 2012 and 2014)
<u>Release pattern:</u> unknown; The Spot Cleaning Model calculates a mean of <b>287 days/yr</b> using a triangular distribution of low-end 250 days/yr (5 day/wk and 50 wk/yr), high-end 312 days/yr (6 day/wk and 52 wk/yr), and mode 300 days/yr (6 day/wk and 50 wk/yr); Spot cleaning is expected to be <b>intermittent throughout the day, week, and year</b>	Not applicable	All Mon.–Sat. except 1/1–1/5, 12/21–12/31, the first Mon. of Feb.–Dec., and the first Tue. of Feb. (and Mar. but only for 2012 and 2014)
<u>Release pattern:</u> unknown; <b>260 days/yr</b> is from the Vapor Degreasing ESD, which is based on 2011 NEI data, and is the median for OTVDs	All Mon.–Fri. except 1/1	Not applicable
<u>Release pattern:</u> unknown; <b>260 days/yr</b> based on <b>5 days/wk and 52 wk/yr</b>	All Mon.–Fri. except 1/1	Not applicable
<u>Release pattern:</u> unknown; <b>250 days/yr</b> is based on the assumption of operations over <b>5 days/wk and 50 wk/yr</b> .	All Mon.–Fri. except 1/1–1/5 and 12/21–12/31	Not applicable
Note: Some of the “Provided Language for Release Pattern” is specific to an OES. yr = year; wk = week; Mon. = Monday; Sat. = Saturday; Feb. = February; Sep. = September; Oct. = October; Dec. = December; Tue. = Tuesday; Mar. = March.		


2

1 The release assessments included emission rates for each facility in kilograms per site per year, for  
2 fugitive and stack sources as appropriate. In most cases, one emission rate was included per source type  
3 per facility (*i.e.*, one rate for fugitive emissions, one rate for stack emissions), though in some cases,  
4 where releases were estimated, releases were provided as a range of values. The ranges of values  
5 typically were a central tendency and a 95th percentile or higher-end value. In some cases, both a mean  
6 and a 50th percentile value was provided (mean being an arithmetic mean value and the 50th percentile  
7 being a median value). Typically, the mean and 50th percentile releases were similar, so EPA used the  
8 50th-percentile value and excluded the mean value for modeling purposes. Central tendency and high-  
9 end emission scenarios were modeled separately.

10  
11 Some TRI reporting facilities had emissions lower than the required reporting thresholds for TRI and  
12 reported emissions using TRI’s “Form A.” These forms have a reporting threshold of 500 lb/year of total  
13 facility releases and were included in the release assessments as the release rate for both fugitive and  
14 stack sources. Since fugitive and stack releases are modeled differently within AERMOD (point source  
15 vs area source), and there was no way to parse out the total release across fugitive and stack releases,  
16 Form A reported releases were modeled as two different scenarios, one where the 500 lb of total releases  
17 were all fugitive releases (with no stack emissions) and another where the 500 lb of the total releases  
18 were all stack releases (with no fugitive emissions).<sup>15</sup>

19  
20 Emission rates included in the release assessments were converted to units needed by AERMOD (grams  
21 per second for stack sources; grams per second per square meter (m<sup>2</sup>) for fugitive sources). The  
22 conversion from per-hour to per-second utilized the number of emitting hours per year based on the  
23 assumed temporal release patterns. The area of fugitive sources was 100 m<sup>2</sup>.

24  
25 All modeling scenarios utilized a region of gridded receptors placed around a ring/radial at varying  
26 distances from the facility being modeled. Receptors were placed every 22.5 degrees (starting due north  
27 of the facility) around each ring resulting in 16 receptors around each ring as shown in Figure 2-6.  
28




29  
30 **Figure 2-6. Receptor Locations around Each Distance Ring**  
31

---

<sup>15</sup> Although this may be viewed as a potential double counting of these releases, EPA utilized only the highest estimated releases from a single exposure scenario from the suite of exposure scenarios modeled for surrogate/estimated facility releases as exposure estimates and for associated risk calculations.


32 Rings were placed at eight finite distances from a facility (5, 10, 30, 60, 100, 2,500, 5,000, and 10,000  
33 meters) forming concentric circles around a modeled facility. One additional distance was modeled to  
34 cover an “area” of receptors between 100 and 1,000 meters from a facility. These can be seen in  
35 **Figure 2-7.**  
36



37  
38  
39 **Figure 2-7. Modeled Distances from Facility**  
40

41 For the “area” of receptors, receptors were regularly spaced at 100-m intervals every 22.5 degrees in all  
42 directions within the area between 100 m and 1,000 meters from the facility, which is necessary to average  
43 the modeled concentrations across the area. This can be seen in Figure 2-8.  
44

45 All receptors were set at 1.8 m above ground, as a proxy for breathing height of an average receptor.  
46 EPA assumed flat terrain for all modeling scenarios and used a local-coordinate system centered at (0, 0)  
47 for the source of the release. Although AERMOD is capable of modeling elevations for source locations  
48 and receptor locations, a flat terrain was modeled for simplicity and the absence of reasonably available  
49 information on elevation data for sources and receptors modeled for purposes the screening level  
50 analysis.  
51



**Figure 2-8. Receptor Locations between 100 and 1,000 m**

52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84

**Exposure Concentration Outputs**

Daily- and period-average outputs were provided for every run for each receptor around the ring (each of 16 receptors around a ring or within the 100 to 1,000 meters area distance scenario). Period averages were 1 year for TRI reporting facilities and 5 years for facilities where releases were estimated. Outputs were stratified by different source scenarios, such as urban/not urban setting or emission-strengths where needed. Outputs from AERMOD are provided in units of micrograms per cubic meter ( $\mu\text{g}/\text{m}^3$ ) requiring conversion to parts per million (ppm) for purposes of risk calculations and comparison to applicable health endpoints for this work. The following formula was used for this conversion:

$$C_{\text{ppm}} = (24.45 * (C_{\text{AERMOD}}) / 1,000) / \text{MW}$$

Where:

- $C_{\text{ppm}}$  = Concentration (ppm),
- 24.45 = molar volume of a gas at 25 °C and 1 atmosphere pressure,
- $C_{\text{AERMOD}}$  = Concentration from AERMOD ( $\mu\text{g}/\text{m}^3$ ), and
- MW = Molecular weight of the chemical of interest (g/mole).

Post-processing scripts were used to extract and summarize the output concentrations at each facility and for each meteorological or source scenario. The following statistics for daily- and period-average concentrations at each of the receptor groups (*i.e.*, each ring and grid of receptors) were extracted or calculated from the results (also see Table 2-4):

- Minimum
- Maximum
- Average
- Standard deviation
- 10th, 25th, 50th, 75th, and 95th percentiles

AERMOD provides daily-average concentrations for each day of the modeled year for each receptor around a ring at each distance modeled. For TRI reporting facilities (which used 2016 calendar year meteorological data), this results in one daily average concentration for each of 366 days for a total of

85 366 values at each receptor. For EPA estimated releases (which used 2011 to 2015 meteorological data),  
 86 this results in 5 daily average concentrations (for each year of meteorological data) for each of 365 (or  
 87 366) days for a total of 1,826 values at each receptor. AERMOD also provides a period-average  
 88 concentration at each of the 16 receptors placed around the ring of a given modeled distance. This  
 89 results in a total of 16 values for each ring derived from either averaging the daily averages across the  
 90 single year of meteorological data used (2016) for TRI reporting facilities or across the multi-year  
 91 meteorological data used (2011 to 2015) for EPA estimated releases.

92  
 93 **Table 2-4. Description of Daily or Period Average and Air Concentration Statistics**

Statistic	Description
Minimum	The minimum daily or period average concentration estimated at any receptor location on any day at the modeled distance.
Maximum	The maximum daily or period average concentration estimated at any receptor location on any day at the modeled distance.
Average	Arithmetic mean of all daily or period average concentrations estimated at all receptor locations on all days at the modeled distance. This incorporates lower values (from days when the receptor location largely was upwind from the facility) and higher values (from days when the receptor location largely was downwind from the facility).
Percentiles	The daily or period average concentration estimate representing the numerical percentile value across the entire distribution of all concentrations at all receptor locations on any day at the modeled distance. The 50th percentile represents the median of the daily or period average concentration across all concentration values for all receptor locations on any day at the modeled distance.

94  
 95 ***Exposure Results and Risks***

96 Modeled exposure concentration results from the full-screening level analysis were reviewed and  
 97 summarized on a facility-by-facility basis (and each alternative release estimate) for each scenario  
 98 modeled. EPA used the 10th, 50th, and 95th percentile estimated concentrations for each facility (and  
 99 each alternative release estimate) at each distance evaluated for risk calculation purposes. Risk  
 100 calculations were used to estimate the MOE and excess cancer risk for comparison to the equivalent  
 101 human health endpoints and benchmark values presented within the respective published final risk  
 102 evaluations.

103  
 104 ***Land Use Considerations***

105 EPA conducted a review of land use patterns around facilities where there was an indication of risk. This  
 106 review was limited to those facilities with real Global Information System (GIS) locations that showed  
 107 risk and did not include alternative release estimates showing risk. The purpose of this review was to  
 108 determine if EPA can reasonably expect an exposure to fence-line communities to occur within the  
 109 modeled distances where there was an indication of risk. This detailed review consisted of visual  
 110 analysis using aerial imagery and interpreting land use/zoning practices around the facility. More  
 111 specifically, EPA used ESRI ArcGIS (Version 10.8) and Google maps to characterize land use patterns  
 112 within the radial distances evaluated in this work where there was an indication of risk. For locations  
 113 where residential or industrial/commercial businesses or other public spaces are present within those  
 114 radial distances indicating risk, EPA includes those receptors within the fence-line communities category  
 115 and reasonably expects an exposure and therefore an associated potential risk. Where the radial

116 distances showing an indication of risk occur within the boundaries of the facility or is limited to  
117 uninhabited areas, EPA does not reasonably expect an exposure to fenceline communities to occur and  
118 therefore does not expect an associated risk.

119

### 120 *Case Studies*

121 Chemical specific details and associated results of EPA’s application of this full screening methodology  
122 for 1-BP and MC are provided in Sections 3.1.4 and 3.2.4. Risk calculations and associated risk findings  
123 for 1-BP and MC are provided in Sections 3.1.5 and 3.2.5.

#### 124 **2.1.2.3 Ambient Air Co-resident Screening Methodology**

---

125 The co-resident screening methodology was developed to allow EPA to evaluate exposures and  
126 associated risks to a specific subset of receptors falling under the fenceline community category living  
127 above or directly adjacent to a facility releasing a chemical undergoing risk evaluation under case-  
128 specific exposure scenarios and are referred to as co-resident receptors. Although this methodology can  
129 be applied for any chemical falling under an appropriate case-specific exposure scenario, in this report it  
130 is only applied to 1-BP. The exposure scenarios addressed in this report are chemical-specific releases  
131 from dry-cleaning facilities and effects on co-resident receptors. For purposes of this report, co-resident  
132 receptors are defined as a person who lives above or directly adjacent to a dry-cleaning facility utilizing  
133 the chemical undergoing risk evaluation.

134

135 The objectives of this co-resident screening methodology are to (1) develop an approach to estimate air  
136 concentrations and exposures to co-resident receptors for the dry-cleaning condition of use; (2) estimate  
137 the interzonal air flow—a key parameter for contaminant transport from the source zone to the living  
138 spaces—by using the value calibrated against field monitoring data from the literature and other  
139 methods applicable to the co-resident exposure scenarios; and (3) develop high-end and central tendency  
140 estimates of air concentrations and exposures to co-resident receptors for acute and chronic scenarios.

141

142 A deterministic indoor air quality model was used to predict chemical transport from the dry-cleaning  
143 facilities to the co-resident spaces followed by calculation of the 8-hr, 24-hr, 7-day, and annual time-  
144 weighted average (TWA) concentrations in the living space. The unadjusted and adjusted TWA  
145 concentrations were then used to calculate potential acute, chronic, and lifetime doses, and potential  
146 risks.

147

### 148 *Model*

149 The co-resident screening methodology uses EPA’s Indoor Environment Concentration in Buildings  
150 with Conditioned and Unconditioned Zones (IECCU) model. IECCU is a deterministic model which can  
151 be used as (1) a general-purpose indoor exposure model in buildings with multiple zones, multiple  
152 chemicals and multiple sources and sinks or (2) as a special-purpose concentration model for simulating  
153 the effects of sources in unconditioned zones on the indoor environmental concentrations in conditioned  
154 zones. Readers can learn more about the IECCU model, equations within the model, detailed input and  
155 output parameters, and supporting documentation by reviewing the IIOAC users guide ([U.S. EPA,  
156 2019a](#)).

157

### 158 *Releases*

159 The emission rates for dry-cleaning operations were generated using EPA’s dry-cleaning model  
160 (sections 2.3.1.16 and 4.3.1.6 of the *Risk Evaluation for 1-Bromopropane*). The data set contains nine  
161 emission scenarios, representing a variety of operational scales and conditions. The co-resident  
162 screening methodology for this work considered both dry-cleaning and spot cleaning operations, as  
163 applicable for the chemical undergoing risk evaluation.



164

165 **Exposure Scenarios**

166 IECCU was used to predict the concentrations in the co-resident space, as illustrated in Figure 2-9. The  
 167 model assumes the dry-cleaning shop and the co-resident space are two air zones, the air is well mixed  
 168 within each zone, and the contaminated indoor air in the dry-cleaning facility can be transported to the  
 169 co-resident space by the interzonal air flow  $Q_{12}$ .

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201


202

203

204

205

206



200 **Figure 2-9. Schematic Representation of the Two-Zone Model for Co-resident Exposure**

202 The mass balance equations for the chemical of concern are given by Equations 1 and 2.

$$203 \quad V_1 \frac{dC_1}{dt} = R(t) + Q_{01} C_0 - Q_{10} C_1 - Q_{12} C_1 + Q_{21} C_2 \quad (1)$$

$$204 \quad V_2 \frac{dC_2}{dt} = Q_{02} C_0 - Q_{20} C_2 + Q_{12} C_1 - Q_{21} C_2 \quad (2)$$

205 Where:

206  $V_1$  and  $V_2$  are volumes of zone 1 and zone 2 ( $m^3$ ),

207  $C_1$  and  $C_2$  are the concentrations of the chemical of concern in zone 1 and zone 2 ( $\mu\text{g}/\text{m}^3$ ),  
 208  $t$  is the elapsed time (h),  
 209  $R(t)$  is the time-varying emission rate ( $\mu\text{g}/\text{h}$ ),  
 210  $C_0$  is the concentration of the chemical being evaluated in ambient air ( $\mu\text{g}/\text{m}^3$ ), and  
 211  $Q_{ij}$  is the air flow rate from zone  $i$  to zone  $j$ .

212  
 213 In this model, the interzonal air flow  $Q_{12}$  is considered a major contaminant transport route and, thus,  
 214 assume  $C_0 = 0$ . Given a set of initial conditions (typically  $C_1 = 0$  and  $C_2 = 0$  at  $t = 0$ ), Equations 1 and 2  
 215 can be solved numerically to give chemical concentrations in the two zones ( $C_1$  and  $C_2$ ) as a function of  
 216 time.

217  
 218 This model requires six input parameters, listed below. IECCU does not provide default values for input  
 219 parameters at this time, therefore, model inputs are derived from empirical data or modeled estimates.

- 220 • Zone volumes,  $V_1$  and  $V_2$
- 221 • Ventilation air flow rates,  $Q_{10}$  and  $Q_{20}$
- 222 • Chemical emission rate,  $R(t)$
- 223 • Interzonal air flows,  $Q_{12}/Q_{21}$

224  
 225 The zone volume and ventilation rate ( $N_1$  and  $N_2$ ) for the dry-cleaning facility are those utilized in the  
 226 dry-cleaning model. The zone volume and ventilation rate for the co-resident apartment are based on  
 227 values from EPA’s Exposure Factors Handbook ([U.S. EPA, 2011a](#)). The ventilation air flow rate is the  
 228 product of the zone volume and ventilation rate of the respective zone (e.g.,  $Q_{10} = V_1 \times N_1$ ).

229  
 230 Chemical emission rates are from the results of the dry-cleaning model runs. Emission rates were  
 231 provided as 10-minute averages and converted to 1-hour averages for use as an input for IECCU.

232  
 233 The interzonal air flow ( $Q_{12}$ ) plays a key role in determining the rate of contaminant transfer from the  
 234 dry-cleaning shop to the co-resident space. To estimate this parameter, the co-resident exposure  
 235 scenarios considered two building configurations (B1 and B2) and four methods to estimate the  
 236 interzonal flow rate as described in Table 2-5.

237  
 238 **Table 2-5. Summary of Two Building Configurations and Methods to Estimate Interzonal Flow**  
 239 **Rate**

Building Configuration	Description of Configuration	Method for Estimating Interzonal Flow Rate	Description of Method
B1	The two zones are architecturally separated as two building units. Such co-resident spaces can be commonly found in mixed-use buildings where the dry-cleaning shop is located on the first floor and the co-resident apartment is above the shop on the second floor. Air convection can occur between the two zones through the cracks and crevices along the	Method 1	Uses a literature value in which the $Q_{12}$ was calibrated against field monitoring data for perchloroethylene from dry-cleaning shops based on a study from McDermott et al. ( <a href="#">McDermott et al., 2005</a> ).
		Method 2	Estimates $Q_{12}$ based on the stack effect. ( <a href="#">Khoukhi and Al-Maqbali, 2011</a> ) In general, this concept assumes when the air in the dry-

Building Configuration	Description of Configuration	Method for Estimating Interzonal Flow Rate	Description of Method
	wall joints due to the pressure difference.		cleaning shop is warmer than in the second-floor apartment, the rising air draft serves as a driving force for air flow $Q_{12}$ . For purposes of the co-resident effort, EPA assumes a 2° C temperature difference between the dry-cleaning shop and co-resident apartment, although this is a rough estimate due to the potential influence of ambient temperature in different locations across the country.
B2	The two zones are architecturally interconnected. This is a more uncommon case, where the owner uses part of a building unit ( <i>e.g.</i> , the first floor of a two-story condominium) as a small dry-cleaning shop and the rest space ( <i>e.g.</i> , second floor) as living quarters. In such cases, the opening along the stairways allows the air to move between the two zones.	Method 3	Calculates the $Q_{12}$ based on a recommended interzonal air exchange rate of 0.7 hr <sup>-1</sup> from a study by Jayjock and Havics ( <a href="#">Jayjock and Havics, 2018</a> ).
		Method 4	Assumes the two zones share the same HVAC system and calculates the $Q_{12}$ based on an assumed residential HVAC system recirculation rate of 5 per hour or hr <sup>-1</sup> .

240

241

### Exposure Results and Risks

242

Modeled exposure concentration results from the co-resident screening effort were reviewed and summarized for each scenario modeled. EPA used the unadjusted 24-hour TWA and adjusted annual

243

TWA exposure concentrations for risk calculations to estimate the MOE and excess cancer risk for

244

comparison to the equivalent human health endpoints and benchmark values within the respective

245

published final risk evaluations. The calculated risks were then compared to the benchmark values for

246

the respective chemical of interest to determine if there was an indication of potential added risk for

247

either or both acute and chronic non-cancer effects (calculated MOE below the benchmark MOE for the

248

specific chemical) or if there was an indication of potential excess risk for cancer (calculated values

249

greater than the benchmark of  $1 \times 10^6$  for fence-line communities).

250

251

252

Chemical specific details and associated exposure results of the co-resident effort are provided in

253

Section 3.1.4. Risk calculations and associated risk findings are provided in Section 3.1.5.2.


254

255

256  
257  
258  
259  
260  
261  
262  
263  
264

## 2.2 Ambient Water Pathway

Figure 2-10 provides an overview of EPA’s screening level methodology for the ambient water pathway. EPA modeled water releases from facilities and POTWs in its final risk evaluations to estimate waterbody concentrations for environmental exposure assessment. As part of this screening level ambient water analysis, EPA used the same release scenarios along with results of previous E-FAST modeling runs to estimate drinking water and incidental oral/dermal exposures to fence-line communities to the receiving water body. Explication of what constitutes these fence-line communities is given in the EXECUTIVE SUMMARY and INTRODUCTION.




265  
266

Figure 2-10. Overview of EPA’s Screening Level Ambient Water Pathway Methodology

267  
268  
269  
270  
271

### 2.2.1 Environmental Water Releases

This section describes the general methodology (Figure 2-11) that was used to develop estimates of water releases from facilities as part of EPA’s screening level ambient water pathway methodology. The results of applying this methodology to NMP and MC are presented in Section 3 (Case Study Results).



272  
273  
274  
275

Figure 2-11. General Methodology for Estimating Water Releases

276

### **2.2.1.1 Step 1: Obtain TRI and DMR Data**

---

277 The first step in the methodology for estimating water releases was to obtain TRI data for the chemical  
278 from EPA’s [Basic Plus Data Files \(U.S. EPA, 2021\)](#) and DMR data from EPA’s [Water Pollutant](#)  
279 [Loading Tool](#) within EPA’s Enforcement and Compliance History Online (ECHO) ([U.S. EPA, 2016a](#)) to  
280 query all point source water discharges for the chemical of interest. Where water releases were assessed  
281 in the final risk evaluation report, EPA used the same TRI and DMR data as used in the risk evaluation  
282 report. TRI data included both Form R and Form A submissions in the fenceline analysis. Facilities may  
283 submit a Form A instead of a Form R if the amount of chemical manufactured, processed, or otherwise  
284 used do not exceed 1,000,000 lb/year and the total annual reportable releases do not exceed 500 lb/year.  
285 Facilities do not need to report release quantities or uses/sub-uses on Form A. For Form A submissions,  
286 the methodology to estimate emissions differs slightly from what is described below. Specifically, in  
287 Step 2, EPA does not have use/sub-use information for Form A submissions, so instead relies on North  
288 American Industry Classification System (NAICS) codes and facility information from internet searches  
289 to map these facilities to an OES. For DMR data, the only use information reported is the facility’s  
290 Standard Industrial Classification (SIC) code. Therefore, EPA relied solely on these codes to map DMR  
291 facilities to an OES. These differences are highlighted in the sections below.

292

### **2.2.1.2 Step 2: Map TRI and DMR to Occupational Exposure Scenarios**

---

293 In the next step of fenceline analysis development, EPA mapped the chemical’s TRI and DMR data to  
294 the OES that were in the published risk evaluation for the chemical. Where water releases were assessed  
295 in the risk evaluation, the OES mapping did not change. During risk evaluation, EPA used the following  
296 procedure to map TRI and DMR data to OES:

- 297 1. [Review TRI uses and NAICS code](#): EPA reviewed TRI uses (note: sub-use data not available in  
298 TRI until 2018) and NAICS codes for each facility and assigned an OES based on this  
299 information
- 300 2. [Form A’s](#): For Form A submissions, there were no reported TRI uses. To determine the OES for  
301 these facilities, EPA used the NAICS codes, market data, public comments, industry meetings  
302 and internet searches to determine the type of products and operations at the facility.
- 303 3. [DMR](#): For DMR data, there are no reported use information. To determine the OES for these  
304 facilities, EPA first cross walked the facilities to TRI facilities and applied the same OES as TRI  
305 if the facility reported in both. If the facility did not report in TRI, EPA used the SIC codes,  
306 market data, public comments, industry meetings and internet searches to make a reasonable  
307 determination regarding the type of products and operations at the facility.

308 If water releases were not assessed in the final risk evaluation, EPA followed the same methodology as  
309 described for air releases in Section 2.1.1.2 but with the added step of mapping DMR data as described  
310 in Step #3 above.

311

### **2.2.1.3 Step 3: Estimate Number of Release Days for Each OES**

---

312 TRI and DMR water release data are provided on an annual basis, in pounds of chemical released per  
313 year. However, for the exposure modeling described in Section 2.2.2, releases are needed on a daily  
314 basis. To estimate daily releases, EPA needs the number of release days for each facility. Because  
315 number of release days is not reported in TRI or DMR, EPA used general guidance to estimate the  
316 number of operating days for each OES. In general, the number of operating days in the published risk  
317 evaluations for the first round of chemicals were based on the same logic as described in Section 2.1.1.3  
318 for air emissions. This approach assumes the number of release days for a facility is equal to the  
319 estimated number of operating days for its assigned OES.

#### 320 **2.2.1.4 Step 4: Estimate Water Releases for OES with No TRI or DMR Data**

321 TRI and DMR data were not available for every OES. In such cases, the risk evaluations assessed  
 322 releases using data from literature, relevant Emission Scenario Documents (ESDs) or Generic Scenarios  
 323 (GSs), existing EPA models (*e.g.*, EPA Water Saturation Loss Model), and/or relevant Effluent  
 324 Limitation Guidelines (ELG). ELG are national regulatory standards set forth by EPA for wastewater  
 325 discharges to surface water and municipal sewage treatment plants. In some cases, there were  
 326 insufficient information to estimate water releases from an OES. For these instances, EPA did a  
 327 qualitative assessment.


#### 328 **2.2.1.5 Step 5: Prepare Water Release Summary for Ambient Water Exposure** 329 **Modeling**

330 The final step was to prepare a summary of the water releases. Water releases assessed in the risk  
 331 evaluations were summarized and used in the fence line analysis.

### 332 **2.2.2 Ambient Water Concentrations and Exposures**

333 This section describes the methodologies utilized to assess exposures for members of the fence line  
 334 communities to waterbodies receiving MC or NMP discharges. These exposures were evaluated by first  
 335 reviewing available monitored drinking water information for both MC and NMP, and then by using  
 336 modeling to estimate drinking water exposure and incidental oral and dermal exposures from swimming  
 337 (see Figure 2-12). Ambient surface water data was evaluated for both MC and NMP as part of their  
 338 original REs ([U.S. EPA, 2020c](#); [U.S. EPA, 2020d](#)) with no ambient surface water information found for  
 339 NMP and data for MC described in Section 3.2.4.2.1.

340



341

342 **Figure 2-12. General Methodology for Estimating Ambient Water Exposures**

#### 343 **2.2.2.1 Step 1: Obtain Measured Drinking Water Concentrations**

344 Where possible, reasonably available data for monitored drinking water concentrations for both MC and  
 345 NMP were evaluated. No monitoring data for NMP were found, but MC data were found via EPA's six-  
 346 year review process of drinking water standards as required under the Safe Drinking Water Act  
 347 (SDWA). As part of this process, EPA analyzes compliance monitoring data from public water supplies  
 348 for regulated drinking water contaminants. A full description and purpose of the six-year review process  
 349 can be found at the [Six-Year Review of Drinking Water Standards](#).

350

351 Methylene chloride was evaluated under this program during the third six-year review cycle covering  
 352 January 2006 through December 2011. During this time period, public water systems (PWSs)  
 353 compliance monitoring data were provided by states and primacy agencies to EPA via their voluntary  
 354 Information Collection Request (ICR). This dataset is referred to as the National Compliance

355 Monitoring ICR Dataset for the third six-year review (or “SYR3 ICR Dataset”). The SYR3 data and  
356 User Guide for Downloading the data can be found at [Six-Year Review 3 Compliance Monitoring Data](#)  
357 [\(2006-2011\) | US EPA](#).  
358

359 Data for MC was obtained to characterize potential exposures found in drinking water. The SYR3 data  
360 for MC was located under the Organic and Inorganic Chemicals category Phase 3 chemical set and  
361 downloaded as a zip file on September 8, 2021. The zip file (SYR3\_PhaseChem\_3.zip) contained a tab  
362 delimited text file specific for MC. The text file was imported into Microsoft Excel using the procedure  
363 outlined in the User Guide. Once in the spreadsheet, the dataset was filtered to identify non-detect (ND)  
364 samples and their reported detection limits. For all ND samples, one-half the reported detection limit  
365 was used for summary calculation purposes. If a detection limit was not provided, calculations were  
366 performed using one-half the average of the reported detection limits in all samples (calculated as 0.28  
367 µg/L). Reported detection limits without units were assumed to be µg/L. When applying the one-half  
368 detection limits or one-half the average detection limits as needed, this can create a range, average, and  
369 standard deviation based only on detection limit data rather than sampled data when detected sample  
370 concentrations fall inside the range of one-half detection limits. Similar discrepancies may appear in the  
371 data when considering the concentrations in all samples against the concentrations only in the samples  
372 above the detection limit. As an example, when considering the 2011 ground water data set, there were  
373 52,124 samples total and of those samples there were 207 samples with detected values which were used  
374 for the statistical analysis. For these samples, the detection limits were between 0.5 to 2 µg/L with  
375 detected concentrations ranged from 0.1 to 88 µg/L. For the non-detect samples, the detection limits  
376 were between  $5.0 \times 10^{-4}$  to 1,000 µg/L. Since samples that did not have a detection were provided with  
377 a value of one-half of its detection limit, the values applied to these samples for the purpose of the  
378 statistical analysis ranged between  $2.5 \times 10^{-4}$  to 500 µg/L.

#### 379 **2.2.2.2 Step 2: Model Surface Water Concentrations from Facility Releases**

380 Exposure via drinking water, incidental oral ingestion and incidental dermal contact were evaluated  
381 based off modeled stream and water body concentrations using E-FAST 2014 ([U.S. EPA, 2014](#)) as  
382 described and documented in the risk evaluations for both chemicals (MC and NMP, ([U.S. EPA, 2020c;](#)  
383 [2020d](#))). These E-FAST 2014 outputs were based on model runs for the release activities identified for  
384 the chemical(s) of interest and acted as the input surface water concentrations. No additional modeling  
385 using E-FAST 2014 for instream surface water concentrations was conducted For complete description  
386 on the approach and methodology behind initial surface water modeling and results of those efforts, see  
387 the MC and NMP risk evaluations ([U.S. EPA, 2020c; 2020d](#)).  
388

389 Data for both MC and NMP from the previous E-FAST 2014 model results were extracted and  
390 organized using the following data elements:

- 391 • Release activity names
- 392 • Chemical IDs
- 393 • Facility names and locations
- 394 • NPDES and SIC codes
- 395 • Occupational exposure scenarios (OES)
- 396 • Total release amounts
- 397 • Per site release amounts
- 398 • Release days per year
- 399 • Harmonic mean flows and concentrations
- 400 • 30Q5 flows and concentrations
- 401 • Concentrations in still water or large water bodies (such as lakes, bays, or oceans)

- 402 • Drinking water exposure metrics such as lifetime average daily dose (LADD), lifetime average  
403 daily concentration (LADC), and acute dose rate (ADR)

404 **2.2.2.3 Step 3: Estimate Drinking Water Exposure**

405 Once the above information was extracted and compiled into tables, the E-FAST 2014 drinking water  
406 exposure calculations were recreated in Excel to verify the inputs and equations used. This validation  
407 was done for the adult age group (21+) only, as that is the only age group assessed in E-FAST 2014.  
408 After validating that the E-FAST 2014 calculations for LADD, LADC, and ADR could be replicated  
409 using equations in Excel, the chemical spreadsheets were expanded to include additional age groups and  
410 possible inputs. Calculations were also added for chronic average daily dose (ADD) using the same  
411 equation as that for LADD in E-FAST 2014 but modified with inputs to represent a chronic scenario for  
412 a specified time frame rather than for the lifetime. The equations utilized for drinking water exposure  
413 calculations are

415 
$$ADR_{POT} = \frac{SWC \times \left(1 - \frac{DWT}{100}\right) \times IR_{dw} \times RD \times CF1}{BW \times AT}$$

417 
$$ADD_{POT} = \frac{SWC \times \left(1 - \frac{DWT}{100}\right) \times IR_{dw} \times ED \times RD \times CF1}{BW \times AT \times CF2}$$

419 
$$LADD_{POT} = \frac{SWC \times \left(1 - \frac{DWT}{100}\right) \times IR_{dw} \times ED \times RD \times CF1}{BW \times AT \times CF2}$$

421 
$$LADC_{POT} = \frac{SWC \times \left(1 - \frac{DWT}{100}\right) \times ED \times RD \times CF1}{AT \times CF2}$$

422 Where:

423 SWC = Surface water concentration (ppb or µg/L)

424 DWT = Removal during drinking water treatment (%)

425 IR<sub>dw</sub> = Drinking water intake rate (L/day)

426 RD = Release days (days/year for ADD, LADD and LADC; 1 day for ADR)

427 ED = Exposure duration (years for ADD, LADD and LADC; 1 day for ADR)

428 BW = Body weight (kg)

429 AT = Exposure duration (years for ADD, LADD and LADC; 1 day for ADR)

430 CF1 = Conversion factor (1.0×10<sup>-03</sup> mg/µg)

431 CF2 = Conversion factor (365 days/year)

432

433 For drinking water estimates, concentrations in estuaries or bays are not considered as they are unlikely  
434 to be potable waters. Drinking water exposures are also not considered for large lakes due to high  
435 uncertainty in the applicable dilution factors. This is in alignment with the methodology used in E-FAST  
436 2014 ([U.S. EPA, 2014](#)). ADR or acute exposure concentrations used the modeled 30Q5 stream  
437 concentrations while the ADD, LADD, and LADC or chronic calculations used the modeled harmonic  
438 mean stream concentrations. Drinking water treatment removal (DWT) was set to 0% to represent a  
439 conservative estimate of possible drinking water exposures.  
440  
441



442 Inputs for body weight, averaging time (AT), and exposure duration were applied the same across the  
443 evaluation of drinking water, incidental oral exposure, and incidental dermal exposure, but are described  
444 here. For all calculations, mean body weight data were used from Chapter 8, Table 8-1 in the U.S.  
445 *Exposure Factors Handbook* (EFH) ([U.S. EPA, 2011a](#)). To align with the age groups of interest, weight  
446 averages were calculated for the infant age group (birth to <1 year) and toddlers (1 to 5 years). The  
447 ranges given in the EFH were weighted by their fraction of the age group of interest. For example, the  
448 EFH provides body weight for 0 to 1 month, 1 to 3 months, 3 to 6 months, and 6 to 12 months. Each of  
449 those body weights were weighted by their number of months out of 12 to determine the weighted  
450 average for an infant 0 to 1 year old. For all ADR calculations, the AT is 1 day, and the days of release  
451 are assumed to be 1 according to the methodology used in E-FAST 2014 ([U.S. EPA, 2014](#)). For all ADD  
452 calculations, the AT and the ED are both equal to the number of years in the relevant age group up to the  
453 95th percentile of the expected duration at a single residence, 33 years ([U.S. EPA, 2011a](#)). For example,  
454 estimates for a child between 6 and 10 years old would be based on an AT and ED of 5 years. For all  
455 LADD and LADC calculations, the AT is the lifetime of 78 years, and the ED is the number of years in  
456 the relevant age group, up to 33 years.

457  
458 Drinking water exposure was estimated for the following age groups: Adult (21+ years), Youth (16-20  
459 years), Youth (10 to 15 years), Child (6 to 10 years), Toddler (1 to 5 years), and infant (birth to <1 year).  
460 For NMP, exposure was also estimated for pregnant females as a susceptible population. Drinking water  
461 intake rates are provided in the 2019 update of Chapter 3 of the EFH ([U.S. EPA, 2019e](#)). Weighted  
462 averages were calculated for acute and chronic drinking water intakes for adults 21+ and toddlers 1 to 5  
463 years. From Table 3-17, 95th percentile consumer data were used for acute drinking water intake rates.  
464 From Table 3-9, mean per capita data were used for chronic drinking water intake rates. The intake rates  
465 from Table 3-3 were used for pregnant females in NMP exposure estimates.

466  
467 Supplemental Files *SF\_FLA\_Water Pathway Exposure Data for MC* and *SF\_FLA\_Water Pathway*  
468 *Exposure Data for NMP* (Appendix B) provide additional details on inputs and assumptions for MC and  
469 NMP respectively as well as complete results for each chemical as described Section 3.2.4.2.3 (MC) and  
470 Section 3.3.4.1 (NMP).

#### 471 **2.2.2.4 Step 4: Estimate Incidental Oral Exposures from Swimming**

472 Estimated surface water concentrations from the initial risk evaluations of MC ([U.S. EPA, 2020c](#)) and  
473 NMP ([U.S. EPA, 2020d](#)) were used to estimate acute and chronic incidental oral exposure from  
474 swimming following methodologies originally published in the 1,4-dioxane RE ([U.S. EPA, 2020e](#))  
475 and NMP RE ([U.S. EPA, 2020d](#)). Those methodologies presented in the previous risk evaluations have  
476 been updated here to include more updated input parameters (*e.g.*, incidental ingestion rates) and  
477 consistency amongst evaluated age groups. This screening-level analysis focuses on health endpoints  
478 relevant to the most sensitive human population for each evaluated chemical, but also provides the adult  
479 population (if different from most sensitive) as a point of comparison across chemicals. For MC, the  
480 most sensitive health endpoint is youths aged 11 to 15 years due to greatest exposure when considering  
481 age-specific ingestion rate, body weight and duration of exposure. For NMP, the most sensitive groups  
482 are pregnant women (due to pregnancy-specific hazards) and youths aged 11 to 15 years (due to greater  
483 exposure).

484  
485 The equations used to estimate the acute daily dose rate (ADR) and average daily dose (ADD) for  
486 incidental oral ingestion are shown below ([U.S. EPA, 2014](#)):

$$487 \text{ADR} = \frac{SWC * IR * CF1}{BW}$$

489

490

491

$$ADD = \frac{SWC * IR * ED * RD * CF1}{BW * AT * CF2}$$

492

493 Where:

494 SWC = Surface water concentration (ppb or µg/L)

495 IR = Daily ingestion rate (L/day)

496 RD = Release days (days/yr)

497 ED = Exposure duration (years)

498 BW = Body weight (kg)

499 AT = Averaging time (years)

500 CF1 = Conversion factor (0.001 mg/µg)

501 CF2 = Conversion factor (365 days/year)

502

503 All receiving water bodies were considered for evaluation of incidental oral ingestion using modeled  
 504 30Q5 and harmonic surface water concentrations. Predicted 30Q5 surface water concentrations are used  
 505 in the calculation of ADRs and ranged from  $2.82 \times 10^{-07}$  to 61.9 µg/L for MC and  $4.52 \times 10^{-04}$  to 812 µg/L  
 506 for NMP, while predicted harmonic mean surface water concentrations used in the calculation of ADDs  
 507 ranged from  $1.26 \times 10^{-07}$  to 14.3 µg/L for MC and  $3.01 \times 10^{-04}$  to 812 µg/L for NMP (*SF\_FLA\_Water*  
 508 *Pathway Exposure Data for MC* and *SF\_FLA\_Water Pathway Exposure Data for NMP*; Appendix B).  
 509 Key inputs/exposure factors used to estimate these oral exposures are included in Table 2-6.

510

511 Supplemental Files *SF\_FLA\_Water Pathway Exposure Data for MC* and *SF\_FLA\_Water Pathway*  
 512 *Exposure Data for NMP* (Appendix B) provide additional details on inputs and assumptions for MC and  
 513 NMP respectively as well as complete results for each chemical as described Section 3.2.4.2.4 (MC) and  
 514 Section 3.3.4.2 (NMP).

515

516 **Table 2-6. Incidental Oral Exposure Factors for MC and NMP**

Input	Description (units)	Age Group			Notes
		Adult (21+ years)	Youth (11–15 years)	Pregnant Female (NMP only)	
IR <sub>inc</sub>	Incidental ingestion rate (L/hr)	0.092	0.152	0.092	Upper percentile hourly ingestion rate for respective age groups from <i>Exposure Factors Handbook</i> , Table 3-7 ( <a href="#">U.S. EPA, 2019e</a> )
BW	Body weight (kg)	80	56.8	65.9	Recommended mean body weight for each population from the <i>Exposure Factors Handbook</i> , Table 8-1 ( <a href="#">U.S. EPA, 2011a</a> ). Values for NMP for pregnant woman age class are taken from the young women/ female adolescent age class (aged 16–21 years)

Input	Description (units)	Age Group			Notes
		Adult (21+ years)	Youth (11–15 years)	Pregnant Female (NMP only)	
ET	Exposure time (hr/day)	3	2	3	High-end default short-term duration from EPA Swimmer Exposure Assessment Model ( <a href="#">SWIMODEL</a> ); based on competitive swimmers in the respective age class ( <a href="#">U.S. EPA, 2015</a> )
IR <sub>inc-daily</sub>	Incidental daily ingestion rate (L/day)	0.276	0.304	0.276	Ingestion rate × exposure time
IR/BW	Weighted incidental daily ingestion rate (L/kg-day)	0.0035	0.0054	0.0042	
ED	Exposure duration (year for ADD)	33	5	33	
AT	Averaging time (years for ADD)	33	5	33	
CF1	Conversion factor (mg/μg)	1.00E-03	1.00E-03	1.00E-03	
CF2	Conversion factor (days/yr)	365	365	365	

517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527

### 2.2.2.5 Step 5: Estimate Incidental Dermal Exposure from Swimming

All receiving water bodies were considered for evaluation of incidental dermal contact using modeled 30Q5 and harmonic surface water concentrations. Predicted 30Q5 surface water concentrations are used in the calculation of ADRs and ranged from  $2.82 \times 10^{-07}$  to  $61.9 \mu\text{g/L}$  for MC and  $4.52 \times 10^{-04}$  to  $812 \mu\text{g/L}$  for NMP, while predicted harmonic mean surface water concentrations used in the calculation of ADDs ranged from  $1.26 \times 10^{-07}$  to  $14.3 \mu\text{g/L}$  for MC and  $3.01 \times 10^{-04}$  to  $812 \mu\text{g/L}$  for NMP (*SF\_FLA\_Water Pathway Exposure Data for MC* and *SF\_FLA\_Water Pathway Exposure Data for NMP*; Appendix B). This screening-level analysis focused on the adult (MC) and pregnant female (NMP) age classes, as they represent the worst-case exposure conditions when considering the age-specific surface area to body weight ratio and duration of exposure (Table 2-7).

528 The equations used to estimate the acute daily dose rate (ADR) and average daily dose (ADD) for  
529 incidental dermal exposure are shown below ([U.S. EPA, 2015](#)):

530  
531 
$$ADR = \frac{SWC * Kp * SA * ET * CF1 * CF2}{BW}$$

532  
533  
534 
$$ADD = \frac{SWC * Kp * SA * ET * RD * ED * CF1 * CF2}{BW * AT * CF3}$$

535  
536 Where:

- 537 ADR = Acute Dose Rate (mg/kg/day)  
538 ADD = Average Daily Dose (mg/kg/day)  
539 SWC = Chemical concentration in water (µg/L)  
540 Kp = Permeability coefficient (cm/hr)  
541 SA = Skin surface area exposed (cm<sup>2</sup>)  
542 ET = Exposure time (hr/day)  
543 RD = Release days (days/yr)  
544 ED = Exposure duration (years)  
545 BW = Body weight (kg)  
546 AT = Averaging time (years)  
547 CF1 = Conversion factor (1.0×10<sup>-03</sup> mg/µg)  
548 CF2 = Conversion factor (1.0×10<sup>-03</sup> L/cm<sup>3</sup>)  
549 CF3 = Conversion factor (365 days/year)

550  
551 Key inputs/exposure factors used to estimate these dermal exposures are included in Table 2-7.

552  
553 Supplemental Files *SF\_FLA\_Water Pathway Exposure Data for MC* and *SF\_FLA\_Water Pathway*  
554 *Exposure Data for NMP* (Appendix B) provide additional details on inputs and assumptions for MC and  
555 NMP respectively as well as complete results for each chemical as described Section 3.2.4.2.5 (MC) and  
556 Section 3.3.4.3 (NMP).  
557

558 **Table 2-7. Incidental Dermal Exposure Factors for MC and NMP**

Input	Description (units)	MC Adult (≥21 years)	NMP (Pregnant Female)	Notes
BW	Body weight (kg)	80	65.9	Recommended mean body weight for each population from the <i>Exposure Factors Handbook</i> , Table 8-1 ( <a href="#">U.S. EPA, 2011a</a> ). Values for NMP for pregnant woman age class are taken from the young women/ female adolescent age class (aged 16 – 21 years)
SA	Skin surface area exposed (cm <sup>2</sup> )	19,500	18,500	MC: Default dermal contact surface area for the adult age class in <a href="#">SWIMODEL</a> ( <a href="#">U.S. EPA, 2015</a> ) NMP: Mean total surface area of adult females from the <i>Exposure Factors Handbook</i> , Table 7-13 ( <a href="#">U.S. EPA, 2011a</a> )
ET	Exposure time (hours/day)	3	3	High-end default short-term duration from EPA Swimmer Exposure Assessment Model ( <a href="#">SWIMODEL</a> ); based on competitive swimmers in the respective age class ( <a href="#">U.S. EPA, 2015</a> )
Kp	Permeability coefficient (cm/hr)	7.17E-03	4.78E-04	MC: Estimated from Consumer Exposure Model ( <a href="#">U.S. EPA, 2017</a> ) NMP: Recalibrated from data in <a href="#">Poet et al. (2010)</a>
ED	Exposure duration (years for ADD)	33	33	Number of years in age group, up to the 95th percentile residential occupancy period. U.S. EPA <i>Exposure Factors Handbook</i> , Chapter 16, Table 16-5 ( <a href="#">U.S. EPA, 2011a</a> )
AT	Averaging time (years for ADD)	33	33	Number of years in age group, up to the 95th percentile residential occupancy period. U.S. EPA <i>Exposure Factors Handbook</i> , Chapter 16, Table 16-5 ( <a href="#">U.S. EPA, 2011a</a> )
CF1	Conversion factor (mg/μg)	1.00E-03	1.00E-03	
CF2	Conversion factor (L/cm <sup>3</sup> )	1.00E-03	1.00E-03	
CF3	Conversion factor (days/year)	365	365	

559 **2.3 Risk Estimation Approach**

560 To calculate risks from fence-line exposures through air and water, EPA used the same methods used in  
561 previously published risk evaluations.

562 **2.3.1 Characterization of Non-cancer Risks**

563 EPA used a Margin of Exposure (MOE) approach to identify potential non-cancer risks. The MOE is the  
564 ratio of the non-cancer POD divided by a human exposure dose. Acute and chronic MOEs for non-  
565 cancer inhalation and dermal risk were calculated using the following equation:  
566

$$567 \text{MOE}_{\text{acute or chronic}} = \frac{\text{Non – cancer Hazard value (POD)}}{\text{Human Exposure}}$$

568

569 Where:  
 570 MOE = Margin of exposure (unitless)  
 571 Hazard value (POD)= HEC (ppm) or HED (mg/kg-d)  
 572 Human Exposure = Exposure estimate (in ppm or mg/kg-d)

573

574 MOEs allow for the presentation of a range of risk estimates. EPA interpreted the MOE risk estimates  
 575 for each use scenario in reference to benchmark MOEs. Benchmark MOEs are the total UF for each  
 576 non-cancer POD. The MOE estimate was interpreted as a human health risk if the MOE estimate was  
 577 less than the benchmark MOE (*i.e.*, the total UF). On the other hand, the MOE estimate indicated  
 578 negligible concerns for adverse human health effects if the MOE estimate was equal to or exceeded the  
 579 benchmark MOE. Typically, the larger MOE, the more unlikely it is that a non-cancer adverse effect  
 580 would occur.

### 581 **2.3.2 Characterization of Cancer Risks**

582 Extra cancer risks for repeated exposures to a chemical were estimated using the following equations:

583

584 
$$\text{Inhalation Cancer Risk} = \text{Human Exposure} \times \text{IUR}$$

585 or

586 
$$\text{Dermal/Oral Cancer Risk} = \text{Human Exposure} \times \text{CSF}$$

587

588 Where:

589 Risk = Extra cancer risk (unitless)

590 Human exposure = Exposure estimate (LADC in ppm)

591 IUR = Inhalation unit risk ( $1 \times 10^{-6}$  per ppm)

592 CSF = Cancer slope factor ( $1.2 \times 10^{-1}$  per mg/kg-d)

593

594 Estimates of extra cancer risks are interpreted as the incremental probability of an individual developing  
 595 cancer over a lifetime following exposure (*i.e.*, incremental or extra individual lifetime cancer risk).  
 596 EPA used  $1 \times 10^{-6}$  as the benchmark for cancer risk in fence-line communities. This is consistent with the  
 597 cancer benchmark used for general population cancer risk in several other EPA programs and in  
 598 previous risk evaluations. It is important to note that exposure related considerations (duration,  
 599 magnitude, specific population exposed) can affect EPA's estimates of the excess lifetime cancer risk  
 600 (ELCR).

601

602 In order to address increased exposure and sensitivity of younger lifestages, total lifetime cancer risk  
 603 across lifestages was calculated by integrating partial risk for each lifestage based on differential  
 604 exposure. For chemicals with a mutagenic mode of action, EPA applied age-dependent adjustment  
 605 factors (ADAFs) using methods consistent with EPA's supplemental guidance for assessing  
 606 susceptibility for early-life exposure to carcinogens, ([U.S. EPA, 2005](#)). Specifically, for chemical with a  
 607 mutagenic mode of action, EPA applied a 10-fold adjustment for exposure before 2 years of age, a 3-  
 608 fold adjustment for exposures between 2 and <16 years of age and no additional adjustment for  
 609 exposures at 16 years of age and above.

## 610 **2.4 Key Assumptions and Uncertainties**

### 611 **2.4.1 Assumptions and Uncertainties in Release Estimation**

612 EPA estimated releases using reported data from TRI and DMR. TRI and DMR data were determined to  
 613 have a "medium" confidence rating through EPA's systematic review process. However, when using  
 614 TRI data to analyze chemical releases, it is important to acknowledge that TRI reporting does not

615 include all releases of the chemical and therefore, the number of sites for a given OES may be  
616 underestimated. Due to limiting the scope of this screening-level analysis to facilities that report releases  
617 to TRI and DMR, it is uncertain, the extent to which, sites not captured in these databases have air  
618 emissions or water releases of a chemical and whether any air emissions would be stack or fugitive and  
619 whether water releases would be to surface water, POTW, or non-POTW WWT. TRI data do not  
620 include

- 621 • Releases from any facility that used the chemical in quantities below the applicable annual  
622 chemical activity threshold (*e.g.*, 25,000 lb manufactured or processed, or 10,000 lb otherwise  
623 used, for most chemicals);
- 624 • Releases from any facility that is not in a TRI covered sector; and
- 625 • Releases from any facility that does not meet the TRI employment threshold of greater than 10  
626 full-time employee equivalents (20,000 labor hours) for the year.

627  
628 EPCRA section 313 states that facilities may estimate their release quantities using “readily available  
629 data,” including monitoring data, collected for other purposes. When data are not readily available,  
630 EPCRA section 313 states that “reasonable estimates” may be used. The facility is not required to  
631 monitor or measure the quantities, concentration, or frequency of any toxic chemical release for TRI  
632 reporting. TRI guidance states that not using readily available information, such as relevant monitoring  
633 data collected for compliance with other regulations, could result in enforcement and penalties.

634  
635 For each release quantity reported, TRI facilities select a “Basis of estimate” code indicating the  
636 principal method used to determine the amount of the release. TRI provides six basis of estimate codes  
637 to choose from: continuous monitoring, periodic monitoring, mass balance, published emissions factors,  
638 site-specific emissions factors, or engineering calculations/best engineering judgment. In facilities where  
639 a chemical is used in multiple operations, the facility may use a combination of methods to calculate the  
640 release reported. In such cases, TRI instructs the facility to enter the basis of estimate code of the  
641 method that applies to the largest portion of the release quantity. Additional details on the basis of  
642 estimate, such as any calculations and underlying assumptions, are not reported.

643  
644 For any release quantity that is less than 1,000 lb, facilities may report either the estimated quantity or a  
645 range code. The 1,000-pound limit for range code reporting applies to each type of release reported to  
646 TRI - fugitive air emissions, stack air emissions, water discharges, each type of land disposal, and each  
647 type of off-site transfer. There are three TRI range codes: 1–10; 11–499; and 500–999 lb. TRI data tools  
648 display the approximate midpoint of the range (*i.e.*, 5, 250, or 750 lb). Although analyses using data that  
649 was reported as a range code may add uncertainty, it is not clear that the uncertainty associated with a  
650 range code is greater than that associated with any other estimated release value. Range code reporting is  
651 not permitted for chemicals of special concern.

652  
653 TRI facilities enter the facility’s primary six-digit North American Industry Classification System  
654 (NAICS) code indicating the primary economic activity at the facility. Facilities can also enter  
655 secondary NAICS codes. NAICS codes are reported for the facility as a whole and are not chemical  
656 specific. When using TRI chemical release data for a facility that also reported secondary NAICS codes,  
657 there may be uncertainty as to which NAICS is associated with the use of the chemical.

658  
659 TRI guidance states that release estimates need not be reported to more than two significant figures.  
660 However, the guidance also states that facilities should report release quantities at a level of precision  
661 supported by the accuracy of the underlying data and the estimation techniques on which the estimate  
662 was based. If a facility’s release calculations support reporting an amount that is more precise than two

663 significant digits, then the facility should report that more precise amount. The facility makes the  
664 determination of the accuracy of their estimate and the appropriate significant digits to use.

665  
666 For chemicals that meet certain criteria, facilities have the option of submitting a TRI Form A  
667 Certification Statement instead of a TRI Form R. The Form A does not include any details on the  
668 chemical release or waste management quantities. The criteria for a Form A are that during the reporting  
669 year, the chemical (1) did not exceed 500 lb for the total annual reportable amount (including the sum of  
670 on- and off-site quantities released, treated, recycled, and used for energy recovery); (2) amounts  
671 manufactured, processed, or otherwise used do not exceed 1 million lb; and (3) the chemical is not a  
672 chemical of special concern. When conducting analyses of chemical releases and a facility has submitted  
673 a Form A for the chemical, there is no way to discern the quantity released to each medium or even if  
674 there were any releases. For air emissions, where facilities reported to TRI with a Form A, EPA used the  
675 Form A threshold for total releases of 500 lb/year. EPA used the entire 500 lb/year for both the fugitive  
676 and stack air release estimates; however, since this threshold is for total site releases, these 500 lb/year  
677 are either to fugitive air or stack air for this analysis, not both (since that would double count the releases  
678 and exceed the total release threshold for Form A). Furthermore, the threshold represents an upper limit  
679 on total releases to all environmental media from the facility; therefore, assessing the air emissions at the  
680 threshold value likely overestimates actual air emissions from the facility.

681  
682 In addition, information on the use of the chemical at facilities in TRI and DMR is limited; therefore,  
683 there is some uncertainty as to whether the mapping of each facility to an OES does in fact represent that  
684 specific OES. If facilities were categorized under a different OES, the annual air emissions or water  
685 releases for each site would remain unchanged; however, average daily releases may change depending  
686 on the release days expected for the different OES.

687  
688 Facilities reporting to TRI and DMR only report annual releases; to assess daily releases, EPA estimated  
689 the release days and averaged the annual releases over these days. There is some uncertainty that all  
690 facilities for a given OES operate for the assumed duration; therefore, the average daily release may be  
691 higher if sites have fewer release days or lower if they have greater release days. Furthermore, chemical  
692 concentrations in air emissions and wastewater streams at each facility may vary from day-to-day such  
693 that on any given day the actual daily releases may be higher or lower than the estimated average daily  
694 discharge.

695  
696 In some cases, the number of facilities for a given OES was estimated using data from the U.S. Census.  
697 In such cases, the average daily release calculated from sites reporting to TRI or DMR was applied to  
698 the total number of sites reported in ([U.S. Census Bureau, 2015](#)). It is uncertain how accurate this  
699 average release is to actual releases at these sites; therefore, releases may be higher or lower than the  
700 calculated amount.

701  
702 For air emissions, where facilities reported to TRI with a Form A, EPA used the Form A threshold for  
703 total releases of 500 lb/yr. EPA used the entire 500 lb/year for both the fugitive and stack air release  
704 estimates; however, since this threshold is for total site releases, these 500 lb/year are either to fugitive  
705 air or stack air for this analysis, not both (since that would double count the releases and exceed the total  
706 release threshold for Form A). EPA used the entire 500 lb/year for both the fugitive and stack air release  
707 estimates; however, since this threshold is for total site releases, these 500 lb/year are either to fugitive  
708 air or stack air for this analysis, not both (since that would double count the releases and exceed the total  
709 release threshold for Form A). Furthermore, the threshold represents an upper limit on total releases to  
710 all environmental media from the facility; therefore, assessing the air emissions at the threshold value  
711 likely overestimates actual air emissions from the facility.



712

713 For release estimates developed for an OES when 2019 TRI data were not available, there are  
714 uncertainties related to the use of prior year TRI data or, in their absence, the use of modeling. Use of  
715 the past years' TRI data may introduce uncertainties related to whether those releases are currently  
716 ongoing or the extent to which past years' data reflects current releases. Although no new models were  
717 developed for this screening level fenceline analysis, the adaptations made to and uses of these models  
718 as part of the screening-level fenceline analysis may result in release estimates higher or lower than the  
719 actual amount. Additionally, the approach used for scenario development for estimated releases based  
720 on modeling or other data sources differs from the facility-specific approach used for OES for which  
721 TRI data were available (as described in section 2.1.2.2). This may introduce uncertainties that differ  
722 from those of the scenarios using TRI data, described above. TRI guidance states that release estimates  
723 need not be reported to more than two significant figures. However, the guidance also states that  
724 facilities should report release quantities at a level of precision supported by the accuracy of the  
725 underlying data and the estimation techniques on which the estimate was based. If a facility's release  
726 calculations support reporting an amount that is more precise than two significant digits, then the facility  
727 should report that more precise amount. The facility makes the determination of the accuracy of their  
728 estimate and the appropriate significant digits to use.

729

730 For chemicals that meet certain criteria, facilities have the option of submitting a TRI Form A  
731 Certification Statement instead of a TRI Form R. The Form A does not include any details on the  
732 chemical release or waste management quantities. The criteria for a Form A are that during the reporting  
733 year, the chemical (1) did not exceed 500 lb for the total annual reportable amount (including the sum of  
734 on- and off-site quantities released, treated, recycled, and used for energy recovery); (2) amounts  
735 manufactured, processed, or otherwise used do not exceed 1 million lb; and (3) the chemical is not a  
736 chemical of special concern. When conducting analyses of chemical releases and a facility has submitted  
737 a Form A for the chemical, there is no way to discern the quantity released to each medium or even if  
738 there were any releases. For air emissions, where facilities reported to TRI with a Form A, EPA used the  
739 Form A threshold for total releases of 500 lb/year. EPA used the entire 500 lb/year for both the fugitive  
740 and stack air release estimates; however, since this threshold is for total site releases, these 500 lb/year  
741 are either to fugitive air or stack air for this analysis, not both (since that would double count the releases  
742 and exceed the total release threshold for Form A). Furthermore, the threshold represents an upper limit  
743 on total releases to all environmental media from the facility; therefore, assessing the air emissions at the  
744 threshold value may overestimate actual air emissions from the facility.

745

#### 2.4.2 Assumptions and Uncertainties in Air Pathway Exposure Modeling

---

746

##### *Pre-screening Analysis*

747

748 IIOAC provides exposure concentrations at three pre-defined distances (100 meters, 100 to 1,000  
749 meters, and 1,000 meters) which is a limitation to the model itself (it does not estimate exposure  
750 concentrations closer or farther out than these distances). Based on this current fenceline work,  
751 exposures from fugitive releases were found to peak around 10 meters from a facility and rapidly decay  
752 at farther distances and stack releases were found to peak around 100 meters. Therefore, where a  
753 facility's releases are primarily fugitive in nature, the inherent distance limitations of the model prohibit  
754 it from estimating exposures to receptors closer to a facility (less than 100 meters from the facility). This  
755 could result in the pre-screening modeling methodology not identifying or capturing exposures and  
756 associated potential risk from such fugitive releases for receptors closer than 100 meters. Taking the  
757 IIOAC pre-screening results alone, without considering release type (stack/fugitive) and other factors,  
758 could then lead to a decision to screen out a pathway due to no risk at 100 meters, when there is  
759 exposure and associated risk at distances closer than 100 meters. This issue could be avoided by taking a

760 closer look at exposure concentrations and associated risks at 100 meters to see how close to (or far off)  
761 the estimated risks are from the relevant benchmarks. Even if risk is not explicitly indicated at 100  
762 meters, if it is close to indicating a risk (e.g., close to a benchmark), it may warrant a full screening level  
763 analysis to be conducted.

764 .

765 Meteorological data can have a significant impact on exposure concentrations upwind and downwind of  
766 a releasing facility. The use of 14 pre-defined meteorological stations representing regions of the United  
767 States generalizes the meteorological data across a wide area where competing conditions can  
768 significantly influence the exposure concentrations modeled. However, when using IIOAC for pre-  
769 screening work, EPA used the meteorological stations within IIOAC which provided high end and  
770 central tendency exposure concentration estimates, based on a sensitivity analysis, therefore maintaining  
771 a conservative estimate of the exposure concentrations used to calculate risk. This approach adds  
772 confidence to the findings by ensuring under a high-end exposure scenario potential risks would be  
773 captured.

774

### 775 **Screening Analysis**

776 AERMOD is EPA's regulatory model and has been thoroughly peer reviewed therefore the general  
777 confidence in results from the model is high but reliant on the integrity and quality of the inputs used  
778 and interpretation of the results. For the full-screening level analysis, EPA used 2019 TRI data for  
779 release information. There is uncertainty around the use of only 2019 TRI data for the full-screening  
780 level analysis.

781

782 The 2019 TRI dataset used for the full-screening level analysis does not have actual release point  
783 locations which can affect the estimated concentrations at varying distances modeled. For the release  
784 location, EPA used a local-coordinate system. EPA centered a facility's emissions on one location which  
785 was assigned the local coordinate of (0,0) and concentrations were estimated at modeled distances in  
786 concentric rings from that location. However, the (0,0) coordinate was placed at a location which  
787 represents the latitude/longitude (lat/long) information reported to TRI. That lat/long may represent the  
788 mailing address location of the office building associated with a very large facility rather than the actual  
789 release location (e.g., a specific process stack). This discrepancy between the (0,0) coordinate from  
790 which an exposure concentration is modeled for the full-screening level analysis and the actual release  
791 point could result in an exposure concentration that does not represent the actual distance where  
792 fence-line communities may be exposed. This is particularly relevant for larger facilities where the actual  
793 release point may be several hundred meters to the northeast of the office building. In this situation, the  
794 exposure concentrations estimated at several hundred meters from the (0,0) coordinate (office building)  
795 may be located within the facility property-line; however, the exposure concentration should be applied  
796 from the actual release point. This could shift the actual modeled exposure concentration from within the  
797 facility property-line to well outside of the facility property-line where fence-line communities may be  
798 exposed (e.g., the actual release point may be directly next to a residential community or school yard  
799 just outside the facility property-line).

800

801 The 2019 dataset used for full-screening level analysis does not include source specific physical  
802 characteristics like stack height, exit gas temperature, etc. which can affect plume characteristics and  
803 associated dispersion of the plume. For the source specific characteristics, EPA used physical stack  
804 parameters and plume characteristics consistent with those used in IIOAC, including, but not limited to:  
805 stack emissions released from a point source at 10 meters above ground from a 2-m inside diameter  
806 stack, with an exit gas temperature of 300 °Kelvin and an exit gas velocity of 5 m per second (see Table  
807 6 of the IIOAC User Guide). EPA acknowledges these stack parameters represent conservative plume  
808 characteristics which resemble a slow-moving, low-to-the-ground plume with limited dispersion but

809 believe are appropriate for screening level purposes. None-the-less, use of these conservative parameters  
810 may overestimate emissions for certain facilities modeled. Additionally, while these default values are  
811 based on national averages and some research into typical stack parameters and conditions, they may not  
812 be applicable or representative of all sources evaluated in this fenceline work.

813

814 As discussed in the release section, some facilities modeled relied on release data from the TRI Form A  
815 (which has a reporting threshold of 500 lb). Since there is no source attribution associated with a Form  
816 A reporting value, EPA modeled each facility associated with a Form A submittal twice, once assuming  
817 all 500 lb of the reporting threshold was fugitive and once assuming all 500 lb of the reporting threshold  
818 was stack. This maintains a conservative estimate, in terms of total release, but may overestimate  
819 exposure concentrations associated with these releases if a facility did not actually release all 500 lb. At  
820 the same time, although it maintains a conservative estimate the resulting modeled concentrations for  
821 Form A facilities tended to be low in comparison to the majority of TRI reporting facilities reporting an  
822 actual stack and/or fugitive release across a given OES. Additionally, in each case Form A modeled  
823 facilities tended to have higher exposure concentrations resulting from the fugitive release scenario  
824 compared to the stack release scenario. Although this approach could lead to a potential concern over  
825 double counting a facility release, when presenting potential exposures EPA relies on the highest (more  
826 conservative) exposure concentration between the two release types for purposes of evaluating potential  
827 risks to fenceline communities. As discussed above, this tended to result in EPA considering the  
828 scenario where 500 lb of release occurred under the fugitive release scenario for purposes of presenting  
829 potential exposures and associated potential risks.

830

### 831 *Co-resident Screening Analysis*

832 IECCU does not include default values for select input parameters and relies on user derived input  
833 parameters. In many cases, the availability of reference data for the input parameters is limited or non-  
834 existent and therefore inputs rely on other models to estimate an input parameter. This places a higher  
835 reliance on the efficacy of the models used to estimate input parameters which may or may not be  
836 appropriate or thoroughly reviewed. EPA minimized this uncertainty by using reference data, where  
837 reasonably available and by relying on other EPA reviewed and/or approved models to derive input  
838 parameters.

839

840 As described in the model documentation, the  $Q_{12}$  flow is a significant factor when estimating transport  
841 of the chemical of concern into the adjacent living space and therefore should be well established to  
842 ensure confidence in the results. EPA minimized uncertainty by estimating the  $Q_{12}$  two different ways  
843 for each of the two buildings configuration. Not only does this approach provide a variation in the  $Q_{12}$ ,  
844 but it also provides results which can be compared for consistency. Comparison of the two approaches  
845 for the  $Q_{12}$  values showed consistency across both methods within a building configuration and therefore  
846 helps provide added confidence that the results are reliable.

847

### 848 **2.4.3 Assumption and Uncertainties in Drinking Water Monitoring Results**

849 Drinking water monitoring data were identified only for MC and only through the discussed data found  
850 in the Six-Year Review of Drinking Water Standards. It is noted that the date range of this dataset is  
851 between 2006 and 2011 and those monitored values may not represent current conditions, nevertheless  
852 they represented the most recent available monitored information on drinking water concentrations and  
853 provide relevant information to possible drinking water exposures. Additionally, these measurements are  
854 taken at the point of drinking water distribution meaning the sampled location may be temporally or  
855 spatially separate from the initial point of chemical release. Finally, due to the different years between  
856 modeled and monitored information available for MC, the monitored results were not linked to physical

857 locations or compared to modeled estimates of instream and drinking water concentrations from facility  
858 releases.

859 **2.4.4 Assumptions and Uncertainties in Water Pathway Exposure Modeling**

860 Estimation of all water pathway exposures is dependent on modeling done through E-FAST 2014 ([U.S.](#)  
861 [EPA, 2014](#)) which is subject to a number of assumptions and uncertainties. Since modeling was not  
862 redone for this evaluation the original risk evaluations for both MC ([U.S. EPA, 2020c](#)) and NMP ([U.S.](#)  
863 [EPA, 2020d](#)) go into greater depth on these uncertainties and assumptions, but they are briefly discussed  
864 here .

865  
866 The modeled scenarios used and estimated high and low days of release frequency for all direct releasers  
867 and a high days of release frequency for all indirect releasers. The greater the number of release days,  
868 the more a per-day release will be diluted assuming the same overall annual loading estimate. The  
869 selection of both a high and low number of release days is intended to bracket and provide the range of  
870 possible releases to stream waterbodies, but release days may vary across and between industries and  
871 may not be accurately represented by these assumed values.

872  
873 The applied stream flow distribution is another key parameter determining output results. The modeled  
874 30Q5 and harmonic mean surface water concentrations are used to calculate the estimated water  
875 pathway exposures for drinking water, incidental oral, and incidental dermal exposures. The flow  
876 distributions are applied by selecting a facility-specific NPDES code in E-FAST 2014. When site-  
877 specific or surrogate site-specific stream flow data were not available, flow data based on a  
878 representative industry sector were used in the assessment. This includes cases where a receiving facility  
879 for an indirect release could not be determined. In such cases, it is likely that the stream concentration  
880 estimates are higher than they would be if a facility-specific NPDES code was able to be applied, except  
881 in certain cases (*e.g.*, NPDES associated with low-flow or intermittent streams or bays). Additionally,  
882 the stream flow data currently available in E-FAST 2014 are 15 to 30 years old and may not represent  
883 current conditions at a particular location. Due to the age and spatial resolution of this dataset, the input  
884 waterbody flow values may represent either an overestimate or underestimate of actual flow conditions  
885 depending on location. Nevertheless, the used datasets represent the most comprehensive and accurate  
886 nationwide datasets available for modeling evaluation and analysis.

887  
888 The use of E-FAST 2014 also estimates waterbody surface water concentrations at the point of release,  
889 without considering post-release environmental fate or degradation processes such as volatilization,  
890 biodegradation, photolysis, hydrolysis, or partitioning. Additionally, E-FAST 2014 does not estimate  
891 stream concentrations based on the potential for downstream transport and dilution. These  
892 considerations tend to lead to higher predicted surface water concentrations. Dilution is incorporated,  
893 but it is based on the stream flow applied.

894  
895 Estimated drinking water exposures were based on the assumption that an individual is exposed to  
896 potential waterbody concentrations as the point of release without any potential for transport, dilution, or  
897 treatment. Estimation of waterbody concentrations at the point of actual drinking water intakes or the  
898 distances to these locations was beyond the scope of this evaluation, but in most cases, it would be  
899 expected that waterbody concentrations at these locations would be lower even without treatment.  
900 Therefore, our analysis represents a higher-end estimate of possible drinking water exposures.

901  
902 Estimation of incidental dermal and oral exposures used default inputs for exposure time from EPA's  
903 SWIMODEL. These exposure time defaults are based on swimming pool use patterns rather than  
904 freshwater bodies assumed here and thus represents an uncertainty about the application of swimming

905 pool duration data to this analysis. Additionally, these evaluations are based on estimated waterbody  
906 concentrations at the point of release with the assumption that an individual would be incidentally  
907 exposed at that location. This assumption represents a higher-end estimate of possible exposure, as  
908 activities occurring farther downstream would be expected to have lower waterbody concentrations.

#### 909 **2.4.5 Assumptions and Uncertainties in Risk Characterization**

---

##### 910 ***Exposure Duration***

911 This analysis provides exposure and hazard values based on a 24-hour exposure. This assessment  
912 assumes that an individual living nearby a facility will be exposed to a chemical at a similar  
913 concentration for all hours of the day—either they are present at home all day or remain close-by. This  
914 uncertainty may result in an overestimation of exposure and risk, especially for chronic durations, for  
915 exposed individuals who may regularly travel farther away from exposure sources and would not be  
916 chronically exposed at the same concentration continuously. Similarly, chronic and lifetime exposure  
917 and risk estimates are only relevant to individuals who reside at the same location for years or decades.  
918 These longer-term exposures would vary for individuals who did not remain within the same range of a  
919 particular facility.  
920

##### 921 ***Distance Where Risk Identified***

922 IIOAC and AERMOD provided exposure concentrations at discrete distances. EPA calculated risk at  
923 modeled discrete distances. Therefore, there is uncertainty of risk between the two distances modeled.  
924 For example, if we found risk at 100 meters and we did not find risk at 1000 meters, EPA is uncertain if  
925 there is risk at 101 to 999 meters. To not underestimate risk beyond the risk showing distance (*e.g.*, at  
926 101 meters), or overestimate risk closer to the distance where risk was not found (*e.g.*, at 999 meters),  
927 remodeling may be required to determine exposure concentrations, and thus calculating risk between the  
928 two discrete distances previously modeled.  
929

930  
931 As discussed in Section 2.1.2.2, EPA review of land use patterns was limited to those facilities with GIS  
932 locations that showed risk. Because estimated releases do not have a physical location associated with a  
933 facility, EPA was unable to visually examine land use patterns around the theoretical facility. Therefore,  
934 EPA was unable to conduct such analysis for alternative release estimates showing risk. Additionally,  
935 reported TRI facility's location data (latitude/longitude) may not represent the actual location of the  
936 releasing source (*e.g.*, a processes stack).  
937

##### 938 ***Potentially Exposed or Susceptible Subpopulations***

939 Human health toxicity values for this analysis incorporate the same considerations for PESS as were  
940 described in the respective risk evaluations for each chemical. For oral and dermal exposures, risks were  
941 additionally estimated for multiple relevant lifestages and subpopulations, with the most sensitive results  
942 (based on elevated exposure) presented in this analysis alongside adult estimates. Inhalation risk  
943 estimates are based on air concentrations and were not adjusted for potential lifestage-specific  
944 differences, consistent with current EPA guidance which assumes that lifestage-specific differences in  
945 inhalation dosimetry are covered by the 10× intraspecies uncertainty factor (UF<sub>H</sub>) ([U.S. EPA, 2012a](#)).

### 3 CASE STUDY RESULTS

EPA presents three case study chemicals in this section: two case study chemicals for the air pathway (1-BP and MC) and two case study chemicals for the water pathway (MC and NMP). The purpose of these case study chemicals is to show the application and efficacy of the proposed screening level methodology to estimate releases, potential exposures and capture potential risks to fenceline communities for select pathways not previously evaluated in published risk evaluations. While these case study chemicals are among the seven chemicals for which EPA published risk evaluations between 2020 and 2021 and intends to conduct a screening level analysis following finalization of the screening level methodology and framework development, the results presented here are for illustrative purposes only and not final agency action. Any results, risks, or risk conclusions, as presented here, are not intended to be used to support risk management actions or rulemaking.

#### 3.1 1-Bromopropane (Air Pathway)

##### 3.1.1 Background for 1-BP

1-Bromopropane (1-BP) is a highly volatile, liquid organic compound. It degrades slowly in the atmosphere and can be transported over long distances. Its volatility and biodegradability are such that intermittent releases to surface water are not expected to accumulate. However, continuous releases can lead to persistent concentrations. It has low affinity for organic surfaces and is therefore expected to be mobile in groundwater ([U.S. EPA, 2020b](#)). The physical-chemical properties of 1-BP are summarized in Table\_Apx A-1.

##### 3.1.2 Human Health Hazard Endpoints for 1-BP

All hazard values used to calculate risk for 1-BP in this report are derived from the previously peer-reviewed PODs published in the Final Risk Evaluation for 1-Bromopropane ([U.S. EPA, 2020b](#)). In the Final Risk Evaluation, EPA utilized the endpoints shown in Table 3-1 for risk determination. For 1-BP, distinct human equivalent concentrations (HECs) for non-cancer endpoints were derived for occupational and consumer scenarios. Additionally, an inhalation unit risk (IUR) for lifetime cancer risk was applied for both occupational and consumer scenarios for COUs where it was applicable.

**Table 3-1. Hazard Values Used for Risk Estimation in the 1-BP Risk Evaluation**

Scenario	Endpoint	Occupational POD	Consumer POD	Benchmark	Reference
Acute	Developmental: Post-implantation loss	17 ppm	6 ppm	100	<a href="#">(W.I.L. Research, 2001)</a>
Chronic	Developmental: Post-implantation loss	17 ppm	6 ppm	100	<a href="#">(W.I.L. Research, 2001)</a>
Cancer	Respiratory adenomas/carcinoma	4E-03 per ppm	6E-03 per ppm	1E-4 (occup.); 1E-6 (cons.)	<a href="#">(NTP, 2011)</a>

For the analyses in this report, EPA derived POD values for fenceline communities based on a continuous exposure scenario. The noncancer HECs were derived from the original benchmark concentration levels (BMCLs) from the animal studies as presented in Table 3-8 of ([U.S. EPA, 2020b](#)). The acute and chronic HECs are for the developmental endpoint of post-implantation loss, with a BMCL<sub>1</sub> of 23 ppm following 6 hr/day daily inhalation exposure of pregnant rats from pre-mating through gestational day 20. In adjusting for continuous 24 hr/day exposure, the resulting HEC matches

the value used for consumers in the Final Risk Evaluation. For cancer, the IUR value used for consumers was already adjusted to continuous exposure and did not require any further extrapolation for evaluation of risks to fenceline communities. The adjusted POD values for fenceline communities are presented below in Table 3-2.

**Table 3-2. Hazard Values for 1-BP Used in this Fenceline Analysis**

Scenario	Endpoint	Fenceline HEC/IUR	Benchmark	Reference
Acute	Developmental: Post-implantation loss	6 ppm	100	( <a href="#">W.I.L. Research, 2001</a> )
Chronic	Developmental: Post-implantation loss	6 ppm	100	( <a href="#">W.I.L. Research, 2001</a> )
Cancer	Respiratory adenomas/carcinoma	6E-03 per ppm	1E-6	( <a href="#">NTP, 2011</a> )

### **3.1.2.1 Assumptions and Uncertainties for 1-BP Human Health Hazard**

The PODs used for the fenceline analysis match those used in the risk evaluation, so there is no uncertainty associated with any additional extrapolation for fenceline communities. Any other assumptions or uncertainties inherent to the human health hazard assessment in the Final Risk Evaluation for 1-Bromopropane ([U.S. EPA, 2020b](#)) are still applicable for this analysis.

### **3.1.3 Environmental Releases for 1-BP**

This case study provides information specific to the 1-BP fenceline environmental release analysis that is not captured in the general methodology described in Section 2.1.1.

#### **3.1.3.1 Step 1: Obtain 2019 TRI Data**

For 1-BP, the 2019 TRI dataset used for this fenceline analysis includes a total of 59 sites that reported stack and fugitive air releases ([U.S. EPA, 2021](#)). These data include nine Form A submissions and 50 Form R submissions.

#### **3.1.3.2 Step 2: Map 2019 TRI to OES**

EPA followed the methodology described in Section 2.1.1.2 to map the facilities in 2019 TRI to the OES in the published 1-BP Risk Evaluation ([U.S. EPA, 2020b](#)) (see Appendix E). However, there were a few deviations from this general methodology that EPA encountered during the mapping of 1-BP 2019 TRI sites to OES, which are described below.

- The 1-BP Risk Evaluation is unique in that it makes a distinction between the “Import” and “Repackaging” OES, even though the “Import” OES is expected to also include repackaging operations ([U.S. EPA, 2020b](#)). The mapping of the 2019 TRI data to the “Import” and “Repackaging” OES was based largely on the mapping of 2018 TRI ([U.S. EPA, 2019b](#)), 2016 TRI ([U.S. EPA, 2017](#)), and preliminary 2017 TRI ([U.S. EPA, 2020a](#)) data to OES. The assignment of these OES was also informed in part by 2016 CDR ([U.S. EPA, 2016b](#)).
- The 2019 TRI data for 1-BP includes many sites that report the TRI uses/sub-uses for “Ancillary or Other use – Cleaner” and “Ancillary or Other use – Degreaser” ([U.S. EPA, 2021](#)). EPA was unable to determine the specific types of cleaning or degreasing from the TRI uses/sub-uses, NAICS codes, or internet searches of the facilities. Therefore, for these facilities, EPA assigned the OES as “Degreasing (Batch Vapor Degreaser (Open-Top); Batch Vapor Degreaser (Closed-

Loop); In-Line Vapor Degreaser (Conveyorized); Cold Cleaner.” This OES designation is a grouping of the following COUs from the 1-BP Risk Evaluation: Batch Vapor Degreaser (Open-Top), Batch Vapor Degreaser (Closed-Loop), In-Line Vapor Degreaser (Conveyorized), and Cold Cleaner. EPA did not include the OES for Aerosol Spray Degreaser/Cleaner, Dry Cleaning, or Spot Cleaner/Stain Remover in this grouping because facilities conducting these types of cleaning and degreasing are not expected to be captured in TRI because they likely use 1-BP at quantities below the reporting threshold or do not use a NAICS code that is included in a TRI-covered industry sector.

- There were multiple sites in the 1-BP 2019 TRI data set that initially mapped to the COU for “Functional fluids (closed systems) – refrigerant” ([U.S. EPA, 2021](#)). However, upon review of NAICS codes and research into these facilities, EPA determined that the COU for “Functional fluids (open system) – cutting oils” was more appropriate because these facilities produce fabricated metal products. The use of 1-BP in metalworking fluids at quantities that would trigger TRI reporting is much more likely than the use of 1-BP in refrigerant flushes at these types of sites.
- One facility reported the TRI use/sub-use for “Processing: Repackaging”; however, this facility reported the NAICS code 562211, Hazardous Waste Treatment and Disposal ([U.S. EPA, 2021](#)). Based on the NAICS code, EPA assigned the “Disposal and Recycling” OES. An additional site reported the TRI use/sub-use of “Ancillary or other use as a fuel” and the NAICS code 327310, Cement Manufacturing. Because 1-BP is not typically used in cement manufacturing, EPA interpreted this as the combustion of 1-BP in an incineration process with energy recovery, which is covered in the “Disposal and Recycling” OES ([U.S. EPA, 2021](#)).

The 1-BP fenceline analysis spreadsheet, *SF\_FLA\_Environmental Releases to Ambient Air for 1-BP* (Appendix B), contains the rationale for the mapping of each facility in 2019 TRI to an OES. Refer to this spreadsheet for details of the mapping at the facility-level.

### 3.1.3.3 Step 3: Estimate Number of Release Days for Each OES

EPA estimated the number of release days for each 1-BP OES according to the methodology in Section 2.1.1.3. Specifically, the number of release days was assumed to be equal to the number of operating days, which were estimated for each OES as shown in Table 3-3.

**Table 3-3. Number of Release Days for Each 1-BP OES**

OES	Number of Release Days (days/year)	Basis for Number of Release Days
Manufacture	350	Number of release days for “Manufacture of Solvents” discussed in Section 2.1.1.3
Import	250	Number of release days for “All Other Scenarios”
Processing as a Reactant	350	Number of release days for “Processing as a Reactant”
Processing – Incorporation into Formulation, Mixture, or Reaction Product	300	Number of release days for “Other Chemical Plant Scenarios”
Processing – Incorporation into Articles	250	Number of release days for “All Other Scenarios”
Repackaging	250	Number of release days for “All Other Scenarios”



OES	Number of Release Days (days/year)	Basis for Number of Release Days
Degreasing, which includes the following OES: Batch Vapor Degreasing (Open-Top) Batch Vapor Degreasing (Closed-Loop) In-line Vapor Degreasing (Conveyorized) Cold Cleaning	260	Vapor Degreasing ESD ( <a href="#">Organization for Economic and Development, 2017</a> )
Aerosol Spray Degreaser/Cleaner	260 (low-end) and 364 (high-end)	Brake Servicing Near-Field/Far-Field Inhalation Exposure Model
Dry Cleaning	250 (low-end) and 312 (high-end)	Dry Cleaning Multi-Zone Inhalation Exposure Model
Spot Cleaner/Stain Remover	289 (50th percentile) and 307 (95th percentile)	Spot Cleaning Near-Field/Far-Field Inhalation Exposure Model
Spray Adhesives	260	Based on 5 days/week and 52 weeks/year per literature ( <a href="#">Trinity Consultants, 2015</a> )
THERMAX Installation	N/A	Ambient air release estimates are not provided for this OES because it is specific to occupational and consumer exposures resulting from off-gassing of 1-BP from the installed product and not expected to result in exposure to fence-line communities.
Other Uses – Cutting Oils	250	Number of release days for “All Other Scenarios”
Other Uses – Asphalt Extraction	250	Number of release days for “All Other Scenarios”
Disposal and Recycling	250	Number of release days for “All Other Scenarios”

101  
102  
103  
104  
105  
106  
107  
108

#### **3.1.3.4 Step 4: Estimate Air Emissions for OES with No TRI Data**

A summary of the air release assessment approaches for each 1-BP OES is included in Table 3-4. Of the 15 OES listed in in Table 3-4, 7 have directly applicable 2019 TRI data that were used. For the remaining eight OES without 2019 TRI data, EPA used the hierarchy of alternate air assessment approaches described in Section 2.1.1.4. Specifically, EPA estimated air releases with past years’ TRI data for three OES, modeling for two OES, literature values for one OES, and a combination of modeling and literature values for one OES. Air estimates are not required for the remaining one OES.

109

**Table 3-4. Summary of Air Release Estimation Approaches for Each 1-BP OES**

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Stack Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
Manufacture	227 to 3,045 <sup>f,g</sup>	227 to 2,307 <sup>f,g</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for two sites (one Form A).
Import	227 (same for all sites) <sup>g</sup>	227 (same for all sites) <sup>g</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for four sites (all Form As).
Processing as a Reactant	635 (same for all years) <sup>f</sup>	1.36 to 2.72 <sup>f</sup>	Past years' TRI data ( <a href="#">U.S. EPA, 2020a</a> , <a href="#">2019b</a> , <a href="#">2017</a> )	2019 TRI data are not available for this OES. However, one site reported use of 1-BP as a reactant in 2016 through 2018 TRI (this site did not report for 1-BP in 2019 TRI). Because only three data points are available, EPA presented the central tendency (50th percentile) and maximum of these three years' data for fugitive and stack air releases for this site.
Processing – Incorporation into Formulation, Mixture, or Reaction Product	0 to 1,105 <sup>c,d,e,f,g</sup>	0 to 340 <sup>c,d,e,f,g</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 11 sites (three Form As).
Processing – Incorporation into Articles	508 to 520 <sup>e</sup>	943 to 974 <sup>e</sup>	Past years' TRI data ( <a href="#">U.S. EPA, 2020a</a> , <a href="#">2019b</a> , <a href="#">2017</a> )	2019 TRI data are not available for this OES. However, one site reported use of 1-BP for articles in 2016 through 2018 TRI (this site did not report for 1-BP in 2019 TRI). Because only three data points are available, EPA presented the central tendency (50th percentile) and maximum of these three years' data for fugitive and stack air releases for this site.
Repackaging	88 (1 site) <sup>c</sup>	0 (1 site)	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for one site (not a Form A).
Degreasing, which includes the following OES: Batch Vapor Degreasing (Open-Top), Batch Vapor	0 to 53,319 <sup>a,c,d,e,f,g</sup>	0 to 50,615 <sup>a,c,e,f,g</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 34 sites (one Form A).

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Stack Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
Degreasing (Closed-Loop), In-line Vapor Degreasing (conveyorized), Cold Cleaning				
Aerosol Spray Degreaser/Cleaner	277 (CT) to 377 (HE)	0 (all fugitive)	Modeling	2019 TRI data and past years' TRI data are not available for this OES. EPA modeled air releases from this OES using the <i>Brake Servicing Near-Field/Far-Field Inhalation Exposure Model</i> .
Dry Cleaning	57 to 1,294	0 (all fugitive)	Literature ( <a href="#">Trinity Consultants</a> , 2015) and modeling (pending discussion with exposure assessors)	2019 TRI data and past years' TRI data are not available for this OES. 1-BP emission data are available in a Trinity report ( <a href="#">Trinity Consultants, 2015</a> ) for two companies (data are from 2014). The Trinity report is cited in the published 1-BP Risk Evaluation. EPA presented these emission data for each company, assuming the releases were entirely to fugitive air. The data available from the Trinity report were insufficient to calculate a 50th and 95th percentile, so the low-end and high-end values were presented.  In addition to air releases for air modeling for fenceline communities, EPA required air release modeling for co-residence communities (people who live in a building with a dry cleaner on the ground floor) using the model for 3rd generation dry cleaning machines ( <a href="#">U.S. EPA, 2020b</a> ).
Spot Cleaner/Stain Remover	75.3 (CT) to 80 (HE)	0 (all fugitive)	Modeling	2019 TRI data and past years' TRI data are not available for this OES. EPA adapted the Spot Cleaning Model and ran it to estimate daily air emissions for this OES.
Spray Adhesives	0 (1 site, all stack)	614 (1 site)	Literature ( <a href="#">Trinity</a> )	2019 TRI data and past years' TRI data are not available for this OES. Additionally, there are no current

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Stack Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
			<a href="#">Consultants, 2015)</a>	applicable modeling approaches for this OES. 1-BP emission data are available in the Trinity report ( <a href="#">Trinity Consultants, 2015</a> ) for one company (data are from 2013). The Trinity report is cited in the published 1-BP Risk Evaluation. EPA presented these emission data, which the report indicates are entirely to stack air.
THERMAX Installation	N/A	N/A	N/A	Ambient air release estimates are not provided for this OES because it is specific to occupational and consumer exposures resulting from off-gassing of 1-BP from the installed product and not expected to result in exposure to fenceline communities.
Other Uses – Cutting Oils	0 to 663 <sup>b c f</sup>	0 to 207 <sup>b f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for five sites for use of 1-BP in functional fluids (open system) - cutting oils (no Form As).
Other Uses – Asphalt Extraction	7,235 (1 site) <sup>b</sup>	9,862 (1 site) <sup>d</sup>	Past years' TRI data ( <a href="#">U.S. EPA, 2020a, 2019b, 2017</a> )	2019 TRI data are not available for this OES. However, data are available for the asphalt extraction OES for one site in 2016 and 2017 TRI (this site did not report for 1-BP to 2018 or 2019 TRI). EPA presented these 2016 and 2017 TRI data for this one site. Note that for year 2016, these air releases were reported entirely to fugitive air, and for year 2017, these air releases were reported entirely to stack air.
Disposal and Recycling	18.1 to 29.3 <sup>f</sup>	5.22 to 5.31 <sup>f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for two sites (no Form A's).

<sup>a</sup> This range includes estimates based on continuous monitoring data or measurements.

<sup>b</sup> This range includes estimates based on periodic or random monitoring data or measurements .

<sup>c</sup> This range includes estimates based on mass balance calculations, such as calculation of the amount in streams entering and leaving process equipment.

<sup>d</sup> This range includes estimates based on published emissions factors, such as those relating release quantity to through-put or equipment type (e.g., air emissions factors).

<sup>e</sup> This range includes estimates based on site-specific emissions factors, such as those relating release quantity to through-put or equipment type (e.g., air emissions factors).

<sup>f</sup> This range includes estimates based on other approaches such as engineering calculations (e.g., estimating volatilization using published mathematical formulas) or best engineering judgment.

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Stack Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
<sup>g</sup> This range includes Form A submissions, for which EPA used the entire 500 lb/year for both the fugitive and stack air release estimates; however, since this threshold is for total site releases, these 500 lb/year are either to fugitive air or stack air for this analysis, not both.				

110

### **3.1.3.5 Step 5: Prepare Air Emission Summary for Ambient Air Exposure Modeling**

111

Using the work completed in Steps 1 through 4, EPA compiled a summary of air releases on a per-site basis for each 1-BP OES, in the format of Table 2-1. See the supplemental fenceline analysis spreadsheet *SF\_FLA\_Environmental Releases to Ambient Air for 1-BP* (Appendix B) for this summary. To model exposures resulting from these air emissions, EPA used the daily emissions, site identity and location information, and release duration and pattern information from this summary. Additional information on the modeled 1-BP exposures is provided in the next section.

112

113

114

115

116

117

### **3.1.4 Exposures for 1-BP**

118

All three fenceline exposure methodologies (pre-screening, screening, and co-resident screening) were utilized to evaluate potential exposures to fenceline communities for 1-BP.

119

120

121

#### ***Pre-screening Analysis***

122

Pre-screening work for 1-BP is included in Appendix D. Inputs for all IIOAC model runs for all exposure scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Input Parameters for IIOAC for 1-BP and MC* (Appendix B). Based on the pre-screening analysis, there is an indication of potential exposures and associated risks to fenceline communities and therefore EPA conducted a full-screening level analysis for 1-BP.

123

124

125

126

127

128

#### ***Full-Screening Analysis***

129

A total of 14 OES were evaluated for 1-BP as presented in Table 3-5. A total of 59 real facilities and 5 surrogate facilities were modeled. Exposure modeling was also performed for those OES where releases were estimated, although there is no real facility associated with those estimates and therefore a “number of facilities” is not available for those OES. Inputs for all AERMOD model runs for all exposure scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Input Parameters for AERMOD for 1-BP and MC* (Appendix B).

130

131

132

133

134

135

136

**Table 3-5. Fenceline Community Exposure Scenarios for 1-BP**

OES	Release Data Source	Number of Facilities in OES <sup>a</sup>
Aerosol Spray Degreaser/Cleaner	Estimate	–
Asphalt Extraction	TRI (2016–2017)	1 surrogate
Degreasing	TRI (2019)	34
Dry-Cleaning	Estimate	– (2 surrogate)
Processing into Formulation	TRI	11
Import	TRI	4

OES	Release Data Source	Number of Facilities in OES <sup>a</sup>
Processing-Incorporation into Articles	TRI (2016–2018)	1 surrogate
Manufacturing	TRI	2
Other Uses – Cutting Oils	TRI	5
Processing as Reactant	TRI (2016–2018)	1 surrogate
Recycling and Disposal	TRI	2
Repackaging	TRI	1
Spot Cleaner/Stain Remover	Estimate	–
Spray Adhesives	Estimate	–
	<b>Total</b>	<b>59 (+5 surrogate)</b>
<sup>a</sup> When (–) is indicated for the number of facilities in OES, no facilities were identified via TRI reporting. The provided estimates are based on modeling of theoretical facilities.		

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

Modeling results for inhalation exposure concentrations are categorized by OES and presented by facility. Daily and annual average concentrations are summarized for three percentile concentrations (10th, 50th, 95th) to cover the range of exposure concentrations across all nine distances modeled (5, 10, 30, 60, 100, 100 to 1,000, 2,500, 5,000, and 10,000 meters) and can be found in the Supplemental File *SF\_FLA\_Air Pathway Full-Screen Results for 1-BP* (Appendix B). Exposure concentrations are presented as a total concentration to inform the total exposure to a given receptor at each modeled distance from each releasing facility. EPA did not identify air monitoring data to which modeled concentrations could be compared at the distances modeled.

EPA conducted a source attribution analysis which provides exposure concentrations from each release type (fugitive and stack) at each modeled distance for each facility in anticipation of informing future risk management actions and the potential need for a more detailed analysis if risks are identified. For facilities reporting both fugitive and stack releases within TRI, adding the exposure concentrations for each release type at each modeled distance provides the total concentration used for risk calculation purposes in this report.

EPA further distilled exposure results for the 95th percentile values across all facilities within each OES, at all nine distances modeled, and is presenting them in Table 3-6. The purpose of this further distillation is to present a smaller subset of results within the body of this report. The further distilled results presented here are carried into the risk characterization section of the body of this report for risk calculation purposes.

The minimum and maximum concentrations in Table 3-6 represent the lowest and highest 95th percentile concentrations, respectively, among all facilities categorized into the respective OES at each distance modeled. The mean 95th percentile concentrations in Table 3-6 represent arithmetic averages across all facilities within the given OES at each distance modeled. Additionally, for certain OES, there are a variety of industry types and release points (stack, fugitive, stack, and fugitive) categorized within an OES which may not be directly comparable. This results in a wide range of modeled exposure

166 concentrations which, in some cases, extends over many orders of magnitude. For example, in the  
167 degreaser OES, there are 34 facilities that may include open-top degreasers, batch degreasers, closed-  
168 loop degreasers, and others. Although releases within an industry type may be comparable, releases  
169 across industry types may have considerably different emission profiles and therefore may not be  
170 comparable. Further, looking at the release points, EPA found that fugitive releases do not have much  
171 lift or dispersion resulting in higher concentrations very near facilities (around 10 meters) and lower  
172 concentrations around 100 meters. In contrast, stack releases often have more lift and dispersion  
173 resulting in lower concentrations around 10 meters and higher concentrations around 100 meters. Even  
174 with these different concentration profiles, the modeled exposure concentrations from stacks are still  
175 several orders of magnitude lower than fugitive concentrations. This can skew the mean of the 95th  
176 percentile modeled concentrations across multiple facilities orders of magnitude lower, thus  
177 underestimating exposures and associated risks.

178  
179  
180

1 **Table 3-6. 95th Percentile Exposure Concentration Summary across Facilities within Each OES for 1-BP**

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Aerosol Spray Degreaser/Cleaner		5		3.92E-03	6.70E-03	9.91E-03		8.11E-04	1.83E-03	3.08E-03
		10		6.91E-03	9.65E-03	1.27E-02		1.47E-03	2.57E-03	3.88E-03
		30		2.81E-03	3.39E-03	3.97E-03		5.83E-04	8.13E-04	1.08E-03
		60		9.54E-04	1.17E-03	1.40E-03		2.12E-04	2.78E-04	3.49E-04
		100		3.55E-04	4.42E-04	5.40E-04		8.30E-05	1.06E-04	1.30E-04
		100-1,000		9.22E-06	1.11E-05	1.31E-05		5.61E-06	6.93E-06	8.22E-06
		2,500		3.49E-07	4.24E-07	5.07E-07		8.65E-08	1.29E-07	2.10E-07
		5,000		9.58E-08	1.19E-07	1.41E-07		2.40E-08	3.97E-08	6.78E-08
		10,000		3.08E-08	4.44E-08	5.88E-08		1.04E-08	1.64E-08	2.69E-08
Asphalt Extraction	1	5	7.59E-02				2.88E-02			
		10	1.57E-01				6.77E-02			
		30	8.57E-02				3.73E-02			
		60	3.71E-02				1.62E-02			
		100	1.92E-02				8.46E-03			
		100-1,000	1.62E-03				8.43E-04			
		2,500	1.72E-04				6.39E-05			
		5,000	5.89E-05				2.13E-05			
		10,000	1.98E-05				7.04E-06			



OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Degreasing	34	5		1.79E-12	1.96E-01	1.79E+00		3.19E-11	6.69E-02	6.53E-01
		10		3.29E-10	2.46E-01	2.13E+00		2.16E-09	8.50E-02	8.23E-01
		30		2.12E-06	8.27E-02	6.43E-01		5.21E-07	2.69E-02	2.42E-01
		60		1.48E-05	3.08E-02	2.28E-01		5.60E-06	9.74E-03	8.32E-02
		100		3.15E-05	1.37E-02	9.53E-02		1.26E-05	4.27E-03	3.48E-02
		100–1,000		7.13E-06	8.41E-04	5.30E-03		4.20E-06	4.52E-04	3.01E-03
		2,500		1.04E-06	7.27E-05	4.09E-04		3.25E-07	2.10E-05	1.42E-04
		5,000		5.01E-07	2.58E-05	1.62E-04		1.39E-07	7.37E-06	4.62E-05
		10,000		1.99E-07	9.20E-06	6.93E-05		6.25E-08	2.77E-06	1.82E-05
Dry Cleaning	–	5		7.10E-04	9.66E-03	3.73E-02		1.59E-04	2.99E-03	1.37E-02
		10		1.22E-03	1.32E-02	4.55E-02		2.91E-04	4.18E-03	1.71E-02
		30		5.89E-04	5.25E-03	1.64E-02		1.37E-04	1.54E-03	5.80E-03
		60		2.27E-04	2.07E-03	6.68E-03		5.15E-05	5.85E-04	2.26E-03
		100		9.85E-05	9.01E-04	2.97E-03		2.22E-05	2.60E-04	1.04E-03
		100–1,000		4.95E-06	4.40E-05	1.46E-04		2.40E-06	2.80E-05	1.05E-04
		2,500		2.54E-07	2.49E-06	7.81E-06		7.54E-08	1.30E-06	5.44E-06
		5,000		6.92E-08	7.08E-07	2.18E-06		2.50E-08	4.27E-07	1.90E-06
		10,000		2.29E-08	2.31E-07	7.20E-07		8.61E-09	1.44E-07	6.63E-07

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Processing into Formulation	11	5		2.41E-11	5.73E-03	2.55E-02		2.20E-11	2.29E-03	1.17E-02
		10		7.63E-10	7.28E-03	3.87E-02		8.07E-10	3.02E-03	1.62E-02
		30		4.22E-07	2.91E-03	1.83E-02		1.50E-07	1.22E-03	8.04E-03
		60		6.70E-06	1.19E-03	7.80E-03		2.47E-06	4.95E-04	3.41E-03
		100		1.72E-05	5.78E-04	3.84E-03		6.01E-06	2.38E-04	1.67E-03
		100–1,000		5.57E-06	4.67E-05	3.06E-04		2.70E-06	2.59E-05	1.72E-04
		2,500		6.54E-07	4.23E-06	2.49E-05		2.01E-07	1.46E-06	8.93E-06
		5,000		2.51E-07	1.54E-06	8.55E-06		7.63E-08	5.06E-07	2.89E-06
		10,000		8.70E-08	5.59E-07	2.95E-06		2.82E-08	1.78E-07	9.46E-07
Import	4	5		7.82E-16	2.92E-03	7.09E-03		3.06E-13	6.37E-04	1.56E-03
		10		9.90E-12	4.41E-03	1.03E-02		2.98E-10	8.76E-04	1.95E-03
		30		1.03E-06	1.46E-03	3.12E-03		3.52E-07	2.55E-04	5.72E-04
		60		2.64E-05	4.91E-04	9.90E-04		6.52E-06	8.81E-05	1.89E-04
		100		5.65E-05	2.02E-04	3.62E-04		1.28E-05	3.78E-05	6.86E-05
		100–1,000		5.59E-06	6.37E-06	7.38E-06		3.40E-06	4.12E-06	5.23E-06
		2,500		1.53E-07	1.94E-07	2.40E-07		5.54E-08	6.41E-08	7.61E-08
		5,000		1.69E-08	3.94E-08	6.55E-08		1.76E-08	2.17E-08	2.76E-08
		10,000		1.57E-09	1.04E-08	1.92E-08		7.86E-09	1.01E-08	1.32E-08

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Processing– Incorporation into Articles	1	5	1.86E-02				5.03E-03			
		10	1.99E-02				5.52E-03			
		30	6.36E-03				1.74E-03			
		60	2.48E-03				6.73E-04			
		100	1.18E-03				3.26E-04			
		100–1,000	1.12E-04				5.39E-05			
		2,500	1.26E-05				3.07E-06			
		5,000	4.44E-06				1.04E-06			
		10,000	1.51E-06				3.50E-07			
Manufacturing	2	5		2.86E-10	3.87E-02	1.08E-01		1.86E-10	1.45E-02	4.06E-02
		10		4.80E-09	5.19E-02	1.45E-01		1.70E-09	1.96E-02	5.48E-02
		30		9.30E-07	1.82E-02	5.08E-02		2.44E-07	7.48E-03	2.09E-02
		60		1.01E-05	7.45E-03	2.08E-02		3.95E-06	3.00E-03	8.39E-03
		100		2.30E-05	3.52E-03	9.83E-03		8.94E-06	1.41E-03	3.94E-03
		100–1,000		7.95E-06	2.89E-04	8.03E-04		3.83E-06	1.67E-04	4.65E-04
		2,500		2.02E-06	2.69E-05	7.45E-05		6.55E-07	8.86E-06	2.46E-05
		5,000		9.75E-07	1.05E-05	2.91E-05		2.94E-07	3.16E-06	8.75E-06
		10,000		4.41E-07	4.08E-06	1.13E-05		1.27E-07	1.15E-06	3.17E-06

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Other Uses – Cutting Oil	5	5		7.89E-10	8.32E-03	3.81E-02		4.38E-07	3.63E-03	1.69E-02
		10		1.47E-06	8.53E-03	3.66E-02		2.68E-06	4.16E-03	1.87E-02
		30		4.13E-05	2.75E-03	1.10E-02		1.12E-05	1.36E-03	5.91E-03
		60		1.76E-05	1.04E-03	4.04E-03		8.44E-06	5.12E-04	2.18E-03
		100		8.84E-06	4.76E-04	1.79E-03		4.20E-06	2.32E-04	9.73E-04
		100–1,000		7.59E-07	3.29E-05	1.19E-04		4.36E-07	2.04E-05	7.81E-05
		2,500		7.33E-08	2.68E-06	9.11E-06		2.78E-08	1.17E-06	4.51E-06
		5,000		2.99E-08	8.98E-07	3.04E-06		1.04E-08	3.79E-07	1.44E-06
		10,000		1.20E-08	3.05E-07	1.04E-06		3.95E-09	1.23E-07	4.65E-07
Processing as Reactant	1	5	9.90E-03				3.61E-03			
		10	1.43E-02				5.66E-03			
		30	6.10E-03				2.30E-03			
		60	2.49E-03				9.16E-04			
		100	1.16E-03				4.26E-04			
		100–1,000	8.19E-05				5.03E-05			
		2,500	6.45E-06				1.94E-06			
		5,000	2.13E-06				6.35E-07			
		10,000	7.07E-07				2.10E-07			

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Recycling and Disposal	2	5		2.68E-04	3.90E-04	5.11E-04		7.19E-05	1.05E-04	1.38E-04
		10		5.00E-04	7.00E-04	8.99E-04		1.48E-04	1.93E-04	2.37E-04
		30		2.64E-04	3.61E-04	4.57E-04		7.50E-05	9.65E-05	1.18E-04
		60		1.09E-04	1.52E-04	1.95E-04		3.02E-05	3.94E-05	4.86E-05
		100		5.43E-05	7.50E-05	9.57E-05		1.42E-05	1.91E-05	2.39E-05
		100–1,000		3.88E-06	5.53E-06	7.18E-06		1.82E-06	2.63E-06	3.44E-06
		2,500		3.53E-07	4.88E-07	6.22E-07		7.26E-08	1.05E-07	1.38E-07
		5,000		1.15E-07	1.63E-07	2.11E-07		2.42E-08	3.51E-08	4.60E-08
		10,000		3.88E-08	5.30E-08	6.72E-08		8.20E-09	1.19E-08	1.55E-08
Repackaging	1	5	2.69E-03				6.19E-04			
		10	3.84E-03				8.12E-04			
		30	1.24E-03				2.32E-04			
		60	3.96E-04				7.48E-05			
		100	1.42E-04				2.73E-05			
		100–1,000	2.79E-06				1.82E-06			
		2,500	6.84E-08				3.62E-08			
		5,000	1.04E-08				1.40E-08			
		10,000	1.22E-09				7.11E-09			

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Spot Cleaner/Stain Remover	–	5		1.03E-03	1.54E-03	2.03E-03		2.12E-04	4.41E-04	6.74E-04
		10		1.84E-03	2.25E-03	2.64E-03		3.94E-04	6.27E-04	8.66E-04
		30		7.58E-04	8.00E-04	8.40E-04		1.60E-04	2.01E-04	2.43E-04
		60		2.58E-04	2.77E-04	2.98E-04		5.89E-05	6.90E-05	7.89E-05
		100		9.61E-05	1.05E-04	1.14E-04		2.35E-05	2.66E-05	2.95E-05
		100–1,000		2.55E-06	2.74E-06	2.93E-06		1.67E-06	1.82E-06	2.08E-06
		2,500		9.40E-08	1.04E-07	1.17E-07		2.52E-08	3.37E-08	4.60E-08
		5,000		2.77E-08	2.92E-08	3.15E-08		6.85E-09	1.02E-08	1.48E-08
		10,000		9.60E-09	1.10E-08	1.22E-08		2.82E-09	4.02E-09	5.59E-09
Spray Adhesives	–	5	1.68E-11				5.01E-11			
		10	1.66E-08				6.42E-09			
		30	9.56E-06				2.48E-06			
		60	7.33E-05				2.35E-05			
		100	1.33E-04				4.34E-05			
		100–1,000	1.63E-05				1.03E-05			
		2,500	8.95E-07				2.90E-07			
		5,000	3.58E-07				1.11E-07			
		10,000	1.62E-07				5.08E-08			

OES <sup>a</sup>	Number of TRI Facilities Evaluated <sup>b</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
<p><sup>a</sup> Thermax Installation was not evaluated for general population exposure as it is an indoor installation activity and EPA does not expect general population exposure to occur from such activity. Thermax Installation was evaluated for occupational and consumer exposure as a condition of use in the 2020 published risk evaluation for 1-BP.</p> <p><sup>b</sup> When (–) is indicated for the total number of facilities, no facilities were identified via TRI reporting. The provided estimates are based on modeling of theoretical facilities.</p>										

2  
3  
4

**Co-resident Analysis**

EPA evaluated one OES (dry-cleaning) using the co-resident screening methodology. Site specific emission data was not identified for dry-cleaners using 1-BP so far-field indoor air concentrations within the dry-cleaner shop were modeled, and estimated emission rates were for third generation dry-cleaning machines. For this work, all emissions from dry cleaning activities are assumed to be fugitive emissions. EPA considered both dry-cleaning and spot-cleaning operations for 1-BP.

Estimated emission rates were provided for nine emission scenarios, representing a variety of operational scales, conditions, and source strengths. Exposure scenarios include two building configurations, each with two different methods for estimating Q12, resulting in a total of 36 exposure scenarios which were modeled with IECCU. Table 3-7 provides a summary of the 36 exposure scenarios evaluated for 1-BP co-resident analysis. Inputs for all IECCU model runs for all exposure scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Information for Co-Resident Exposure Modeling for 1-BP* (Appendix B).

**Table 3-7. Simulation Matrix for Evaluating Co-resident Exposures from Dry-Cleaning Operations (IECCU) for 1-BP**

Serial No.	Building Type	Method for Estimating Q12	1-BP Emission Scenario	Model File Name
1	B1 –Two zones – architecturally separated	Method 1 – Literature (monitored)	1	01-B1-M1-S1.IEC
2			2	02-B1-M1-S2.IEC
3			3	03-B1-M1-S3.IEC
4			4	04-B1-M1-S4.IEC
5			5	05-B1-M1-S5.IEC
6			6	06-B1-M1-S6.IEC
7			7	07-B1-M1-S7.IEC
8			8	08-B1-M1-S8.IEC
9			9	09-B1-M1-S9.IEC
10		Method 2 – Stack effect	1	10-B1-M2-S1.IEC
11			2	11-B1-M2-S2.IEC
12			3	12-B1-M2-S3.IEC
13			4	13-B1-M2-S4.IEC
14			5	14-B1-M2-S5.IEC
15			6	15-B1-M2-S6.IEC
16			7	16-B1-M2-S7.IEC
17			8	17-B1-M2-S8.IEC
18			9	18-B1-M2-S9.IEC



Serial No.	Building Type	Method for Estimating Q12	1-BP Emission Scenario	Model File Name
19	B2 – Two zones – architecturally inter-connected	Method 3 –Literature (recommended)	1	19-B2-M3-S1.IEC
20			2	20-B2-M3-S2.IEC
21			3	21-B2-M3-S3.IEC
22			4	22-B2-M3-S4.IEC
23			5	23-B2-M3-S5.IEC
24			6	24-B2-M3-S6.IEC
25			7	25-B2-M3-S7.IEC
26			8	26-B2-M3-S8.IEC
27			9	27-B2-M3-S9.IEC
28		Method 4 – HVAC Recirculation Rate	1	28-B2-M4-S1.IEC
29			2	29-B2-M4-S2.IEC
30			3	30-B2-M4-S3.IEC
31			4	31-B2-M4-S4.IEC
32			5	32-B2-M4-S5.IEC
33			6	33-B2-M4-S6.IEC
34			7	34-B2-M4-S7.IEC
35			8	35-B2-M4-S8.IEC
36			9	36-B2-M4-S9.IEC

18  
19  
20  
21  
22  
23  
24

The maximum and central tendency unadjusted 24-hour TWA and adjusted annual TWA predicted 1-BP concentrations from IECCU are summarized in Table 3-8. All exposure concentrations and associated calculated TWA values for all IECCU model runs for all exposure scenarios are included in Supplemental File SF\_FL\_Air Pathway Information for Co-Resident Exposure Modeling for 1-BP (Appendix B).

25 **Table 3-8. Predicted 1-BP Concentrations for Co-resident Apartment**

Building Configuration	Method for Estimating Q <sub>12</sub>	Predicted 1-BP Concentrations (ppm)			
		Unadjusted 24-hour TWA		Adjusted Annual TWA	
		High End	Central Tendency	High End	Central Tendency
B1	Method 1 (Q <sub>12</sub> = 0.822 m <sup>3</sup> /hr)	0.10	0.02	0.09	0.02
	Method 2 (Q <sub>12</sub> = 3.39 m <sup>3</sup> /hr)	0.42	0.07	0.36	0.06
B2	Method 3 (Q <sub>12</sub> = 134 m <sup>3</sup> /hr)	5.15	1.16	4.41	0.95
	Method 4 (Q <sub>12</sub> = 1,960 m <sup>3</sup> /hr)	5.16	1.35	4.41	1.11

26 **3.1.5 Risk Characterization for 1-BP**27 **3.1.5.1 Fenceline Inhalation Risk for 1-BP**

28 EPA calculated risk estimates for each of the endpoints in Table 3-2 across all known TRI reporters and  
 29 other modeled facilities under each OES. EPA calculated risk estimates for each facility using the 10th,  
 30 50th, and 95th percentile of modeled exposure concentrations around the releasing facility. The 95th  
 31 percentile estimates were then further distilled across facilities within a given OES to present the range  
 32 from minimum to maximum risk.

33  
 34 Based on the 95th percentile values, risks were indicated for at least one facility relative to benchmarks  
 35 for 13 of 14 OES. Risks were not indicated for any OES beyond 1,000 m from a facility. These results  
 36 are summarized below in Table 3-9. Results for 10th and 50th percentile measurements along with  
 37 facility-specific results are provided in SF\_FL\_Air Pathway Full-Screen Results for 1-BP (Appendix  
 38 B).

1 **Table 3-9. 1-BP Inhalation Risk across OES at Various Distances from Releasing Facility (Based on 95th Percentile Exposure**  
 2 **Concentrations)**

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 100)				Chronic (Benchmark 100)										
	Total <sup>a</sup>	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Aerosol Spray Degreaser/Cleaner	-	-	5	N/A	1,531	895	605	N/A	7,398	3,271	1,948	N/A	4.9E-06	1.1E-05	1.8E-05
			10	N/A	868	622	472	N/A	4,082	2,337	1,546	N/A	8.8E-06	1.5E-05	2.3E-05
			30	N/A	2,135	1,771	1,511	N/A	1.0E+04	7,377	5,556	N/A	3.5E-06	4.9E-06	6.5E-06
			60	N/A	6,289	5,131	4,286	N/A	2.8E+04	2.2E+04	1.7E+04	N/A	1.3E-06	1.7E-06	2.1E-06
			100	N/A	1.7E+04	1.4E+04	1.1E+04	N/A	7.2E+04	5.7E+04	4.6E+04	N/A	5.0E-07	6.4E-07	7.8E-07
			100-1,000	N/A	6.5E+05	5.4E+05	4.6E+05	N/A	1.1E+06	8.7E+05	7.3E+05	N/A	3.4E-08	4.2E-08	4.9E-08
			2,500	N/A	1.7E+07	1.4E+07	1.2E+07	N/A	6.9E+07	4.7E+07	2.9E+07	N/A	5.2E-10	7.7E-10	1.3E-09
			5,000	N/A	6.3E+07	5.1E+07	4.3E+07	N/A	2.5E+08	1.5E+08	8.8E+07	N/A	1.4E-10	2.4E-10	4.1E-10
10,000	N/A	1.9E+08	1.4E+08	1.0E+08	N/A	5.8E+08	3.7E+08	2.2E+08	N/A	6.2E-11	9.8E-11	1.6E-10			
Asphalt Extraction	1	1	5	79	-	-	-	208	-	-	-	1.7E-04			
			10	38	-	-	-	89	-	-	-	4.1E-04			
			30	70	-	-	-	161	-	-	-	2.2E-04			
			60	162	-	-	-	370	-	-	-	9.7E-05			
			100	313	-	-	-	709	-	-	-	5.1E-05			
			100-1,000	3,704	-	-	-	7,117	-	-	-	5.1E-06			
			2,500	3.4E+3	-	-	-	9.4E+04	-	-	-	3.8E-07			
			5,000	1.0E+05	-	-	-	2.8E+05	-	-	-	1.3E-07			
10,000	3.0E+05	-	-	-	8.5E+05	-	-	-	4.2E-08						
Degreasing	34	30	5	N/A	3.4E+12	31	3	N/A	1.9E+11	90	9	N/A	1.9E-13	4.0E-04	3.9E-03
			10	N/A	1.8E+10	24	3	N/A	2.8E+09	71	7	N/A	1.3E-11	5.1E-04	4.9E-03
			30	N/A	2.8E+06	73	9	N/A	1.2E+07	223	25	N/A	3.1E-09	1.6E-04	1.5E-03
			60	N/A	4.1E+05	195	26	N/A	1.1E+06	616	72	N/A	3.4E-08	5.8E-05	5.0E-04
			100	N/A	1.9E+05	438	63	N/A	4.8E+05	1,404	172	N/A	7.6E-08	2.6E-05	2.1E-04
			100-1,000	N/A	8.4E+05	7,134	1,132	N/A	1.4E+06	1.3E+04	1,993	N/A	2.5E-08	2.7E-06	1.8E-05
			2,500	N/A	5.8E+06	8.3E+04	1.5E+04	N/A	1.8E+07	2.9E+05	4.2E+04	N/A	2.0E-09	1.3E-07	8.5E-07
			5,000	N/A	1.2E+07	2.3E+05	3.7E+04	N/A	4.3E+07	8.1E+05	1.3E+05	N/A	8.3E-10	4.4E-08	2.8E-07

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 100)				Chronic (Benchmark 100)										
	Total <sup>a</sup>	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Dry Cleaning	-	-	10,000	N/A	3.0E+07	6.5E+05	8.7E+04	N/A	9.6E+07	2.2E+06	3.3E+05	N/A	3.8E-10	1.7E-08	1.1E-07
			5	N/A	8,451	621	161	N/A	3.8E+04	2,004	438	N/A	9.5E-07	<b>1.8E-05</b>	<b>8.2E-05</b>
			10	N/A	4,918	456	132	N/A	2.1E+04	1,434	351	N/A	<b>1.7E-06</b>	<b>2.5E-05</b>	<b>1.0E-04</b>
			30	N/A	1.0E+04	1,143	366	N/A	4.4E+04	3,886	1,034	N/A	8.2E-07	<b>9.3E-06</b>	<b>3.5E-05</b>
			60	N/A	2.6E+04	2,903	898	N/A	1.2E+05	1.0E+04	2,655	N/A	3.1E-07	<b>3.5E-06</b>	<b>1.4E-05</b>
			100	N/A	6.1E+04	6,659	2,020	N/A	2.7E+05	2.3E+04	5,769	N/A	1.3E-07	<b>1.6E-06</b>	<b>6.2E-06</b>
			100-1,000	N/A	1.2E+06	1.4E+05	4.1E+04	N/A	2.5E+06	2.1E+05	5.7E+04	N/A	1.4E-08	1.7E-07	6.3E-07
			2,500	N/A	2.4E+07	2.4E+06	7.7E+05	N/A	8.0E+07	4.6E+06	1.1E+06	N/A	4.5E-10	7.8E-09	3.3E-08
			5,000	N/A	8.7E+07	8.5E+06	2.8E+06	N/A	2.4E+08	1.4E+07	3.2E+06	N/A	1.5E-10	2.6E-09	1.1E-08
10,000	N/A	2.6E+08	2.6E+07	8.3E+06	N/A	7.0E+08	4.2E+07	9.0E+06	N/A	5.2E-11	8.6E-10	4.0E-09			
Processing into Formulation	11	9	5	N/A	2.5E+11	1,048	235	N/A	2.7E+11	2,617	513	N/A	1.3E-13	<b>1.4E-05</b>	<b>7.0E-05</b>
			10	N/A	7.9E+09	824	155	N/A	7.4E+09	1,986	370	N/A	4.8E-12	<b>1.8E-05</b>	<b>9.7E-05</b>
			30	N/A	1.4E+07	2,063	328	N/A	4.0E+07	4,912	746	N/A	9.0E-10	<b>7.3E-06</b>	<b>4.8E-05</b>
			60	N/A	9.0E+05	5,046	769	N/A	2.4E+06	1.2E+04	1,760	N/A	1.5E-08	<b>3.0E-06</b>	<b>2.0E-05</b>
			100	N/A	3.5E+05	1.0E+04	1,563	N/A	1.0E+06	2.5E+04	3,593	N/A	3.6E-08	<b>1.4E-06</b>	<b>1.0E-05</b>
			100-1,000	N/A	1.1E+06	1.3E+05	2.0E+04	N/A	2.2E+06	2.3E+05	3.5E+04	N/A	1.6E-08	1.6E-07	<b>1.0E-06</b>
			2,500	N/A	9.2E+06	1.4E+06	2.4E+05	N/A	3.0E+07	4.1E+06	6.7E+05	N/A	1.2E-09	8.7E-09	5.4E-08
			5,000	N/A	2.4E+07	3.9E+06	7.0E+05	N/A	7.9E+07	1.2E+07	2.1E+06	N/A	4.6E-10	3.0E-09	1.7E-08
			10,000	N/A	6.9E+07	1.1E+07	2.0E+06	N/A	2.1E+08	3.4E+07	6.3E+06	N/A	1.7E-10	1.1E-09	5.7E-09
Import	4	4	5	N/A	7.7E+15	2,054	846	N/A	2.0E+13	9,417	3,846	N/A	1.8E-15	<b>3.8E-06</b>	<b>9.4E-06</b>
			10	N/A	6.1E+11	1,361	583	N/A	2.0E+10	6,847	3,077	N/A	1.8E-12	<b>5.3E-06</b>	<b>1.2E-05</b>
			30	N/A	5.8E+06	4,108	1,923	N/A	1.7E+07	2.4E+04	1.0E+04	N/A	2.1E-09	<b>1.5E-06</b>	<b>3.4E-06</b>
			60	N/A	2.3E+05	1.2E+04	6,061	N/A	9.2E+05	6.8E+04	3.2E+04	N/A	3.9E-08	5.3E-07	<b>1.1E-06</b>
			100	N/A	1.1E+05	3.0E+04	1.7E+04	N/A	4.7E+05	1.6E+05	8.7E+04	N/A	7.7E-08	2.3E-07	4.1E-07
			100-1,000	N/A	1.1E+06	9.4E+05	8.1E+05	N/A	1.8E+06	1.5E+06	1.1E+06	N/A	2.0E-08	2.5E-08	3.1E-08
			2,500	N/A	3.9E+07	3.1E+07	2.5E+07	N/A	1.1E+08	9.4E+07	7.9E+07	N/A	3.3E-10	3.8E-10	4.6E-10
			5,000	N/A	3.6E+08	1.5E+08	9.2E+07	N/A	3.4E+08	2.8E+08	2.2E+08	N/A	1.1E-10	1.3E-10	1.7E-10
			10,000	N/A	3.8E+09	5.8E+08	3.1E+08	N/A	7.6E+08	6.0E+08	4.5E+08	N/A	4.7E-11	6.0E-11	7.9E-11

Public Comment Draft – Do Not Cite or Quote

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 100)				Chronic (Benchmark 100)				Single Facility	Min Risk	Mean Risk	Max Risk			
	Single Facility	Min Risk <sup>b</sup>		Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk					Max Risk		
Total <sup>a</sup>	w/ Risk														
Processing-Incorporation into Articles	1	1	5	323	–	–	–	1,193	–	–	–	3.0E-05			
			10	302	–	–	–	1,087	–	–	–	3.3E-05			
			30	943	–	–	–	3,448	–	–	–	1.0E-05			
			60	2,419	–	–	–	8,915	–	–	–	4.0E-06			
			100	5,085	–	–	–	1.8E+04	–	–	–	2.0E-06			
			100–1,000	5.4E+04	–	–	–	1.1E+05	–	–	–	3.2E-07			
			2,500	4.8E+05	–	–	–	2.0E+06	–	–	–	1.8E-08			
			5,000	1.4E+06	–	–	–	5.8E+06	–	–	–	6.2E-09			
			10,000	4.0E+06	–	–	–	1.7E+07	–	–	–	2.1E-09			
Manufacturing	2	2	5	N/A	2.1E+10	155	56	N/A	3.2E+10	413	148	N/A	1.1E-12	8.7E-05	2.4E-04
			10	N/A	1.3E+09	116	41	N/A	3.5E+09	306	109	N/A	1.0E-11	1.2E-04	3.3E-04
			30	N/A	6.5E+06	330	118	N/A	2.5E+07	802	287	N/A	1.5E-09	4.5E-05	1.3E-04
			60	N/A	5.9E+05	805	288	N/A	1.5E+06	1,997	715	N/A	2.4E-08	1.8E-05	5.0E-05
			100	N/A	2.6E+05	1,704	610	N/A	6.7E+05	4,251	1,523	N/A	5.4E-08	8.5E-06	2.4E-05
			100–1,000	N/A	7.5E+05	2.1E+04	7,472	N/A	1.6E+06	3.6E+04	1.3E+04	N/A	2.3E-08	1.0E-06	2.8E-06
			2,500	N/A	3.0E+06	2.2E+05	8.1E+04	N/A	9.2E+06	6.8E+05	2.4E+05	N/A	3.9E-09	5.3E-08	1.5E-07
			5,000	N/A	6.2E+06	5.7E+05	2.1E+05	N/A	2.0E+07	1.9E+06	6.9E+05	N/A	1.8E-09	1.9E-08	5.3E-08
			10,000	N/A	1.4E+07	1.5E+06	5.3E+05	N/A	4.7E+07	5.2E+06	1.9E+06	N/A	7.6E-10	6.9E-09	1.9E-08
Other Uses-Cutting Oils	5	2	5	N/A	7.6E+09	721	157	N/A	1.4E+07	1,654	355	N/A	2.6E-09	2.2E-05	1.0E-04
			10	N/A	4.1E+06	704	164	N/A	2.2E+06	1,441	321	N/A	1.6E-08	2.5E-05	1.1E-04
			30	N/A	1.5E+05	2,179	545	N/A	5.4E+05	4,408	1,015	N/A	6.7E-08	8.2E-06	3.5E-05
			60	N/A	3.4E+05	5,743	1,485	N/A	7.1E+05	1.2E+04	2,752	N/A	5.1E-08	3.1E-06	1.3E-05
			100	N/A	6.8E+05	1.3E+04	3,352	N/A	1.4E+06	2.6E+04	6,166	N/A	2.5E-08	1.4E-06	5.8E-06
			100–1,000	N/A	7.9E+06	1.8E+05	5.0E+04	N/A	1.4E+07	2.9E+05	7.7E+04	N/A	2.6E-09	1.2E-07	4.7E-07
			2,500	N/A	8.2E+07	2.2E+06	6.6E+05	N/A	2.2E+08	5.1E+06	1.3E+06	N/A	1.7E-10	7.0E-09	2.7E-08
			5,000	N/A	2.0E+08	6.7E+06	2.0E+06	N/A	5.8E+08	1.6E+07	4.2E+06	N/A	6.2E-11	2.3E-09	8.6E-09
			10,000	N/A	5.0E+08	2.0E+07	5.8E+06	N/A	1.5E+09	4.9E+07	1.3E+07	N/A	2.4E-11	7.4E-10	2.8E-09

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 100)				Chronic (Benchmark 100)				Single Facility	Min Risk	Mean Risk	Max Risk			
	Single Facility	Min Risk <sup>b</sup>		Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk					Max Risk		
Total <sup>a</sup>	w/ Risk														
Processing as Reactant	1	1	5	606	–	–	–	1,662	–	–	–	2.2E-05			
			10	420	–	–	–	1,060	–	–	–	3.4E-05			
			30	984	–	–	–	2,609	–	–	–	1.4E-05			
			60	2,410	–	–	–	6,550	–	–	–	5.5E-06			
			100	5,172	–	–	–	1.4E+04	–	–	–	2.6E-06			
			100–1,000	7.3E+04	–	–	–	1.2E+05	–	–	–	3.0E-07			
			2,500	9.3E+05	–	–	–	3.1E+06	–	–	–	1.2E-08			
			5,000	2.8E+06	–	–	–	9.4E+06	–	–	–	3.8E-09			
			10,000	8.5E+06	–	–	–	2.9E+07	–	–	–	1.3E-09			
Recycling and Disposal	2	1	5	N/A	2.2E+04	1.5E+04	1.2E+04	N/A	8.3E+04	5.7E+04	4.3E+04	N/A	4.3E-07	6.3E-07	8.3E-07
			10	N/A	1.2E+04	8,578	6,674	N/A	4.1E+04	3.1E+04	2.5E+04	N/A	8.9E-07	1.2E-06	1.4E-06
			30	N/A	2.3E+04	1.7E+04	1.3E+04	N/A	8.0E+04	6.2E+04	5.1E+04	N/A	4.5E-07	5.8E-07	7.1E-07
			60	N/A	5.5E+04	3.9E+04	3.1E+04	N/A	2.0E+05	1.5E+05	1.2E+05	N/A	1.8E-07	2.4E-07	2.9E-07
			100	N/A	1.1E+05	8.0E+04	6.3E+04	N/A	4.2E+05	3.1E+05	2.5E+05	N/A	8.5E-08	1.1E-07	1.4E-07
			100–1,000	N/A	1.5E+06	1.1E+06	8.4E+05	N/A	3.3E+06	2.3E+06	1.7E+06	N/A	1.1E-08	1.6E-08	2.1E-08
			2,500	N/A	1.7E+07	1.2E+07	9.6E+06	N/A	8.3E+07	5.7E+07	4.3E+07	N/A	4.4E-10	6.3E-10	8.3E-10
			5,000	N/A	5.2E+07	3.7E+07	2.8E+07	N/A	2.5E+08	1.7E+08	1.3E+08	N/A	1.5E-10	2.1E-10	2.8E-10
			10,000	N/A	1.5E+08	1.1E+08	8.9E+07	N/A	7.3E+08	5.1E+08	3.9E+08	N/A	4.9E-11	7.1E-11	9.3E-11
Repackaging	1	1	5	2,230	–	–	–	9,693	–	–	–	3.7E-06			
			10	1,563	–	–	–	7,389	–	–	–	4.9E-06			
			30	4,839	–	–	–	2.6E+04	–	–	–	1.4E-06			
			60	1.5E+04	–	–	–	8.0E+04	–	–	–	4.5E-07			
			100	4.2E+04	–	–	–	2.2E+05	–	–	–	1.6E-07			
			100–1,000	2.2E+06	–	–	–	3.3E+06	–	–	–	1.1E-08			
			2,500	8.8E+07	–	–	–	1.7E+08	–	–	–	2.2E-10			
			5,000	5.8E+08	–	–	–	4.3E+08	–	–	–	8.4E-11			
			10,000	4.9E+09	–	–	–	8.4E+08	–	–	–	4.3E-11			

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 100)				Chronic (Benchmark 100)				Single Facility	Min Risk	Mean Risk	Max Risk			
	Single Facility	Min Risk <sup>b</sup>		Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk					Max Risk		
Spot Cleaner/ Stain Remover	-	-	5	N/A	5,825	3,896	2,956	N/A	2.8E+04	1.4E+04	8,902	N/A	1.3E-06	2.6E-06	4.0E-06
			10	N/A	3,261	2,668	2,273	N/A	1.5E+04	9,564	6,928	N/A	2.4E-06	3.8E-06	5.2E-06
			30	N/A	7,916	7,505	7,143	N/A	3.8E+04	3.0E+04	2.5E+04	N/A	9.6E-07	1.2E-06	1.5E-06
			60	N/A	2.3E+04	2.2E+04	2.0E+04	N/A	1.0E+05	8.7E+04	7.6E+04	N/A	3.5E-07	4.1E-07	4.7E-07
			100	N/A	6.2E+04	5.7E+04	5.3E+04	N/A	2.6E+05	2.3E+05	2.0E+05	N/A	1.4E-07	1.6E-07	1.8E-07
			100-1,000	N/A	2.4E+06	2.2E+06	2.0E+06	N/A	3.6E+06	3.3E+06	2.9E+06	N/A	1.0E-08	1.1E-08	1.2E-08
			2,500	N/A	6.4E+07	5.8E+07	5.1E+07	N/A	2.4E+08	1.8E+08	1.3E+08	N/A	1.5E-10	2.0E-10	2.8E-10
			5,000	N/A	2.2E+08	2.1E+08	1.9E+08	N/A	8.8E+08	5.9E+08	4.1E+08	N/A	4.1E-11	6.1E-11	8.9E-11
10,000	N/A	6.3E+08	5.4E+08	4.9E+08	N/A	2.1E+09	1.5E+09	1.1E+09	N/A	1.7E-11	2.4E-11	3.4E-11			
Spray Adhesives	-	-	5	3.6E+11	-	-	-	1.2E+11	-	-	-	3.0E-13			
			10	3.6E+08	-	-	-	9.3E+08	-	-	-	3.9E-11			
			30	6.3E+05	-	-	-	2.4E+06	-	-	-	1.5E-08			
			60	8.2E+04	-	-	-	2.6E+05	-	-	-	1.4E-07			
			100	4.5E+04	-	-	-	1.4E+05	-	-	-	2.6E-07			
			100-1,000	3.7E+05	-	-	-	5.8E+05	-	-	-	6.2E-08			
			2,500	6.7E+06	-	-	-	2.1E+07	-	-	-	1.7E-09			
			5,000	1.7E+07	-	-	-	5.4E+07	-	-	-	6.7E-10			
10,000	3.7E+07	-	-	-	1.2E+08	-	-	-	3.0E-10						

<sup>a</sup> When (-) is indicated for the total number of facilities, no facilities were identified via TRI reporting. The provided estimates are based on modeling of theoretical facilities.  
<sup>b</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>c</sup> The mean risk value is the arithmetic mean MOE.  
<sup>d</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

3  
4

### 3.1.5.1.1 Land Use Considerations

EPA identified risk for 52 of the 64 real or surrogate facilities evaluated based on modeled air concentrations. GIS locations were available for 49 of the 52 facilities with risk. For each of these 49 facilities, EPA evaluated land use patterns to determine whether fenceline community exposures are reasonably anticipated at locations where risk is indicated. Details of this methodology are provided in Section 2.1.2.2. In short, EPA evaluated whether residential, industrial/commercial businesses, or other public spaces are present within those radial distances indicating risk (as opposed to uninhabited areas), as well as whether the radial distance lies outside the boundaries of the facility.

Based on characterization of land use patterns, fenceline community exposures are anticipated for 35 of the 49 (71 percent) GIS-located facilities where risk is indicated based on modeled fenceline air concentrations. Table 3-10 summarizes the number of facilities in each OES for which risk is indicated and where fenceline community exposures are anticipated.

**Table 3-10. Summary of Fenceline Community Exposures Expected near Facilities Where Modeled Air Concentrations Indicated Risk for 1-BP**

OES <sup>a</sup>	Total Number of Facilities Evaluated	Number of Facilities with Risk Indicated	Number of Facilities with Risk Indicated and Exposures Expected	Percent of Total Facilities with Risk Indicated and Exposures Expected
Degreasing	34	30	26	77%
Formulation	11	9	6	55%
Import	4	4	2	50%
Other Uses-Cutting Oils	5	2	1	20%
Manufacturing	2	2	0	0%
Repackaging	1	1	0	0%
Recycling and Disposal	2	1	0	0%

<sup>a</sup> This table is limited to facilities with specific location information. It excludes surrogate facilities and OES for which TRI data were not available.

### 3.1.5.2 Co-resident Inhalation Risk

EPA also calculated risk estimated for each of the endpoints in Table 3-2 based on modeling of co-residents living above or adjacent to dry cleaning facilities. See Section 2.1.2.3 for details on the exposure modeling methodology. All risk calculations are provided in Supplemental File SF\_FL\_Air Pathway Co-Resident Exposure Results for 1-BP (Appendix B). Risks were indicated for all endpoints under all scenarios modeled at high-end exposures and for three of four scenarios at central tendency exposures.



25 **Table 3-11. 1-BP Inhalation Risk for Co-residents of Dry Cleaning Facilities**

Building Type	Method for Estimating Q12	Estimated MOE				Estimated Cancer Risk	
		Non-cancer				Cancer (Benchmark 1E-06)	
		Acute (Benchmark 100)		Chronic (Benchmark 100)		CT <sup>a</sup> Risk	HE <sup>b</sup> Risk
		CT <sup>a</sup> Risk	HE <sup>b</sup> Risk	CT <sup>a</sup> Risk	HE <sup>b</sup> Risk		
Building 1	Method 1	325	58	377	67	9.5E-05	5.4E-04
	Method 2	82	14	97	17	3.7E-04	2.2E-03
Building 2	Method 1	5	1	6	1	5.7E-03	2.7E-02
	Method 2	4	1	5	1	6.6E-03	2.7E-02

<sup>a</sup> CT = central tendency; risk estimates are based on the 50th percentile of exposure estimates.  
<sup>b</sup> HE = central tendency; risk estimates are based on the 95th percentile of exposure estimates.

26

27 **3.1.6 Confidence and Risk Conclusions for 1-BP Case Study Results**

28 This section illustrates by example EPA's use of results from applying the proposed screening level  
29 methodology to make risk conclusions and does not represent final agency action. Any results or risk  
30 conclusions presented here are not intended to be used in support of risk management actions or  
31 rulemakings as presented.

32

33 EPA identified risks relative to the benchmarks at fenceline air concentrations of 1-BP for 52 of the 64  
34 real or surrogate facilities assessed, representing 13 of 14 OES. Based on characterization of land use  
35 patterns, fenceline community exposures are anticipated for 35 of the 49 GIS located facilities with risk.  
36 EPA also identified risk relative to the benchmarks from 1-BP inhalation for co-residents of dry cleaning  
37 facilities in all scenarios modeled.

38

39 Risk estimates in Table 3-9 are based on the 95th percentile values of modeled exposure concentrations  
40 around individual facilities, and the range of risk estimates covers all facilities under an OES. The  
41 consideration of land use patterns also confirms that facilities indicating risk are likely of concern to an  
42 expected fenceline community cohort. Therefore, EPA determines that the proposed screening level  
43 methodology, as applied for this report, sufficiently captures expected risk to the fenceline communities  
44 around these facilities for the exposure pathways evaluated. 95th percentile values represent a  
45 conservative, screening-level analysis and may potentially overestimate chronic and/or lifetime cancer  
46 risks. However, analysis of risk estimates based on 10th and 50th percentile exposure concentrations in  
47 SF\_FL\_Air Pathway Full-Screen Results for 1-BP (Appendix B) demonstrates that for most facilities  
48 cancer risk is also present at lower percentiles, mitigating this uncertainty.

49 **3.2 Methylene Chloride – Air and Water Pathways**50 **3.2.1 Background for MC**

51 Methylene chloride (MC) is a highly volatile, liquid organohalogen. If released to surface water and soil,  
52 it will most likely volatilize and enter the atmosphere, where it is persistent and mobile over long ranges.  
53 Methylene chloride is also mobile in groundwater but will slowly hydrolyze ([U.S. EPA, 2020c](#)). A  
54 summary of its physical-chemical properties can be found in Table\_Apx A-1.

### 55 3.2.2 Human Health Hazard Endpoints for MC

56 All hazard values used to calculated risk for MC in this report are derived from the previously peer-  
 57 reviewed PODs in the Final Risk Evaluation for Methylene Chloride ([U.S. EPA, 2020c](#)). In the Final  
 58 Risk Evaluation, EPA utilized the endpoints shown in Table 3-1 for risk determination. For MC, human  
 59 equivalent concentrations/doses (HECs/HEDs) for non-cancer endpoints were derived for use in  
 60 occupational and consumer scenarios. Additionally, an inhalation unit risk (IUR) for lifetime cancer risk  
 61 was applied for both occupational scenarios. Oral/dermal hazard values were extrapolated from  
 62 inhalation PODs based on an assumed 1.25 m<sup>3</sup>/hr inhalation rate for occupational scenarios.

63  
 64 **Table 3-12. Hazard Values Used for Risk Estimation in the Methylene Chloride Risk Evaluation**

Scenario	Endpoint	Inhalation Hazard Value	Oral/Dermal Hazard Value	Benchmark	Reference
Acute	Neurological: Decreased visual performance	696 mg/m <sup>3</sup> [1.5-hr exposure]	16 mg/kg [1.5-hr exposure]	30	( <a href="#">Putz et al., 1979</a> )
Chronic	Liver: Vacuolization and cell foci	17.2 mg/m <sup>3</sup>	2.15 mg/kg	10	( <a href="#">Nitschke et al., 1988</a> )
Cancer	Lung and liver tumors	1.38E-06 per mg/m <sup>3</sup>	1.1E-05 per mg/kg	1E-4 (occupational)	( <a href="#">NTP, 1986</a> )

65  
 66 For the analyses in this report, EPA derived POD values for fenceline communities based on a  
 67 continuous exposure scenario. The acute HEC was derived using the equation from ([ten Berge et al., 1986](#)),  
 68  $C_n \times T = K$ , where  $n = 2$  based on the original study conditions of 1.5 hr exposure. This equation  
 69 was used to derive a 24-hr HEC, although there is significant uncertainty associated with extrapolation  
 70 to a significantly longer duration. The chronic liver HEC was derived through a PBPK model on a  
 71 continuous exposure basis, so no adjustment was required. For cancer, the IUR value used in the Risk  
 72 Evaluation was for occupational scenarios of 8 hr/day, 5 days/week. This value was adjusted for  
 73 continuous exposure. Additionally, ADAFs were applied to cancer hazard values for younger lifestages  
 74 based on the conclusion that MC is carcinogenic through a mutagenic mode of action ([U.S. EPA, 2020c](#)).  
 75 HEDs and slope factors were extrapolated from inhalation values similar to the risk evaluation,  
 76 however for this analysis they were derived based on continuous exposure and 14.7 m<sup>3</sup>/day inhalation  
 77 rate for the general population ([U.S. EPA, 2011a](#)). The adjusted POD values for fenceline communities  
 78 are presented below in Table 3-13. Inhalation hazard values in the Final Risk Evaluation were presented  
 79 primarily in units of mg/m<sup>3</sup>; however, for consistency in risk calculations they have also been converted  
 80 to ppm using the following equation:

$$81 \text{ ppm} = \frac{\text{mg}}{\text{m}^3} \times 0.2879 .$$

82  
 83

84 **Table 3-13. Hazard Values for MC Used in this Fenceline Analysis**

Scenario	Endpoint	Fenceline HEC/ IUR	Fenceline HED/ SF	Benchmark	Reference
Acute	Neurological: Decreased visual performance	174 mg/m <sup>3</sup> (50 ppm)	32 mg/kg	30	( <a href="#">Putz et al., 1979</a> )
Chronic	Liver: Vacuolization and Cell Foci	17.2 mg/m <sup>3</sup> (5.0 ppm)	3 mg/kg	10	( <a href="#">Nitschke et al., 1988</a> )
Cancer	Lung and liver tumors	5.8E-06 per mg/m <sup>3</sup> (2.0E-05 per ppm)	4.6E-05 per mg/kg	1E-6	( <a href="#">NTP, 1986</a> )

85 **3.2.2.1 Assumptions and Uncertainties for MC Human Health Hazard**

86 There is some significant uncertainty in the acute POD by applying the ([ten Berge et al., 1986](#)) equation  
87 to extrapolate from a 1.5 hr study exposure to a 24-hr basis, however it is unknown whether this  
88 uncertainty may result in an overestimation or underestimation of toxicity. The chronic non-cancer POD  
89 is identical to what was applied in ([U.S. EPA, 2020c](#)), while the cancer IUR is adjusted by traditional  
90 Haber’s rule from an occupational to continuous exposure basis, so there is reduced uncertainty  
91 associated with those endpoints. Any other assumptions or uncertainties inherent to the human health  
92 hazard assessment in the Final Risk Evaluation for Methylene Chloride ([U.S. EPA, 2020c](#)) are still  
93 applicable for this analysis.

94 **3.2.3 Environmental Releases for MC**

95 This case study provides information specific to MC fenceline environmental release analysis that is not  
96 captured in the general methodology described in Section 2.1.1 and 2.2.1.

97 **3.2.3.1 Step 1: Obtain TRI Data and DMR**

98 For MC, the 2019 TRI dataset used for the air emissions fenceline analysis includes a total of 244 sites  
99 that reported stack and fugitive air releases ([U.S. EPA, 2021](#)). These data include 16 Form A  
100 submissions and 228 Form R submissions.

101  
102 For MC, the 2016 TRI dataset used for the water release fenceline analysis includes a total of 43 sites  
103 that reported water releases ([U.S. EPA, 2017](#)). These data do not include Form A submissions (Form A  
104 submission assessed as having zero water releases). The 2016 DMR dataset used for the water release  
105 fenceline analysis includes a total of 76 sites that reported water releases ([U.S. EPA, 2016a](#)).

106 **3.2.3.2 Step 2: Map TRI and DMR to OES**

107 EPA followed the methodology described in Section 2.1.1.2 to map the facilities in 2019 TRI to the OES  
108 in the published 2020 Methylene Chloride Risk Evaluation ([U.S. EPA, 2020c](#)) (see Appendix E).  
109 However, there were a few deviations from this general methodology that EPA encountered during the  
110 mapping of MC 2019 TRI sites to OES, which are described below.

- 111 • The 2019 TRI data for MC includes many sites that report the TRI uses/sub-uses for “Ancillary  
112 or Other use – Cleaner” and “Ancillary or Other use – Degreaser” ([U.S. EPA, 2021](#)). EPA was  
113 unable to determine the specific types of cleaning or degreasing from the TRI uses/sub-uses,  
114 NAICS codes, or internet searches of the facilities. Therefore, for these facilities, EPA assigned  
115 the OES as “Cleaner/Degreaser – Unknown.” This OES designation is a grouping of the

- 116 following COUs from the 2020 Methylene Chloride Risk Evaluation ([U.S. EPA, 2020c](#)):
- 117 Conveyorized Vapor Degreasing and Cold Cleaning. EPA did not include the OES for
- 118 Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care
- 119 Products) in this grouping because facilities conducting these types of cleaning and degreasing
- 120 are not expected to be captured in TRI because they likely use MC at quantities below the
- 121 reporting threshold or do not use a NAICS code that is included in a TRI-covered industry
- 122 sector. Batch-Open Top Vapor Degreasing was also not included in this grouping because it had
- 123 one mapped entry in the 2019 TRI.
- 124 • After mapping of the 2019 TRI data to CDR codes using the TRI-to-CDR Use Mapping
  - 125 crosswalk (see Appendix C), EPA found that many CDR codes could not be cleanly mapped to
  - 126 an OES. For these cases, mapping was performed using the primary NAICS code and an internet
  - 127 search of the facility.
  - 128 • TRI sub-use “Otherwise Use: As a chemical processing aid (Process Solvents)” was mapped to
  - 129 the CDR code U029 “Solvents (for cleaning or degreasing).” These facilities were mapped
  - 130 according to the NAICS code and an internet search of the facility name.
  - 131 • There were multiple sites in the methylene chloride 2019 TRI data that mapped to the COU for
  - 132 pharmaceutical use ([U.S. EPA, 2021](#)). These uses were not assessed in the 2020 Methylene
  - 133 Chloride Risk Evaluation ([U.S. EPA, 2020c](#)) and are not included in the fenceline analysis.
  - 134 • The 2020 Methylene Chloride Risk Evaluation is unique in that it contains an OES for
  - 135 “Miscellaneous Non-aerosol Industrial and Commercial Uses” ([U.S. EPA, 2020c](#)). Facilities that
  - 136 could not be classified into other OES were grouped into this miscellaneous category.

137 The MC fenceline analysis spreadsheet, *SF\_FLA\_Environmental Releases to Ambient Air for MC*

138 (Appendix B), contains the rationale for the mapping of each facility in 2019 TRI to an OES. Refer to

139 this spreadsheet for details of the mapping at the facility-level.

140

141 EPA followed the methodology described in Section 2.2.1.2 to map the facilities in 2016 TRI ([U.S.](#)

142 [EPA, 2017](#)) and 2016 DMR ([U.S. EPA, 2016a](#)) to the OES in the published 2020 Methylene Chloride

143 Risk Evaluation ([U.S. EPA, 2020c](#)).

### 144 **3.2.3.3 Step 3: Estimate Number of Release Days for Each OES**

145 EPA estimated the number of release days for each MC OES according to the methodology in Section

146 2.1.1.3 and 2.2.1.3. Specifically, the number of release days was assumed to be equal to the number of

147 operating days, which were estimated for each OES as shown in Table 3-14.

148

149 **Table 3-14. Number of Release Days for Each MC OES**

OES	Number of Release Days (days/yr)	Basis for Number of Release Days
Manufacturing	350	Number of release days for “Manufacture of Solvents” discussed in Section 2.1.1.3
Processing as a Reactant	350	Number of release days for “Processing as a Reactant”
Processing – Incorporation into Formulation, Mixture, or Reaction Product	300	Number of release days for “Other Chemical Plant Scenarios”
Repackaging	250	Number of release days for “All Other Scenarios”

OES	Number of Release Days (days/yr)	Basis for Number of Release Days
Batch Open-Top Vapor Degreasing	260	Vapor Degreasing ESD ( <a href="#">Organization for Economic and Develop.m.ent, 2017</a> )
Conveyorized Vapor Degreasing	260	Vapor Degreasing ESD ( <a href="#">Organization for Economic and Develop.m.ent, 2017</a> )
Cold Cleaning	260	Vapor Degreasing ESD ( <a href="#">Organization for Economic and Develop.m.ent, 2017</a> )
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	260 (low-end) and 364 (high-end)	Brake Servicing Near-Field/Far-Field Inhalation Exposure Model
Adhesives and Sealants	250	Number of release days for “All Other Scenarios”
Paints and Coatings	250	Number of release days for “All Other Scenarios”
Adhesive and Caulk Removers	250	Number of release days for “All Other Scenarios”
Fabric Finishing	250	Number of release days for “All Other Scenarios”
Spot Cleaning	289 (50th percentile) and 307 (95th percentile)	Spot Cleaning Near-Field/Far-Field Inhalation Exposure Model
Cellulose Triacetate Film Production	250	Number of release days for “All Other Scenarios”
Flexible Polyurethane Foam Manufacturing	250	Number of release days for “All Other Scenarios”
Laboratory Use	250	Number of release days for “All Other Scenarios”
Plastic Product Manufacturing	250	Number of release days for “All Other Scenarios”
Lithographic Printing Plate Cleaning	250	Number of release days for “All Other Scenarios”
Miscellaneous Non-aerosol Industrial and Commercial Uses	250	Number of release days for “All Other Scenarios”
Waste Handling, Disposal, Treatment, and Recycling	250	Number of release days for “All Other Scenarios”
Paint Remover	250	Number of release days for “All Other Scenarios”

#### 3.2.3.4 Step 4: Estimate Air Emissions for OES with No 2019 TRI Data and Water Releases for OES with No TRI or DMR Data

A summary of the air emission assessment approaches for each MC OES is included in Table 3-15. Of the 21 OES listed in Table 3-15, 16 have directly applicable 2019 TRI data that were used for air

150  
151  
152  
153

154 emissions. For the remaining five OES without 2019 TRI data, EPA used the hierarchy of alternate air  
 155 assessment approaches described in Section 2.1.1.4. Specifically, EPA estimated air releases with  
 156 modeling (two OES) and surrogate OES data (three OES).

157

158

**Table 3-15. Summary of Air Release Estimation Approaches for Each MC OES**

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Fugitive Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
Manufacturing	0 to 2,456 <sup>a b c d</sup>	0 to 5,767 <sup>b c d e</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 11 sites (no Form As).
Processing as a Reactant	0 to 4,128 <sup>a c d f</sup>	0 to 6,350 <sup>a c d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 15 sites (no Form As).
Processing – Incorporation into Formulation, Mixture, or Reaction Product	0 to 59,528 <sup>b c d f</sup>	0 to 4,808 <sup>a b c d e f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 50 sites (four Form As).
Repackaging	0 to 331 <sup>b c d f</sup>	0 to 723 <sup>a b c d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 24 sites (9 Form As).
Batch Open-Top Vapor Degreasing	0 to 11,106 <sup>b d f</sup>	0 to 21,870 <sup>b d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 1 site (not Form A).
Conveyorized Vapor Degreasing	0 to 11,106 <sup>b d f</sup>	0 to 12,175 <sup>b d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	No sites were classified specifically as conveyorized vapor degreasing. 2019 TRI data are available for 16 sites (one Form A) under “Cleaner/Degreaser – unknown.”
Cold Cleaning	0 to 11,106 <sup>b d f</sup>	0 to 12,175 <sup>b d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	No sites were classified specifically as cold cleaning. 2019 TRI data are available for 16 sites (one Form A) under “Cleaner/Degreaser – unknown.”
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	188 to 267	0 (all fugitive)	Modeling	2019 TRI data are not available for this OES. EPA adapted the <i>Brake Servicing Near-Field/Far-Field Inhalation Exposure Model</i> and ran it to estimate daily and annual air emissions for this OES.
Adhesives and Sealants	0 to 113,359 <sup>a b c d f</sup>	0 to 75,001 <sup>b c d f</sup>	Surrogate 2019 TRI	No 2019 TRI data available for this OES. Industrial applications of this COU are

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Fugitive Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
			<a href="#">(U.S. EPA, 2021)</a>	already accounted for within the TRI sites in the "Miscellaneous Non-aerosol Industrial and Commercial Uses" OES and the commercial applications are not applicable for fence-line analysis.
Paints and Coatings	0 to 113,359 <sup>a b c d f</sup>	0 to 75,001 <sup>b c d f</sup>	Surrogate 2019 TRI <a href="#">(U.S. EPA, 2021)</a>	No 2019 TRI data available for this OES. Industrial applications of this COU are already accounted for within the TRI sites in the "Miscellaneous Non-aerosol Industrial and Commercial Uses" OES and the commercial applications are not applicable for fence-line analysis.
Adhesive and Caulk Removers	0 to 113,359 <sup>a b c d f</sup>	0 to 75,001 <sup>b c d f</sup>	Surrogate 2019 TRI <a href="#">(U.S. EPA, 2021)</a>	No 2019 TRI data available for this OES. Industrial applications of this COU are already accounted for within the TRI sites in the "Miscellaneous Non-aerosol Industrial and Commercial Uses" OES and the commercial applications are not applicable for fence-line analysis.
Fabric Finishing	340 <sup>b</sup> (1 site)	0 (all fugitive)	2019 TRI <a href="#">(U.S. EPA, 2021)</a>	2019 TRI data are available for 1 site (not Form A).
Spot Cleaning	35.6 to 38.4	0 (all fugitive)	Modeling	2019 TRI data are not available for this OES. EPA adapted the <i>Spot Cleaning Model</i> and ran it to estimate daily air emissions for this OES.
Cellulose Triacetate Film Production	20 to 13,438 <sup>b d</sup>	0 to 630 <sup>b d</sup>	2019 TRI <a href="#">(U.S. EPA, 2021)</a>	2019 TRI data are available for 2 sites (no Form As).
Flexible Polyurethane Foam Manufacturing	0 to 102,743 <sup>b</sup>	0 to 6,305 <sup>b f</sup>	2019 TRI <a href="#">(U.S. EPA, 2021)</a>	2019 TRI data are available for 2 sites (no Form As).

OES	Range of Annual Fugitive Air Release (kg/site-yr)	Range of Annual Fugitive Air Release (kg/site-yr)	Air Release Estimation Approach	Notes
Laboratory Use	0 to 436 <sup>a b c f</sup>	55 to 7,200 <sup>b c d</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 5 sites (no Form As).
Plastic Product Manufacturing	0 to 54,431 <sup>b d</sup>	0 to 18,144 <sup>b d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 7 sites (no Form As).
Lithographic Printing Plate Cleaning	0 (all stack) <sup>b</sup>	2,295 (1 site) <sup>b</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 1 site (not Form A).
Miscellaneous Non-aerosol Industrial and Commercial Uses	0 to 113,359 <sup>a b c d f</sup>	0 to 75,001 <sup>b c d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 33 sites (two Form As).
Waste Handling, Disposal, Treatment, and Recycling	0 to 755 <sup>b c d f</sup>	0 to 7,058 <sup>b c d f</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 32 sites (no Form As).
Paint Remover	0 to 7,467 <sup>b c d</sup>	4,058 to 21,137 <sup>b c d</sup>	2019 TRI ( <a href="#">U.S. EPA, 2021</a> )	2019 TRI data are available for 3 sites (no Form As).

<sup>a</sup> This range includes estimates based on periodic or random monitoring data or measurements.

<sup>b</sup> This range includes estimates based on mass balance calculations, such as calculation of the amount of chemical in streams entering and leaving process equipment.

<sup>c</sup> This range includes estimates based on published emissions factors, such as those relating release quantity to through-put or equipment type (e.g., air emissions factors). This may include emissions factors in a trade association's publication or AP-42.

<sup>d</sup> This range includes estimates based on other approaches such as engineering calculations (e.g., estimating volatilization using published mathematical formulas) or best engineering judgment. This would include applying estimated removal efficiency to a waste stream, even if the composition of the stream before treatment was fully identified through monitoring data.

<sup>e</sup> This range includes estimates based on continuous monitoring data or measurements.

<sup>f</sup> This range includes estimates based on site-specific emissions factors, such as those relating release quantity to through-put or equipment type (e.g., air emissions factors). This may include emissions factors that are developed for a specific piece of equipment and that consider climate conditions on-site.

159

160

A summary of the water release assessment approaches for each MC OES is included in Table 3-16. Of

161

the 20 OES listed in Table 3-16, 10 have directly applicable 2016 TRI or 2016 DMR data that were used

162

for water releases. For the remaining 10 OES without TRI or DMR data, EPA used an alternative to the

163

water release approaches described in Section 2.2.1.4. Specifically, EPA estimated water releases using

164

a qualitative approach for all 10 OES without 2016 TRI or 2016 DMR data. Specifically, for the 10 OES

165

where releases are expected but TRI and DMR data were not available, EPA included a qualitative

166

discussion of potential release sources in the initial risk evaluation.

167

168

169

**Table 3-16. Summary of Water Release Estimation Approaches for Each Methylene Chloride OES**

OES	Range of Water Releases (kg/site-yr)	Water Release Estimation Approach	Notes
Manufacturing	0.1 to 76 <sup>a b c d e</sup>	2016 TRI and 2016 DMR	2016 TRI data are available for 8 sites and



OES	Range of Water Releases (kg/site-yr)	Water Release Estimation Approach	Notes
			2016 DMR data are available for 12 sites.
Processing as a Reactant	0.1 to 213 <sup>ab</sup> e	2016 TRI and 2016 DMR	2016 TRI data are available for 2 sites and 2016 DMR data are available for 1 site.
Processing – Incorporation into Formulation, Mixture, or Reaction Product	0.2 to 5,785 <sup>acde</sup>	2016 TRI and 2016 DMR	2016 TRI data are available for 5 sites and 2016 DMR data are available for 4 sites.
Repackaging	2.8E-2 to 144 <sup>acde</sup>	2016 TRI and 2016 DMR	2016 TRI data are available for 3 sites and 2016 DMR data are available for 2 sites.
Batch Open-Top Vapor Degreasing	N/A	Qualitative	No quantitative assessment made.
Conveyorized Vapor Degreasing	N/A	Qualitative	No quantitative assessment made.
Cold Cleaning	N/A	Qualitative	No quantitative assessment made.
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	N/A	None expected	Due to the volatility of methylene chloride the majority of releases from the use of aerosol products will likely be to air as methylene chloride evaporates from the aerosolized mist and the substrate surface.
Adhesives and Sealants	N/A	Qualitative	No quantitative assessment made; majority of methylene chloride expected to be released to air.
Paints and Coatings	N/A	Qualitative	No quantitative assessment made; majority of methylene chloride expected to be released to air.
Adhesive and Caulk Removers	N/A	Qualitative	No quantitative assessment made; majority of methylene chloride expected to be released to air.
Fabric Finishing	N/A	Qualitative	No quantitative assessment made;

OES	Range of Water Releases (kg/site-yr)	Water Release Estimation Approach	Notes
			majority of methylene chloride expected to be released to air.
Spot Cleaning	0.1 (1 site) <sup>f</sup>	2016 DMR	2016 DMR data are available for 1 site.
Cellulose Triacetate Film Production	29 (1 site) <sup>f</sup>	2016 DMR	2016 DMR data are available for 1 site.
Flexible Polyurethane Foam Manufacturing	2.3 (1 site) <sup>b f</sup>	2016 TRI	2016 TRI data are available for 1 site.
Laboratory Use	N/A	Qualitative	No quantitative assessment made, majority of methylene chloride expected to be released to air or disposed as hazardous waste.
Plastic Product Manufacturing	2.3E-2 to 28 <sup>e f</sup>	2016 TRI and 2016 DMR	2016 TRI data are available for 1 site and 2016 DMR data are available for 8 sites.
Lithographic Printing Plate Cleaning	9.3E-4 (1 site) <sup>f</sup>	2016 DMR	2016 DMR data are available for 1 site.
Miscellaneous Non-aerosol Industrial and Commercial Uses	N/A	Qualitative	No quantitative assessment made; majority of methylene chloride expected to be released to air.
Waste Handling, Disposal, Treatment, and Recycling	2.4E-2 to 115,059 <sup>a b d e</sup>	2016 TRI and 2016 DMR	2016 TRI data are available for 7 sites and 2016 DMR data are available for 6 sites.
<p><sup>a</sup> This range includes both direct and indirect discharges.</p> <p><sup>b</sup> This range includes TRI estimates based on continuous monitoring data or measurements.</p> <p><sup>c</sup> This range includes TRI estimates based on mass balance calculations, such as calculation of the amount of chemical in streams entering and leaving process equipment.</p> <p><sup>d</sup> This range includes TRI estimates based on other approaches such as engineering calculations (<i>e.g.</i>, estimating volatilization using published mathematical formulas) or best engineering judgment. This would include applying estimated removal efficiency to a waste stream, even if the composition of the stream before treatment was fully identified through monitoring data.</p> <p><sup>e</sup> This range includes TRI estimates based on periodic or random monitoring data or measurements.</p> <p><sup>f</sup> This range includes direct discharges only.</p>			

170

171

### 3.2.3.5 Step 5: Prepare Air Emission and Water Release Summary for Ambient Air and Water Exposure Modeling

172

173

174

175

176

Using the work completed in Steps 1 through 4, EPA compiled a summary of air releases on a per-site basis for each MC OES, in the format of Table 2-1. See the supplemental fence line analysis spreadsheet *SF\_FLA\_Environmental Releases to Ambient Air for MC* (Appendix B) for this summary. To model exposures resulting from these air emissions, EPA used the daily emissions, site identity and location information, and release duration and pattern information from this summary. For water releases, EPA

177 used the same release estimates as those used in the risk evaluation report and no additional summary  
 178 was created. Additional information on the modeled MC exposures is provided in the next section.

### 179 **3.2.4 Exposures for MC**

#### 180 **3.2.4.1 Air Pathway**

181 Pre-screening and full-screening level methodologies were utilized to evaluate potential exposures to  
 182 fenceline communities for MC.

##### 183 **Pre-screening Analysis**

184 Pre-screening work for MC is included in Appendix D. Inputs for all IIOAC model runs for all exposure  
 185 scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Input Parameters for IIOAC for 1-BP*  
 186 *and MC* (Appendix B). Based on the pre-screening analysis, there is an indication of potential exposures  
 187 and associated risks to fenceline communities and therefore EPA conducted a full-screening level  
 188 analysis for MC.

##### 189 **Screening Analysis**

190 A total of 17 OES were evaluated for MC as presented in Table 3-17. A total of 195 real facilities were  
 191 modeled. Exposure modeling was also performed for those OES where releases were estimated,  
 192 although there is no real facility associated with those estimates and therefore a “number of facilities” is  
 193 not applicable for those OES. Inputs for all AERMOD model runs for all exposure scenarios are  
 194 included in Supplemental File *SF\_FLA\_Fenceline Air Pathway Input Parameters for AERMOD for 1-*  
 195 *BP and MC* (Appendix B).

196 **Table 3-17. Fenceline Community Exposure Scenarios for MC**

OES	Release Data Source	Number of Facilities in OES <sup>a</sup>
Batch Open-Top Degreasing	TRI (2019)	1
Cellulose Triacetate Film Production	TRI (2019)	2
Cleaner/Degreaser – Unknown <sup>b</sup>	TRI (2019)	16
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	Estimate	N/A
Fabric Finishing	TRI (2019)	1
Flexible Polyurethane Foam Manufacturing	TRI (2019)	1
Laboratory Use	TRI (2019)	5
Lithographic Printing Plate Cleaning	TRI (2019)	1
Manufacturing	TRI (2019)	11
Miscellaneous Non-aerosol Industrial and Commercial Uses <sup>c</sup>	TRI (2019)	31
Plastic Product Manufacturing	TRI (2019)	7

OES	Release Data Source	Number of Facilities in OES <sup>a</sup>
Processing – Incorporation into Formulation, Mixture, or Reaction Product	TRI (2019)	50
Processing as a Reactant	TRI (2019)	14
Repackaging	TRI (2019)	22
Spot Cleaning	Estimate	N/A
Waste Handling, Disposal, Treatment, and Recycling	TRI (2019)	30
Paint Remover	TRI (2019)	3
<b>Total</b>		<b>195</b>
<sup>a</sup> N/A: No real facilities identified <sup>b</sup> This OES designation is a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Conveyorized Vapor Degreasing and Cold Cleaning. See Section 3.2.3.2. <sup>c</sup> This OES designation includes a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Adhesives and Sealants, Paints and Coatings, and Adhesive and Caulk Removers		

200 Modeling results for inhalation exposure concentrations are categorized by OES and presented by  
201 facility. Daily and annual average concentrations are summarized for three percentile concentrations  
202 (10th, 50th, 95th) to cover the range of exposure concentrations across all nine distances modeled (5; 10;  
203 30; 60; 100; 100 to 1,000; 2,500; 5,000; and 10,000 meters) and can be found in Supplemental File  
204 *SF\_FLA\_Air Pathway Full-Screen Results for MC* (Appendix B). Exposure concentrations are presented  
205 as total concentration to inform the total exposure to a given receptor at each modeled distance from  
206 each releasing facility. EPA did not identify air monitoring data to which modeled concentrations could  
207 be compared at the distances modeled. EPA conducted a source attribution analysis which provides  
208 exposure concentrations from each release type (fugitive and stack) at each modeled distance for each  
209 facility in anticipation of informing future risk management actions and the potential need for a more  
210 detailed analyses if risks are identified. For facilities reporting both fugitive and stack releases within  
211 TRI, adding the exposure concentrations for each release type at each modeled distance provides the  
212 total concentration.

213  
214 EPA further distilled exposure results for the 95th percentile values across all facilities within each OES,  
215 at all nine distances modeled, and presents them in Table 3-18. The purpose of this further distillation is  
216 to present a smaller subset of results within the body of this report. The further distilled results presented  
217 here are carried into the risk characterization section of the body of this report for risk calculation  
218 purposes.

219  
220 The minimum and maximum concentrations in Table 3-18 represent the lowest and highest 95th  
221 percentile concentrations, respectively, among all facilities categorized into the respective OES at each  
222 distance modeled. The mean 95th percentile concentrations in Table 3-18 represent arithmetic averages  
223 across all facilities within the given OES at each distance modeled. Additionally, for certain OES, there  
224 are a variety of industry types and release points (stack, fugitive, stack and fugitive) categorized within  
225 an OES which may not be directly comparable. This results in a wide range of modeled exposure

226 concentrations which, in some cases, extends over many orders of magnitude. For example, in the  
227 Miscellaneous Non-aerosol Industrial and Commercial Uses OES, there are 31 facilities which may  
228 include a variety of industry types. Although releases within an industry type may be comparable,  
229 releases across industry types may have considerably different emission profiles and therefore may not  
230 be comparable. Further, looking at the release points, EPA found that fugitive releases do not have much  
231 lift or dispersion resulting in higher concentrations very close to facilities (around 10 meters) and lower  
232 concentrations further away (around 100 meters). In contrast, stack releases often have more lift and  
233 dispersion resulting in lower concentrations around 10 meters and higher concentrations around 100  
234 meters. Even with these different concentration profiles, the modeled exposure concentrations from  
235 stacks are still several orders of magnitude lower than fugitive concentrations. This can skew the mean  
236 of the 95th percentile modeled concentrations across multiple facilities orders of magnitude lower, thus  
237 underestimating exposures and associated risks.

1 Table 3-18. 95th Percentile Exposure Concentration Summary across Facilities within Each OES for MC

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Batch Open-Top Degreasing	1	5	7.44E-04	–	–	–	1.84E-04	–	–	–
		10	1.03E-03	–	–	–	2.52E-04	–	–	–
		30	5.01E-04	–	–	–	1.20E-04	–	–	–
		60	1.20E-03	–	–	–	3.30E-04	–	–	–
		100	2.10E-03	–	–	–	5.63E-04	–	–	–
		100–1,000	4.78E-04	–	–	–	1.99E-04	–	–	–
		2,500	7.78E-05	–	–	–	1.65E-05	–	–	–
		5,000	2.88E-05	–	–	–	6.28E-06	–	–	–
		10,000	1.05E-05	–	–	–	2.33E-06	–	–	–
Cellulose Triacetate Film Production	2	5	–	3.86E-04	1.63E-01	3.25E-01	–	1.64E-04	7.11E-02	1.42E-01
		10	–	4.77E-04	2.14E-01	4.27E-01	–	2.24E-04	9.46E-02	1.89E-01
		30	–	1.72E-04	7.11E-02	1.42E-01	–	8.20E-05	2.88E-02	5.76E-02
		60	–	8.49E-05	2.66E-02	5.31E-02	–	4.06E-05	9.87E-03	1.97E-02
		100	–	7.06E-05	1.18E-02	2.36E-02	–	3.02E-05	4.08E-03	8.13E-03
		100–1,000	–	1.80E-05	7.14E-04	1.41E-03	–	9.36E-06	3.81E-04	7.53E-04
		2,500	–	3.33E-06	5.82E-05	1.13E-04	–	1.48E-06	1.89E-05	3.64E-05
		5,000	–	1.21E-06	1.91E-05	3.70E-05	–	5.33E-07	6.22E-06	1.19E-05
		10,000	–	4.02E-07	6.15E-06	1.19E-05	–	1.81E-07	2.06E-06	3.93E-06

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Cleaner/Degreaser – Unknown <sup>b</sup>	16	5	–	4.81E-12	4.00E-02	1.54E-01	–	8.00E-12	1.30E-02	5.86E-02
		10	–	3.55E-10	5.16E-02	2.49E-01	–	2.20E-10	1.67E-02	6.74E-02
		30	–	6.51E-07	1.84E-02	1.07E-01	–	2.69E-07	5.64E-03	2.45E-02
		60	–	1.12E-05	7.10E-03	4.23E-02	–	2.91E-06	2.14E-03	9.47E-03
		100	–	2.39E-05	3.42E-03	1.91E-02	–	5.93E-06	1.01E-03	4.35E-03
		100–1,000	–	4.83E-06	2.41E-04	9.98E-04	–	2.03E-06	1.24E-04	5.16E-04
		2,500	–	6.47E-07	2.21E-05	6.33E-05	–	1.55E-07	6.36E-06	2.20E-05
		5,000	–	2.49E-07	7.71E-06	1.98E-05	–	6.95E-08	2.31E-06	7.32E-06
		10,000	–	8.98E-08	2.72E-06	6.69E-06	–	2.97E-08	8.63E-07	2.55E-06
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	–	5	–	1.93E-03	3.38E-03	5.08E-03	–	3.98E-04	9.23E-04	1.58E-03
		10	–	3.40E-03	4.87E-03	6.53E-03	–	7.24E-04	1.29E-03	1.99E-03
		30	–	1.38E-03	1.71E-03	2.04E-03	–	2.86E-04	4.10E-04	5.52E-04
		60	–	4.69E-04	5.89E-04	7.20E-04	–	1.04E-04	1.40E-04	1.79E-04
		100	–	1.74E-04	2.23E-04	2.77E-04	–	4.08E-05	5.35E-05	6.64E-05
		100–1,000	–	4.53E-06	5.59E-06	6.73E-06	–	2.76E-06	3.49E-06	4.21E-06
		2,500	–	1.71E-07	2.14E-07	2.60E-07	–	4.25E-08	6.48E-08	1.07E-07
		5,000	–	4.71E-08	5.98E-08	7.26E-08	–	1.18E-08	2.00E-08	3.48E-08
		10,000	–	1.51E-08	2.24E-08	3.01E-08	–	5.11E-09	8.23E-09	1.38E-08

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Fabric Finishing	1	5	6.33E-03	–	–	–	1.98E-03	–	–	–
		10	7.84E-03	–	–	–	2.85E-03	–	–	–
		30	2.89E-03	–	–	–	1.12E-03	–	–	–
		60	1.14E-03	–	–	–	4.39E-04	–	–	–
		100	5.27E-04	–	–	–	1.99E-04	–	–	–
		100–1,000	3.25E-05	–	–	–	1.86E-05	–	–	–
		2,500	2.50E-06	–	–	–	8.56E-07	–	–	–
		5,000	8.07E-07	–	–	–	2.66E-07	–	–	–
		10,000	2.64E-07	–	–	–	8.46E-08	–	–	–
Flexible Polyurethane Foam Manufacturing	1	5	2.89E+00	–	–	–	1.09E+00	–	–	–
		10	3.76E+00	–	–	–	1.30E+00	–	–	–
		30	1.25E+00	–	–	–	4.75E-01	–	–	–
		60	4.94E-01	–	–	–	1.90E-01	–	–	–
		100	2.30E-01	–	–	–	8.75E-02	–	–	–
		100–1,000	1.47E-02	–	–	–	8.51E-03	–	–	–
		2,500	1.27E-03	–	–	–	4.70E-04	–	–	–
		5,000	4.11E-04	–	–	–	1.53E-04	–	–	–
		10,000	1.36E-04	–	–	–	4.99E-05	–	–	–



OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Laboratory Use	5	5	–	4.34E-10	1.54E-03	5.05E-03	–	4.35E-10	6.00E-04	1.96E-03
		10	–	6.11E-08	2.65E-03	9.80E-03	–	1.41E-08	1.01E-03	3.76E-03
		30	–	5.22E-06	1.29E-03	5.20E-03	–	1.67E-06	4.16E-04	1.68E-03
		60	–	2.52E-05	6.00E-04	2.25E-03	–	1.69E-05	1.91E-04	6.95E-04
		100	–	3.49E-05	3.70E-04	1.13E-03	–	1.98E-05	1.25E-04	3.42E-04
		100–1,000	–	3.13E-06	4.96E-05	1.28E-04	–	1.97E-06	2.68E-05	6.97E-05
		2,500	–	4.91E-07	1.09E-05	3.87E-05	–	2.49E-07	3.57E-06	1.30E-05
		5,000	–	2.56E-07	5.71E-06	2.16E-05	–	1.26E-07	1.89E-06	7.40E-06
		10,000	–	1.17E-07	2.80E-06	1.12E-05	–	5.58E-08	8.85E-07	3.61E-06
Lithographic Printing Plate Cleaning	1	5	1.62E-11	–	–	–	2.76E-11	–	–	–
		10	3.26E-09	–	–	–	4.08E-09	–	–	–
		30	4.49E-06	–	–	–	1.64E-06	–	–	–
		60	7.20E-05	–	–	–	3.07E-05	–	–	–
		100	1.62E-04	–	–	–	6.64E-05	–	–	–
		100–1,000	6.29E-05	–	–	–	2.43E-05	–	–	–
		2,500	1.19E-05	–	–	–	2.47E-06	–	–	–
		5,000	4.72E-06	–	–	–	9.70E-07	–	–	–
		10,000	1.77E-06	–	–	–	3.81E-07	–	–	–

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Manufacturing	11	5	–	2.78E-15	9.34E-03	2.93E-02	–	2.72E-15	4.22E-03	1.46E-02
		10	–	7.58E-14	1.55E-02	5.34E-02	–	5.75E-14	7.20E-03	2.78E-02
		30	–	2.54E-11	7.11E-03	2.66E-02	–	1.09E-11	3.23E-03	1.36E-02
		60	–	3.92E-10	3.04E-03	1.15E-02	–	2.70E-10	1.37E-03	5.78E-03
		100	–	9.85E-10	1.58E-03	5.78E-03	–	6.08E-10	7.08E-04	2.87E-03
		100–1,000	–	4.06E-10	1.61E-04	4.94E-04	–	2.11E-10	9.22E-05	3.07E-04
		2,500	–	6.73E-11	2.06E-05	5.04E-05	–	2.21E-11	7.81E-06	2.15E-05
		5,000	–	2.83E-11	8.28E-06	2.10E-05	–	8.55E-12	3.09E-06	9.18E-06
		10,000	–	1.15E-11	3.18E-06	8.24E-06	–	3.15E-12	1.15E-06	3.51E-06
Miscellaneous Non-aerosol Industrial and Commercial Uses <sup>c</sup>	31	5	–	6.27E-12	1.27E-01	3.88E+00	–	8.96E-12	5.85E-02	1.82E+00
		10	–	7.68E-10	1.42E-01	4.20E+00	–	9.99E-10	6.81E-02	2.07E+00
		30	–	4.42E-07	4.83E-02	1.36E+00	–	1.75E-07	2.16E-02	6.35E-01
		60	–	6.63E-06	1.89E-02	5.20E-01	–	2.95E-06	8.25E-03	2.37E-01
		100	–	1.19E-05	9.08E-03	2.36E-01	–	4.26E-06	3.87E-03	1.06E-01
		100–1,000	–	2.63E-06	7.20E-04	1.48E-02	–	1.07E-06	4.30E-04	9.96E-03
		2,500	–	5.87E-07	7.93E-05	1.23E-03	–	1.74E-07	2.85E-05	5.09E-04
		5,000	–	2.13E-07	2.97E-05	3.97E-04	–	9.23E-08	1.02E-05	1.64E-04
		10,000	–	7.27E-08	1.07E-05	1.33E-04	–	3.31E-08	3.58E-06	5.39E-05

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Plastic Product Manufacturing	7	5	–	8.69E-13	2.32E-01	9.13E-01	–	1.59E-11	7.31E-02	2.88E-01
		10	–	4.36E-10	4.07E-01	1.51E+00	–	1.92E-09	1.31E-01	4.71E-01
		30	–	5.63E-06	1.91E-01	6.61E-01	–	1.90E-06	6.34E-02	2.32E-01
		60	–	2.39E-06	8.09E-02	2.80E-01	–	7.67E-07	2.66E-02	9.86E-02
		100	–	1.19E-06	3.99E-02	1.40E-01	–	3.72E-07	1.31E-02	4.98E-02
		100–1,000	–	9.80E-08	3.10E-03	1.14E-02	–	4.75E-08	1.52E-03	5.35E-03
		2,500	–	1.02E-08	2.88E-04	1.11E-03	–	2.72E-09	7.76E-05	3.18E-04
		5,000	–	3.86E-09	1.02E-04	4.00E-04	–	9.43E-10	2.63E-05	1.10E-04
		10,000	–	1.38E-09	3.50E-05	1.40E-04	–	3.24E-10	8.88E-06	3.75E-05
Processing – Incorporation into Formulation, Mixture, or Reaction Product	50	5	–	2.10E-13	3.10E-02	9.23E-01	–	6.95E-13	1.31E-02	3.92E-01
		10	–	6.12E-11	4.36E-02	1.51E+00	–	3.52E-11	1.81E-02	6.07E-01
		30	–	1.22E-08	1.80E-02	6.66E-01	–	4.41E-09	6.86E-03	2.39E-01
		60	–	8.19E-08	7.41E-03	2.79E-01	–	4.98E-08	2.74E-03	9.64E-02
		100	–	1.56E-07	3.54E-03	1.33E-01	–	8.59E-08	1.29E-03	4.50E-02
		100–1,000	–	5.61E-08	2.59E-04	9.29E-03	–	2.70E-08	1.53E-04	5.56E-03
		2,500	–	1.03E-08	2.29E-05	7.70E-04	–	3.46E-09	7.54E-06	2.35E-04
		5,000	–	3.76E-09	7.81E-06	2.50E-04	–	1.22E-09	2.54E-06	7.61E-05
		10,000	–	1.28E-09	2.68E-06	8.22E-05	–	4.19E-10	8.63E-07	2.49E-05

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Processing as a Reactant	14	5	–	7.33E-12	1.11E-02	1.05E-01	–	1.51E-12	4.22E-03	3.96E-02
		10	–	1.14E-10	1.55E-02	1.41E-01	–	3.75E-11	5.92E-03	5.34E-02
		30	–	3.60E-08	5.71E-03	4.95E-02	–	7.96E-09	2.32E-03	2.04E-02
		60	–	4.53E-07	2.37E-03	2.03E-02	–	1.58E-07	9.52E-04	8.22E-03
		100	–	1.01E-06	1.19E-03	9.73E-03	–	4.14E-07	4.78E-04	3.94E-03
		100–1,000	–	3.99E-07	1.19E-04	8.51E-04	–	1.90E-07	6.72E-05	5.03E-04
		2,500	–	1.01E-07	1.47E-05	9.25E-05	–	3.69E-08	4.82E-06	3.07E-05
		5,000	–	4.87E-08	6.27E-06	3.85E-05	–	1.52E-08	1.88E-06	1.16E-05
		10,000	–	1.93E-08	2.53E-06	1.55E-05	–	5.68E-09	7.22E-07	4.40E-06
Repackaging	22	5	–	6.55E-20	2.15E-03	7.95E-03	–	1.14E-15	5.18E-04	1.85E-03
		10	–	1.80E-13	3.10E-03	8.22E-03	–	3.73E-12	6.87E-04	1.95E-03
		30	–	3.47E-07	1.02E-03	3.03E-03	–	2.25E-07	1.99E-04	5.50E-04
		60	–	6.98E-06	3.51E-04	1.06E-03	–	1.34E-06	6.90E-05	1.83E-04
		100	–	2.55E-06	1.50E-04	4.42E-04	–	4.90E-07	3.05E-05	8.35E-05
		100–1,000	–	5.02E-08	5.03E-06	1.88E-05	–	3.71E-08	3.30E-06	1.15E-05
		2,500	–	1.25E-09	1.56E-07	6.20E-07	–	4.75E-10	5.93E-08	2.12E-07
		5,000	–	2.04E-10	3.19E-08	1.64E-07	–	1.61E-10	2.05E-08	7.67E-08
		10,000	–	3.14E-11	9.67E-09	5.44E-08	–	7.62E-11	9.57E-09	3.60E-08

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Spot Cleaning	-	5	-	3.53E-04	5.31E-04	7.05E-04	-	7.25E-05	1.52E-04	2.34E-04
		10	-	6.31E-04	7.76E-04	9.17E-04	-	1.35E-04	2.16E-04	3.00E-04
		30	-	2.60E-04	2.76E-04	2.91E-04	-	5.49E-05	6.92E-05	8.42E-05
		60	-	8.85E-05	9.55E-05	1.03E-04	-	2.02E-05	2.38E-05	2.74E-05
		100	-	3.29E-05	3.61E-05	3.97E-05	-	8.05E-06	9.16E-06	1.02E-05
		100-1,000	-	8.73E-07	9.45E-07	1.02E-06	-	5.71E-07	6.27E-07	7.22E-07
		2,500	-	3.22E-08	3.58E-08	4.04E-08	-	8.64E-09	1.16E-08	1.60E-08
		5,000	-	9.48E-09	1.01E-08	1.09E-08	-	2.35E-09	3.50E-09	5.14E-09
		10,000	-	3.29E-09	3.80E-09	4.23E-09	-	9.67E-10	1.38E-09	1.94E-09
Waste Handling, Disposal, Treatment, and Recycling	30	5	-	9.98E-11	2.73E-03	3.85E-02	-	1.95E-10	1.14E-03	1.96E-02
		10	-	1.08E-08	3.50E-03	3.24E-02	-	2.66E-08	1.46E-03	1.81E-02
		30	-	1.15E-06	1.40E-03	8.63E-03	-	3.80E-07	5.54E-04	4.86E-03
		60	-	4.70E-07	5.83E-04	3.67E-03	-	1.58E-07	2.21E-04	1.70E-03
		100	-	2.33E-07	2.98E-04	1.81E-03	-	7.81E-08	1.09E-04	7.53E-04
		100-1,000	-	2.10E-08	2.86E-05	2.07E-04	-	1.03E-08	1.43E-05	8.11E-05
		2,500	-	2.74E-09	3.20E-06	3.17E-05	-	7.52E-10	9.68E-07	8.38E-06
		5,000	-	1.21E-09	1.15E-06	1.13E-05	-	3.26E-10	3.36E-07	2.95E-06
		10,000	-	4.59E-10	3.99E-07	3.82E-06	-	1.34E-10	1.16E-07	1.01E-06

OES	Number of TRI Facilities Evaluated <sup>a</sup>	Distance from Facility (meters)	Concentration (ppm)							
			Daily Average				Annual Average			
			Single Facility	Minimum	Arithmetic Mean	Maximum	Single Facility	Minimum	Arithmetic Mean	Maximum
Paint Remover	3	5	–	1.2E-09	5.74E-02	1.58E-01	–	1.42E-09	2.43E-02	6.81E-02
		10	–	2.84E-07	9.50E-02	2.63E-01	–	9.30E-08	4.47E-02	1.26E-01
		30	–	5.30E-05	4.23E-02	1.18E-01	–	3.48E-05	2.00E-02	5.65E-02
		60	–	3.65E-04	1.77E-02	4.76E-02	–	2.35E-04	8.32E-03	2.29E-02
		100	–	6.72E-04	9.31E-03	2.23E-02	–	3.42E-04	4.23E-03	1.07E-02
		100–1,000	–	2.08E-04	9.66E-04	1.47E-03	–	1.37E-04	4.87E-04	8.10E-04
		2,500	–	3.90E-05	1.61E-04	3.22E-04	–	2.37E-05	5.96E-05	1.01E-04
		5,000	–	1.48E-05	7.04E-05	1.57E-04	–	8.59E-06	2.62E-05	5.21E-05
		10,000	–	5.22E-06	2.94E-05	7.02E-05	–	2.94E-06	1.05E-05	2.26E-05

<sup>a</sup> When (–) is indicated for the total number of facilities, no facilities were identified via TRI reporting. The provided estimates are based on modeling of theoretical facilities.

<sup>b</sup> This OES designation is a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Conveyorized Vapor Degreasing and Cold Cleaning. See Section 3.2.3.2.

<sup>c</sup> This OES designation includes a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Adhesives and Sealants, Paints and Coatings, and Adhesive and Caulk Removers.

2  
3

## 3.2.4.2 Water Pathway

---

### 3.2.4.2.1 Ambient Water Monitoring Results

---

Available monitored and measured ambient surface water information was evaluated as part of the original risk evaluation for MC to assess environmental risk ([U.S. EPA, 2020c](#)) by evaluating two principal sources of information: (1) extract submitted data to [EPA's Water Quality Portal](#), and (2) conduct a systematic review of surface water concentrations in peer reviewed and grey literature. Full description of these results are available in [U.S. EPA \(2020c\)](#). No new information was found during this evaluation. As described in [U.S. EPA \(2020c\)](#), WQP data ranged from ND to 29 µg/L for the years 2013 to 2017.

Measured concentrations from published literature within the United States was found in two studies. A nation-wide survey of 375 samples collected between 1999 and 2000 found a single detectable value of 2.6 µg/L ([USGS, 2003](#)). In another study conducted between 1979 to 1981, MC was detected in 93 percent of samples collected from the Eastern Pacific Ocean with values ranging from below detection limit to 0.008 µg/L, with a mean of 0.0031 µg/L ([Singh et al., 1983](#)). For measured published values outside the United States, concentrations between the years of 1993 to 2013 ranged from below detection limit to 134 µg/L.

### 3.2.4.2.2 Drinking Water Monitoring Results

---

The retrieved six-year review dataset for MC contained 371,905 entries for sample years 2006 through 2011 (See Section 2.2.2.1 for description of dataset). Observations were made in 48 states, the District of Columbia, and American Samoa at 55,712 unique monitoring sites, with 1 to 10,539 samples collected per site (Table 3-19).

For the entire dataset (all years combined), the detection frequency was 0.55% and the reported detection limits ranged from  $5.0 \times 10^{-5}$  to 1,000 µg/L (or  $2.5 \times 10^{-5}$  to 500 µg/L when using one-half the detection limit). Since one-half of the detection limit is used in the statistical analysis and some of the samples had reported detection limits that were greater than measured concentrations in other samples, the concentrations ranged from ND ( $< 2.5 \times 10^{-5}$  µg/L) to ND ( $< 500$  µg/L).

For the sample concentrations from sample residues detected above the detection limit, concentrations ranged from  $5.0 \times 10^{-4}$  to 326 µg/L ( $1.0 \times 10^{-3}$  to 100 µg/L in 2006,  $5.0 \times 10^{-4}$  to 23 µg/L in 2007,  $1.3 \times 10^{-3}$  to 54 µg/L in 2008,  $1.4 \times 10^{-2}$  to 290 µg/L in 2009, 0.14 to 326 µg/L in 2010, and 0.10 to 88 µg/L in 2011) with an average concentration of 3.0 µg/L and a standard deviation of 16 µg/L (Table 3-19).

The percentage of detections above methylene chloride's maximum contaminant level (MCL) of 5 µg/L was calculated by dividing the number of sample concentrations greater than 5 µg/L by the number of samples with detected values greater than the detection limit. Overall, the percentage of detections exceeding the MCL is 6.2 percent.

Each year, the evaluated datasets contained between 60,436 and 64,738 drinking water samples collected from 23,229 to 27,168 unique monitoring stations from one of three source water types. The three source water types are groundwater under direct influence of surface water (GU), groundwater (GW), and surface water (SW). When looking at the most current 2011 data set, the detection frequency ranged from 0.31% (SW) to 1.1% (GU). For all 2011 samples, the number of samples ranged from 554 (GU) to 52,124 (GW), with concentrations ranging from ND ( $< 2.5 \times 10^{-4}$  µg/L) to ND ( $< 500$  µg/L), both

47 from GW. When only looking at the sample concentrations from samples detected above the detection  
48 limit in 2011, concentrations ranged from 0.10 µg/L (GW) to 88 µg/L (GW) with an overall average  
49 concentration of 1.9 µg/L and a standard deviation of 6.1 µg/L. The percentage of detections above  
50 methylene chloride's MCL ranged from 0% (GU) to 21% (SW). Each source water type percentage  
51 calculation was based on the number of samples with detections above the detection limit representing  
52 that water type and not water types combined.

53  
54



1 **Table 3-19. Measured Concentrations of MC in Drinking Water Obtained from the Six-Year Review Data (2006–2011)<sup>a</sup>**

Year	Source Water Type	Detection Frequency (%)	Concentration in All Samples (µg/L)			Concentrations Only in Samples above the Detection Limit (µg/L)			
			No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	Percentage of Detects > MCL (5 µg/L)
2006	Groundwater Under Direct Infl. of Surf. Water (GU)	0	543 (270)	ND (<5.0E-02) to ND (<1.2)	ND (<0.277) ± 0.14	0 (0)	–	–	–
	Groundwater (GW)	0.62	50,636 (21,033)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.30 ± 3.0	315 (240)	1.0E-03 to 100	2.6 ± 7.5	7.9%
	Surface Water (SW)	0.43	9,257 (3,054)	ND (<2.5E-03) to ND <sup>c</sup> (<250)	0.30 ± 2.6	40 (35)	0.21 to 17	2.4 ± 3.6	10%
	All Types	0.59	6,0436 (24,357)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.31 ± 2.9	355 (275)	1.0E-03 to 100	2.6 ± 7.1	8.2%
2007	Groundwater Under Direct Influence of Surf. Water (GU)	0.20	500 (239)	ND (<5.0E-02) to 1.0	0.27 ± 0.11	1 (1)	6.0E-02	6.0E-02	0%
	Groundwater (GW)	0.87	52,083 (21,417)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.30 ± 2.9	451 (253)	5.0E-04 to 21	1.5 ± 2.2	3.8%
	Surface Water (SW)	0.59	8,937 (3,048)	ND (<2.5E-04) to 23	0.27 ± 0.29	53 (41)	6.0E-02 to 23	1.9 ± 3.2	3.8%
	All Types	0.82	61,520 (24,704)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.29 ± 2.7	505 (295)	5.0E-04 to 23	1.5 ± 2.4	3.8%
2008	Groundwater Under Direct Influence of Surf. Water (GU)	1.2	561 (264)	ND (<5.0E-02) to 17	0.31 ± 0.72	7 (4)	0.38 to 17	3.1 ± 6.2	14%
	Groundwater (GW)	0.58	52,850 (20,206)	ND (<2.5E-05) to ND <sup>c</sup> (<250)	0.33 ± 4.1	306 (208)	1.3E-03 to 54	1.8 ± 4.4	4.9%
	Surface Water (SW)	0.59	9,100 (3,276)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.32 ± 3.7	54 (31)	0.34 to 24	1.8 ± 3.2	3.7%
	All Types	0.59	62,511 (23,746)	ND (<2.5E-05) to ND <sup>c</sup> (<250)	0.33 ± 4.0	367 (243)	1.3E-03 to 54	1.8 ± 4.3	4.9%

Public Comment Draft – Do Not Cite of Quote

Year	Source Water Type	Detection Frequency (%)	Concentration in All Samples (µg/L)			Concentrations Only in Samples above the Detection Limit (µg/L)			
			No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	Percentage of Detects > MCL (5 µg/L)
2009	Groundwater Under Direct Influence of Surf. Water (GU)	0.53	571 (282)	ND (<2.5E-04) to 9.8	0.28 ± 0.44	3 (3)	0.99 to 9.8	4.3 ± 4.8	33%
	Groundwater (GW)	0.48	5,1423 (21,180)	ND (<2.5E-04) to 290	0.28 ± 2.2	247 (195)	1.4E-02 to 290	4.3 ± 21	7.3%
	Surface Water (SW)	0.56	8,605 (3,059)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.29 ± 2.7	48 (37)	0.34 to 11	1.9 ± 2.4	10%
	All Types	0.49	60,599 (24,521)	ND (<2.5E-04) to 290	0.29 ± 2.3	298 (235)	1.4E-02 to 290	3.9 ± 19	8.1%
2010	Groundwater Under Direct Influence of Surf. Water (GU)	0.38	527 (265)	ND (<2.5E-04) to 4.0	0.26 ± 0.17	2 (1)	0.79 to 4.0	2.4 ± 2.3	0%
	Groundwater (GW)	0.43	55,211 (23,793)	ND (<2.5E-04) to 326	0.29 ± 2.6	240 (195)	0.14 to 326	8.5 ± 39	8.3%
	Surface Water (SW)	0.27	9,000 (3,110)	ND (<2.5E-02) to ND <sup>c</sup> (<250)	0.33 ± 4.0	24 (18)	0.50 to 137	6.9 ± 28	4.2%
	All Types	0.41	64,738 (27,168)	ND (<2.5E-04) to 326	0.29 ± 2.8	266 (214)	0.14 to 326	8.3 ± 38	7.9%
2011	Groundwater Under Direct Influence of Surf. Water (GU)	1.1	554 (274)	ND (<5.0E-02) to 4.1	0.27 ± 0.18	6 (6)	0.14 to 4.1	1.3 ± 1.5	0%
	Groundwater (GW)	0.40	52,124 (19,606)	ND (<2.5E-04) to ND <sup>c</sup> (<500)	0.27 ± 2.2	207 (172)	0.10 to 88	1.7 ± 6.2	4.3%
	Surface Water (SW)	0.31	9423 (3,349)	ND (<2.5E-04) to 18	0.25 ± 0.35	29 (20)	0.50 to 18	3.7 ± 5.3	21%
	All Types	0.39	62,101 (23,229)	ND (<2.5E-04) to ND <sup>c</sup> (<500)	0.27 ± 2.0	242 (198)	0.10 to 88	1.9 ± 6.1	6.2%
All 6 Years	Groundwater Under Direct Influence of Surf. Water (GU)	0.58	3,256 (451)	ND (<2.5E-04) to 17	0.28 ± 0.37	19 (11)	6.0E-02 to 17	2.5 ± 4.2	11%
	Groundwater (GW)	0.56	314,327 (51,283)	ND (<2.5E-05) to ND <sup>c</sup> (<500)	0.30 ± 2.9	1,766 (1,100)	5.0E-04 to 326	3.1 ± 17	5.9%
	Surface Water (SW)	0.46	54,322 (3,978)	ND (<2.5E-04) to ND <sup>c</sup> (<250)	0.29 ± 2.7	248 (149)	6.0E-02 to 137	2.6 ± 9.2	8.1%
	All Types	0.55	37,1905 (55,712)	ND (<2.5E-05) to ND <sup>c</sup> (<500)	0.30 ± 2.9	2,033 (1,260)	5.0E-04 to 326	3.0 ± 16	6.2%

Year	Source Water Type	Detection Frequency (%)	Concentration in All Samples (µg/L)			Concentrations Only in Samples above the Detection Limit (µg/L)			
			No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	No. of Samples (No. of Stations)	Range <sup>b</sup>	Average ± Standard Deviation	Percentage of Detects > MCL (5 µg/L)
<sup>a</sup> Data were downloaded from the SYR3 website ( <a href="#">Six-Year Review 3 Compliance Monitoring Data (2006-2011)   US EPA</a> ) on September 8, 2021. <sup>b</sup> ND = Not Detected. Value in parentheses represents one-half the reported detection limit or ½ the average overall detection limit for non-detect samples without reported detection limits (overall average detection limit is 0.561 µg/L and one-half overall average is 0.28 µg/L). Reported Detection Limits ranged from 5.0E-05 to 1.0E+03 µg/L. <sup>c</sup> Maximum value represents ½ detection limit which was greater than the maximum detected value for all samples.									

2

1                    **3.2.4.2.3 Modeled Drinking Water**

2 Modeled drinking water estimates are summarized by OES category in Table 3-20 for the 20-day release  
3 scenario and in Table 3-21 for the maximum days of release scenario. Results are presented for the adult  
4 and infant age class, but complete by facility results across all age classes for all evaluated releases are  
5 available in *SF\_FLA\_Water Pathway Exposure Data for MC* (Appendix B).

6  
7 For the 20-day release scenario, a total of 66 releases were modeled across all OES with drinking water  
8 ADRs across both age classes ranging from  $5.0 \times 10^{-10}$  to  $8.7 \times 10^{-03}$  mg/kg-day, ADDs ranging from  
9  $2.4 \times 10^{-12}$  to  $2.2 \times 10^{-05}$  mg/kg-day and LADDs ranging from  $3.1 \times 10^{-14}$  to  $2.8 \times 10^{-07}$  mg/kg-day. For  
10 the maximum days of release scenario, a total of 87 releases were modeled across all OES with drinking  
11 water ADRs across both age classes ranging from  $4.0 \times 10^{-11}$  to 1.5 mg/kg-day, ADDs ranging from  
12  $2.4 \times 10^{-12}$  to  $6.8 \times 10^{-02}$  mg/kg-day, and LADDs ranging from  $3.1 \times 10^{-14}$  to  $8.8 \times 10^{-04}$  mg/kg-day. In  
13 all cases, estimated exposures were highest in the infant age class in the 20-day release scenarios.  
14  
15  
16  
17

1 Table 3-20. Summary of MC Drinking Water Exposure by OES for 20 Days of Release Scenarios

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)			LADD (mg/kg-day)		
			Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>	Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>	Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>
Manufacturing	12	Adult (21+)	7.8E-09	1.2E-04	1.3E-03	4.3E-11	3.0E-07	3.0E-06	1.8E-11	1.3E-07	1.3E-06
		Infant (birth to <1)	2.8E-08	4.4E-04	4.6E-03	1.1E-10	7.6E-07	7.8E-06	1.4E-12	9.7E-09	1.0E-07
Import and Repackaging	2	Adult (21+)	4.4E-06	8.7E-06	1.3E-05	2.1E-08	4.4E-08	6.6E-08	9.1E-09	1.9E-08	2.8E-08
		Infant (birth to <1)	1.6E-05	3.0E-05	4.5E-05	5.5E-08	1.1E-07	1.7E-07	7.0E-10	1.4E-09	2.2E-09
Processing as a Reactant	2	Adult (21+)	5.4E-05	7.7E-05	1.0E-04	3.5E-07	3.6E-07	3.7E-07	1.5E-07	1.5E-07	1.6E-07
		Infant (birth to <1)	1.9E-04	2.7E-04	3.5E-04	8.9E-07	9.2E-07	9.4E-07	1.1E-08	1.2E-08	1.2E-08
Processing: Formulation	5	Adult (21+)	3.0E-08	5.0E-04	2.5E-03	1.6E-10	6.4E-07	3.2E-06	6.9E-11	2.7E-07	1.3E-06
		Infant (birth to <1)	1.0E-07	1.8E-03	8.7E-03	4.2E-10	1.6E-06	8.1E-06	5.3E-12	2.1E-08	1.0E-07
Polyurethane Foam	1	Adult (21+)	3.3E-04	3.3E-04	3.3E-04	1.5E-06	1.5E-06	1.5E-06	6.5E-07	6.5E-07	6.5E-07
		Infant (birth to <1)	1.2E-03	1.2E-03	1.2E-03	3.9E-06	3.9E-06	3.9E-06	5.0E-08	5.0E-08	5.0E-08
Plastics Manufacturing	9	Adult (21+)	1.8E-08	2.7E-04	1.3E-03	9.6E-11	1.3E-06	5.8E-06	4.1E-11	5.4E-07	2.5E-06
		Infant (birth to <1)	6.2E-08	9.6E-04	4.4E-03	2.5E-10	3.2E-06	1.5E-05	3.2E-12	4.2E-08	1.9E-07
CTA Film Manufacturing	1	Adult (21+)	3.8E-05	3.8E-05	3.8E-05	2.4E-07	2.4E-07	2.4E-07	1.0E-07	1.0E-07	1.0E-07
		Infant (birth to <1)	1.3E-04	1.3E-04	1.3E-04	6.2E-07	6.2E-07	6.2E-07	7.9E-09	7.9E-09	7.9E-09
Lithographic Printer Cleaner	1	Adult (21+)	1.7E-08	1.7E-08	1.7E-08	9.3E-11	9.3E-11	9.3E-11	3.9E-11	3.9E-11	3.9E-11
		Infant (birth to <1)	6.0E-08	6.0E-08	6.0E-08	2.4E-10	2.4E-10	2.4E-10	3.0E-12	3.0E-12	3.0E-12
Spot Cleaner	1	Adult (21+)	1.9E-06	1.9E-06	1.9E-06	3.2E-09	3.2E-09	3.2E-09	1.4E-09	1.4E-09	1.4E-09
		Infant (birth to <1)	6.6E-06	6.6E-06	6.6E-06	8.2E-09	8.2E-09	8.2E-09	1.1E-10	1.1E-10	1.1E-10
Recycling and Disposal	5	Adult (21+)	3.7E-06	5.0E-04	1.9E-03	1.8E-08	1.1E-06	2.7E-06	7.8E-09	4.8E-07	1.2E-06
		Infant (birth to <1)	1.3E-05	1.8E-03	6.7E-03	4.7E-08	2.9E-06	7.0E-06	6.0E-10	3.7E-08	9.0E-08
Other	10	Adult (21+)	1.4E-10	5.0E-06	3.0E-05	9.5E-13	1.4E-08	9.0E-08	4.0E-13	6.1E-09	3.8E-08
		Infant (birth to <1)	5.0E-10	1.7E-05	1.0E-04	2.4E-12	3.7E-08	2.3E-07	3.1E-14	4.7E-10	3.0E-09
DOD	1	Adult (21+)	6.3E-07	6.3E-07	6.3E-07	4.0E-09	4.0E-09	4.0E-09	1.7E-09	1.7E-09	1.7E-09
		Infant (birth to <1)	2.2E-06	2.2E-06	2.2E-06	1.0E-08	1.0E-08	1.0E-08	1.3E-10	1.3E-10	1.3E-10
WWTP	16	Adult (21+)	4.0E-08	1.3E-04	4.7E-04	2.9E-10	1.5E-06	8.6E-06	1.2E-10	6.5E-07	3.6E-06
		Infant (birth to <1)	1.4E-07	4.4E-04	1.7E-03	7.5E-10	3.9E-06	2.2E-05	9.6E-12	5.1E-08	2.8E-07
Overall	66	Adult (21+)	1.4E-10	1.8E-04	2.5E-03	9.5E-13	7.8E-07	8.6E-06	4.0E-13	3.3E-07	3.6E-06
		Infant (birth to <1)	5.0E-10	6.2E-04	8.7E-03	2.4E-12	2.0E-06	2.2E-05	3.1E-14	2.5E-08	2.8E-07

<sup>a</sup>The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup>The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup>The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

3 **Table 3-21. Summary of MC Drinking Water Exposure by OES for Maximum Days of Release Scenarios**

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)			LADD (mg/kg-day)		
			Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>	Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>	Min Exp. <sup>a</sup>	Mean Exp. <sup>b</sup>	Max Exp. <sup>c</sup>
Manufacturing	16	Adult (21+)	4.5E-10	5.7E-06	7.4E-05	4.3E-11	2.5E-07	3.1E-06	1.8E-11	1.0E-07	1.3E-06
		Infant (birth to <1)	1.6E-09	2.0E-05	2.6E-04	1.1E-10	6.3E-07	7.8E-06	1.4E-12	8.0E-09	1.0E-07
Import and Repackaging	5	Adult (21+)	1.6E-09	1.6E-04	8.1E-04	1.1E-10	1.0E-05	5.1E-05	4.8E-11	4.3E-06	2.1E-05
		Infant (birth to <1)	5.8E-09	5.7E-04	2.8E-03	2.9E-10	2.6E-05	1.3E-04	3.7E-12	3.4E-07	1.7E-06
Processing as a Reactant	3	Adult (21+)	4.6E-07	3.1E-06	5.6E-06	3.9E-08	2.5E-07	3.7E-07	1.7E-08	1.1E-07	1.5E-07
		Infant (birth to <1)	1.6E-06	1.1E-05	2.0E-05	1.0E-07	6.4E-07	9.3E-07	1.3E-09	8.2E-09	1.2E-08
Processing: Formulation	9	Adult (21+)	9.3E-11	4.3E-03	3.8E-02	7.6E-12	2.7E-04	2.4E-03	3.2E-12	1.1E-04	1.0E-03
		Infant (birth to <1)	3.2E-10	1.5E-02	0.14	1.9E-11	6.8E-04	6.1E-03	2.5E-13	8.7E-06	7.8E-05
Polyurethane Foam	1	Adult (21+)	2.7E-05	2.7E-05	2.7E-05	1.5E-06	1.5E-06	1.5E-06	6.4E-07	6.4E-07	6.4E-07
		Infant (birth to <1)	9.3E-05	9.3E-05	9.3E-05	3.8E-06	3.8E-06	3.8E-06	4.9E-08	4.9E-08	4.9E-08
Plastics Manufacturing	9	Adult (21+)	1.4E-09	2.2E-05	1.0E-04	9.6E-11	1.3E-06	5.9E-06	4.0E-11	5.4E-07	2.5E-06
		Infant (birth to <1)	4.9E-09	7.7E-05	3.6E-04	2.4E-10	3.2E-06	1.5E-05	3.1E-12	4.2E-08	1.9E-07
CTA Film Manufacturing	1	Adult (21+)	3.0E-06	3.0E-06	3.0E-06	2.4E-07	2.4E-07	2.4E-07	1.0E-07	1.0E-07	1.0E-07
		Infant (birth to <1)	1.1E-05	1.1E-05	1.1E-05	6.2E-07	6.2E-07	6.2E-07	7.9E-09	7.9E-09	7.9E-09
Lithographic Printer Cleaner	1	Adult (21+)	1.4E-09	1.4E-09	1.4E-09	9.2E-11	9.2E-11	9.2E-11	3.9E-11	3.9E-11	3.9E-11
		Infant (birth to <1)	4.8E-09	4.8E-09	4.8E-09	2.3E-10	2.3E-10	2.3E-10	3.0E-12	3.0E-12	3.0E-12
Spot Cleaner	1	Adult (21+)	1.5E-07	1.5E-07	1.5E-07	3.2E-09	3.2E-09	3.2E-09	1.4E-09	1.4E-09	1.4E-09
		Infant (birth to <1)	5.3E-07	5.3E-07	5.3E-07	8.2E-09	8.2E-09	8.2E-09	1.1E-10	1.1E-10	1.1E-10
Recycling and Disposal	12	Adult (21+)	1.0E-07	3.6E-02	0.43	1.4E-08	2.3E-03	2.7E-02	5.8E-09	9.6E-04	1.1E-02
		Infant (birth to <1)	3.6E-07	0.13	1.5	3.5E-08	5.8E-03	6.8E-02	4.5E-10	7.4E-05	8.8E-04
Other	12	Adult (21+)	1.1E-11	2.0E-05	2.4E-04	9.5E-13	1.3E-06	1.5E-05	4.0E-13	5.3E-07	6.2E-06
		Infant (birth to <1)	4.0E-11	7.1E-05	8.3E-04	2.4E-12	3.2E-06	3.8E-05	3.1E-14	4.1E-08	4.8E-07
DOD	1	Adult (21+)	5.0E-08	5.0E-08	5.0E-08	4.0E-09	4.0E-09	4.0E-09	1.7E-09	1.7E-09	1.7E-09
		Infant (birth to <1)	1.8E-07	1.8E-07	1.8E-07	1.0E-08	1.0E-08	1.0E-08	1.3E-10	1.3E-10	1.3E-10
WWTP	16	Adult (21+)	2.2E-09	6.9E-06	2.6E-05	2.9E-10	1.5E-06	8.7E-06	1.2E-10	6.6E-07	3.7E-06
		Infant (birth to <1)	7.7E-09	2.4E-05	9.0E-05	7.5E-10	4.0E-06	2.2E-05	9.6E-12	5.1E-08	2.8E-07
Overall	87	Adult (21+)	1.1E-11	5.4E-03	0.43	9.5E-13	3.4E-04	2.7E-02	4.0E-13	1.4E-04	1.1E-02
		Infant (birth to <1)	4.0E-11	1.9E-02	1.5	2.4E-12	8.7E-04	6.8E-02	3.1E-14	1.1E-05	8.8E-04

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

#### 3.2.4.2.4 Incidental Oral for MC

Modeled incidental oral estimates are summarized by OES category in Table 3-22 for the 20-day release scenario and in Table 3-23 for the maximum days of release scenario. Results are presented for the adult and youth (11-15 years) age class, but complete by facility results across all age classes for all evaluated releases are available in *SF\_FLA\_Water Pathway Exposure Data for MC* (Appendix B).

For the 20-day release scenario, a total of 82 releases were modeled across all OES with incidental oral ingestion exposure ADRs across both age groups ranging from  $1.2 \times 10^{-11}$  to  $3.1 \times 10^{-02}$  mg/kg-day and ADDs ranging from  $3.0 \times 10^{-13}$  to  $1.7 \times 10^{-03}$  mg/kg-day. For the maximum days of release scenario, a total of 106 releases were modeled across all OES with incidental oral ingestion exposure ADRs across both age groups ranging from  $9.7 \times 10^{-13}$  to  $5.7 \times 10^{-02}$  mg/kg-day and ADDs ranging from  $3.0 \times 10^{-13}$  to  $1.3 \times 10^{-02}$  mg/kg-day. Youths (11 to 15 years) had higher exposures than their adult counterparts due to this age class's higher weighted incidental daily ingestion rate (Table 2-6).

Results here were compared to an alternative method for evaluating incidental oral exposure ([U.S. EPA, 2019d](#)). Due to methodological differences between the two methods, in [U.S. EPA \(2019d\)](#) the 6 to 10 year age class has the highest estimated exposures as compared to the 11 to 15 year age class in the presented method. Weighted incidental daily ingestion rates between the two methods for the highest exposure age class between the two models are  $6.6 \times 10^{-03}$  L/kg-day and  $5.4 \times 10^{-03}$  L/kg-day respectively, resulting in slightly higher, but comparable overall exposure values. Using the [U.S. EPA \(2019d\)](#) method, the 20-day scenario had a maximum ADR of  $3.9 \times 10^{-02}$  mg/kg-day and ADD of  $2.1 \times 10^{-03}$  mg/kg-day, while the maximum days of release scenario had a maximum ADR of  $7.0 \times 10^{-02}$  mg/kg-day and ADD of  $1.6 \times 10^{-02}$  mg/kg-day. These results are comparable between the two methodologies and supports confidence in the presented estimated exposures. Complete results for evaluation of incidental oral ingestion using the [U.S. EPA \(2019d\)](#) method are available in *SF\_FLA\_Water Pathway Exposure Data for MC* (Appendix B).

1 Table 3-22. Summary of MC Incidental Oral Ingestion Exposure by OES for 20 Days of Release Scenarios

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Manufacturing	14	Adult (21+)	6.7E-10	3.2E-05	2.9E-04	1.3E-11	1.3E-06	1.6E-05
		Youth (11-15)	1.0E-09	4.9E-05	4.4E-04	2.1E-11	2.0E-06	2.4E-05
Import and Repackaging	2	Adult (21+)	3.8E-07	7.4E-07	1.1E-06	6.7E-09	1.4E-08	2.1E-08
		Youth (11-15)	5.9E-07	1.2E-06	1.7E-06	1.0E-08	2.1E-08	3.2E-08
Processing as a Reactant	2	Adult (21+)	4.6E-06	6.6E-06	8.6E-06	1.1E-07	1.1E-07	1.2E-07
		Youth (11-15)	7.2E-06	1.0E-05	1.3E-05	1.7E-07	1.7E-07	1.8E-07
Processing: Formulation	5	Adult (21+)	2.5E-09	4.3E-05	2.1E-04	5.1E-11	2.0E-07	9.9E-07
		Youth (11-15)	4.0E-09	6.6E-05	3.3E-04	7.9E-11	3.1E-07	1.5E-06
Polyurethane Foam	1	Adult (21+)	2.8E-05	2.8E-05	2.8E-05	4.8E-07	4.8E-07	4.8E-07
		Youth (11-15)	4.4E-05	4.4E-05	4.4E-05	7.4E-07	7.4E-07	7.4E-07
Plastics Manufacturing	9	Adult (21+)	1.5E-09	2.4E-05	1.1E-04	3.0E-11	4.0E-07	1.8E-06
		Youth (11-15)	2.3E-09	3.7E-05	1.7E-04	4.7E-11	6.2E-07	2.8E-06
CTA Film Manufacturing	1	Adult (21+)	3.2E-06	3.2E-06	3.2E-06	7.6E-08	7.6E-08	7.6E-08
		Youth (11-15)	5.0E-06	5.0E-06	5.0E-06	1.2E-07	1.2E-07	1.2E-07
Lithographic Printer Cleaner	1	Adult (21+)	1.5E-09	1.5E-09	1.5E-09	2.9E-11	2.9E-11	2.9E-11
		Youth (11-15)	2.3E-09	2.3E-09	2.3E-09	4.5E-11	4.5E-11	4.5E-11
Spot Cleaner	1	Adult (21+)	1.6E-07	1.6E-07	1.6E-07	1.0E-09	1.0E-09	1.0E-09
		Youth (11-15)	2.5E-07	2.5E-07	2.5E-07	1.6E-09	1.6E-09	1.6E-09
Recycling and Disposal	6	Adult (21+)	3.1E-07	2.4E-04	1.2E-03	5.8E-09	1.4E-06	6.7E-06
		Youth (11-15)	4.9E-07	3.7E-04	1.9E-03	9.0E-09	2.2E-06	1.0E-05
Other	10	Adult (21+)	1.2E-11	4.3E-07	2.6E-06	3.0E-13	4.5E-09	2.8E-08
		Youth (11-15)	1.9E-11	6.6E-07	4.0E-06	4.6E-13	7.0E-09	4.4E-08
DOD	1	Adult (21+)	5.4E-08	5.4E-08	5.4E-08	1.2E-09	1.2E-09	1.2E-09
		Youth (11-15)	8.4E-08	8.4E-08	8.4E-08	1.9E-09	1.9E-09	1.9E-09
WWTP	29	Adult (21+)	3.4E-09	7.2E-04	2.0E-02	9.2E-11	3.9E-05	1.1E-03
		Youth (11-15)	5.3E-09	1.1E-03	3.1E-02	1.4E-10	6.1E-05	1.7E-03
Overall	82	Adult (21+)	1.2E-11	2.8E-04	2.0E-02	3.0E-13	1.4E-05	1.1E-03
		Youth (11-15)	1.9E-11	4.4E-04	3.1E-02	4.6E-13	2.2E-05	1.7E-03

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.



2 Table 3-23. Summary of MC Incidental Oral Ingestion Exposure by OES for Maximum Days of Release Scenarios

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Manufacturing	20	Adult (21+)	3.8E-11	1.3E-06	1.6E-05	1.3E-11	9.2E-07	1.6E-05
		Youth (11-15)	5.9E-11	2.0E-06	2.5E-05	2.1E-11	1.4E-06	2.4E-05
Import and Repackaging	5	Adult (21+)	1.4E-10	1.4E-05	6.9E-05	3.5E-11	3.2E-06	1.6E-05
		Youth (11-15)	2.2E-10	2.2E-05	1.1E-04	5.5E-11	5.0E-06	2.5E-05
Processing as a Reactant	3	Adult (21+)	4.0E-08	2.6E-07	4.8E-07	1.2E-08	7.9E-08	1.1E-07
		Youth (11-15)	6.2E-08	4.1E-07	7.5E-07	1.9E-08	1.2E-07	1.8E-07
Processing: Formulation	9	Adult (21+)	7.9E-12	3.7E-04	3.3E-03	2.4E-12	8.4E-05	7.5E-04
		Youth (11-15)	1.2E-11	5.7E-04	5.1E-03	3.7E-12	1.3E-04	1.2E-03
Polyurethane Foam	1	Adult (21+)	2.3E-06	2.3E-06	2.3E-06	4.7E-07	4.7E-07	4.7E-07
		Youth (11-15)	3.5E-06	3.5E-06	3.5E-06	7.3E-07	7.3E-07	7.3E-07
Plastics Manufacturing	9	Adult (21+)	1.2E-10	1.9E-06	8.7E-06	3.0E-11	4.0E-07	1.8E-06
		Youth (11-15)	1.9E-10	2.9E-06	1.3E-05	4.7E-11	6.2E-07	2.9E-06
CTA Film Manufacturing	1	Adult (21+)	2.6E-07	2.6E-07	2.6E-07	7.6E-08	7.6E-08	7.6E-08
		Youth (11-15)	4.0E-07	4.0E-07	4.0E-07	1.2E-07	1.2E-07	1.2E-07
Lithographic Printer Cleaner	1	Adult (21+)	1.2E-10	1.2E-10	1.2E-10	2.9E-11	2.9E-11	2.9E-11
		Youth (11-15)	1.8E-10	1.8E-10	1.8E-10	4.5E-11	4.5E-11	4.5E-11
Spot Cleaner	1	Adult (21+)	1.3E-08	1.3E-08	1.3E-08	1.0E-09	1.0E-09	1.0E-09
		Youth (11-15)	2.0E-08	2.0E-08	2.0E-08	1.6E-09	1.6E-09	1.6E-09
Recycling and Disposal	14	Adult (21+)	8.8E-09	2.7E-03	3.7E-02	4.3E-09	6.1E-04	8.4E-03
		Youth (11-15)	1.4E-08	4.1E-03	5.7E-02	6.7E-09	9.5E-04	1.3E-02
Other	12	Adult (21+)	9.7E-13	1.7E-06	2.0E-05	3.0E-13	4.0E-07	4.6E-06
		Youth (11-15)	1.5E-12	2.7E-06	3.1E-05	4.6E-13	6.1E-07	7.2E-06
DOD	1	Adult (21+)	4.3E-09	4.3E-09	4.3E-09	1.2E-09	1.2E-09	1.2E-09
		Youth (11-15)	6.7E-09	6.7E-09	6.7E-09	1.9E-09	1.9E-09	1.9E-09
WWTP	29	Adult (21+)	1.9E-10	4.0E-05	1.1E-03	9.2E-11	4.0E-05	1.1E-03
		Youth (11-15)	2.9E-10	6.2E-05	1.7E-03	1.4E-10	6.1E-05	1.7E-03
Overall	106	Adult (21+)	9.7E-13	4.0E-04	3.7E-02	3.0E-13	9.9E-05	8.4E-03
		Youth (11-15)	1.5E-12	6.1E-04	5.7E-02	4.6E-13	1.5E-04	1.3E-02

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

#### 3.2.4.2.5 Incidental Dermal for MC

---

Modeled incidental dermal estimates are summarized by OES category in Table 3-24 for the 20-day release scenario and in Table 3-25 for the maximum days of release scenario. Results are presented for the adult (21+ years) age class, but complete by facility results across all age classes for all evaluated releases are available in *SF\_FLA\_Water Pathway Exposure Data for MC* (Appendix B).

For the 20-day release scenario, a total of 82 releases were modeled across all OES with incidental dermal exposure ADRs ranging from  $1.9 \times 10^{-11}$  to  $3.1 \times 10^{-02}$  mg/kg-day and ADDs ranging from  $4.5 \times 10^{-13}$  to  $1.7 \times 10^{-03}$  mg/kg-day. For the maximum release scenario, a total of 106 releases were modeled across all OES with incidental dermal exposure ADRs ranging from  $1.5 \times 10^{-12}$  to  $5.6 \times 10^{-02}$  mg/kg-day and ADDs ranging from  $4.5 \times 10^{-13}$  to  $1.3 \times 10^{-02}$  mg/kg-day.

1 **Table 3-24. Summary of MC Incidental Dermal Exposure by OES for 20 Days of Release Scenarios**

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Manufacturing	14	Adult (21+)	1.0E-09	4.8E-05	4.3E-04	2.1E-11	2.0E-06	2.4E-05
Import and Repackaging	2	Adult (21+)	5.8E-07	1.1E-06	1.7E-06	1.0E-08	2.1E-08	3.2E-08
Processing as a Reactant	2	Adult (21+)	7.0E-06	1.0E-05	1.3E-05	1.7E-07	1.7E-07	1.8E-07
Processing: Formulation	5	Adult (21+)	3.9E-09	6.5E-05	3.2E-04	7.8E-11	3.0E-07	1.5E-06
Polyurethane Foam	1	Adult (21+)	4.3E-05	4.3E-05	4.3E-05	7.3E-07	7.3E-07	7.3E-07
Plastics Manufacturing	9	Adult (21+)	2.3E-09	3.6E-05	1.6E-04	4.6E-11	6.1E-07	2.8E-06
CTA Film Manufacturing	1	Adult (21+)	4.9E-06	4.9E-06	4.9E-06	1.1E-07	1.1E-07	1.1E-07
Lithographic Printer Cleaner	1	Adult (21+)	2.2E-09	2.2E-09	2.2E-09	4.4E-11	4.4E-11	4.4E-11
Spot Cleaner	1	Adult (21+)	2.4E-07	2.4E-07	2.4E-07	1.5E-09	1.5E-09	1.5E-09
Recycling and Disposal	6	Adult (21+)	4.8E-07	3.6E-04	1.9E-03	8.8E-09	2.1E-06	1.0E-05
Other	10	Adult (21+)	1.9E-11	6.5E-07	3.9E-06	4.5E-13	6.8E-09	4.3E-08
DOD	1	Adult (21+)	8.2E-08	8.2E-08	8.2E-08	1.9E-09	1.9E-09	1.9E-09
WWTP	29	Adult (21+)	5.2E-09	1.1E-03	3.1E-02	1.4E-10	6.0E-05	1.7E-03
Overall	82	Adult (21+)	1.9E-11	4.3E-04	3.1E-02	4.5E-13	2.2E-05	1.7E-03

<sup>a</sup>The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>b</sup>The arithmetic exposure ADR for the identified days of release, within the identified OES, and for the identified age group.  
<sup>c</sup>The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

2  
3

4 **Table 3-25. Summary of Methylene Chloride Incidental Dermal Exposure by OES for Maximum Days of Release Scenarios**

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Manufacturing	20	Adult (21+)	5.8E-11	2.0E-06	2.5E-05	2.1E-11	1.4E-06	2.4E-05
Import and Repackaging	5	Adult (21+)	2.1E-10	2.1E-05	1.1E-04	5.4E-11	4.9E-06	2.4E-05
Processing as a Reactant	3	Adult (21+)	6.0E-08	4.0E-07	7.3E-07	1.9E-08	1.2E-07	1.7E-07
Processing: Formulation	9	Adult (21+)	1.2E-11	5.6E-04	5.0E-03	3.6E-12	1.3E-04	1.1E-03
Polyurethane Foam	1	Adult (21+)	3.5E-06	3.5E-06	3.5E-06	7.2E-07	7.2E-07	7.2E-07
Plastics Manufacturing	9	Adult (21+)	1.8E-10	2.9E-06	1.3E-05	4.6E-11	6.1E-07	2.8E-06
CTA Film Manufacturing	1	Adult (21+)	3.9E-07	3.9E-07	3.9E-07	1.1E-07	1.1E-07	1.1E-07
Lithographic Printer Cleaner	1	Adult (21+)	1.8E-10	1.8E-10	1.8E-10	4.4E-11	4.4E-11	4.4E-11
Spot Cleaner	1	Adult (21+)	2.0E-08	2.0E-08	2.0E-08	1.5E-09	1.5E-09	1.5E-09
Recycling and Disposal	14	Adult (21+)	1.3E-08	4.0E-03	5.6E-02	6.6E-09	9.3E-04	1.3E-02
Other	12	Adult (21+)	1.5E-12	2.6E-06	3.1E-05	4.5E-13	6.0E-07	7.0E-06
DOD	1	Adult (21+)	6.6E-09	6.6E-09	6.6E-09	1.9E-09	1.9E-09	1.9E-09
WWTP	29	Adult (21+)	2.9E-10	6.0E-05	1.7E-03	1.4E-10	6.0E-05	1.7E-03
Overall	106	Adult (21+)	1.5E-12	6.0E-04	5.6E-02	4.5E-13	1.5E-04	1.3E-02

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic exposure ADR for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

5

1           **3.2.5 Risk Characterization for MC**

---

2                   **3.2.5.1 Risk Characterization for the Air Pathway**

---

3 EPA calculated risk estimates for each of the endpoints in Table 3-13 across all known TRI reporters  
4 and other modeled facilities under each OES. EPA calculated risk estimates for each facility using the  
5 10th, 50th, and 95th percentile of modeled exposure concentrations around the releasing facility. The  
6 95th percentile estimates were then further distilled across facilities within each OES to present the  
7 range from minimum to maximum risk.

8  
9 Based on the 95th percentile values, risks were indicated for at least one facility relative to benchmark  
10 for 8 of 17 OES. Risks were not indicated for any OES beyond 100 meters from a facility. These results  
11 are summarized below in Table 3-26. Results for 10th and 50th percentile measurements along with  
12 facility-specific results are provided in *SF\_FLA\_Air Pathway Full-Screen Results for MC* (Appendix B).

1 **Table 3-26. MC Inhalation Risk across OES at Various Distances from Releasing Facility (Based on 95th percentile exposure**  
 2 **Concentrations)**

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Batch Open-Top Degreasing	1	0	5	6.7E+04	–	–	–	2.7E+04	–	–	–	3.7E-09	–	–	–
			10	4.9E+04	–	–	–	2.0E+04	–	–	–	5.0E-09	–	–	–
			30	1.0E+05	–	–	–	4.2E+04	–	–	–	2.4E-09	–	–	–
			60	4.2E+04	–	–	–	1.5E+04	–	–	–	6.6E-09	–	–	–
			100	2.4E+04	–	–	–	88,881	–	–	–	1.1E-08	–	–	–
			100–1,000	1.0E+05	–	–	–	2.5E+04	–	–	–	4.0E-09	–	–	–
			2,500	6.4E+05	–	–	–	3.0E+05	–	–	–	3.3E-10	–	–	–
			5,000	1.7E+06	–	–	–	8.0E+05	–	–	–	1.3E-10	–	–	–
10,000	4.8E+06	–	–	–	2.1E+06	–	–	–	4.7E-11	–	–	–			
Cellulose Triacetate Film Production	2	1	5	N/A	1.3E+05	307	154	N/A	3.0E+04	70	35	N/A	3.3E-09	1.4E-06	2.8E-06
			10	N/A	1.0E+05	234	117	N/A	2.2E+04	53	26	N/A	4.5E-09	1.9E-06	3.8E-06
			30	N/A	2.9E+05	703	352	N/A	6.1E+04	173	87	N/A	1.6E-09	5.8E-07	1.2E-06
			60	N/A	5.9E+05	1,880	942	N/A	1.2E+05	507	254	N/A	8.1E-10	2.0E-07	3.9E-07
			100	N/A	7.1E+05	4,225	2,119	N/A	1.7E+05	1,225	615	N/A	6.0E-10	8.2E-08	1.6E-07
			100–1,000	N/A	2.8E+06	7.0E+04	3.5E+04	N/A	5.3E+05	1.3E+04	6,640	N/A	1.9E-10	7.6E-09	1.5E-08
			2,500	N/A	1.5E+07	8.6E+05	4.4E+05	N/A	3.4E+06	2.6E+05	1.4E+05	N/A	3.0E-11	3.8E-10	7.3E-10
			5,000	N/A	4.1E+07	2.6E+06	1.4E+06	N/A	9.4E+06	8.0E+05	4.2E+05	N/A	1.1E-11	1.2E-10	2.4E-10
10,000	N/A	1.2E+08	8.1E+06	4.2E+06	N/A	2.8E+07	2.4E+06	1.3E+06	N/A	3.6E-12	4.1E-11	7.9E-11			
Cleaner/ Degreaser – Unknown <sup>e</sup>	16	3	5	N/A	1.0E+13	1,250	325	N/A	6.3E+11	384	85	N/A	1.6E-16	2.6E-07	1.2E-06
			10	N/A	1.4E+11	968	201	N/A	2.3E+10	300	74	N/A	4.4E-15	3.3E-07	1.3E-06
			30	N/A	7.7E+07	2,721	467	N/A	1.9E+07	887	204	N/A	5.4E-12	1.1E-07	4.9E-07
			60	N/A	4.5E+06	7,046	1,182	N/A	1.7E+06	2,332	528	N/A	5.8E-11	4.3E-08	1.9E-07
			100	N/A	2.1E+06	1.5E+04	2,618	N/A	8.4E+05	4,940	1,149	N/A	1.2E-10	2.0E-08	8.7E-08
			100–1,000	N/A	1.0E+07	2.1E+05	5.0E+04	N/A	2.5E+06	4.0E+04	9,690	N/A	4.1E-11	2.5E-09	1.0E-08
			2,500	N/A	7.7E+07	2.3E+06	7.9E+05	N/A	3.2E+07	7.9E+05	2.3E+05	N/A	3.1E-12	1.3E-10	4.4E-10
			5,000	N/A	2.0E+08	6.5E+06	2.5E+06	N/A	7.2E+07	2.2E+06	6.8E+05	N/A	1.4E-12	4.6E-11	1.5E-10

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
			10,000	N/A	5.6E+08	1.8E+07	7.5E+06	N/A	1.7E+08	5.8E+06	2.0E+06	N/A	5.9E-13	1.7E-11	5.1E-11
Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	- <sup>a</sup>	-	5	N/A	2.6E+04	1.5E+04	9,843	N/A	1.3E+04	5,415	3,165	N/A	8.0E-09	1.8E-08	3.2E-08
			10	N/A	1.5E+04	1.0E+04	7,657	N/A	6,906	3,862	2,513	N/A	1.4E-08	2.6E-08	4.0E-08
			30	N/A	3.6E+04	2.9E+04	2.5E+04	N/A	1.7E+04	1.2E+04	9,058	N/A	5.7E-09	8.2E-09	1.1E-08
			60	N/A	1.1E+05	8.5E+04	6.9E+04	N/A	4.8E+04	3.6E+04	2.8E+04	N/A	2.1E-09	2.8E-09	3.6E-09
			100	N/A	2.9E+05	2.2E+05	1.8E+05	N/A	1.2E+05	9.4E+04	7.5E+04	N/A	8.2E-10	1.1E-09	1.3E-09
			100-1,000	N/A	1.1E+07	9.0E+06	7.4E+06	N/A	1.8E+06	1.4E+06	1.2E+06	N/A	5.5E-11	7.0E-11	8.4E-11
			2,500	N/A	2.9E+08	2.3E+08	1.9E+08	N/A	1.2E+08	7.7E+07	4.7E+07	N/A	8.5E-13	1.3E-12	2.1E-12
			5,000	N/A	1.1E+09	8.4E+08	6.9E+08	N/A	4.2E+08	2.5E+08	1.4E+08	N/A	2.4E-13	4.0E-13	7.0E-13
10,000	N/A	3.3E+09	2.2E+09	1.7E+09	N/A	9.8E+08	6.1E+08	3.6E+08	N/A	1.0E-13	1.6E-13	2.8E-13			
Fabric Finishing	1	0	5	7,899	-	-	-	2,525	-	-	-	4.0E-08	-	-	-
			10	6,378	-	-	-	1,754	-	-	-	5.7E-08	-	-	-
			30	1.7E+04	-	-	-	4,464	-	-	-	2.2E-08	-	-	-
			60	4.4E+04	-	-	-	1.1E+04	-	-	-	8.8E-09	-	-	-
			100	9.5E+04	-	-	-	2.5E+04	-	-	-	4.0E-09	-	-	-
			100-1,000	1.5E+06	-	-	-	2.7E+05	-	-	-	3.7E-10	-	-	-
			2,500	2.0E+07	-	-	-	5.8E+06	-	-	-	1.7E-11	-	-	-
			5,000	6.2E+07	-	-	-	1.9E+07	-	-	-	5.3E-12	-	-	-
10,000	1.9E+08	-	-	-	5.9E+07	-	-	-	1.7E-12	-	-	-			
Flexible Polyurethane Foam Manufacturing	1	1	5	17	-	-	-	5	-	-	-	2.2E-05	-	-	-
			10	13	-	-	-	4	-	-	-	2.6E-05	-	-	-
			30	40	-	-	-	11	-	-	-	9.5E-06	-	-	-
			60	101	-	-	-	26	-	-	-	3.8E-06	-	-	-
			100	217	-	-	-	57	-	-	-	1.8E-06	-	-	-
			100-1,000	3,401	-	-	-	588	-	-	-	1.7E-07	-	-	-
			2,500	3.9E+04	-	-	-	1.1E+04	-	-	-	9.4E-09	-	-	-
			5,000	1.2E+05	-	-	-	3.3E+04	-	-	-	3.1E-09	-	-	-
10,000	3.7E+05	-	-	-	1.0E+05	-	-	-	1.0E-09	-	-	-			

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Laboratory Use	5	0	5	N/A	1.2E+11	3.2E+04	9,901	N/A	1.1E+10	8,335	2,551	N/A	8.7E-15	1.2E-08	3.9E-08
			10	N/A	8.2E+08	1.9E+04	5,102	N/A	3.5E+08	4,942	1,330	N/A	2.8E-13	2.0E-08	7.5E-08
			30	N/A	9.6E+06	3.9E+04	9,615	N/A	3.0E+06	1.2E+04	2,976	N/A	3.3E-11	8.3E-09	3.4E-08
			60	N/A	2.0E+06	8.3E+04	2.2E+04	N/A	3.0E+05	2.6E+04	7,194	N/A	3.4E-10	3.8E-09	1.4E-08
			100	N/A	1.4E+06	1.4E+05	4.4E+04	N/A	2.5E+05	4.0E+04	1.5E+04	N/A	4.0E-10	2.5E-09	6.8E-09
			100-1,000	N/A	1.6E+07	1.0E+06	3.9E+05	N/A	2.5E+06	1.9E+05	7.2E+04	N/A	3.9E-11	5.4E-10	1.4E-09
			2,500	N/A	1.0E+08	4.6E+06	1.3E+06	N/A	2.0E+07	1.4E+06	3.8E+05	N/A	5.0E-12	7.1E-11	2.6E-10
			5,000	N/A	2.0E+08	8.8E+06	2.3E+06	N/A	4.0E+07	2.7E+06	6.8E+05	N/A	2.5E-12	3.8E-11	1.5E-10
10,000	N/A	4.3E+08	1.8E+07	4.5E+06	N/A	9.0E+07	5.7E+06	1.4E+06	N/A	1.1E-12	1.8E-11	7.2E-11			
Lithographic Printing Plate Cleaning	1	0	5	3.1E+12	-	-	-	1.8E+11	-	-	-	5.5E-16	-	-	-
			10	1.5E+10	-	-	-	1.2E+09	-	-	-	8.2E-14	-	-	-
			30	1.1E+07	-	-	-	3.0E+06	-	-	-	3.3E-11	-	-	-
			60	6.9E+05	-	-	-	1.6E+05	-	-	-	6.1E-10	-	-	-
			100	3.1E+05	-	-	-	7.5E+04	-	-	-	1.3E-09	-	-	-
			100-1,000	7.9E+05	-	-	-	2.1E+05	-	-	-	4.9E-10	-	-	-
			2,500	4.2E+06	-	-	-	2.0E+06	-	-	-	4.9E-11	-	-	-
			5,000	1.1E+07	-	-	-	5.2E+06	-	-	-	1.9E-11	-	-	-
10,000	2.8E+07	-	-	-	1.3E+07	-	-	-	7.6E-12	-	-	-			
Manufacturing	11	0	5	N/A	1.8E+16	5,354	1,706	N/A	1.8E+15	1,185	342	N/A	5.4E-20	8.4E-08	2.9E-07
			10	N/A	6.6E+14	3,235	936	N/A	8.7E+13	694	180	N/A	1.2E-18	1.4E-07	5.6E-07
			30	N/A	2.0E+12	7,032	1,880	N/A	4.6E+11	1,548	368	N/A	2.2E-16	6.5E-08	2.7E-07
			60	N/A	1.3E+11	1.6E+04	4,348	N/A	1.9E+10	3,646	865	N/A	5.4E-15	2.7E-08	1.2E-07
			100	N/A	5.1E+10	3.2E+04	8,651	N/A	8.2E+09	7,061	1,742	N/A	1.2E-14	1.4E-08	5.7E-08
			100-1,000	N/A	1.2E+11	3.1E+05	1.0E+05	N/A	2.4E+10	5.4E+04	1.6E+04	N/A	4.2E-15	1.8E-09	6.1E-09
			2,500	N/A	7.4E+11	2.4E+06	9.9E+05	N/A	2.3E+11	6.4E+05	2.3E+05	N/A	4.4E-16	1.6E-10	4.3E-10
			5,000	N/A	1.8E+12	6.0E+06	2.4E+06	N/A	5.8E+11	1.6E+06	5.4E+05	N/A	1.7E-16	6.2E-11	1.8E-10
10,000	N/A	4.3E+12	1.6E+07	6.1E+06	N/A	1.6E+12	4.3E+06	1.4E+06	N/A	6.3E-17	2.3E-11	7.0E-11			



Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk	Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk	
Miscellaneous Non-aerosol Industrial and Commercial Uses <sup>f</sup>	31	2	5	N/A	8.0E+12	394	13	N/A	5.6E+11	85	3	N/A	1.8E-16	1.2E-06	3.6E-05
			10	N/A	6.5E+10	351	12	N/A	5.0E+09	73	2	N/A	2.0E-14	1.4E-06	4.1E-05
			30	N/A	1.1E+08	1,036	37	N/A	2.9E+07	232	8	N/A	3.5E-12	4.3E-07	1.3E-05
			60	N/A	7.5E+06	2,642	96	N/A	1.7E+06	606	21	N/A	5.9E-11	1.6E-07	4.7E-06
			100	N/A	4.2E+06	5,506	212	N/A	1.2E+06	1,293	47	N/A	8.5E-11	7.7E-08	2.1E-06
			100-1,000	N/A	1.9E+07	6.9E+04	3,378	N/A	4.7E+06	1.2E+04	502	N/A	2.1E-11	8.6E-09	2.0E-07
			2,500	N/A	8.5E+07	6.3E+05	4.1E+04	N/A	2.9E+07	1.8E+05	9,823	N/A	3.5E-12	5.7E-10	1.0E-08
			5,000	N/A	2.3E+08	1.7E+06	1.3E+05	N/A	5.4E+07	4.9E+05	3.0E+04	N/A	1.8E-12	2.0E-10	3.3E-09
10,000	N/A	6.9E+08	4.7E+06	3.8E+05	N/A	1.5E+08	1.4E+06	9.3E+04	N/A	6.6E-13	7.2E-11	1.1E-09			
Plastic Product Manufacturing	7	2	5	N/A	5.8E+13	215	55	N/A	3.1E+11	68	17	N/A	3.2E-16	1.5E-06	5.8E-06
			10	N/A	1.1E+11	123	33	N/A	2.6E+09	38	11	N/A	3.8E-14	2.6E-06	9.4E-06
			30	N/A	8.9E+06	261	76	N/A	2.6E+06	79	22	N/A	3.8E-11	1.3E-06	4.6E-06
			60	N/A	2.1E+07	618	179	N/A	6.5E+06	188	51	N/A	1.5E-11	5.3E-07	2.0E-06
			100	N/A	4.2E+07	1,253	357	N/A	1.3E+07	380	100	N/A	7.4E-12	2.6E-07	1.0E-06
			100-1000	N/A	5.1E+08	1.6E+04	4,386	N/A	1.1E+08	3,297	935	N/A	9.5E-13	3.0E-08	1.1E-07
			2,500	N/A	4.9E+09	1.7E+05	4.5E+04	N/A	1.8E+09	6.4E+04	1.6E+04	N/A	5.4E-14	1.6E-09	6.4E-09
			5,000	N/A	1.3E+10	4.9E+05	1.3E+05	N/A	5.3E+09	1.9E+05	4.5E+04	N/A	1.9E-14	5.3E-10	2.2E-09
10,000	N/A	3.6E+10	1.4E+06	3.6E+05	N/A	1.5E+10	5.6E+05	1.3E+05	N/A	6.5E-15	1.8E-10	7.5E-10			
Processing – Incorporation into Formulation, Mixture, or Reaction Product	50	3	5	N/A	2.4E+14	1,615	54	N/A	7.2E+12	382	13	N/A	1.4E-17	2.6E-07	7.8E-06
			10	N/A	8.2E+11	1,148	33	N/A	1.4E+11	276	8	N/A	7.0E-16	3.6E-07	1.2E-05
			30	N/A	4.1E+09	2,780	75	N/A	1.1E+09	728	21	N/A	8.8E-14	1.4E-07	4.8E-06
			60	N/A	6.1E+08	6,745	179	N/A	1.0E+08	1,826	52	N/A	1.0E-12	5.5E-08	1.9E-06
			100	N/A	3.2E+08	1.4E+04	376	N/A	5.8E+07	3,887	111	N/A	1.7E-12	2.6E-08	9.0E-07
			100-1000	N/A	8.9E+08	1.9E+05	5,382	N/A	1.9E+08	3.3E+04	899	N/A	5.4E-13	3.1E-09	1.1E-07
			2500	N/A	4.9E+09	2.2E+06	6.5E+04	N/A	1.4E+09	6.6E+05	2.1E+04	N/A	6.9E-14	1.5E-10	4.7E-09
			5000	N/A	1.3E+10	6.4E+06	2.0E+05	N/A	4.1E+09	2.0E+06	6.6E+04	N/A	2.4E-14	5.1E-11	1.5E-09
10000	N/A	3.9E+10	1.9E+07	6.1E+05	N/A	1.2E+10	5.8E+06	2.0E+05	N/A	8.4E-15	1.7E-11	5.0E-10			

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Processing as a Reactant	14	1	5	N/A	6.8E+12	4,502	476	N/A	3.3E+12	1,184	126	N/A	3.0E-17	8.4E-08	7.9E-07
			10	N/A	4.4E+11	3,236	355	N/A	1.3E+11	845	94	N/A	7.5E-16	1.2E-07	<b>1.1E-06</b>
			30	N/A	1.4E+09	8,755	1,010	N/A	6.3E+08	2,152	245	N/A	1.6E-13	4.6E-08	4.1E-07
			60	N/A	1.1E+08	2.1E+04	2,463	N/A	3.2E+07	5,250	608	N/A	3.2E-12	1.9E-08	1.6E-07
			100	N/A	5.0E+07	4.2E+04	5,139	N/A	1.2E+07	1.0E+04	1,269	N/A	8.3E-12	9.6E-09	7.9E-08
			100-1,000	N/A	1.3E+08	4.2E+05	5.9E+04	N/A	2.6E+07	7.4E+04	9,940	N/A	3.8E-12	1.3E-09	1.0E-08
			2,500	N/A	5.0E+08	3.4E+06	5.4E+05	N/A	1.4E+08	1.0E+06	1.6E+05	N/A	7.4E-13	9.6E-11	6.1E-10
			5,000	N/A	1.0E+09	8.0E+06	1.3E+06	N/A	3.3E+08	2.7E+06	4.3E+05	N/A	3.0E-13	3.8E-11	2.3E-10
10000	N/A	2.6E+09	2.0E+07	3.2E+06	N/A	8.8E+08	6.9E+06	1.1E+06	N/A	1.1E-13	1.4E-11	8.8E-11			
Repackaging	22	0	5	N/A	7.6E+20	2.3E+04	6,289	N/A	4.4E+15	9,658	2,703	N/A	2.3E-20	1.0E-08	3.7E-08
			10	N/A	2.8E+14	1.6E+04	6,083	N/A	1.3E+12	7,279	2,564	N/A	7.5E-17	1.4E-08	3.9E-08
			30	N/A	1.4E+08	4.9E+04	1.7E+04	N/A	2.2E+07	2.5E+04	9,091	N/A	4.5E-12	4.0E-09	1.1E-08
			60	N/A	7.2E+06	1.4E+05	4.7E+04	N/A	3.7E+06	7.2E+04	2.7E+04	N/A	2.7E-11	1.4E-09	3.7E-09
			100	N/A	2.0E+07	3.3E+05	1.1E+05	N/A	1.0E+07	1.6E+05	6.0E+04	N/A	9.8E-12	6.1E-10	1.7E-09
			100-1,000	N/A	1.0E+09	9.9E+06	2.7E+06	N/A	1.3E+08	1.5E+06	4.3E+05	N/A	7.4E-13	6.6E-11	2.3E-10
			2,500	N/A	4.0E+10	3.2E+08	8.1E+07	N/A	1.1E+10	8.4E+07	2.4E+07	N/A	9.5E-15	1.2E-12	4.2E-12
			5,000	N/A	2.5E+11	1.6E+09	3.0E+08	N/A	3.1E+10	2.4E+08	6.5E+07	N/A	3.2E-15	4.1E-13	1.5E-12
10,000	N/A	1.6E+12	5.2E+09	9.2E+08	N/A	6.6E+10	5.2E+08	1.4E+08	N/A	1.5E-15	1.9E-13	7.2E-13			
Spot Cleaning	-	-	5	N/A	1.4E+05	9.4E+04	7.1E+04	N/A	6.9E+04	3.3E+04	2.1E+04	N/A	1.5E-09	3.0E-09	4.7E-09
			10	N/A	7.9E+04	6.4E+04	5.5E+04	N/A	3.7E+04	2.3E+04	1.7E+04	N/A	2.7E-09	4.3E-09	6.0E-09
			30	N/A	1.9E+05	1.8E+05	1.7E+05	N/A	9.1E+04	7.2E+04	5.9E+04	N/A	1.1E-09	1.4E-09	1.7E-09
			60	N/A	5.6E+05	5.2E+05	4.9E+05	N/A	2.5E+05	2.1E+05	1.8E+05	N/A	4.0E-10	4.8E-10	5.5E-10
			100	N/A	1.5E+06	1.4E+06	1.3E+06	N/A	6.2E+05	5.5E+05	4.9E+05	N/A	1.6E-10	1.8E-10	2.0E-10
			100-1,000	N/A	5.7E+07	5.3E+07	4.9E+07	N/A	8.8E+06	8.0E+06	6.9E+06	N/A	1.1E-11	1.3E-11	1.4E-11
			2,500	N/A	1.6E+09	1.4E+09	1.2E+09	N/A	5.8E+08	4.3E+08	3.1E+08	N/A	1.7E-13	2.3E-13	3.2E-13
			5,000	N/A	5.3E+09	5.0E+09	4.6E+09	N/A	2.1E+09	1.4E+09	9.7E+08	N/A	4.7E-14	7.0E-14	1.0E-13
10,000	N/A	1.5E+10	1.3E+10	1.2E+10	N/A	5.2E+09	3.6E+09	2.6E+09	N/A	1.9E-14	2.8E-14	3.9E-14			

Occupational Exposure Scenario	Number of TRI Facilities		Distance from Facility (meters)	Estimated MOE								Estimated Cancer Risk			
				Non-cancer								Cancer (Benchmark 1E-06)			
	Acute (Benchmark 30)				Chronic (Benchmark 10)										
	Total	w/ Risk		Single Facility	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Single Facility	Min Risk	Mean Risk	Max Risk	Single Facility	Min Risk	Mean Risk	Max Risk
Waste Handling, Disposal, Treatment, and Recycling	30	0	5	N/A	5.0E+11	1.8E+04	1,299	N/A	2.6E+10	4,384	255	N/A	3.9E-15	2.3E-08	3.9E-07
			10	N/A	4.6E+09	1.4E+04	1,543	N/A	1.9E+08	3,425	276	N/A	5.3E-13	2.9E-08	3.6E-07
			30	N/A	4.3E+07	3.6E+04	5,794	N/A	1.3E+07	9,023	1,029	N/A	7.6E-12	1.1E-08	9.7E-08
			60	N/A	1.1E+08	8.6E+04	1.4E+04	N/A	3.2E+07	2.3E+04	2,941	N/A	3.2E-12	4.4E-09	3.4E-08
			100	N/A	2.1E+08	1.7E+05	2.8E+04	N/A	6.4E+07	4.6E+04	6,640	N/A	1.6E-12	2.2E-09	1.5E-08
			100-1,000	N/A	2.4E+09	1.7E+06	2.4E+05	N/A	4.9E+08	3.5E+05	6.2E+04	N/A	2.1E-13	2.9E-10	1.6E-09
			2,500	N/A	1.8E+10	1.6E+07	1.6E+06	N/A	6.6E+09	5.2E+06	6.0E+05	N/A	1.5E-14	1.9E-11	1.7E-10
			5,000	N/A	4.1E+10	4.3E+07	4.4E+06	N/A	1.5E+10	1.5E+07	1.7E+06	N/A	6.5E-15	6.7E-12	5.9E-11
10,000	N/A	1.1E+11	1.3E+08	1.3E+07	N/A	3.7E+10	4.3E+07	5.0E+06	N/A	2.7E-15	2.3E-12	2.0E-11			
Paint Remover	3	1	5	N/A	4.2E+10	871	316	N/A	3.5E+09	206	73	N/A	2.8E-14	4.9E-07	<b>1.4E-06</b>
			10	N/A	1.8E+08	526	190	N/A	5.4E+07	112	40	N/A	1.9E-12	8.9E-07	<b>2.5E-06</b>
			30	N/A	9.4E+05	1,181	424	N/A	1.4E+05	249	88	N/A	7.0E-10	4.0E-07	<b>1.1E-06</b>
			60	N/A	1.5E+05	2,826	1,050	N/A	2.14E+04	601	218	N/A	4.7E-09	1.7E-07	4.6E-07
			100	N/A	7.4E+04	5,372	2,242	N/A	1.5E+04	1,183	467	N/A	6.8E-09	8.5E-08	2.1E-07
			100-1,000	N/A	2.4E+04	5.2E+04	3.4E+04	N/A	3.6E+04	1.0E+04	6,173	N/A	2.7E-09	9.7E-09	1.6E-08
			2,500	N/A	1.3E+06	3.1E+05	1.6E+05	N/A	2.1E+05	8.4E+04	5.0E+04	N/A	4.7E-10	1.2E-09	2.0E-09
			5,000	N/A	3.4E+06	7.1E+05	3.2E+05	N/A	5.8E+05	1.9E+05	9.6E+04	N/A	1.7E-10	5.2E-10	1.0E-09
10,000	N/A	9.6E+06	1.7E+06	7.1E+05	N/A	1.7E+06	4.7E+05	2.2E+05	N/A	5.9E-11	2.1E-10	4.5E-10			

<sup>a</sup> When (-) is indicated for the total number of facilities, no facilities were identified via TRI reporting. The provided estimates are based on modeling of theoretical facilities.

<sup>b</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>c</sup> The mean risk value is the arithmetic mean MOE.

<sup>d</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

<sup>e</sup> This OES designation is a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Conveyorized Vapor Degreasing and Cold Cleaning. See Section 3.2.3.2.

<sup>f</sup> This OES designation includes a grouping of the following COUs from the 2020 Methylene Chloride Risk Evaluation: Adhesives and Sealants, Paints and Coatings, and Adhesive and Caulk Removers.

### 3.2.5.1.1 Land Use Considerations

EPA identified risk for 14 of the 248 facilities evaluated based on modeled air concentrations. GIS locations were available for all 14 facilities with risk. For each of these 14 facilities, EPA evaluated land use patterns to determine whether fenceline community exposures are reasonably anticipated at locations where risk is indicated. Details of this methodology are provided in Section 2.1.2.2. In short, EPA evaluated whether residential, industrial/commercial businesses, or other public spaces are present within those radial distances indicating risk (as opposed to uninhabited areas), as well as whether the radial distance lies outside the boundaries of the facility.

Based on characterization of land use patterns, fenceline community exposures are reasonably anticipated for 2 of the 14 facilities (14 percent) where risk is indicated based on modeled fenceline air concentrations. Table 3-28 summarizes the number of facilities in each OES for which risk is indicated and where fenceline community exposures are reasonably anticipated.

**Table 3-27. Summary of Fenceline Community Exposures Expected near Facilities Where Modeled Air Concentrations Indicated Risk for MC**

OES	Total Number of Facilities Evaluated	Number of Facilities with Risk Indicated	Number of Facilities with Risk Indicated and Exposures Expected	Percent of Total Facilities with Risk Indicated and Exposures Expected
Miscellaneous Non-aerosol	31	2	1	3%
Cellulose	2	1	0	0%
Processing – Incorporation into Formulation, Mixture or Reaction Product	50	3	0	0%
Flexible Polyurethane Foam Manufacturing	1	1	1	100%
Plastic Product Manufacturing	7	2	0	0%
Processing-Reactant	14	1	0	0%
Cleaner/Degreaser	16	3	0	0%
Paint Remover	3	1	0	0%

17 **3.2.5.2 Risk Characterization for the Water Pathway**18 **3.2.5.2.1 Drinking Water Risk for MC**

19 EPA calculated risk estimates for each of the endpoints in Table 3-13 across all known facilities and  
 20 modeled release scenarios under each OES. These estimates were then summarized across facilities to  
 21 present the range from minimum to maximum risk for multiple lifestages under each OES. For cancer,  
 22 total lifetime cancer risk across lifestages was calculated by integrating partial risk for each lifestage  
 23 based on differential exposure and consideration of age-dependent adjustment factors (ADAFs, ([U.S.  
 24 EPA, 2005](#))). For MC, ADAFs were applied for younger lifestages based on the conclusion that MC is  
 25 carcinogenic through a mutagenic mode of action ([U.S. EPA, 2020c](#)).

26  
 27 For the maximum days of release scenario, acute but not chronic non-cancer risks (Table 3-30) and  
 28 cancer risks (Table 3-31) were indicated relative to the benchmarks for MC for at least one facility in the  
 29 recycling and disposal OES. Risks relative to benchmark for MC were not indicated for any OES for the  
 30 20-day release scenario (Table 3-28, Table 3-29).

31  
 32 **Table 3-28. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES under**  
 33 **20 Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	12	Adult (21+)	4.1E+09	9.6E+08	2.5E+04	7.0E+10	1.9E+10	9.9E+05
		Infant (birth to <1)	1.2E+09	2.7E+08	7,012	2.7E+10	7.4E+09	3.9E+05
Import and Repackaging	2	Adult (21+)	7.2E+06	4.9E+06	2.5E+06	1.4E+08	9.3E+07	4.5E+07
		Infant (birth to <1)	2.1E+06	1.4E+06	7.1E+05	5.5E+07	3.6E+07	1.8E+07
Processing as a Reactant	2	Adult (21+)	5.9E+05	4.6E+05	3.2E+05	8.6E+06	8.4E+06	8.2E+06
		Infant (birth to <1)	1.7E+05	1.3E+05	9.1E+04	3.4E+06	3.3E+06	3.2E+06
Processing: Formulation	5	Adult (21+)	1.1E+09	2.5E+08	1.3E+04	1.8E+10	4.5E+09	9.5E+05
		Infant (birth to <1)	3.1E+08	7.3E+07	3,660	7.2E+09	1.8E+09	3.7E+05
Polyurethane Foam	1	Adult (21+)	9.7E+04	9.7E+04	9.7E+04	2.0E+06	2.0E+06	2.0E+06
		Infant (birth to <1)	2.8E+04	2.8E+04	2.8E+04	7.7E+05	7.7E+05	7.7E+05
Plastics Manufacturing	9	Adult (21+)	1.8E+09	2.5E+08	2.5E+04	3.1E+10	4.2E+09	5.2E+05
		Infant (birth to <1)	5.2E+08	7.3E+07	7,232	1.2E+10	1.6E+09	2.0E+05
CTA Film Manufacturing	1	Adult (21+)	8.5E+05	8.5E+05	8.5E+05	1.2E+07	1.2E+07	1.2E+07
		Infant (birth to <1)	2.4E+05	2.4E+05	2.4E+05	4.9E+06	4.9E+06	4.9E+06
Lithographic Printer Cleaner	1	Adult (21+)	1.9E+09	1.9E+09	1.9E+09	3.2E+10	3.2E+10	3.2E+10
		Infant (birth to <1)	5.3E+08	5.3E+08	5.3E+08	1.3E+10	1.3E+10	1.3E+10
Spot Cleaner	1	Adult (21+)	1.7E+07	1.7E+07	1.7E+07	9.3E+08	9.3E+08	9.3E+08
		Infant (birth to <1)	4.9E+06	4.9E+06	4.9E+06	3.7E+08	3.7E+08	3.7E+08
Recycling and Disposal	5	Adult (21+)	8.7E+06	2.6E+06	1.7E+04	1.6E+08	4.9E+07	1.1E+06
		Infant (birth to <1)	2.5E+06	7.5E+05	4,749	6.4E+07	1.9E+07	4.3E+05
Other	10	Adult (21+)	2.3E+11	2.3E+10	1.1E+06	3.2E+12	3.2E+11	3.3E+07
		Infant (birth to <1)	6.4E+10	6.5E+09	3.1E+05	1.2E+12	1.2E+11	1.3E+07
DOD	1	Adult (21+)	5.1E+07	5.1E+07	5.1E+07	7.5E+08	7.5E+08	7.5E+08
		Infant (birth to <1)	1.4E+07	1.4E+07	1.4E+07	2.9E+08	2.9E+08	2.9E+08
WWTP	16	Adult (21+)	8.0E+08	5.2E+07	6.8E+04	1.0E+10	6.7E+08	3.5E+05
		Infant (birth to <1)	2.3E+08	1.5E+07	1.9E+04	4.0E+09	2.6E+08	1.4E+05

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Overall	66	Adult (21+)	2.3E+11	3.7E+09	1.3E+04	3.2E+12	5.3E+10	3.5E+05
		Infant (birth to <1)	6.4E+10	1.1E+09	3,660	1.2E+12	2.1E+10	1.4E+05

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

34  
35  
36

**Table 3-29. Summary of Cancer Risk Estimates from Drinking Water Exposure by OES under 20 Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Cancer Risk		
			Min Risk	Mean Risk	Max Risk
Manufacturing	12	Adult (21+)	8.4E-16	5.8E-12	5.9E-11
		Total Lifetime	6.0E-14	4.2E-10	4.2E-09
Import and Repackaging	2	Adult (21+)	4.2E-13	8.5E-13	1.3E-12
		Total Lifetime	3.0E-11	6.1E-11	9.2E-11
Processing as a Reactant	2	Adult (21+)	6.8E-12	7.0E-12	7.2E-12
		Total Lifetime	4.9E-10	5.0E-10	5.1E-10
Processing: Formulation	5	Adult (21+)	3.2E-15	1.2E-11	6.2E-11
		Total Lifetime	2.3E-13	8.9E-10	4.4E-09
Polyurethane Foam	1	Adult (21+)	3.0E-11	3.0E-11	3.0E-11
		Total Lifetime	2.1E-09	2.1E-09	2.1E-09
Plastics Manufacturing	9	Adult (21+)	1.9E-15	2.5E-11	1.1E-10
		Total Lifetime	1.3E-13	1.8E-09	8.1E-09
CTA Film Manufacturing	1	Adult (21+)	4.7E-12	4.7E-12	4.7E-12
		Total Lifetime	3.4E-10	3.4E-10	3.4E-10
Lithographic Printer Cleaner	1	Adult (21+)	1.8E-15	1.8E-15	1.8E-15
		Total Lifetime	1.3E-13	1.3E-13	1.3E-13
Spot Cleaner	1	Adult (21+)	6.2E-14	6.2E-14	6.2E-14
		Total Lifetime	4.5E-12	4.5E-12	4.5E-12
Recycling and Disposal	5	Adult (21+)	3.6E-13	2.2E-11	5.3E-11
		Total Lifetime	2.6E-11	1.6E-09	3.8E-09
Other	10	Adult (21+)	1.8E-17	2.8E-13	1.8E-12
		Total Lifetime	1.3E-15	2.0E-11	1.3E-10
DOD	1	Adult (21+)	7.8E-14	7.8E-14	7.8E-14
		Total Lifetime	5.6E-12	5.6E-12	5.6E-12
WWTP	16	Adult (21+)	5.7E-15	3.0E-11	1.7E-10
		Total Lifetime	4.1E-13	2.2E-09	1.2E-08
Overall	66	Adult (21+)	1.8E-17	1.5E-11	1.7E-10
		Total Lifetime	1.3E-15	1.1E-09	1.2E-08

37

38  
39**Table 3-30. Summary of Risk Estimates for Drinking Water Exposures by OES under Maximum Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	16	Adult (21+)	7.2E+10	1.4E+10	4.3E+05	7.0E+10	1.6E+10	9.8E+05
		Infant (birth to <1)	2.0E+10	4.1E+09	1.2E+05	2.7E+10	6.2E+09	3.8E+05
Import and Repackaging	5	Adult (21+)	1.9E+10	3.9E+09	4.0E+04	2.7E+10	5.4E+09	5.9E+04
		Infant (birth to <1)	5.5E+09	1.1E+09	1.1E+04	1.0E+10	2.1E+09	2.3E+04
Processing as a Reactant	3	Adult (21+)	6.9E+07	2.8E+07	5.7E+06	7.7E+07	3.1E+07	8.2E+06
		Infant (birth to <1)	2.0E+07	8.1E+06	1.6E+06	3.0E+07	1.2E+07	3.2E+06
Processing: Formulation	9	Adult (21+)	3.5E+11	4.1E+10	831	3.9E+11	4.6E+10	1,252
		Infant (birth to <1)	9.9E+10	1.2E+10	237	1.5E+11	1.8E+10	490
Polyurethane Foam	1	Adult (21+)	1.2E+06	1.2E+06	1.2E+06	2.0E+06	2.0E+06	2.0E+06
		Infant (birth to <1)	3.4E+05	3.4E+05	3.4E+05	7.8E+05	7.8E+05	7.8E+05
Plastics Manufacturing	9	Adult (21+)	2.3E+10	3.2E+09	3.2E+05	3.1E+10	4.2E+09	5.1E+05
		Infant (birth to <1)	6.6E+09	9.2E+08	9.0E+04	1.2E+10	1.6E+09	2.0E+05
CTA Film Manufacturing	1	Adult (21+)	1.1E+07	1.1E+07	1.1E+07	1.2E+07	1.2E+07	1.2E+07
		Infant (birth to <1)	3.0E+06	3.0E+06	3.0E+06	4.9E+06	4.9E+06	4.9E+06
Lithographic Printer Cleaner	1	Adult (21+)	2.3E+10	2.3E+10	2.3E+10	3.3E+10	3.3E+10	3.3E+10
		Infant (birth to <1)	6.7E+09	6.7E+09	6.7E+09	1.3E+10	1.3E+10	1.3E+10
Spot Cleaner	1	Adult (21+)	2.1E+08	2.1E+08	2.1E+08	9.3E+08	9.3E+08	9.3E+08
		Infant (birth to <1)	6.1E+07	6.1E+07	6.1E+07	3.7E+08	3.7E+08	3.7E+08
Recycling and Disposal	12	Adult (21+)	3.1E+08	5.2E+07	75	2.2E+08	5.0E+07	112
		Infant (birth to <1)	8.9E+07	1.5E+07	<b>21</b>	8.5E+07	2.0E+07	44
Other	12	Adult (21+)	2.8E+12	2.4E+11	1.4E+05	3.2E+12	2.6E+11	2.0E+05
		Infant (birth to <1)	8.0E+11	6.7E+10	3.9E+04	1.2E+12	1.0E+11	8.0E+04
DOD	1	Adult (21+)	6.4E+08	6.4E+08	6.4E+08	7.6E+08	7.6E+08	7.6E+08
		Infant (birth to <1)	1.8E+08	1.8E+08	1.8E+08	3.0E+08	3.0E+08	3.0E+08
WWTP	16	Adult (21+)	1.5E+10	9.5E+08	1.2E+06	1.0E+10	6.7E+08	3.5E+05
		Infant (birth to <1)	4.2E+09	2.7E+08	3.5E+05	4.0E+09	2.6E+08	1.4E+05
Overall	87	Adult (21+)	2.8E+12	4.0E+10	75	3.2E+12	4.6E+10	112
		Infant (birth to <1)	8.0E+11	1.2E+10	<b>21</b>	1.2E+12	1.8E+10	44

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>b</sup> The mean risk value is the arithmetic mean MOE.

<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR. The risk identified represents the results of one facility within the OES.

40

41 **Table 3-31. Summary of Cancer Risk Estimates from Drinking Water Exposure by OES under**  
 42 **Maximum Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Cancer Risk		
			Min Risk	Mean Risk	Max Risk
Manufacturing	16	Adult (21+)	8.4E-16	4.8E-12	6.0E-11
		Total Lifetime	3.4E-15	2.0E-11	2.4E-10
Import and Repackaging	5	Adult (21+)	2.2E-15	2.0E-10	9.9E-10
		Total Lifetime	1.3E-14	1.1E-09	5.7E-09
Processing as a Reactant	3	Adult (21+)	7.6E-13	4.9E-12	7.1E-12
		Total Lifetime	3.1E-12	2.0E-11	2.9E-11
Processing: Formulation	9	Adult (21+)	1.5E-16	5.2E-09	4.7E-08
		Total Lifetime	7.1E-16	2.5E-08	2.2E-07
Polyurethane Foam	1	Adult (21+)	2.9E-11	2.9E-11	2.9E-11
		Total Lifetime	1.7E-10	1.7E-10	1.7E-10
Plastics Manufacturing	9	Adult (21+)	1.9E-15	2.5E-11	1.1E-10
		Total Lifetime	1.1E-14	1.4E-10	6.6E-10
CTA Film Manufacturing	1	Adult (21+)	4.7E-12	4.7E-12	4.7E-12
		Total Lifetime	2.7E-11	2.7E-11	2.7E-11
Lithographic Printer Cleaner	1	Adult (21+)	1.8E-15	1.8E-15	1.8E-15
		Total Lifetime	1.0E-14	1.0E-14	1.0E-14
Spot Cleaner	1	Adult (21+)	6.3E-14	6.3E-14	6.3E-14
		Total Lifetime	3.6E-13	3.6E-13	3.6E-13
Recycling and Disposal	12	Adult (21+)	2.7E-13	4.4E-08	5.2E-07
		Total Lifetime	1.5E-12	2.5E-07	<b>3.0E-06</b>
Other	12	Adult (21+)	1.8E-17	2.5E-11	2.9E-10
		Total Lifetime	1.1E-16	1.4E-10	1.6E-09
DOD	1	Adult (21+)	7.7E-14	7.7E-14	7.7E-14
		Total Lifetime	4.4E-13	4.4E-13	4.4E-13
WWTP	16	Adult (21+)	5.7E-15	3.0E-11	1.7E-10
		Total Lifetime	2.2E-14	1.2E-10	6.6E-10
Overall	87	Adult (21+)	1.8E-17	6.7E-09	5.2E-07
		Total Lifetime	1.1E-16	3.8E-08	<b>3.0E-06</b>

### 43 3.2.5.2.2 Incidental Swimming Risk for MC

44 EPA calculated risk estimates from incidental swimming for each of the endpoints in Table 3-13 across  
 45 all known facilities and modeled release scenarios under each OES. These estimates were then  
 46 summarized across facilities to present the range from minimum to maximum risk for multiple lifestages  
 47 under each OES. Aggregate risk from incidental ingestion and dermal contact during recreational  
 48 contact with water are not presented. Risk estimates calculated for each route of exposure independently  
 49 are at least an order of magnitude from the benchmarks, indicating that aggregating risk across these  
 50 routes would not result in different risk conclusions. Cancer risk was not estimated for this scenario  
 51 because regular, repeated exposures from incidental swimming in a particular water body are not  
 52 expected to continue across a lifetime.  
 53



54 **Oral Ingestion**

55 For exposures associated with incidental oral ingestion, risk estimates are shown for adults as well as 11  
 56 to 15 years old, the age group with the greatest estimated incidental exposures. Risks relative to  
 57 benchmark for MC were not indicated for either 20-day (Table 3-32) or maximum (Table 3-33) release  
 58 scenarios, with all risk estimates greater than an order of magnitude from benchmarks. Therefore, oral  
 59 ingestion risk from incidental swimming is not expected to result from releases of MC facilities.  
 60

61 **Table 3-32. Summary of Non-cancer Risk Estimates for Incidental Oral Ingestion Exposures by**  
 62 **OES under 20 Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 10)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	14	Adult (21+)	4.8E+10	9.6E+09	1.1E+05	2.2E+11	5.2E+10	1.9E+05
		Youth (11–15)	3.1E+10	6.2E+09	7.2E+04	1.4E+11	3.3E+10	1.2E+05
Import and Repackaging	2	Adult (21+)	8.4E+07	5.7E+07	2.9E+07	4.5E+08	3.0E+08	1.4E+08
		Youth (11–15)	5.4E+07	3.7E+07	1.9E+07	2.9E+08	1.9E+08	9.3E+07
Processing as a Reactant	2	Adult (21+)	6.9E+06	5.3E+06	3.7E+06	2.7E+07	2.7E+07	2.6E+07
		Youth (11–15)	4.5E+06	3.4E+06	2.4E+06	1.8E+07	1.7E+07	1.7E+07
Processing: Formulation	5	Adult (21+)	1.3E+10	3.0E+09	1.5E+05	5.9E+10	1.4E+10	3.0E+06
		Youth (11–15)	8.1E+09	1.9E+09	9.7E+04	3.8E+10	9.3E+09	1.9E+06
Polyurethane Foam	1	Adult (21+)	1.1E+06	1.1E+06	1.1E+06	6.2E+06	6.2E+06	6.2E+06
		Youth (11–15)	7.3E+05	7.3E+05	7.3E+05	4.0E+06	4.0E+06	4.0E+06
Plastics Manufacturing	9	Adult (21+)	2.1E+10	3.0E+09	3.0E+05	9.9E+10	1.3E+10	1.6E+06
		Youth (11–15)	1.4E+10	1.9E+09	1.9E+05	6.4E+10	8.6E+09	1.1E+06
CTA Film Manufacturing	1	Adult (21+)	9.9E+06	9.9E+06	9.9E+06	4.0E+07	4.0E+07	4.0E+07
		Youth (11–15)	6.4E+06	6.4E+06	6.4E+06	2.6E+07	2.6E+07	2.6E+07
Lithographic Printer Cleaner	1	Adult (21+)	2.2E+10	2.2E+10	2.2E+10	1.0E+11	1.0E+11	1.0E+11
		Youth (11–15)	1.4E+10	1.4E+10	1.4E+10	6.6E+10	6.6E+10	6.6E+10
Spot Cleaner	1	Adult (21+)	2.0E+08	2.0E+08	2.0E+08	3.0E+09	3.0E+09	3.0E+09
		Youth (11–15)	1.3E+08	1.3E+08	1.3E+08	1.9E+09	1.9E+09	1.9E+09
Recycling and Disposal	6	Adult (21+)	1.0E+08	2.6E+07	2.6E+04	5.2E+08	1.3E+08	4.5E+05
		Youth (11–15)	6.6E+07	1.6E+07	1.7E+04	3.3E+08	8.4E+07	2.9E+05
Other	10	Adult (21+)	2.6E+12	2.6E+11	1.3E+07	1.0E+13	1.0E+12	1.1E+08
		Youth (11–15)	1.7E+12	1.7E+11	8.1E+06	6.5E+12	6.6E+11	6.8E+07
DOD	1	Adult (21+)	5.9E+08	5.9E+08	5.9E+08	2.4E+09	2.4E+09	2.4E+09
		Youth (11–15)	3.8E+08	3.8E+08	3.8E+08	1.5E+09	1.5E+09	1.5E+09
WWTP	29	Adult (21+)	9.3E+09	3.6E+08	1,584	3.3E+10	1.2E+09	2,709
		Youth (11–15)	6.0E+09	2.3E+08	1,021	2.1E+10	7.8E+08	1,747

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 10)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Overall	82	Adult (21+)	2.6E+12	3.5E+10	1,584	1.0E+13	1.4E+11	2,709
		Youth (11–15)	1.7E+12	2.2E+10	1,021	6.5E+12	8.8E+10	1,747

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

63  
64  
65

**Table 3-33. Summary of Non-cancer Risk Estimates for Incidental Oral Ingestion Exposures by OES under Maximum Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 10)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	20	Adult (21+)	8.4E+11	1.3E+11	2.0E+06	2.2E+11	4.1E+10	1.9E+05
		Youth (11–15)	5.4E+11	8.7E+10	1.3E+06	1.4E+11	2.6E+10	1.2E+05
Import and Repackaging	5	Adult (21+)	2.3E+11	4.6E+10	4.6E+05	8.5E+10	1.7E+10	1.9E+05
		Youth (11–15)	1.5E+11	2.9E+10	3.0E+05	5.5E+10	1.1E+10	1.2E+05
Processing as a Reactant	3	Adult (21+)	8.1E+08	3.3E+08	6.6E+07	2.4E+08	9.9E+07	2.6E+07
		Youth (11–15)	5.2E+08	2.1E+08	4.3E+07	1.6E+08	6.4E+07	1.7E+07
Processing: Formulation	9	Adult (21+)	4.0E+12	4.7E+11	9,695	1.3E+12	1.5E+11	3,991
		Youth (11–15)	2.6E+12	3.1E+11	6,250	8.1E+11	9.5E+10	2,573
Polyurethane Foam	1	Adult (21+)	1.4E+07	1.4E+07	1.4E+07	6.3E+06	6.3E+06	6.3E+06
		Youth (11–15)	9.1E+06	9.1E+06	9.1E+06	4.1E+06	4.1E+06	4.1E+06
Plastics Manufacturing	9	Adult (21+)	2.7E+11	3.7E+10	3.7E+06	1.0E+11	1.3E+10	1.6E+06
		Youth (11–15)	1.7E+11	2.4E+10	2.4E+06	6.4E+10	8.6E+09	1.0E+06
CTA Film Manufacturing	1	Adult (21+)	1.2E+08	1.2E+08	1.2E+08	4.0E+07	4.0E+07	4.0E+07
		Youth (11–15)	8.0E+07	8.0E+07	8.0E+07	2.6E+07	2.6E+07	2.6E+07
Lithographic Printer Cleaner	1	Adult (21+)	2.7E+11	2.7E+11	2.7E+11	1.0E+11	1.0E+11	1.0E+11
		Youth (11–15)	1.8E+11	1.8E+11	1.8E+11	6.7E+10	6.7E+10	6.7E+10
Spot Cleaner	1	Adult (21+)	2.5E+09	2.5E+09	2.5E+09	3.0E+09	3.0E+09	3.0E+09
		Youth (11–15)	1.6E+09	1.6E+09	1.6E+09	1.9E+09	1.9E+09	1.9E+09
Recycling and Disposal	14	Adult (21+)	3.7E+09	6.6E+08	875	6.9E+08	1.7E+08	357
		Youth (11–15)	2.4E+09	4.2E+08	564	4.5E+08	1.1E+08	230
Other	12	Adult (21+)	3.3E+13	2.8E+12	1.6E+06	1.0E+13	8.4E+11	6.5E+05
		Youth (11–15)	2.1E+13	1.8E+12	1.0E+06	6.5E+12	5.4E+11	4.2E+05
DOD	1	Adult (21+)	7.4E+09	7.4E+09	7.4E+09	2.4E+09	2.4E+09	2.4E+09
		Youth (11–15)	4.8E+09	4.8E+09	4.8E+09	1.6E+09	1.6E+09	1.6E+09
WWTP	29	Adult (21+)	1.7E+11	6.6E+09	2.9E+04	3.3E+10	1.2E+09	2,699
		Youth (11–15)	1.1E+11	4.2E+09	1.9E+04	2.1E+10	7.9E+08	1,740
Overall	106	Adult (21+)	3.3E+13	3.9E+11	875	1.0E+13	1.2E+11	357
		Youth (11–15)	2.1E+13	2.5E+11	564	6.5E+12	7.7E+10	230

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

66  
67

*Dermal*

68 For exposures associated with incidental dermal exposure, risk estimates are shown for adults, the age  
 69 group with the highest relative exposure. Risks relative to benchmarks for MC were not indicated for  
 70 either 20-day (Table 3-34) or maximum (Table 3-35) release scenarios, with all risk estimates greater  
 71 than an order of magnitude from the benchmark. Therefore, dermal risk from incidental swimming is not  
 72 expected to result from releases of MC facilities.

73

74 **Table 3-34. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposures by OES**  
 75 **under 20 Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 10)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	14	Adult (21+)	3.1E+10	6.3E+09	7.4E+04	1.5E+11	3.4E+10	1.3E+05
Import and Repackaging	2	Adult (21+)	5.5E+07	3.7E+07	1.9E+07	2.9E+08	1.9E+08	9.5E+07
Processing as a Reactant	2	Adult (21+)	4.6E+06	3.5E+06	2.4E+06	1.8E+07	1.8E+07	1.7E+07
Processing: Formulation	5	Adult (21+)	8.3E+09	2.0E+09	9.9E+04	3.9E+10	9.5E+09	2.0E+06
Polyurethane Foam	1	Adult (21+)	7.4E+05	7.4E+05	7.4E+05	4.1E+06	4.1E+06	4.1E+06
Plastics Manufacturing	9	Adult (21+)	1.4E+10	2.0E+09	1.9E+05	6.5E+10	8.7E+09	1.1E+06
CTA Film Manufacturing	1	Adult (21+)	6.5E+06	6.5E+06	6.5E+06	2.6E+07	2.6E+07	2.6E+07
Lithographic Printer Cleaner	1	Adult (21+)	1.4E+10	1.4E+10	1.4E+10	6.8E+10	6.8E+10	6.8E+10
Spot Cleaner	1	Adult (21+)	1.3E+08	1.3E+08	1.3E+08	2.0E+09	2.0E+09	2.0E+09
Recycling and Disposal	6	Adult (21+)	6.7E+07	1.7E+07	1.7E+04	3.4E+08	8.6E+07	3.0E+05
Other	10	Adult (21+)	1.7E+12	1.7E+11	8.2E+06	6.7E+12	6.7E+11	7.0E+07
DOD	1	Adult (21+)	3.9E+08	3.9E+08	3.9E+08	1.6E+09	1.6E+09	1.6E+09
WWTP	29	Adult (21+)	6.1E+09	2.4E+08	1,042	2.1E+10	8.0E+08	1,783
Overall	82	Adult (21+)	1.7E+12	2.3E+10	1,042	6.7E+12	9.0E+10	1,783

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

76

77

78 **Table 3-35. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposures by OES**  
 79 **under Maximum Days of Release Scenarios for MC**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 10)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Manufacturing	20	Adult (21+)	5.5E+11	8.9E+10	1.3E+06	1.5E+11	2.7E+10	1.3E+05
Import and Repackaging	5	Adult (21+)	1.5E+11	3.0E+10	3.0E+05	5.6E+10	1.1E+10	1.2E+05
Processing as a Reactant	3	Adult (21+)	5.3E+08	2.2E+08	4.4E+07	1.6E+08	6.5E+07	1.7E+07
Processing: Formulation	9	Adult (21+)	2.7E+12	3.1E+11	6,380	8.2E+11	9.7E+10	2,626
Polyurethane Foam	1	Adult (21+)	9.2E+06	9.2E+06	9.2E+06	4.2E+06	4.2E+06	4.2E+06
Plastics Manufacturing	9	Adult (21+)	1.8E+11	2.5E+10	2.4E+06	6.6E+10	8.8E+09	1.1E+06
CTA Film Manufacturing	1	Adult (21+)	8.2E+07	8.2E+07	8.2E+07	2.6E+07	2.6E+07	2.6E+07
Lithographic Printer Cleaner	1	Adult (21+)	1.8E+11	1.8E+11	1.8E+11	6.8E+10	6.8E+10	6.8E+10
Spot Cleaner	1	Adult (21+)	1.6E+09	1.6E+09	1.6E+09	2.0E+09	2.0E+09	2.0E+09
Recycling and Disposal	14	Adult (21+)	2.4E+09	4.3E+08	576	4.6E+08	1.1E+08	235
Other	12	Adult (21+)	2.2E+13	1.8E+12	1.0E+06	6.6E+12	5.6E+11	4.3E+05
DOD	1	Adult (21+)	4.9E+09	4.9E+09	4.9E+09	1.6E+09	1.6E+09	1.6E+09
WWTP	29	Adult (21+)	1.1E+11	4.3E+09	1.9E+04	2.2E+10	8.0E+08	1,776
Overall	106	Adult (21+)	2.2E+13	2.5E+11	576	6.6E+12	7.8E+10	235

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

80 **3.2.5.2.3 Ambient and Drinking Water Monitoring Information for MC**

81 Ambient surface water monitoring information (Section 3.2.4.2.1) was evaluated as part of the original  
 82 MC risk evaluation for ecological exposures and no new sources of information were found during this  
 83 evaluation. The three modeled releases with coincident monitoring data described in the original risk  
 84 evaluation had no detectable levels of MC in proximate monitored results and showed no drinking  
 85 water, incidental oral, or incidental dermal risk in this evaluation. The one modeled release indicating  
 86 risk in this evaluation had no nearby monitoring information that could be used to ground-truth that  
 87 modeled estimate.

88  
 89 Available monitored drinking water information (Section 3.2.4.2.2) was collected for the years 2006 to  
 90 2011 and was therefore not coincident in time with modeled releases. Relating the physical location of  
 91 the evaluated monitored results was beyond the scope of this fence-line evaluation. Additionally, these  
 92 monitoring results represent concentrations measured at the point of distribution into drinking water  
 93 systems, making relating these concentrations to modeled results difficult. These results show that  
 94 although the majority of sampled results show measures of MC to be below detectable levels, there are  
 95 instances of detectable levels of MC in water being used for drinking water and in some cases greater  
 96 than the MCL of 5 µg/L.

### 3.2.6 Confidence and Risk Conclusions for MC Case Study Results

---

This section illustrates by example EPA’s use of results from applying the proposed screening level methodology to make risk conclusions and does not represent final agency action. Any results or risk conclusions presented here are not intended to be used in support of risk management actions or rulemakings as presented.

EPA identified risk relative to the benchmarks from fenceline air concentrations of MC for 14 of the 248 facilities assessed, representing 8 of 17 OES. Based on characterization of land use patterns, fenceline community exposures are reasonably anticipated for 2 of the 14 facilities where EPA identified risk. Risk estimates in Table 3-26 are based on the 95th percentile of modeled exposure concentrations around individual facilities, and the range of risk estimates covers all facilities under an OES. The consideration of land use patterns also confirms that facilities indicating risk are likely of concern to an expected fenceline community cohort. Therefore, EPA determines that the proposed screening level methodology, as applied for this report, sufficiently captures expected risk to the fenceline communities around these facilities for the exposure pathways evaluated. Ninety-fifth percentile values represent a conservative, screening-level analysis and may potentially overestimate chronic and/or lifetime cancer risks. However, analysis of risk estimates based on 10th and 50th percentile release measurements in *SF\_FLA\_Air Pathway Ful-Screen Results for MC* (Appendix B) demonstrates that risk is also indicated at lower percentiles for 7 out of the 14 facilities demonstrating cancer risk based on 95 percent values. These seven facilities indicating risk at lower percentile exposure concentrations include both facilities with expected general population exposures in Table 3-28, therefore mitigating this uncertainty.

EPA identified acute non-cancer and cancer risks relative to the benchmarks from fenceline exposure to MC through drinking water for at least one facility in the recycling and disposal OES under the maximum days of release scenario. Risks are not expected for adults, however acute non-cancer risks to infants and total lifetime cancer risk were identified. EPA did not identify risks from fenceline exposure to MC through recreational contact with water. The use of surface water concentration estimates based on the point of release are likely to result in a higher-end estimate of fenceline community exposure from drinking water and incidental swimming (Section 2.4.4). When also considering the inclusion of more sensitive lifestages and risk estimates based on maximum releases across all facilities, these risk conclusions incorporate health-protective assumptions based on the parameters used in these analyses.

## 3.3 n-Methylpyrrolidone (Water Pathway)

---

### 3.3.1 Background for NMP

---

N-Methylpyrrolidone (NMP) is a polar, liquid solvent that is fully miscible in water. Because of its high water solubility and low volatility, NMP is most likely to partition to water. It is subject to aerobic biodegradation in surface water and oxidative degradation in the atmosphere, and is therefore unlikely to persist in either medium ([U.S. EPA, 2020d](#)). Table\_Apx A-1 contains a summary of NMP’s physical-chemical properties.

### 3.3.2 Human Health Hazard Endpoints for NMP

---

All hazard values used to calculate risk in this report are derived from the previously peer-reviewed PODs published in the Final Risk Evaluation for n-Methylpyrrolidone ([U.S. EPA, 2020d](#)). In the Final Risk Evaluation, EPA utilized the endpoints shown in Table 3-36 for risk determination. For NMP, internal PODs for non-cancer endpoints were derived using a PBPK model. External oral equivalents were also calculated from the internal rodent doses based on the original study conditions. Cancer risk is not evaluated because EPA concluded that the reasonably available data was insufficient to support a quantitative evaluation of cancer risks from NMP.

143 **Table 3-36. Hazard Values Used for Risk Estimation in the n-Methylpyrrolidone Risk Evaluation**

Scenario	Endpoint	Hazard Value	Benchmark	Reference(s)
Acute	Developmental: Resorptions/fetal mortality	437 mg/L C <sub>max</sub> (418 mg/kg)	30	( <a href="#">Saillenfait et al., 2003</a> ; <a href="#">Saillenfait et al., 2002</a> )
Chronic	Reproductive: Decreased male fertility	183 hr-mg/L AUC (28 mg/kg)	30	( <a href="#">Exxon, 1991</a> )

144

145 The existing human PBPK model is not readily applicable to general population/fenceline exposure  
146 scenarios and is not designed to predict internal doses resulting from drinking water exposures.

147 Therefore, to evaluate risks to fenceline communities, EPA converted the internal dose PODs to external  
148 dose PODs (presented in parentheses in Table 3-36).

149

150 For the analyses in this report, EPA derived POD values for fenceline communities based on a  
151 continuous exposure scenario. All of the studies used for the above PODs involved continuous exposure  
152 and therefore no duration adjustment was required for application to fenceline communities. The  
153 external oral equivalent PODs as published in the Risk Evaluation were based on the rat PBPK model.  
154 Therefore, allometric scaling was applied to those values based on EPA guidance on body weight  
155 scaling ([U.S. EPA, 2011b](#)). Based on the study conditions, the acute POD was adjusted using the  
156 measured body weight value for Sprague–Dawley rats (0.259 kg) from ([Saillenfait et al., 2003](#);  
157 [Saillenfait et al., 2002](#)) and an estimated body weight of 65.9 kg for pregnant adolescent human females  
158 (the body weight assumed for derivation of internal dose PODs in ([U.S. EPA, 2020d](#), see Table 2-77)).  
159 The chronic POD was adjusted using the average of male and female subchronic body weight for  
160 Sprague–Dawley rat adults (0.2355 kg, value taken from ([U.S. EPA, 1988](#))) and the default adult human  
161 body weight of 80 kg. The resulting dosimetric adjustment factors were 0.25 and 0.23 for acute and  
162 chronic PODs, respectively, applied to the external dose PODs from Table 3-36.

163

164 **Table 3-37. Hazard Values for NMP Used in this Fenceline Analysis**

Scenario	Endpoint	Fenceline HED	Benchmark	Reference(s)
Acute	Developmental: Resorptions/fetal mortality	105 mg/kg	30 <sup>a</sup>	( <a href="#">Saillenfait et al., 2003</a> ; <a href="#">Saillenfait et al., 2002</a> )
Chronic	Reproductive: Decreased male fertility	6.5 mg/kg	30 <sup>a</sup>	( <a href="#">Exxon, 1991</a> )

<sup>a</sup> In the Final Risk Evaluation for n-Methylpyrrolidone ([U.S. EPA, 2020d](#)), EPA applied a benchmark MOE of 30 to the risk estimates for incidental ingestion and dermal exposure. Upon reanalysis, EPA determined that those oral equivalent values were rodent-specific and should have used a benchmark MOE of 100. The allometrically scaled values presented above are applied to the correct benchmark MOE of 30.

165

### 3.3.2.1 Assumptions and Uncertainties for NMP Human Health Hazard

166 The HEDs were derived based on allometric scaling in accordance with EPA guidance ([U.S. EPA,](#)  
167 [2011b](#)). Allometric scaling reduces the overall uncertainty in the resulting HED compared to using  
168 standard uncertainty factors, however it is less precise than the internal PBPK-modeled PODs. Body  
169 weight for the acute endpoint was specific to the susceptible subpopulation of pregnant females, and the  
170 more health-protective body weight for a younger pregnant woman was used.

171

172 The endpoint for decreased male fertility was observed in a multigenerational study, so it is unknown if  
 173 any particular lifestage is particularly susceptible to this effect. Both fetal and childhood exposure, and  
 174 potentially also adult exposure, are considered relevant for this health effect. In the absence of more  
 175 information on the most susceptible lifestage, HEDs were derived via allometric scaling based on  
 176 conservatively comparing younger rats to average adults.

177

178 The acute developmental toxicity endpoint is assumed to only be relevant to pregnant females since it  
 179 represents an *in utero* outcome. For the chronic effect of decreased male fertility, the sensitive exposure  
 180 lifestage is unknown because the effect was observed in a 2-generation reproductive toxicity study. In  
 181 this study male reproductive toxicity may have resulted from *in utero* exposure, exposure during  
 182 postnatal development, or as an adult prior to/during mating. Therefore, this endpoint is considered  
 183 applicable to both pregnant women and all male lifestages.

184

185 Any other assumptions or uncertainties inherent to the human health hazard assessment in the Final Risk  
 186 Evaluation for n-Methylpyrrolidone ([U.S. EPA, 2020d](#)) are still applicable for this analysis.

187

### 3.3.3 Environmental Releases for NMP

188 In Appendix E of the Final Risk Evaluation for NMP ([U.S. EPA, 2020d](#)), EPA presented a “first-tier”  
 189 aquatic exposure assessment for NMP by using TRI data for facilities with the highest NMP discharges.  
 190 Specifically, 2015 and 2018 TRI data on direct and indirect environmental releases were used to  
 191 estimate NMP concentrations in surface water ([U.S. EPA, 2019b, 2017](#)). The DMR database does not  
 192 contain NMP data. To capture “high-end” surface water concentrations, EPA compiled the release data  
 193 for nine facilities that reported the largest NMP direct water releases. This represented 100 % of the total  
 194 volume of NMP reported as a direct discharge to surface water during the 2015 and 2018 TRI reporting  
 195 periods. Since there were many more facilities reporting indirect releases of NMP to surface water,  
 196 seven of the facilities reporting the largest indirect water releases (representing ~11 percent of the total  
 197 number of facilities reporting indirect discharges) were compiled. The volume of NMP released from  
 198 these facilities encompassed more than 87 percent of the total volume of NMP reported as an indirect  
 199 discharge to surface water ([U.S. EPA, 2020d](#)).

200

201 A summary of the water releases for each NMP OES is included in Table 3-38. This summary uses the  
 202 same release data used for the first-tier assessment in Appendix E of the Final Risk Evaluation for NMP  
 203 ([U.S. EPA, 2020d](#)). Of the 17 OES listed in Table 3-38, six have directly applicable 2015 and/or 2018  
 204 TRI data that were used for water releases in the first-tier assessment. For the remaining 11 OES without  
 205 TRI data, EPA did not estimate releases for the first-tier assessment.

206

207

**Table 3-38. Summary of Water Release Estimation Approaches for Each NMP OES**

OES	Range of Water Releases (kg/site-yr)	Water Release Estimation Approach	Notes
Manufacturing	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Repackaging	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Chemical Processing, Excluding Formulation	0.91 to 434,458 <sup>a e f g h</sup>	2015 and 2018 TRI ( <a href="#">U.S. EPA, 2019b, 2017</a> )	2015 TRI data are available for 8 sites and 2018 TRI data are available for 10 sites.

OES	Range of Water Releases (kg/site-yr)	Water Release Estimation Approach	Notes
Incorporation into Formulation, Mixture, or Reaction Product	10 to 20 <sup>b e</sup>	2015 and 2018 TRI ( <a href="#">U.S. EPA, 2019b, 2017</a> )	2015 TRI data and 2018 TRI data are available for 1 site (the same site).
Metal Finishing	0.91 (one site) <sup>b f</sup>	2015 TRI ( <a href="#">U.S. EPA, 2017</a> )	2015 TRI data are available for 1 site.
Application of Paints, Coatings, Adhesives and Sealants	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Recycling and Disposal	179,246 (one site) <sup>c d</sup>	2018 TRI ( <a href="#">U.S. EPA, 2019b</a> )	2018 TRI data are available for 1 site.
Removal of Paints, Coatings, Adhesives and Sealants	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Other Electronics Manufacturing	6.4 to 308,443 <sup>a e f g</sup>	2015 and 2018 TRI ( <a href="#">U.S. EPA, 2019b, 2017</a> )	2015 TRI data are available for 2 sites and 2018 TRI data are available for 5 sites.
Semiconductor Manufacturing	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Printing and Writing	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Soldering	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Commercial Automotive Servicing	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Laboratory Use	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Lithium-Ion Cell Manufacturing	N/A	N/A	No assessment was made for this OES in the first-tier assessment.
Cleaning	65,622 (one site) <sup>c e</sup>	2018 TRI ( <a href="#">U.S. EPA, 2019b</a> )	2018 TRI data are available for 1 site.
Fertilizer Application	N/A	N/A	No assessment was made for this OES in the first-tier assessment.

<sup>a</sup> This range includes both direct and indirect discharges.

<sup>b</sup> This range includes direct discharges only.

<sup>c</sup> This range includes indirect discharges only.

<sup>d</sup> This range includes TRI estimates based on continuous monitoring data or measurements.

<sup>e</sup> This range includes TRI estimates based on periodic or random monitoring data or measurements.

<sup>f</sup> This range includes TRI estimates based on mass balance calculations, such as calculation of the amount of chemical in streams entering and leaving process equipment.

<sup>g</sup> This range includes TRI estimates based on published emissions factors, such as those relating release quantity to through-put or equipment type.

<sup>h</sup> This range includes TRI estimates based on other approaches such as engineering calculations (*e.g.*, estimating volatilization using published mathematical formulas) or best engineering judgment. This would include applying estimated removal efficiency to a waste stream, even if the composition of the stream before treatment was fully identified through monitoring data.



208

### 3.3.4 Exposures for NMP

---

209

#### 3.3.4.1 Drinking Water for NMP

---

210

Modeled drinking water estimates are summarized by OES category in Table 3-39 for the 12-day release scenario and in Table 3-40 for the maximum days of release scenario. Results are presented for the adult, pregnant female, and infant age class, but complete by facility results across all age classes for all evaluated releases are available in *SF\_FLA\_Water Pathway Exposure Data for NMP* (Appendix B).

214

215

For the 12-day release scenario, a total of 9 releases were modeled across all OES with drinking water ADRs across all presented age classes ranging from  $2.0 \times 10^{-07}$  to  $1.9 \times 10^{-02}$  mg/kg-day, ADDs ranging from  $1.2 \times 10^{-09}$  to  $4.3 \times 10^{-05}$  mg/kg-day and LADDs ranging from  $3.9 \times 10^{-11}$  to  $1.1 \times 10^{-05}$  mg/kg-day. For the maximum days of release scenario, a total of 19 releases were modeled across all OES with drinking water ADRs across all presented age classes ranging from  $1.8 \times 10^{-08}$  to  $1.9 \times 10^{-02}$  mg/kg-day, ADDs ranging from  $2.7 \times 10^{-09}$  to  $1.9 \times 10^{-02}$  mg/kg-day, and LADDs ranging from  $8.9 \times 10^{-11}$  to  $5.0 \times 10^{-03}$  mg/kg-day.

216

217

218

219

220

221

1 **Table 3-39. Summary of NMP Drinking Water Exposure by OES for 12 Days of Release Scenarios**

OES	No. of Releases Modeled <sup>d</sup>	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)			LADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	2.0E-07	7.8E-04	3.4E-03	1.2E-09	2.2E-06	9.5E-06	5.0E-10	9.2E-07	4.0E-06
		Pregnant Female	2.2E-07	8.7E-04	3.8E-03	1.9E-09	3.5E-06	1.5E-05	8.0E-10	1.5E-06	6.4E-06
		Infant (birth to <1)	7.0E-07	2.7E-03	1.2E-02	3.0E-09	5.5E-06	2.4E-05	3.9E-11	7.1E-08	3.1E-07
Electronics Manufacturing	2	Adult (21+)	1.2E-03	1.6E-03	1.9E-03	2.2E-06	4.3E-06	6.3E-06	9.4E-07	1.8E-06	2.7E-06
		Pregnant Female	1.3E-03	1.7E-03	2.2E-03	3.6E-06	6.8E-06	1.0E-05	1.5E-06	2.9E-06	4.3E-06
		Infant (birth to <1)	4.1E-03	5.5E-03	6.8E-03	5.7E-06	1.1E-05	1.6E-05	7.3E-08	1.4E-07	2.1E-07
Formulation	1	Adult (21+)	5.3E-03	5.3E-03	5.3E-03	1.7E-05	1.7E-05	1.7E-05	7.2E-06	7.2E-06	7.2E-06
		Pregnant Female	5.9E-03	5.9E-03	5.9E-03	2.7E-05	2.7E-05	2.7E-05	1.1E-05	1.1E-05	1.1E-05
		Infant (birth to <1)	1.9E-02	1.9E-02	1.9E-02	4.3E-05	4.3E-05	4.3E-05	5.5E-07	5.5E-07	5.5E-07
Metal Finishing	1	Adult (21+)	6.9E-04	6.9E-04	6.9E-04	1.2E-06	1.2E-06	1.2E-06	5.2E-07	5.2E-07	5.2E-07
		Pregnant Female	7.6E-04	7.6E-04	7.6E-04	1.9E-06	1.9E-06	1.9E-06	8.2E-07	8.2E-07	8.2E-07
		Infant (birth to <1)	2.4E-03	2.4E-03	2.4E-03	3.1E-06	3.1E-06	3.1E-06	4.0E-08	4.0E-08	4.0E-08
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–	–	–	–
Overall	9	Adult (21+)	2.0E-07	1.4E-03	5.3E-03	1.2E-09	4.2E-06	1.7E-05	5.0E-10	1.8E-06	7.2E-06
		Pregnant Female	2.2E-07	1.6E-03	5.9E-03	1.9E-09	6.7E-06	2.7E-05	8.0E-10	2.8E-06	1.1E-05
		Infant (birth to <1)	7.0E-07	5.1E-03	1.9E-02	3.0E-09	1.1E-05	4.3E-05	3.9E-11	1.4E-07	5.5E-07

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>d</sup> For OES with 0 releases, no exposure is anticipated, and thus are represented with a “–.”

2  
3  
4  
5

6 Table 3-40. Summary of NMP Drinking Water Exposure by OES for Maximum Days of Release Scenarios

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)			LADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	1.8E-08	7.6E-03	3.3E-02	2.7E-09	1.2E-03	7.3E-03	1.2E-09	5.1E-04	3.1E-03
		Pregnant Female	2.0E-08	8.4E-03	3.6E-02	4.3E-09	1.9E-03	1.2E-02	1.8E-09	8.2E-04	5.0E-03
		Infant (birth to <1)	6.4E-08	2.7E-02	0.1146475	6.9E-09	3.1E-03	1.9E-02	8.9E-11	4.0E-05	2.4E-04
Electronics Manufacturing	5	Adult (21+)	5.6E-05	5.4E-03	2.6E-02	2.3E-06	2.1E-04	8.5E-04	9.6E-07	9.0E-05	3.6E-04
		Pregnant Female	6.2E-05	5.9E-03	2.8E-02	3.6E-06	3.4E-04	1.4E-03	1.5E-06	1.4E-04	5.8E-04
		Infant (birth to <1)	2.0E-04	1.9E-02	9.0E-02	5.8E-06	5.4E-04	2.2E-03	7.4E-08	6.9E-06	2.8E-05
Formulation	1	Adult (21+)	2.2E-04	2.2E-04	2.2E-04	1.7E-05	1.7E-05	1.7E-05	7.2E-06	7.2E-06	7.2E-06
		Pregnant Female	2.4E-04	2.4E-04	2.4E-04	2.7E-05	2.7E-05	2.7E-05	1.2E-05	1.2E-05	1.2E-05
		Infant (birth to <1)	7.6E-04	7.6E-04	7.6E-04	4.4E-05	4.4E-05	4.4E-05	5.6E-07	5.6E-07	5.6E-07
Metal Finishing	1	Adult (21+)	3.1E-05	3.1E-05	3.1E-05	1.1E-06	1.1E-06	1.1E-06	4.8E-07	4.8E-07	4.8E-07
		Pregnant Female	3.4E-05	3.4E-05	3.4E-05	1.8E-06	1.8E-06	1.8E-06	7.6E-07	7.6E-07	7.6E-07
		Infant (birth to <1)	1.1E-04	1.1E-04	1.1E-04	2.9E-06	2.9E-06	2.9E-06	3.7E-08	3.7E-08	3.7E-08
Disposal and Recycling	1	Adult (21+)	–	–	–	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–	–	–	–
Cleaning	1	Adult (21+)	–	–	–	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–	–	–	–
Overall	19	Adult (21+)	1.8E-08	5.4E-03	3.3E-02	2.7E-09	7.0E-04	7.3E-03	1.2E-09	3.0E-04	3.1E-03
		Pregnant Female	2.0E-08	6.0E-03	3.6E-02	4.3E-09	1.1E-03	1.2E-02	1.8E-09	4.7E-04	5.0E-03
		Infant (birth to <1)	6.4E-08	1.9E-02	0.1146475	6.9E-09	1.8E-03	1.9E-02	8.9E-11	2.3E-05	2.4E-04

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

### 3.3.4.2 Incidental Oral for NMP

Modeled incidental oral estimates are summarized by OES category in Table 3-41 for the 20-day release scenario and in Table 3-42 for the maximum days of release scenario. Results are presented for the adult, pregnant female, and youth (11 to 15 years) age classes, but complete by facility results across all age classes for all evaluated releases are available in *SF\_FLA\_Water Pathway Exposure Data for NMP* (Appendix B).

For the 12-day release scenario, a total of 9 releases were modeled across all OES with incidental oral ingestion exposure ADRs across all presented age groups ranging from  $1.7 \times 10^{-8}$  to  $7.1 \times 10^{-4}$  mg/kg-day and ADDs ranging from  $3.7 \times 10^{-10}$  to  $8.2 \times 10^{-6}$  mg/kg-day. For the maximum days of release scenario, a total of 19 releases were modeled across all OES with incidental oral ingestion exposure ADRs across all presented age groups ranging from  $1.6 \times 10^{-9}$  to  $4.3 \times 10^{-3}$  mg/kg-day and ADDs ranging from  $8.5 \times 10^{-10}$  to  $3.6 \times 10^{-3}$  mg/kg-day. Youths (11 to 15 years) had higher exposures than the other age classes due to this age class's higher weighted incidental daily ingestion rate (Table 2-6).

Results here were compared to an alternative method for evaluating incidental oral exposure ([U.S. EPA, 2019d](#)). Due to methodological differences between the two methods, in [U.S. EPA \(2019d\)](#) the 6 to 10 year age class has the highest estimated exposures as compared to the 11 to 15 year age class in the presented method. Weighted incidental daily ingestion rates between the two methods for the highest exposure age class between the two models are  $6.6 \times 10^{-3}$  L/kg-day and  $5.4 \times 10^{-3}$  L/kg-day respectively, resulting in slightly higher, but comparable overall exposure values. Using the [U.S. EPA \(2019d\)](#) method, the 12-day scenario had a maximum ADR of  $8.8 \times 10^{-4}$  mg/kg-day and ADD of  $1.0 \times 10^{-5}$  mg/kg-day, while the maximum days of release scenario had a maximum ADR of  $5.4 \times 10^{-3}$  mg/kg-day and ADD of  $4.4 \times 10^{-3}$  mg/kg-day. These results are comparable between the two methodologies and supports confidence in the presented estimated exposures. Complete results for evaluation of incidental oral ingestion using the [U.S. EPA \(2019d\)](#) method are available in *SF\_FLA\_Water Pathway Exposure Data for NMP* (Appendix B).

1 **Table 3-41. Summary of NMP Incidental Oral Ingestion Exposure by OES for 12 Days of Release Scenarios**

OES	No. of Releases Modeled <sup>d</sup>	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	1.7E-08	6.7E-05	2.9E-04	3.7E-10	6.8E-07	3.0E-06
		Pregnant Female	2.1E-08	8.1E-05	3.5E-04	4.5E-10	8.2E-07	3.6E-06
		Youth (11-15)	2.6E-08	1.0E-04	4.5E-04	5.8E-10	1.1E-06	4.6E-06
Electronics Manufacturing	2	Adult (21+)	1.0E-04	1.3E-04	1.7E-04	7.0E-07	1.3E-06	2.0E-06
		Pregnant Female	1.2E-04	1.6E-04	2.0E-04	8.5E-07	1.6E-06	2.4E-06
		Youth (11-15)	1.6E-04	2.1E-04	2.6E-04	1.1E-06	2.1E-06	3.1E-06
Formulation	1	Adult (21+)	4.6E-04	4.6E-04	4.6E-04	5.3E-06	5.3E-06	5.3E-06
		Pregnant Female	5.6E-04	5.6E-04	5.6E-04	6.4E-06	6.4E-06	6.4E-06
		Youth (11-15)	7.1E-04	7.1E-04	7.1E-04	8.2E-06	8.2E-06	8.2E-06
Metal Finishing	1	Adult (21+)	5.9E-05	5.9E-05	5.9E-05	3.8E-07	3.8E-07	3.8E-07
		Pregnant Female	7.1E-05	7.1E-05	7.1E-05	4.6E-07	4.6E-07	4.6E-07
		Youth (11-15)	9.1E-05	9.1E-05	9.1E-05	5.9E-07	5.9E-07	5.9E-07
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Youth (11-15)	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Youth (11-15)	–	–	–	–	–	–
Overall	9	Adult (21+)	1.7E-08	1.2E-04	4.6E-04	3.7E-10	1.3E-06	5.3E-06
		Pregnant Female	2.1E-08	1.5E-04	5.6E-04	4.5E-10	1.6E-06	6.4E-06
		Youth (11-15)	2.6E-08	1.9E-04	7.1E-04	5.8E-10	2.0E-06	8.2E-06

<sup>a</sup>The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>b</sup>The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>c</sup>The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>d</sup>For OES with 0 releases, no exposure is anticipated, and thus are represented with a “–.”

2  
3

4 **Table 3-42. Summary of NMP Incidental Oral Ingestion Exposure by OES for Maximum Days of Release Scenarios**

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	1.6E-09	6.5E-04	2.8E-03	8.5E-10	3.8E-04	2.3E-03
		Pregnant Female	1.9E-09	7.9E-04	3.4E-03	1.0E-09	4.6E-04	2.8E-03
		Youth (11-15)	2.4E-09	1.0E-03	4.3E-03	1.3E-09	5.9E-04	3.6E-03
Electronics Manufacturing	5	Adult (21+)	4.8E-06	4.6E-04	2.2E-03	7.1E-07	6.7E-05	2.7E-04
		Pregnant Female	5.8E-06	5.6E-04	2.7E-03	8.6E-07	8.1E-05	3.2E-04
		Youth (11-15)	7.4E-06	7.1E-04	3.4E-03	1.1E-06	1.0E-04	4.2E-04
Formulation	1	Adult (21+)	1.8E-05	1.8E-05	1.8E-05	5.4E-06	5.4E-06	5.4E-06
		Pregnant Female	2.2E-05	2.2E-05	2.2E-05	6.5E-06	6.5E-06	6.5E-06
		Youth (11-15)	2.9E-05	2.9E-05	2.9E-05	8.3E-06	8.3E-06	8.3E-06
Metal Finishing	1	Adult (21+)	2.7E-06	2.7E-06	2.7E-06	3.5E-07	3.5E-07	3.5E-07
		Pregnant Female	3.2E-06	3.2E-06	3.2E-06	4.3E-07	4.3E-07	4.3E-07
		Youth (11-15)	4.1E-06	4.1E-06	4.1E-06	5.5E-07	5.5E-07	5.5E-07
Disposal and Recycling	1	Adult (21+)	5.0E-05	5.0E-05	5.0E-05	1.7E-05	1.7E-05	1.7E-05
		Pregnant Female	6.1E-05	6.1E-05	6.1E-05	2.1E-05	2.1E-05	2.1E-05
		Youth (11-15)	7.8E-05	7.8E-05	7.8E-05	2.7E-05	2.7E-05	2.7E-05
Cleaning	1	Adult (21+)	2.1E-06	2.1E-06	2.1E-06	8.3E-07	8.3E-07	8.3E-07
		Pregnant Female	2.5E-06	2.5E-06	2.5E-06	1.0E-06	1.0E-06	1.0E-06
		Youth (11-15)	3.2E-06	3.2E-06	3.2E-06	1.3E-06	1.3E-06	1.3E-06
Overall	19	Adult (21+)	1.6E-09	4.7E-04	2.8E-03	8.5E-10	2.2E-04	2.3E-03
		Pregnant Female	1.9E-09	5.7E-04	3.4E-03	1.0E-09	2.7E-04	2.8E-03
		Youth (11-15)	2.4E-09	7.2E-04	4.3E-03	1.3E-09	3.4E-04	3.6E-03

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.  
<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

5

1                    **3.3.4.3 Incidental Dermal for NMP**

---

2 Modeled incidental dermal estimates are summarized by OES category in Table 3-43 for the 20-day  
3 release scenario and in Table 3-44 for the maximum days of release scenario. Results are presented for  
4 the adult (21+ years) and pregnant female age class, but complete by facility results across all age  
5 classes for all evaluated releases are available in *SF\_FLA\_Water Pathway Exposure Data for NMP*  
6 (Appendix B).

7  
8 For the 12-day release scenario, a total of 9 releases were modeled across all OES with incidental dermal  
9 exposure ADRs ranging from  $1.7 \times 10^{-09}$  to  $5.3 \times 10^{-05}$  mg/kg-day and ADDs ranging from  $3.8 \times 10^{-11}$   
10 to  $6.2 \times 10^{-07}$  mg/kg-day. For the maximum release scenario, a total of 19 releases were modeled across  
11 all OES with incidental dermal exposure ADRs ranging from  $1.6 \times 10^{-10}$  to  $3.3 \times 10^{-04}$  mg/kg-day and  
12 ADDs ranging from  $8.6 \times 10^{-11}$  to  $2.7 \times 10^{-04}$  mg/kg-day.  
13

1 **Table 3-43. Summary of NMP Incidental Dermal Exposure by OES for 12 Days of Release Scenarios**

OES	No. of Releases Modeled <sup>d</sup>	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	1.7E-09	6.8E-06	3.0E-05	3.8E-11	6.9E-08	3.0E-07
		Pregnant Female	2.0E-09	7.8E-06	3.4E-05	4.4E-11	7.9E-08	3.5E-07
Electronics Manufacturing	2	Adult (21+)	1.0E-05	1.4E-05	1.7E-05	7.1E-08	1.4E-07	2.0E-07
		Pregnant Female	1.2E-05	1.6E-05	1.9E-05	8.2E-08	1.6E-07	2.3E-07
Formulation	1	Adult (21+)	4.6E-05	4.6E-05	4.6E-05	5.4E-07	5.4E-07	5.4E-07
		Pregnant Female	5.3E-05	5.3E-05	5.3E-05	6.2E-07	6.2E-07	6.2E-07
Metal Finishing	1	Adult (21+)	6.0E-06	6.0E-06	6.0E-06	3.9E-08	3.9E-08	3.9E-08
		Pregnant Female	6.9E-06	6.9E-06	6.9E-06	4.5E-08	4.5E-08	4.5E-08
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
Overall	9	Adult (21+)	1.7E-09	1.3E-05	4.6E-05	3.8E-11	1.3E-07	5.4E-07
		Pregnant Female	2.0E-09	1.5E-05	5.3E-05	4.4E-11	1.5E-07	6.2E-07

<sup>a</sup> The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup> The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup> The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>d</sup> For OES with 0 releases, no exposure is anticipated, and thus are represented with a “–.”

2  
3



4 **Table 3-44. Summary of NMP Incidental Dermal Exposure by OES for Maximum Days of Release Scenarios**

OES	No. of Releases Modeled	Age Group	ADR (mg/kg-day)			ADD (mg/kg-day)		
			Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>	Min Exposure <sup>a</sup>	Mean Exposure <sup>b</sup>	Max Exposure <sup>c</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	1.6E-10	6.6E-05	2.8E-04	8.6E-11	3.9E-05	2.3E-04
		Pregnant Female	1.8E-10	7.6E-05	3.3E-04	1.0E-10	4.4E-05	2.7E-04
Electronics Manufacturing	5	Adult (21+)	4.9E-07	4.7E-05	2.2E-04	7.2E-08	6.7E-06	2.7E-05
		Pregnant Female	5.6E-07	5.4E-05	2.6E-04	8.3E-08	7.8E-06	3.1E-05
Formulation	1	Adult (21+)	1.9E-06	1.9E-06	1.9E-06	5.4E-07	5.4E-07	5.4E-07
		Pregnant Female	2.2E-06	2.2E-06	2.2E-06	6.3E-07	6.3E-07	6.3E-07
Metal Finishing	1	Adult (21+)	2.7E-07	2.7E-07	2.7E-07	3.6E-08	3.6E-08	3.6E-08
		Pregnant Female	3.1E-07	3.1E-07	3.1E-07	4.1E-08	4.1E-08	4.1E-08
Disposal and Recycling	1	Adult (21+)	5.1E-06	5.1E-06	5.1E-06	1.8E-06	1.8E-06	1.8E-06
		Pregnant Female	5.9E-06	5.9E-06	5.9E-06	2.0E-06	2.0E-06	2.0E-06
Cleaning	1	Adult (21+)	2.1E-07	2.1E-07	2.1E-07	8.4E-08	8.4E-08	8.4E-08
		Pregnant Female	2.4E-07	2.4E-07	2.4E-07	9.7E-08	9.7E-08	9.7E-08
Overall	19	Adult (21+)	1.6E-10	4.7E-05	2.8E-04	8.6E-11	2.2E-05	2.3E-04
		Pregnant Female	1.8E-10	5.4E-05	3.3E-04	1.0E-10	2.6E-05	2.7E-04

<sup>a</sup>The minimum exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>b</sup>The arithmetic mean exposure for the identified days of release, within the identified OES, and for the identified age group.

<sup>c</sup>The maximum exposure for the identified days of release, within the identified OES, and for the identified age group.

5

### 3.3.5 Risk Characterization for NMP

#### 3.3.5.1 Drinking Water Risk for NMP

EPA calculated risk estimates for each of the endpoints in Table 3-37 across all known facilities and modeled release scenarios under each OES. These estimates were then summarized across facilities to present the range from minimum to maximum risk for multiple lifestages under each OES. In addition to adults, risk estimates are shown for the most sensitive lifestage for each endpoint—pregnant women for developmental toxicity (acute) and infants for male reproductive toxicity (chronic).

Risks relative to benchmark for NMP were not indicated for either 12-day (Table 3-45) or maximum (Table 3-46) release scenarios, with all risk estimates indicating that exposures are more than 10-fold below levels which would result in risk. Therefore, fenceline drinking water risk is not expected to result from releases of NMP facilities.

**Table 3-45. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES for Various Lifestages under 12 Days of Release Scenarios for NMP**

OES	No. of Releases Modeled <sup>a</sup>	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	5.3E+08	1.1E+08	3.1E+04	5.5E+09	1.1E+09	6.9E+05
		Pregnant Female	4.8E+08	9.6E+07	2.8E+04	3.4E+09	6.9E+08	4.3E+05
		Infant (birth to <1)	N/A <sup>e</sup>	N/A	N/A	2.1E+09	4.3E+08	2.7E+05
Electronics Manufacturing	2	Adult (21+)	9.0E+04	7.2E+04	5.4E+04	2.9E+06	2.0E+06	1.0E+06
		Pregnant Female	8.1E+04	6.5E+04	4.9E+04	1.8E+06	1.2E+06	6.4E+05
		Infant (birth to <1)	N/A	N/A	N/A	1.1E+06	7.7E+05	4.0E+05
Formulation	1	Adult (21+)	2.0E+04	2.0E+04	2.0E+04	3.8E+05	3.8E+05	3.8E+05
		Pregnant Female	1.8E+04	1.8E+04	1.8E+04	2.4E+05	2.4E+05	2.4E+05
		Infant (birth to <1)	N/A	N/A	N/A	1.5E+05	1.5E+05	1.5E+05
Metal Finishing	1	Adult (21+)	1.5E+05	1.5E+05	1.5E+05	5.3E+06	5.3E+06	5.3E+06
		Pregnant Female	1.4E+05	1.4E+05	1.4E+05	3.3E+06	3.3E+06	3.3E+06
		Infant (birth to <1)	N/A	N/A	N/A	2.1E+06	2.1E+06	2.1E+06
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Infant (birth to <1)	–	–	–	–	–	–
Overall	9	Adult (21+)	5.3E+08	5.9E+07	2.0E+04	5.5E+09	6.1E+08	3.8E+05
		Pregnant Female	4.8E+08	5.3E+07	1.8E+04	3.4E+09	3.8E+08	2.4E+05
		Infant (birth to <1)	N/A	N/A	N/A	2.1E+09	2.4E+08	1.5E+05

<sup>a</sup> For OES with 0 releases, no risks were estimated, and thus are represented with a “–.”

<sup>b</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>c</sup> The mean risk value is the arithmetic mean MOE.

<sup>d</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

<sup>e</sup> Not applicable to the endpoint used for POD derivation (see Section 3.3.2.1).

17 **Table 3-46. Summary of Non-cancer Risk Estimates for Drinking Water Exposures by OES for**  
 18 **Various Lifestages under Maximum Days of Release Scenarios for NMP**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	5.8E+09	5.8E+08	3,213	2.4E+09	2.4E+08	886
		Pregnant Female	5.2E+09	5.3E+08	2,903	1.5E+09	1.5E+08	554
		Infant (birth to <1)	N/A <sup>d</sup>	N/A	N/A	9.4E+08	9.5E+07	347
Electronics Manufacturing	5	Adult (21+)	1.9E+06	6.8E+05	4,107	2.9E+06	8.1E+05	7,622
		Pregnant Female	1.7E+06	6.1E+05	3,711	1.8E+06	5.1E+05	4,769
		Infant (birth to <1)	N/A	N/A	N/A	1.1E+06	3.2E+05	2,984
Formulation	1	Adult (21+)	4.9E+05	4.9E+05	4.9E+05	3.8E+05	3.8E+05	3.8E+05
		Pregnant Female	4.4E+05	4.4E+05	4.4E+05	2.4E+05	2.4E+05	2.4E+05
		Infant (birth to <1)	N/A	N/A	N/A	1.5E+05	1.5E+05	1.5E+05
Metal Finishing	1	Adult (21+)	3.4E+06	3.4E+06	3.4E+06	5.8E+06	5.8E+06	5.8E+06
		Pregnant Female	3.1E+06	3.1E+06	3.1E+06	3.6E+06	3.6E+06	3.6E+06
		Infant (birth to <1)	N/A	N/A	N/A	2.3E+06	2.3E+06	2.3E+06
Disposal and Recycling	1	Adult (21+)	1.8E+05	1.8E+05	1.8E+05	1.2E+05	1.2E+05	1.2E+05
		Pregnant Female	1.6E+05	1.6E+05	1.6E+05	7.3E+04	7.3E+04	7.3E+04
		Infant (birth to <1)	N/A	N/A	N/A	4.6E+04	4.6E+04	4.6E+04
Cleaning	1	Adult (21+)	4.3E+06	4.3E+06	4.3E+06	2.5E+06	2.5E+06	2.5E+06
		Pregnant Female	3.9E+06	3.9E+06	3.9E+06	1.5E+06	1.5E+06	1.5E+06
		Infant (birth to <1)	N/A	N/A	N/A	9.7E+05	9.7E+05	9.7E+05
Overall	19	Adult (21+)	5.8E+09	3.1E+08	3,213	2.4E+09	1.3E+08	886
		Pregnant Female	5.2E+09	2.8E+08	2,903	1.5E+09	8.1E+07	554
		Infant (birth to <1)	N/A	N/A	N/A	9.4E+08	5.0E+07	347

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.  
<sup>b</sup> The mean risk value is the arithmetic mean MOE.  
<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.  
<sup>d</sup> Not applicable to the endpoint used for POD derivation (see Section 3.3.2.1).

### 19 3.3.5.2 Incidental Swimming Risk for NMP

20 EPA calculated risk estimates from incidental swimming for each of the endpoints in Table 3-37 across  
 21 all known facilities and modeled release scenarios under each OES. These estimates were then  
 22 summarized across facilities to present the range from minimum to maximum risk for multiple lifestages  
 23 under each OES. Aggregate risk from incidental ingestion and dermal contact during recreational  
 24 contact with water are not presented. Risk estimates calculated for each route of exposure independently  
 25 are at least an order of magnitude from the benchmarks, indicating that aggregating risk across these  
 26 routes would not result in different risk conclusions.

#### 27 3.3.5.2.1 Incidental Oral for NMP

28 In addition to adults, risk estimates are shown for more sensitive lifestages/subpopulations for each  
 29 endpoint— both pregnant females and 11-to-15 year olds. Risks relative to benchmark for NMP were  
 30 not indicated for either 12-day (Table 3-47) or maximum (Table 3-48) release scenarios, with all risk  
 31 estimates greater than two orders of magnitude away from benchmark. Therefore, oral ingestion risk  
 32 from incidental swimming is not expected to result from releases of NMP facilities.

33

34 **Table 3-47. Summary of Non-cancer Incidental Oral Ingestion Risk by OES for Various Lifestages**  
 35 **under 12 Days of Release Scenario for NMP**

OES	No. of Releases Modeled <sup>a</sup>	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	6.2E+09	1.2E+09	3.6E+05	1.7E+10	3.5E+09	2.2E+06
		Pregnant Female	5.1E+09	1.0E+09	3.0E+05	1.4E+10	2.9E+09	1.8E+06
		Youth (11–15)	4.0E+09	8.0E+08	2.3E+05	1.1E+10	2.3E+09	1.4E+06
Electronics Manufacturing	2	Adult (21+)	1.1E+06	8.4E+05	6.3E+05	9.3E+06	6.3E+06	3.3E+06
		Pregnant Female	8.7E+05	6.9E+05	5.2E+05	7.7E+06	5.2E+06	2.7E+06
		Youth (11–15)	6.8E+05	5.4E+05	4.1E+05	6.0E+06	4.0E+06	2.1E+06
Formulation	1	Adult (21+)	2.3E+05	2.3E+05	2.3E+05	1.2E+06	1.2E+06	1.2E+06
		Pregnant Female	1.9E+05	1.9E+05	1.9E+05	1.0E+06	1.0E+06	1.0E+06
		Youth (11–15)	1.5E+05	1.5E+05	1.5E+05	7.9E+05	7.9E+05	7.9E+05
Metal Finishing	1	Adult (21+)	1.8E+06	1.8E+06	1.8E+06	1.7E+07	1.7E+07	1.7E+07
		Pregnant Female	1.5E+06	1.5E+06	1.5E+06	1.4E+07	1.4E+07	1.4E+07
		Youth (11–15)	1.1E+06	1.1E+06	1.1E+06	1.1E+07	1.1E+07	1.1E+07
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Youth (11–15)	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
		Youth (11–15)	–	–	–	–	–	–
Overall	9	Adult (21+)	6.2E+09	6.9E+08	2.3E+05	1.7E+10	2.0E+09	1.2E+06
		Pregnant Female	5.1E+09	5.7E+08	1.9E+05	1.4E+10	1.6E+09	1.0E+06
		Youth (11–15)	4.0E+09	4.4E+08	1.5E+05	1.1E+10	1.3E+09	7.9E+05

<sup>a</sup> For OES with 0 releases, no risk is anticipated, and thus are represented with a “–.”

<sup>b</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>c</sup> The mean risk value is the arithmetic mean MOE.

<sup>d</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

36

37

38 **Table 3-48. Summary of Non-cancer Incidental Oral Ingestion Risk by OES for Various Lifestages**  
 39 **under Maximum Days of Release Scenario for NMP**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	6.7E+10	6.8E+09	3.7E+04	7.6E+09	7.8E+08	2,823
		Pregnant Female	5.5E+10	5.6E+09	3.1E+04	6.3E+09	6.4E+08	2,325
		Youth (11–15)	4.3E+10	4.4E+09	2.4E+04	4.9E+09	5.0E+08	1,820
Electronics Manufacturing	5	Adult (21+)	2.2E+07	7.9E+06	4.8E+04	9.2E+06	2.6E+06	2.4E+04
		Pregnant Female	1.8E+07	6.5E+06	3.9E+04	7.6E+06	2.1E+06	2.0E+04
		Youth (11–15)	1.4E+07	5.1E+06	3.1E+04	5.9E+06	1.7E+06	1.6E+04
Formulation	1	Adult (21+)	5.7E+06	5.7E+06	5.7E+06	1.2E+06	1.2E+06	1.2E+06
		Pregnant Female	4.7E+06	4.7E+06	4.7E+06	1.0E+06	1.0E+06	1.0E+06
		Youth (11–15)	3.7E+06	3.7E+06	3.7E+06	7.8E+05	7.8E+05	7.8E+05
Metal Finishing	1	Adult (21+)	4.0E+07	4.0E+07	4.0E+07	1.8E+07	1.8E+07	1.8E+07
		Pregnant Female	3.3E+07	3.3E+07	3.3E+07	1.5E+07	1.5E+07	1.5E+07
		Youth (11–15)	2.5E+07	2.5E+07	2.5E+07	1.2E+07	1.2E+07	1.2E+07
Disposal and Recycling	1	Adult (21+)	2.1E+06	2.1E+06	2.1E+06	3.7E+05	3.7E+05	3.7E+05
		Pregnant Female	1.7E+06	1.7E+06	1.7E+06	3.1E+05	3.1E+05	3.1E+05
		Youth (11–15)	1.3E+06	1.3E+06	1.3E+06	2.4E+05	2.4E+05	2.4E+05
Cleaning	1	Adult (21+)	5.1E+07	5.1E+07	5.1E+07	7.9E+06	7.9E+06	7.9E+06
		Pregnant Female	4.2E+07	4.2E+07	4.2E+07	6.5E+06	6.5E+06	6.5E+06
		Youth (11–15)	3.3E+07	3.3E+07	3.3E+07	5.1E+06	5.1E+06	5.1E+06
Overall	19	Adult (21+)	6.7E+10	3.6E+09	3.7E+04	7.6E+09	4.1E+08	2,823
		Pregnant Female	5.5E+10	3.0E+09	3.1E+04	6.3E+09	3.4E+08	2,325
		Youth (11–15)	4.3E+10	2.3E+09	2.4E+04	4.9E+09	2.6E+08	1,820

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>b</sup> The mean risk value is the arithmetic mean MOE.

<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

#### 40 **3.3.5.2.2 Incidental Dermal for NMP**

41 In addition to adults, risk estimates are shown for the more sensitive subpopulation of pregnant females  
 42 (adult exposure is greater than youth exposure, so risk estimates for that lifestage are not presented).  
 43 Risks relative to benchmark for NMP were not indicated for either 12-day (Table 3-49) or maximum  
 44 (Table 3-50) release scenarios, with all risk estimates greater than two orders of magnitude away from  
 45 benchmark. Therefore, dermal exposure risk from incidental swimming is not expected to result from  
 46 releases of NMP facilities.

47

48 **Table 3-49. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposure by OES for**  
 49 **Various Lifestages under 12 Days of Release Scenario for NMP**

OES	No. of Releases Modeled <sup>a</sup>	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>	Min Risk <sup>b</sup>	Mean Risk <sup>c</sup>	Max Risk <sup>d</sup>
Chemical Processing, Excluding Formulation	5	Adult (21+)	6.1E+10	1.2E+10	3.5E+06	1.7E+11	3.5E+10	2.2E+07
		Pregnant Female	5.3E+10	1.1E+10	3.1E+06	1.5E+11	3.0E+10	1.9E+07
Electronics Manufacturing	2	Adult (21+)	1.0E+07	8.3E+06	6.2E+06	9.2E+07	6.2E+07	3.2E+07
		Pregnant Female	9.0E+06	7.2E+06	5.4E+06	8.0E+07	5.4E+07	2.8E+07
Formulation	1	Adult (21+)	2.3E+06	2.3E+06	2.3E+06	1.2E+07	1.2E+07	1.2E+07
		Pregnant Female	2.0E+06	2.0E+06	2.0E+06	1.0E+07	1.0E+07	1.0E+07
Metal Finishing	1	Adult (21+)	1.8E+07	1.8E+07	1.8E+07	1.7E+08	1.7E+08	1.7E+08
		Pregnant Female	1.5E+07	1.5E+07	1.5E+07	1.5E+08	1.5E+08	1.5E+08
Disposal and Recycling	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
Cleaning	0	Adult (21+)	–	–	–	–	–	–
		Pregnant Female	–	–	–	–	–	–
Overall	9	Adult (21+)	6.1E+10	6.8E+09	2.3E+06	1.7E+11	1.9E+10	1.2E+07
		Pregnant Female	5.3E+10	5.9E+09	2.0E+06	1.5E+11	1.7E+10	1.0E+07

<sup>a</sup> For OES with 0 releases, no risk is anticipated, and thus are represented with a “–”.

<sup>b</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>c</sup> The mean risk value is the arithmetic mean MOE.

<sup>d</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

50

51

52 **Table 3-50. Summary of Non-cancer Risk Estimates for Incidental Dermal Exposure by OES for**  
 53 **Various Lifestages under Maximum Days of Release Scenario for NMP**

OES	No. of Releases Modeled	Age Group	Acute MOE (Benchmark = 30)			Chronic MOE (Benchmark = 30)		
			Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>	Min Risk <sup>a</sup>	Mean Risk <sup>b</sup>	Max Risk <sup>c</sup>
Chemical Processing, Excluding Formulation	10	Adult (21+)	6.6E+11	6.7E+10	3.7E+05	7.5E+10	7.7E+09	2.8E+04
		Pregnant Female	5.8E+11	5.8E+10	3.2E+05	6.5E+10	6.6E+09	2.4E+04
Electronics Manufacturing	5	Adult (21+)	2.2E+08	7.8E+07	4.7E+05	9.1E+07	2.5E+07	2.4E+05
		Pregnant Female	1.9E+08	6.8E+07	4.1E+05	7.9E+07	2.2E+07	2.1E+05
Formulation	1	Adult (21+)	5.6E+07	5.6E+07	5.6E+07	1.2E+07	1.2E+07	1.2E+07
		Pregnant Female	4.9E+07	4.9E+07	4.9E+07	1.0E+07	1.0E+07	1.0E+07
Metal Finishing	1	Adult (21+)	3.9E+08	3.9E+08	3.9E+08	1.8E+08	1.8E+08	1.8E+08
		Pregnant Female	3.4E+08	3.4E+08	3.4E+08	1.6E+08	1.6E+08	1.6E+08
Disposal and Recycling	1	Adult (21+)	2.1E+07	2.1E+07	2.1E+07	3.7E+06	3.7E+06	3.7E+06
		Pregnant Female	1.8E+07	1.8E+07	1.8E+07	3.2E+06	3.2E+06	3.2E+06
Cleaning	1	Adult (21+)	5.0E+08	5.0E+08	5.0E+08	7.8E+07	7.8E+07	7.8E+07
		Pregnant Female	4.3E+08	4.3E+08	4.3E+08	6.7E+07	6.7E+07	6.7E+07
Overall	19	Adult (21+)	6.6E+11	3.5E+10	3.7E+05	7.5E+10	4.1E+09	2.8E+04
		Pregnant Female	5.8E+11	3.1E+10	3.2E+05	6.5E+10	3.5E+09	2.4E+04

<sup>a</sup> The minimum risk value is associated with the maximum MOE and the maximum ADR.

<sup>b</sup> The mean risk value is the arithmetic mean MOE.

<sup>c</sup> The maximum risk value is associated with the minimum MOE and the minimum ADR.

### 54 **3.3.6 Confidence and Risk Conclusions for NMP Case Study Results**

55 This section illustrates by example EPA's use of results from applying the proposed screening level  
 56 methodology to make risk conclusions and does not represent final agency action. Any results or risk  
 57 conclusions presented here are not intended to be used in support of risk management actions or  
 58 rulemakings as presented.

59  
 60 EPA did not identify risks relative to the benchmarks from fenceline exposure to NMP through drinking  
 61 water or recreational contact with water. Exposures were more than 10-fold below levels which would  
 62 result in risk for all exposure scenarios, and therefore EPA does not expect that any small variation in  
 63 assumptions would result in different risk conclusions. The use of surface water concentration estimates  
 64 based on the point of release are likely to result in a higher-end estimate of fenceline community  
 65 exposure from drinking water and incidental swimming (Section 2.4.4). When also considering the  
 66 inclusion of more sensitive lifestages and risk estimates based on maximum releases across all facilities,  
 67 these risk conclusions incorporate health-protective assumptions based on the parameters used in these  
 68 analyses.

69

## 1 REFERENCES

---

- 2 [Ashford, R.](#) (1994). Ashford's dictionary of industrial chemicals: Properties, production, uses. London:  
3 Wavelength.
- 4 [Boublík, T; Fried, V; Hála, E.](#) (1984). The vapour pressures of pure substances: Selected values of the  
5 temperature dependence of the vapour pressures of some pure substances in the normal and low  
6 pressure region. In Physical Sciences Data, Vol 17 (2nd Revised ed.). Amsterdam, The  
7 Netherlands: Elsevier Science Publishers.
- 8 [Daubert, TE; Danner, RP.](#) (1989). Physical and thermodynamic properties of pure chemicals: Data  
9 compilation. Washington, DC: Taylor & Francis.
- 10 [European Solvents Industry Group.](#) (2012). SPERC fact sheet: Manufacture of substance - industrial  
11 (solvent-borne). Brussels, Belgium: European Solvents Industry Group (ESIG).  
12 <https://www.esig.org/reach-ges/environment/>
- 13 [Exxon.](#) (1991). Multigeneration Rat Reproduction Study with N-Methylpyrrolidone, Project Number  
14 236535 [TSCA Submission]. (OTS#: 0532510; New Doc ID: 40-91107125; Old Doc ID: 42114  
15 F1-2). Wayne, USA: GAF Corp.
- 16 [Hansch, C.](#) (1995). Exploring QSAR Fundamentals and applications in chemistry and biology -  
17 hydrophobic, electronic and steric constants. Washington DC: American Chemical Society  
18 Professional Reference Book/Oxford University Press.
- 19 [Holbrook, MT.](#) (2003). Kirk-Othmer Encyclopedia of Chemical Technology. Methylene chloride (4th  
20 ed.). New York, NY: John Wiley & Sons.  
21 <http://dx.doi.org/10.1002/0471238961.1305200808151202.a02.pub2>
- 22 [Horvath, AL.](#) (1982). Halogenated hydrocarbons: Solubility-miscibility with water. New York, NY:  
23 Marcel Dekker, Inc.
- 24 [Jayjock, M; Havics, AA.](#) (2018). Residential inter-zonal ventilation rates for exposure modeling. J  
25 Occup Environ Hyg 15: 376-388.  
26 [https://heronet.epa.gov/heronet/index.cfm/reference/download/reference\\_id/9929964](https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/9929964)
- 27 [Khoukhi, M; Al-Maqbali, A.](#) (2011). Stack pressure and airflow movement in high and medium rise  
28 buildings. Energy Procedia 6: 422-431.  
29 [https://heronet.epa.gov/heronet/index.cfm/reference/download/reference\\_id/9929963](https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/9929963)
- 30 [Kim, BR; Kalis, EM; Dewulf, T; Andrews, KM.](#) (2000). Henry's law constants for paint solvents and  
31 their implications on volatile organic compound emissions from automotive painting. Water  
32 Environ Res 72: 65-74. <http://dx.doi.org/10.2175/106143000X137121>
- 33 [Leighton, DT, Jr.; Calo, JM.](#) (1981). Distribution coefficients of chlorinated hydrocarbons in dilute air-  
34 water systems for groundwater contamination applications. Journal of Chemical and Engineering  
35 Data 26: 382-385. <http://dx.doi.org/10.1021/je00026a010>
- 36 [McDermott, MJ; Mazor, KA; Shost, SJ; Narang, RS; Aldous, KM; Storm, JE.](#) (2005).  
37 Tetrachloroethylene (PCE, Perc) levels in residential dry cleaner buildings in diverse  
38 communities in New York City. Environ Health Perspect 113: 1336-1343.  
39 <http://dx.doi.org/10.1289/ehp.7414>
- 40 [NFPA.](#) (1997). Fire protection guide on hazardous materials (12th ed.). Quincy, MA: National Fire  
41 Protection Assoc.
- 42 [Nitschke, KD; Burek, JD; Bell, TJ; Kociba, RJ; Rampy, LW; McKenna, MJ.](#) (1988). Methylene  
43 chloride: A 2-year inhalation toxicity and oncogenicity study in rats. Fundam Appl Toxicol 11:  
44 48-59. [http://dx.doi.org/10.1016/0272-0590\(88\)90269-2](http://dx.doi.org/10.1016/0272-0590(88)90269-2)
- 45 [NTP.](#) (1986). NTP Toxicology and carcinogenesis studies of dichloromethane (methylene chloride)  
46 (CAS No. 75-09-2) in F344/N rats and B6C3F1 mice (inhalation studies). 306: 1-208.
- 47 [NTP.](#) (2011). NTP technical report on the toxicology and carcinogenesis studies of 1-bromopropane  
48 (CAS No. 106-94-5) in F344/N rats and B6C3F1 mice (inhalation studies) (pp. 195). (NTP TR



- 49 564; NIH Publication No. 11-5906). Research Triangle Park, NC.  
50 [http://ntp.niehs.nih.gov/ntp/htdocs/lt\\_rpts/tr564.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr564.pdf)
- 51 O'Neil, MJ. (2013). The Merck index: An encyclopedia of chemicals, drugs, and biologicals. In MJ  
52 O'Neil (Ed.), (15th ed.). Cambridge, UK: Royal Society of Chemistry.
- 53 O'Neil, MJ; Heckelman, PE; Koch, CB. (2006). The Merck index: An encyclopedia of chemicals, drugs,  
54 and biologicals (14th ed.). Whitehouse Station, NJ: Merck & Co.
- 55 Organization for Economic, C-o; Develop.m.ent. (2017). Draft ESD on Vapor Degreasing - Internal  
56 EPA document. Organization for Economic Co-operation and Develop.m.ent (OECD).
- 57 Patty, FA; Fassett, DW; Irish, DD. (1963). Industrial hygiene and toxicology: Vol. II: Toxicology. In FA  
58 Patty; DW Fassett; DD Irish (Eds.), (2nd revised ed.). New York, NY: Interscience Publishers.
- 59 Poet, TS; Kirman, CR; Bader, M; van Thriel, C; Gargas, ML; Hinderliter, PM. (2010). Quantitative risk  
60 analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark  
61 dose modeling. Toxicol Sci 113: 468-482. <http://dx.doi.org/10.1093/toxsci/kfp264>
- 62 Putz, VR; Johnson, BL; Setzer, JV. (1979). A comparative study of the effects of carbon monoxide and  
63 methylene chloride on human performance. J Environ Pathol Toxicol 2: 97-112.
- 64 Saillenfait, AM; Gallissot, F; Langonné, I; Sabaté, JP. (2002). Developmental toxicity of N-methyl-2-  
65 pyrrolidone administered orally to rats. Food Chem Toxicol 40: 1705-1712.  
66 [http://dx.doi.org/10.1016/S0278-6915\(02\)00115-1](http://dx.doi.org/10.1016/S0278-6915(02)00115-1)
- 67 Saillenfait, AM; Gallissot, F; Morel, G. (2003). Developmental toxicity of N-methyl-2-pyrrolidone in  
68 rats following inhalation exposure. Food Chem Toxicol 41: 583-588.  
69 [http://dx.doi.org/10.1016/S0278-6915\(02\)00300-9](http://dx.doi.org/10.1016/S0278-6915(02)00300-9)
- 70 Sasaki, H; Kojima, M; Mori, Y; Nakamura, J; Shibasaki, J. (1988). Enhancing effect of pyrrolidone  
71 derivatives on transdermal drug delivery. 1. Int J Pharm 44: 15-24.
- 72 Schenk, L; Rauma, M; Fransson, MN; Johanson, G. (2018). Percutaneous absorption of thirty-eight  
73 organic solvents in vitro using pig skin. PLoS ONE 13: e0205458.  
74 <http://dx.doi.org/10.1371/journal.pone.0205458>
- 75 Singh, HB; Salas, LJ; Stiles, RE. (1983). Selected man-made halogenated chemicals in the air and  
76 oceanic environment. J Geophys Res 88: 3675-3683.  
77 <http://dx.doi.org/10.1029/JC088iC06p03675>
- 78 ten Berge, WF; Zwart, A; Appelman, LM. (1986). Concentration-time mortality response relationship of  
79 irritant and systemically acting vapours and gases. J Hazard Mater 13: 301-309.  
80 [http://dx.doi.org/10.1016/0304-3894\(86\)85003-8](http://dx.doi.org/10.1016/0304-3894(86)85003-8)
- 81 Trinity Consultants. (2015). Emission Report, NPB Response – Addendum. Trinity Consultants.
- 82 U.S. Census Bureau. (2015). Statistics of U.S. Businesses (SUSB).  
83 <https://www.census.gov/data/tables/2015/econ/susb/2015-susb-annual.html>
- 84 U.S. EPA. (1988). Recommendations for and documentation of biological values for use in risk  
85 assessment [EPA Report]. (EPA600687008). Cincinnati, OH.  
86 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>
- 87 U.S. EPA. (2005). Supplemental guidance for assessing susceptibility from early-life exposure to  
88 carcinogens [EPA Report]. (EPA/630/R-03/003F). Washington, DC: U.S. Environmental  
89 Protection Agency, Risk Assessment Forum. [https://www.epa.gov/risk/supplemental-](https://www.epa.gov/risk/supplemental-guidance-assessing-susceptibility-early-life-exposure-carcinogens)  
90 [guidance-assessing-susceptibility-early-life-exposure-carcinogens](https://www.epa.gov/risk/supplemental-guidance-assessing-susceptibility-early-life-exposure-carcinogens)
- 91 U.S. EPA. (2011a). Exposure factors handbook: 2011 edition [EPA Report]. (EPA/600/R-090/052F).  
92 Washington, DC: U.S. Environmental Protection Agency, Office of Research and  
93 Develop.m.ent, National Center for Environmental Assessment.  
94 <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=236252>
- 95 U.S. EPA. (2011b). Recommended use of body weight 3/4 as the default method in derivation of the  
96 oral reference dose. (EPA100R110001). Washington, DC.  
97 <https://www.epa.gov/sites/production/files/2013-09/documents/recommended-use-of-bw34.pdf>

- 98 [U.S. EPA.](#) (2012a). Advances in inhalation gas dosimetry for derivation of a reference concentration  
99 (RfC) and use in risk assessment (pp. 1-140). (EPA/600/R-12/044). Washington, DC.  
100 [https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=244650&CFID=50524762&CFTOKEN=](https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=244650&CFID=50524762&CFTOKEN=17139189)  
101 [17139189](https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=244650&CFID=50524762&CFTOKEN=17139189)
- 102 [U.S. EPA.](#) (2015). Evaluation of Swimmer Exposures Using the SWIMODEL Algorithms and  
103 Assumptions. [https://www.epa.gov/sites/production/files/2016-](https://www.epa.gov/sites/production/files/2016-11/documents/swimodel_final.pdf)  
104 [11/documents/swimodel\\_final.pdf](https://www.epa.gov/sites/production/files/2016-11/documents/swimodel_final.pdf)
- 105 [U.S. EPA.](#) (2016b). Public database 2016 chemical data reporting (May 2017 release). Washington, DC:  
106 US Environmental Protection Agency, Office of Pollution Prevention and Toxics.  
107 <https://www.epa.gov/chemical-data-reporting>
- 108 [U.S. EPA.](#) (2017). Consumer Exposure Model (CEM) version 2.0: User guide. U.S. Environmental  
109 Protection Agency, Office of Pollution Prevention and Toxics.  
110 [https://www.epa.gov/sites/production/files/2017-06/documents/cem\\_2.0\\_user\\_guide.pdf](https://www.epa.gov/sites/production/files/2017-06/documents/cem_2.0_user_guide.pdf)
- 111 [U.S. EPA.](#) (2018). User's Guide for the AMS/EPA Regulatory Model (AERMOD). (EPA Document  
112 Number: EPA-454/B-18-001). U.S. EPA.
- 113 [U.S. EPA.](#) (2019a). IECCU 1.1 User's Guide. In Simulation Program for Estimating Chemical  
114 Emissions from Sources and Related Changes to Indoor Environmental Concentrations in  
115 Buildings with Conditioned and Unconditioned Zones (IECCU). (EPA Contract # EP-W-12-  
116 010). Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention  
117 and Toxics.  
118 [https://heronet.epa.gov/heronet/index.cfm?action=search.view&reference\\_id=6305433](https://heronet.epa.gov/heronet/index.cfm?action=search.view&reference_id=6305433)
- 119 [U.S. EPA.](#) (2019c). User's Guide: Integrated Indoor-Outdoor Air Calculator (IIOAC). Washington, DC:  
120 U.S. EPA.  
121 [https://heronet.epa.gov/heronet/index.cfm?action=search.view&reference\\_id=6983117](https://heronet.epa.gov/heronet/index.cfm?action=search.view&reference_id=6983117)
- 122 [U.S. EPA.](#) (2019d). Recommended Human Health Recreational Ambient Water Quality Criteria or  
123 Swimming Advisories for Microcystins and Cylindrospermopsin [EPA Report]. (EPA 822-R-19-  
124 001). Washington, DC. <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100WX86.txt>
- 125 [U.S. EPA.](#) (2019e). Exposure factors handbook chapter 3 (update): Ingestion of water and other select  
126 liquids. (EPA/600/R-18/259F). <https://cfpub.epa.gov/ncea/efp/recordisplay.cfm?deid=343661>
- 127 [U.S. EPA.](#) (2020b). Risk evaluation for 1-bromopropane (n-Propyl bromide), CASRN: 106-94-5 [EPA  
128 Report]. (#740-R1-8013). Washington, DC: Office of Chemical Safety and Pollution Prevention.  
129 <https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0235-0085>
- 130 [U.S. EPA.](#) (2020c). Risk evaluation for methylene chloride (dichloromethane, DCM); CASRN: 75-09-2.  
131 (EPA-740-R1-8010). Washington, DC: Office of Chemical Safety and Pollution Prevention.  
132 <https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0437-0107>
- 133 [U.S. EPA.](#) (2020d). Risk evaluation for n-Methylpyrrolidone (2-Pyrrolidinone, 1-Methyl-) (NMP);  
134 CASRN: 872-50-4 [EPA Report]. (EPA-740-R1-8009). Washington, DC: Office of Chemical  
135 Safety and Pollution Prevention. [https://www.regulations.gov/document/EPA-HQ-OPPT-2019-](https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0236-0081)  
136 [0236-0081](https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0236-0081)
- 137 [U.S. EPA.](#) (2020e). Risk evaluation for 1,4-dioxane (CASRN: 123-91-1) [EPA Report]. (EPA-740-R1-  
138 8007). Washington, DC: Office of Chemical Safety and Pollution Prevention.  
139 <https://www.regulations.gov/document/EPA-HQ-OPPT-2019-0238-0092>
- 140 [USGS.](#) (2003). A national survey of methyl tert-butyl ether and other volatile organic compounds in  
141 drinking-water sources: Results of the random survey. Reston, VA: U.S. Department of the  
142 Interior, U.S. Geological Survey. <https://pubs.er.usgs.gov/publication/wri024079>
- 143 [W.I.L. Research.](#) (2001). An inhalation two-generation reproductive toxicity study of 1-bromopropane  
144 in rats. (Study No. WIL-380001). Ashland, OH.
- 145 [Yalkowsky, SH; He, Y; Jain, P.](#) (2010). Handbook of aqueous solubility data (2nd ed.). Boca Raton, FL:  
146 CRC Press. <http://dx.doi.org/10.1201/EBK1439802458>



148 **Appendix A ABBREVIATIONS AND PHYSICAL-CHEMICAL**  
 149 **PROPERTIES**

---

150 **A.1 Abbreviations**

---

151	1,4-D	1,4-Dioxane
152	1-BP	1-Bromopropane
153	ACGIH	American Conference of Governmental Industrial Hygienists
154	AEGL	Acute Exposure Guideline Level
155	AERMOD	American Meteorological Society/Environmental Protection Agency Regulatory Model
156	ATSDR	Agency for Toxic Substances and Disease Registry
157	BAF	Bioaccumulation factor
158	BCF	Bioconcentration factor
159	BMD	Benchmark dose
160	BMR	Benchmark response
161	CAA	Clean Air Act
162	CASRN	Chemical Abstracts Service Registry Number
163	CBI	Confidential Business Information
164	CDR	Chemical Data Reporting
165	CEHD	Chemical Exposure Health Data
166	CEPA	Canadian List of Toxic Substances
167	CERCLA	Comprehensive Environmental Response, Compensation and Liability Act
168	CFR	Code of Federal Regulations
169	CHIRP	Chemical Risk Information Platform
170	CNS	Central nervous system
171	COC	Concentration(s) of concern
172	CoCAP	Cooperative Chemicals Assessment Program
173	COHb	Carboxyhemoglobin
174	CPSA	Consumer Product Safety Act
175	CPSC	Consumer Product Safety Commission
176	CSCL	Chemical Substances Control Law
177	CSHO	Certified Safety and Health Official
178	CTC	Carbon tetrachloride
179	CWA	Clean Water Act
180	MC	Dichloromethane (methylene chloride)
181	DIY	Do it yourself
182	DMR	Discharge Monitoring Report
183	DOT	Department of Transportation
184	EC50	Effect concentration at which 50% of test organisms exhibit an effect
185	ECHA	European Chemicals Agency
186	E-FAST	Exposure and Fate Assessment Screening Tool
187	EG	Effluent Guidelines
188	EHC	Environmental Health Criteria
189	EPA	Environmental Protection Agency
190	EPCRA	Emergency Planning and Community Right-to-Know Act
191	ESD	Emission Scenario Document
192	EU	European Union
193	FDA	Food and Drug Administration
194	FFDCA	Federal Food, Drug, and Cosmetic Act

195	FSHA	Federal Hazardous Substance Act
196	HAP	Hazardous Air Pollutant
197	HEC	Human Equivalent Concentration
198	HED	Human Equivalent Dose
199	HERO	Health and Environmental Research Online (Database)
200	HFC	Hydrofluorocarbon
201	HHE	Health hazard evaluation
202	HMTA	Hazardous Materials Transportation Act
203	HPV	High Production Volume
204	IARC	International Agency for Research on Cancer
205	ICIS	Integrated Compliance Information System
206	IDLH	Immediately Dangerous to Life and Health
207	IECCU	Indoor Environment Concentration in Buildings with Conditioned and Unconditioned
208		Zones
209	IIOAC	Integrated Indoor/Outdoor Air Calculator
210	IMAP	Inventory Multi-Tiered Assessment and Prioritisation
211	IRIS	Integrated Risk Information System
212	ISHA	Industrial Safety and Health Act
213	Koc	Soil organic carbon: water partitioning coefficient
214	Kow	Octanol: water partition coefficient
215	LC50	Lethal concentration at which 50% of test organisms die
216	LD50	Lethal dose at which 50% of test organisms die
217	LOD	Limit of detection
218	Log Koc	Logarithmic organic carbon: water partition coefficient
219	Log Kow	Logarithmic octanol: water partition coefficient
220	MACT	Maximum Achievable Control Technology
221	MC	Methylene chloride
222	MCL	Maximum Contaminant Level
223	MCLG	Maximum Contaminant Level Goal
224	MOA	Mode of action
225	MSW	Municipal solid waste
226	NAC	National Advisory Committee
227	NAICS	North American Industry Classification System
228	NATA	National Scale Air-Toxics Assessment
229	NAWQA	National Water Quality Assessment Program
230	ND	Non-detect
231	NEI	National Emissions Inventory
232	NESHAP	National Emission Standards for Hazardous Air Pollutants
233	NHANES	National Health and Nutrition Examination Survey
234	NICNAS	National Industrial Chemicals Notification and Assessment Scheme
235	NIH	National Institutes of Health
236	NIOSH	National Institute for Occupational Safety and Health
237	NITE	National Institute of Technology and Evaluation
238	NMP	n-Methyl-2-pyrrolidone
239	NOAA	National Oceanic and Atmospheric Administration
240	NPDES	National Pollutant Discharge Elimination System
241	NPDWR	National Primary Drinking Water Regulation
242	NRC	National Research Council
243	NTP	National Toxicology Program

244	NWIS	National Water Information System
245	OCSPP	Office of Chemical Safety and Pollution Prevention
246	OECD	Organisation for Economic Co-operation and Development
247	OEHHA	Office of Environmental Health Hazard Assessment
248	OEL	Occupational exposure limit
249	OES	Occupational exposure scenario(s)
250	ONU	Occupational non-user
251	OPPT	Office of Pollution Prevention and Toxics
252	OSHA	Occupational Safety and Health Administration
253	OTVD	Open-top vapor degreaser
254	PBPK	Physiologically based pharmacokinetic
255	PBZ	Personal breathing zone
256	PECO	Population, exposure, comparator, and outcome
257	PEL	Permissible Exposure Limit
258	PESS	Potentially exposed or susceptible subpopulations
259	POD	Point of departure
260	POTW	Publicly owned treatment works
261	PPE	Personal protective equipment
262	PSD	Particle size distribution
263	PV	Production volume
264	QC	Quality control
265	RCRA	Resource Conservation and Recovery Act
266	REACH	Registration, Evaluation, Authorization and Restriction of Chemicals (European Union)
267	REL	Recommended Exposure Limit
268	RICE	Reciprocating internal combustion engines
269	RTR	Risk and technology review
270	SDS	Safety data sheet
271	SDWA	Safe Drinking Water Act
272	SIDS	Screening Information Data Set
273	SMAC	Spacecraft Maximum Allowable Concentrations
274	SNAP	Significant New Alternatives Policy
275	SpERC	Specific Environmental Release Categories
276	STEL	Short-Term Exposure Limit
277	STORET	STOrage and RETrieval and Water Quality exchange
278	TCCR	Transparent, clear, consistent, and reasonable
279	TLV	Threshold Limit Value
280	TRI	Toxics Release Inventory
281	TSCA	Toxic Substances Control Act
282	TTO	Total toxic organics
283	TWA	Time-weighted average
284	U.S.	United States
285	USGS	United States Geological Survey
286	VOC	Volatile organic compound
287	VP	Vapor pressure
288	WHO	World Health Organization

## 289 **A.2 Select Physical-Chemical Properties of Case Study Chemicals**

290 Table\_Apx A-1 summarizes the basic physical-chemical properties of the chemicals chosen for the case  
 291 studies in this document. All of the properties appear in the chemicals' respective final risk evaluations,

292 for which they were identified using the systematic review procedures described in those documents (1-  
 293 BP: ([U.S. EPA, 2020b](#)); MC: ([U.S. EPA, 2020c](#)); NMP: ([U.S. EPA, 2020d](#))).

294

295

**Table\_Apx A-1. Select Physical-Chemical Properties of Case Study Chemicals**

Property	1-Bromopropane	Methylene Chloride	N-Methylpyrrolidone
Molecular formula	C <sub>3</sub> H <sub>7</sub> Br	CH <sub>2</sub> Cl <sub>2</sub>	C <sub>5</sub> H <sub>9</sub> ON
Molecular mass	122.99	84.93	99.1
Melting point	-110 °C ( <a href="#">O'Neil, 2013</a> )	-95 °C ( <a href="#">O'Neil, 2013</a> )	-25 °C ( <a href="#">Ashford, 1994</a> )
Boiling point	71 °C ( <a href="#">O'Neil, 2013</a> )	39.7 °C ( <a href="#">O'Neil, 2013</a> )	202 °C ( <a href="#">O'Neil et al., 2006</a> )
Density	1.353 g/cm <sup>3</sup> at 20 °C ( <a href="#">O'Neil, 2013</a> )	1.33 g/cm <sup>3</sup> at 20 °C ( <a href="#">O'Neil, 2013</a> )	1.03 g/cm <sup>3</sup> at 25 °C ( <a href="#">O'Neil et al., 2006</a> )
Vapor pressure	110.8 mmHg at 20 °C ( <a href="#">Boublík et al., 1984</a> )	435 mmHg at 25 °C ( <a href="#">Boublík et al., 1984</a> )	0.345 mmHg at 25 °C ( <a href="#">Daubert and Danner, 1989</a> )
Vapor density (air = 1)	4.25 ( <a href="#">Patty et al., 1963</a> )	2.93 ( <a href="#">Holbrook, 2003</a> )	3.4 ( <a href="#">NFPA, 1997</a> )
Water solubility	2.450 g/L at 20 °C ( <a href="#">Yalkowsky et al., 2010</a> )	13 g/L at 25 °C ( <a href="#">Horvath, 1982</a> )	1,000 g/L at 25 °C (miscible) ( <a href="#">O'Neil et al., 2006</a> )
Henry's law constant	7.3×10 <sup>-3</sup> atm·m <sup>3</sup> /mol ( <a href="#">U.S. EPA, 2012b</a> )	2.91×10 <sup>-3</sup> atm·m <sup>3</sup> /mol ( <a href="#">Leighton and Calo, 1981</a> )	3.2×10 <sup>-9</sup> atm·m <sup>3</sup> /mol ( <a href="#">Kim et al., 2000</a> )
log K <sub>ow</sub>	2.10 ( <a href="#">Hansch, 1995</a> )	2.27 ( <a href="#">Hansch, 1995</a> )	-0.38 ( <a href="#">Sasaki et al., 1988</a> )

296

297

## Appendix B LIST OF SUPPLEMENTAL FILES

---

List of supplemental documents (see Docket: <https://www.regulations.gov/docket/EPA-HQ-OPPT-2021-0415> for access to all files):

01. SF\_FLA\_Air Pathway Input Parameters for AERMOD for 1-BP and MC
02. SF\_FLA\_Air Pathway Pre-screening Results for 1-BP
03. SF\_FLA\_Air Pathway Pre-screening Results for MC
04. SF\_FLA\_Air Pathway Co-Resident Exposure Results for 1-BP
05. SF\_FLA\_Air Pathway Full-Screen Results for 1-BP
06. SF\_FLA\_Air Pathway Full-Screen Results for MC
07. SF\_FLA\_Air Pathway Summary Statistics of Exposure Concentrations for 1-BP
08. SF\_FLA\_Air Pathway Summary Statistics of Exposure Concentrations for MC
09. SF\_FLA\_Air Pathway Information for Co-Resident Modeling for 1-BP
10. SF\_FLA\_Dry-Cleaning Model\_3<sup>rd</sup> Gen\_Emission Results for 1-BP
11. SF\_FLA\_Environmental Releases to Ambient Air for 1-BP
12. SF\_FLA\_Environmental Releases to Ambient Air for MC
13. SF\_FLA\_Water Pathway Exposure Data for MC
14. SF\_FLA\_Water Pathway Exposure Data for NMP
15. SF\_FLA\_Air Pathway Input Parameters for IIOAC for 1-BP and MC
16. SF\_FLA\_README File Co-Resident Exposure Modeling



## Appendix C TRI-CDR CROSSWALK

Table\_Apx C-1 presents the TRI-CDR Crosswalk used to map facilities to the OES for each chemical. Blanks in the 2016 CDR code column indicate there is no corresponding CDR code that matches the TRI code.

**Table\_Apx C-1. TRI-CDR Use Code Crosswalk**

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.1.a	Manufacture: Produce					
3.1.b	Manufacture: Import					
3.1.c	Manufacture: For on-site use/processing					
3.1.d	Manufacture: For sale/distribution					
3.1.e	Manufacture: As a byproduct					
3.1.f	Manufacture: As an impurity					
3.2.a	Processing: As a reactant			PC	Processing as a reactant	Chemical substance is used in chemical reactions for the manufacturing of another chemical substance or product.
3.2.a	Processing: As a reactant	P101	Feedstocks			
3.2.a	Processing: As a reactant	P102	Raw Materials			
3.2.a	Processing: As a reactant	P103	Intermediates	U015	Intermediates	Chemical substances consumed in a reaction to produce other chemical substances for commercial advantage. A residual of the intermediate chemical substance which has no separate function may remain in the reaction product.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.2.a	Processing: As a reactant	P104	Initiators	U024	Process regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators may be consumed or become part of the reaction product.
3.2.a	Processing: As a reactant	P199	Other	U016	Ion exchange agents	Chemical substances, usually in the form of a solid matrix, that are used to selectively remove targeted ions from a solution. Examples generally consist of an inert hydrophobic matrix such as styrenedivinylbenzene or phenol-formaldehyde, cross-linking polymer such as divinylbenzene, and ionic functional groups including sulfonic, carboxylic or phosphonic acids. This code also includes aluminosilicate zeolites.
3.2.a	Processing: As a reactant	P199	Other	U019	Oxidizing/reducing agent	Chemical substances used to alter the valence state of another substance by donating or accepting electrons or by the addition or removal of hydrogen to a substance. Examples of oxidizing agents include nitric acid, perchlorates, hexavalent chromium compounds, and peroxydisulfuric acid salts. Examples of reducing agents include hydrazine, sodium thiosulfate, and coke produced from coal.
3.2.a	Processing: As a reactant	P199	Other	U999	Other (specify)	
3.2.b	Processing: As a formulation component			PF	Processing-incorporation into formulation, mixture, or reaction product	Chemical substance is added to a product (or product mixture) prior to further distribution of the product.
3.2.b	Processing: As a formulation component	P201	Additives	U007	Corrosion inhibitors and antiscaling agents	Chemical substances used to prevent or retard corrosion or the formation of scale. Examples include phenylenediamine, chromates, nitrates, phosphates, and hydrazine.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.2.b	Processing: As a formulation component	P201	Additives	U009	Fillers	Chemical substances used to provide bulk, increase strength, increase hardness, or improve resistance to impact. Fillers incorporated in a matrix reduce production costs by minimizing the amount of more expensive substances used in the production of articles. Examples include calcium carbonate, barium sulfate, silicates, clays, zinc oxide and aluminum oxide.
3.2.b	Processing: As a formulation component	P201	Additives	U010	Finishing agents	Chemical substances used to impart such functions as softening, staticproofing, wrinkle resistance, and water repellence. Substances may be applied to textiles, paper, and leather. Examples include quaternary ammonium compounds, ethoxylated amines, and silicone compounds.
3.2.b	Processing: As a formulation component	P201	Additives	U017	Lubricants and lubricant additives	Chemical substances used to reduce friction, heat, or wear between moving parts or adjacent solid surfaces, or that enhance the lubricity of other substances. Examples of lubricants include mineral oils, silicate and phosphate esters, silicone oil, greases, and solid film lubricants such as graphite and PTFE. Examples of lubricant additives include molybdenum disulphide and tungsten disulphide.
3.2.b	Processing: As a formulation component	P201	Additives	U034	Paint additives and coating additives not described by other codes	Chemical substances used in a paint or coating formulation to enhance properties such as water repellence, increased gloss, improved fade resistance, ease of application, foam prevention, etc. Examples of paint additives and coating additives include polyols, amines, vinyl acetate ethylene emulsions, and aliphatic polyisocyanates.
3.2.b	Processing: As a formulation component	P202	Dyes	U008	Dyes	Chemical substances used to impart color to other materials or mixtures ( <i>i.e.</i> , substrates) by penetrating into the surface of the substrate. Examples types include azo, anthraquinone, amino azo, aniline, eosin, stilbene, acid, basic or cationic, reactive, dispersive, and natural dyes.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.2.b	Processing: As a formulation component	P202	Dyes	U021	Pigments	Chemical substances used to impart color to other materials or mixtures ( <i>i.e.</i> , substrates) by attaching themselves to the surface of the substrate through binding or adhesion. This code includes fluorescent agents, luminescent agents, whitening agents, pearlizing agents, and opacifiers. Examples include metallic oxides of iron, titanium, zinc, cobalt, and chromium; metal powder suspensions; lead chromates; vegetable and animal products; and synthetic organic pigments.
3.2.b	Processing: As a formulation component	P203	Reaction Diluents	U030	Solvents (which become part of product formulation or mixture)	Chemical substances used to dissolve another substance (solute) to form a uniformly dispersed mixture (solution) at the molecular level. Examples include diluents used to reduce the concentration of an active material to achieve a specified effect and low gravity materials added to reduce cost.
3.2.b	Processing: As a formulation component	P203	Reaction Diluents	U032	Viscosity adjustors	Chemical substances used to alter the viscosity of another substance. Examples include viscosity index (VI) improvers, pour point depressants, and thickeners.
3.2.b	Processing: As a formulation component	P204	Initiators	U024	Process Regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators may be consumed or become part of the reaction product.
3.2.b	Processing: As a formulation component	P205	Solvents	U030	Solvents (which become part of product formulation or mixture)	Chemical substances used to dissolve another substance (solute) to form a uniformly dispersed mixture (solution) at the molecular level. Examples include diluents used to reduce the concentration of an active material to achieve a specified effect and low gravity materials added to reduce cost.
3.2.b	Processing: As a formulation component	P206	Inhibitors	U024	Process Regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						may be consumed or become part of the reaction product.
3.2.b	Processing: As a formulation component	P207	Emulsifiers	U003	Adsorbents and Absorbents	Chemical substances used to retain other substances by accumulation on their surface or by assimilation. Examples of adsorbents include silica gel, activated alumina, and activated carbon. Examples of absorbents include straw oil, alkaline solutions, and kerosene.
3.2.b	Processing: As a formulation component	P208	Surfactants	U002	Adhesives and Sealant Chemicals	Chemical substances used to promote bonding between other substances, promote adhesion of surfaces, or prevent seepage of moisture or air. Examples include epoxides, isocyanates, acrylamides, phenol, urea, melamine, and formaldehyde.
3.2.b	Processing: As a formulation component	P208	Surfactants	U023	Plating agents and surface treating agents	Chemical substances applied to metal, plastic, or other surfaces to alter physical or chemical properties of the surface. Examples include metal surface treating agents, strippers, etchants, rust and tarnish removers, and descaling agents.
3.2.b	Processing: As a formulation component	P208	Surfactants	U031	Surface active agents	Chemical substances used to modify surface tension when dissolved in water or water solutions, or reduce interfacial tension between two liquids or between a liquid and a solid or between liquid and air. Examples include carboxylates, sulfonates, phosphates, carboxylic acid, esters, and quaternary ammonium salts.
3.2.b	Processing: As a formulation component	P209	Lubricants	U017	Lubricants and lubricant additives	Chemical substances used to reduce friction, heat, or wear between moving parts or adjacent solid surfaces, or that enhance the lubricity of other substances. Examples of lubricants include mineral oils, silicate and phosphate esters, silicone oil, greases, and solid film lubricants such as graphite and PTFE. Examples of lubricant additives include molybdenum disulphide and tungsten disulphide.
3.2.b	Processing: As a formulation component	P210	Flame Retardants	U011	Flame retardants	Chemical substances used on the surface of or incorporated into combustible materials to reduce or eliminate their tendency to ignite when exposed to heat

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						or a flame for a short period of time. Examples include inorganic salts, chlorinated or brominated organic compounds, and organic phosphates/phosphonates.
3.2.b	Processing: As a formulation component	P211	Rheological Modifiers	U022	Plasticizers	Chemical substances used in plastics, cement, concrete, wallboard, clay bodies, or other materials to increase their plasticity or fluidity. Examples include phthalates, trimellitates, adipates, maleates, and lignosulphonates.
3.2.b	Processing: As a formulation component	P211	Rheological Modifiers	U032	Viscosity adjustors	Chemical substances used to alter the viscosity of another substance. Examples include viscosity index (VI) improvers, pour point depressants, and thickeners.
3.2.b	Processing: As a formulation component	P299	Other	U003	Adsorbents and Absorbents	Chemical substances used to retain other substances by accumulation on their surface or by assimilation. Examples of adsorbents include silica gel, activated alumina, and activated carbon. Examples of absorbents include straw oil, alkaline solutions, and kerosene.
3.2.b	Processing: As a formulation component	P299	Other	U016	Ion exchange agents	Chemical substances, usually in the form of a solid matrix, that are used to selectively remove targeted ions from a solution. Examples generally consist of an inert hydrophobic matrix such as styrenedivinylbenzene or phenol-formaldehyde, cross-linking polymer such as divinylbenzene, and ionic functional groups including sulfonic, carboxylic or phosphonic acids. This code also includes aluminosilicate zeolites.
3.2.b	Processing: As a formulation component	P299	Other	U018	Odor agents	Chemical substances used to control odors, remove odors, mask odors, or impart odors. Examples include benzenoids, terpenes and terpenoids, musk chemicals, aliphatic aldehydes, aliphatic cyanides, and mercaptans.
3.2.b	Processing: As a formulation component	P299	Other	U019	Oxidizing/reducing agent	Chemical substances used to alter the valence state of another substance by donating or accepting electrons or by the addition or removal of hydrogen to a substance. Examples of oxidizing agents include nitric acid, perchlorates, hexavalent chromium compounds, and peroxydisulfuric acid salts. Examples of reducing agents

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						include hydrazine, sodium thiosulfate, and coke produced from coal.
3.2.b	Processing: As a formulation component	P299	Other	U020	Photosensitive chemicals	Chemical substances used for their ability to alter their physical or chemical structure through absorption of light, resulting in the emission of light, dissociation, discoloration, or other chemical reaction. Examples include sensitizers, fluorescents, photovoltaic agents, ultraviolet absorbers, and ultraviolet stabilizers.
3.2.b	Processing: As a formulation component	P299	Other	U027	Propellants and blowing agents	Chemical substances used to dissolve or suspend other substances and either to expel those substances from a container in the form of an aerosol or to impart a cellular structure to plastics, rubber, or thermo set resins. Examples include compressed gasses and liquids and substances which release ammonia, carbon dioxide, or nitrogen.
3.2.b	Processing: As a formulation component	P299	Other	U028	Solid separation agents	Chemical substances used to promote the separation of suspended solids from a liquid. Examples include flotation aids, flocculants, coagulants, dewatering aids, and drainage aids.
3.2.b	Processing: As a formulation component	P299	Other	U999	Other (specify)	
3.2.c	Processing: As an article component			PA	Processing-incorporation into article	Chemical substance becomes an integral component of an article distributed for industrial, trade, or consumer use.
3.2.c	Processing: As an article component			U008	Dyes	Chemical substances used to impart color to other materials or mixtures ( <i>i.e.</i> , substrates) by penetrating into the surface of the substrate. Examples types include azo, anthraquinone, amino azo, aniline, eosin, stilbene, acid, basic or cationic, reactive, dispersive, and natural dyes.
3.2.c	Processing: As an article component			U009	Fillers	Chemical substances used to provide bulk, increase strength, increase hardness, or improve resistance to impact. Fillers incorporated in a matrix reduce

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						production costs by minimizing the amount of more expensive substances used in the production of articles. Examples include calcium carbonate, barium sulfate, silicates, clays, zinc oxide and aluminum oxide.
3.2.c	Processing: As an article component			U021	Pigments	Chemical substances used to impart color to other materials or mixtures ( <i>i.e.</i> , substrates) by attaching themselves to the surface of the substrate through binding or adhesion. This code includes fluorescent agents, luminescent agents, whitening agents, pearlizing agents, and opacifiers. Examples include metallic oxides of iron, titanium, zinc, cobalt, and chromium; metal powder suspensions; lead chromates; vegetable and animal products; and synthetic organic pigments.
3.2.c	Processing: As an article component			U034	Paint additives and coating additives not described by other codes	Chemical substances used in a paint or coating formulation to enhance properties such as water repellence, increased gloss, improved fade resistance, ease of application, foam prevention, etc. Examples of paint additives and coating additives include polyols, amines, vinyl acetate ethylene emulsions, and aliphatic polyisocyanates.
3.2.c	Processing: As an article component			U999	Other (specify)	
3.2.d	Processing: Repackaging			PK	Processing-repackaging	Preparation of a chemical substance for distribution in commerce in a different form, state, or quantity. This includes transferring the chemical substance from a bulk container into smaller containers. This definition does not apply to sites that only relabel or redistribute the reportable chemical substance without removing the chemical substance from the container in which it is received or purchased.
3.2.e	Processing: As an impurity					



TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.2.f	Processing: Recycling					
3.3.a	Otherwise Use: As a chemical processing aid			U	Use-non incorporative Activities	Chemical substance is otherwise used ( <i>e.g.</i> , as a chemical processing or manufacturing aid).
3.3.a	Otherwise Use: As a chemical processing aid	Z101	Process Solvents	U029	Solvents (for cleaning or degreasing)	Chemical substances used to dissolve oils, greases, and similar materials from textiles, glassware, metal surfaces, and other articles. Examples include trichloroethylene, perchloroethylene, methylene chloride, liquid carbon dioxide, and n-propyl bromide.
3.3.a	Otherwise Use: As a chemical processing aid	Z102	Catalysts	U020	Photosensitive chemicals	Chemical substances used for their ability to alter their physical or chemical structure through absorption of light, resulting in the emission of light, dissociation, discoloration, or other chemical reaction. Examples include sensitizers, fluorescents, photovoltaic agents, ultraviolet absorbers, and ultraviolet stabilizers.
3.3.a	Otherwise Use: As a chemical processing aid	Z102	Catalysts	U025	Processing aids, specific to petroleum production	Chemical substances added to water-, oil-, or synthetic drilling muds or other petroleum production fluids to control viscosity, foaming, corrosion, alkalinity and pH, microbiological growth, hydrate formation, etc., during the production of oil, gas, and other products from beneath the earth's surface.
3.3.a	Otherwise Use: As a chemical processing aid	Z102	Catalysts	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.a	Otherwise Use: As a chemical processing aid	Z103	Inhibitors	U024	Process Regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators may be consumed or become part of the reaction product.
3.3.a	Otherwise Use: As a chemical processing aid	Z103	Inhibitors	U025	Processing aids, specific to petroleum production	Chemical substances added to water-, oil-, or synthetic drilling muds or other petroleum production fluids to control viscosity, foaming, corrosion, alkalinity and pH, microbiological growth, hydrate formation, etc., during the production of oil, gas, and other products from beneath the earth's surface.
3.3.a	Otherwise Use: As a chemical processing aid	Z103	Inhibitors	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.
3.3.a	Otherwise Use: As a chemical processing aid	Z104	Initiators	U024	Process Regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators may be consumed or become part of the reaction product.
3.3.a	Otherwise Use: As a chemical processing aid	Z104	Initiators	U025	Processing aids, specific to petroleum production	Chemical substances added to water-, oil-, or synthetic drilling muds or other petroleum production fluids to control viscosity, foaming, corrosion, alkalinity and pH, microbiological growth, hydrate formation, etc., during the production of oil, gas, and other products from beneath the earth's surface.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.a	Otherwise Use: As a chemical processing aid	Z104	Initiators	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.
3.3.a	Otherwise Use: As a chemical processing aid	Z105	Reaction Terminators	U024	Process Regulators	Chemical substances used to change the rate of a chemical reaction, start or stop the reaction, or otherwise influence the course of the reaction. Process regulators may be consumed or become part of the reaction product.
3.3.a	Otherwise Use: As a chemical processing aid	Z105	Reaction Terminators	U025	Processing aids, specific to petroleum production	Chemical substances added to water-, oil-, or synthetic drilling muds or other petroleum production fluids to control viscosity, foaming, corrosion, alkalinity and pH, microbiological growth, hydrate formation, etc., during the production of oil, gas, and other products from beneath the earth's surface.
3.3.a	Otherwise Use: As a chemical processing aid	Z105	Reaction Terminators	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.
3.3.a	Otherwise Use: As a chemical processing aid	Z106	Solution Buffers	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U002	Adhesives and Sealant Chemicals	Chemical substances used to promote bonding between other substances, promote adhesion of surfaces, or prevent seepage of moisture or air. Examples include epoxides, isocyanates, acrylamides, phenol, urea, melamine, and formaldehyde.
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U006	Bleaching agents	Chemical substances used to lighten or whiten a substrate through chemical reaction, usually an oxidative process which degrades the color system. Examples generally fall into one of two groups: chlorine containing bleaching agents ( <i>e.g.</i> , chlorine, hypochlorites, N-chloro compounds and chlorine dioxide); and, peroxygen bleaching agents ( <i>e.g.</i> , hydrogen peroxide, potassium permanganate, and sodium perborate).
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U018	Odor agents	Chemical substances used to control odors, remove odors, mask odors, or impart odors. Examples include benzenoids, terpenes and terpenoids, musk chemicals, aliphatic aldehydes, aliphatic cyanides, and mercaptans.
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U023	Plating agents and surface treating agents	Chemical substances applied to metal, plastic, or other surfaces to alter physical or chemical properties of the surface. Examples include metal surface treating agents, strippers, etchants, rust and tarnish removers, and descaling agents.
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U025	Processing aids, specific to petroleum production	Chemical substances added to water-, oil-, or synthetic drilling muds or other petroleum production fluids to control viscosity, foaming, corrosion, alkalinity and pH, microbiological growth, hydrate formation, etc., during the production of oil, gas, and other products from beneath the earth's surface.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U026	Processing aids, not otherwise listed	Chemical substances used to improve the processing characteristics or the operation of process equipment or to alter or buffer the pH of the substance or mixture, when added to a process or to a substance or mixture to be processed. Processing agents do not become a part of the reaction product and are not intended to affect the function of a substance or article created. Examples include buffers, dehumidifiers, dehydrating agents, sequestering agents, and chelators.
3.3.a	Otherwise Use: As a chemical processing aid	Z199	Other	U028	Solid separation agents	Chemical substances used to promote the separation of suspended solids from a liquid. Examples include flotation aids, flocculants, coagulants, dewatering aids, and drainage aids.
3.3.b	Otherwise Use: As a manufacturing aid			U	Use-non incorporative Activities	Chemical substance is otherwise used ( <i>e.g.</i> , as a chemical processing or manufacturing aid).
3.3.b	Otherwise Use: As a manufacturing aid	Z201	Process Lubricants	U017	Lubricants and lubricant additives	Chemical substances used to reduce friction, heat, or wear between moving parts or adjacent solid surfaces, or that enhance the lubricity of other substances. Examples of lubricants include mineral oils, silicate and phosphate esters, silicone oil, greases, and solid film lubricants such as graphite and PTFE. Examples of lubricant additives include molybdenum disulphide and tungsten disulphide.
3.3.b	Otherwise Use: As a manufacturing aid	Z202	Metalworking Fluids	U007	Corrosion inhibitors and antiscaling agents	Chemical substances used to prevent or retard corrosion or the formation of scale. Examples include phenylenediamine, chromates, nitrates, phosphates, and hydrazine.
3.3.b	Otherwise Use: As a manufacturing aid	Z202	Metalworking Fluids	U014	Functional fluids (open systems)	Liquid or gaseous chemical substances used for one or more operational properties in an open system. Examples include antifreezes and de-icing fluids such as ethylene and propylene glycol, sodium formate, potassium

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
						acetate, and, sodium acetate. This code also includes substances incorporated into metal working fluids.
3.3.b	Otherwise Use: As a manufacturing aid	Z203	Coolants	U013	Functional fluids (closed systems)	Liquid or gaseous chemical substances used for one or more operational properties in a closed system. Examples include: heat transfer agents ( <i>e.g.</i> , coolants and refrigerants) such as polyalkylene glycols, silicone oils, liquified propane, and carbon dioxide; hydraulic/transmission fluids such as mineral oils, organophosphate esters, silicone, and propylene glycol; and dielectric fluids such as mineral insulating oil and high flash point kerosene. This code does not include fluids used as lubricants.
3.3.b	Otherwise Use: As a manufacturing aid	Z204	Refrigerants	U013	Functional fluids (closed systems)	Liquid or gaseous chemical substances used for one or more operational properties in a closed system. Examples include: heat transfer agents ( <i>e.g.</i> , coolants and refrigerants) such as polyalkylene glycols, silicone oils, liquified propane, and carbon dioxide; hydraulic/transmission fluids such as mineral oils, organophosphate esters, silicone, and propylene glycol; and dielectric fluids such as mineral insulating oil and high flash point kerosene. This code does not include fluids used as lubricants.
3.3.b	Otherwise Use: As a manufacturing aid	Z205	Hydraulic Fluids	U013	Functional fluids (closed systems)	Liquid or gaseous chemical substances used for one or more operational properties in a closed system. Examples include: heat transfer agents ( <i>e.g.</i> , coolants and refrigerants) such as polyalkylene glycols, silicone oils, liquified propane, and carbon dioxide; hydraulic/transmission fluids such as mineral oils, organophosphate esters, silicone, and propylene glycol; and dielectric fluids such as mineral insulating oil and high flash point kerosene. This code does not include fluids used as lubricants.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.b	Otherwise Use: As a manufacturing aid	Z299	Other	U013	Functional fluids (closed systems)	Liquid or gaseous chemical substances used for one or more operational properties in a closed system. Examples include: heat transfer agents ( <i>e.g.</i> , coolants and refrigerants) such as polyalkylene glycols, silicone oils, liquified propane, and carbon dioxide; hydraulic/transmission fluids such as mineral oils, organophosphate esters, silicone, and propylene glycol; and dielectric fluids such as mineral insulating oil and high flash point kerosene. This code does not include fluids used as lubricants.
3.3.b	Otherwise Use: As a manufacturing aid	Z299	Other	U023	Plating agents and surface treating agents	Chemical substances applied to metal, plastic, or other surfaces to alter physical or chemical properties of the surface. Examples include metal surface treating agents, strippers, etchants, rust and tarnish removers, and descaling agents.
3.3.c	Otherwise Use: Ancillary or other use			U	Use—non incorporative Activities	Chemical substance is otherwise used ( <i>e.g.</i> , as a chemical processing or manufacturing aid).
3.3.c	Otherwise Use: Ancillary or other use	Z301	Cleaner	U007	Corrosion inhibitors and antiscaling agents	Chemical substances used to prevent or retard corrosion or the formation of scale. Examples include phenylenediamine, chromates, nitrates, phosphates, and hydrazine.
3.3.c	Otherwise Use: Ancillary or other use	Z301	Cleaner	U029	Solvents (for cleaning or degreasing)	Chemical substances used to dissolve oils, greases, and similar materials from textiles, glassware, metal surfaces, and other articles. Examples include trichloroethylene, perchloroethylene, methylene chloride, liquid carbon dioxide, and n-propyl bromide.
3.3.c	Otherwise Use: Ancillary or other use	Z302	Degreaser	U003	Adsorbents and Absorbents	Chemical substances used to retain other substances by accumulation on their surface or by assimilation. Examples of adsorbents include silica gel, activated alumina, and activated carbon. Examples of absorbents include straw oil, alkaline solutions, and kerosene.

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.c	Otherwise Use: Ancillary or other use	Z302	Degreaser	U029	Solvents (for cleaning or degreasing)	Chemical substances used to dissolve oils, greases, and similar materials from textiles, glassware, metal surfaces, and other articles. Examples include trichloroethylene, perchloroethylene, methylene chloride, liquid carbon dioxide, and n-propyl bromide.
3.3.c	Otherwise Use: Ancillary or other use	Z303	Lubricant	U017	Lubricants and lubricant additives	Chemical substances used to reduce friction, heat, or wear between moving parts or adjacent solid surfaces, or that enhance the lubricity of other substances. Examples of lubricants include mineral oils, silicate and phosphate esters, silicone oil, greases, and solid film lubricants such as graphite and PTFE. Examples of lubricant additives include molybdenum disulphide and tungsten disulphide.
3.3.c	Otherwise Use: Ancillary or other use	Z304	Fuel	U012	Fuels and fuel additives	Chemical substances used to create mechanical or thermal energy through chemical reactions, or which are added to a fuel for the purpose of controlling the rate of reaction or limiting the production of undesirable combustion products, or which provide other benefits such as corrosion inhibition, lubrication, or detergency. Examples of fuels include coal, oil, gasoline, and various grades of diesel fuel. Examples of fuel additives include oxygenated compound such as ethers and alcohols, antioxidants such as phenylenediamines and hindered phenols, corrosion inhibitors such as carboxylic acids, amines, and amine salts, and blending agents such as ethanol.
3.3.c	Otherwise Use: Ancillary or other use	Z305	Flame Retardant	U011	Flame retardants	Chemical substances used on the surface of or incorporated into combustible materials to reduce or eliminate their tendency to ignite when exposed to heat or a flame for a short period of time. Examples include inorganic salts, chlorinated or brominated organic compounds, and organic phosphates/phosphonates.



TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.c	Otherwise Use: Ancillary or other use	Z306	Waste Treatment	U006	Bleaching agents	Chemical substances used to lighten or whiten a substrate through chemical reaction, usually an oxidative process which degrades the color system. Examples generally fall into one of two groups: chlorine containing bleaching agents ( <i>e.g.</i> , chlorine, hypochlorites, N-chloro compounds and chlorine dioxide); and peroxygen bleaching agents ( <i>e.g.</i> , hydrogen peroxide, potassium permanganate, and sodium perborate).
3.3.c	Otherwise Use: Ancillary or other use	Z306	Waste Treatment	U018	Odor agents	Chemical substances used to control odors, remove odors, mask odors, or impart odors. Examples include benzenoids, terpenes and terpenoids, musk chemicals, aliphatic aldehydes, aliphatic cyanides, and mercaptans.
3.3.c	Otherwise Use: Ancillary or other use	Z306	Waste Treatment	U019	Oxidizing/reducing agent	Chemical substances used to alter the valence state of another substance by donating or accepting electrons or by the addition or removal of hydrogen to a substance. Examples of oxidizing agents include nitric acid, perchlorates, hexavalent chromium compounds, and peroxydisulfuric acid salts. Examples of reducing agents include hydrazine, sodium thiosulfate, and coke produced from coal.
3.3.c	Otherwise Use: Ancillary or other use	Z306	Waste Treatment	U028	Solid separation agents	Chemical substances used to promote the separation of suspended solids from a liquid. Examples include flotation aids, flocculants, coagulants, dewatering aids, and drainage aids.
3.3.c	Otherwise Use: Ancillary or other use	Z307	Water Treatment	U006	Bleaching agents	Chemical substances used to lighten or whiten a substrate through chemical reaction, usually an oxidative process which degrades the color system. Examples generally fall into one of two groups: chlorine containing bleaching agents ( <i>e.g.</i> , chlorine, hypochlorites, N-chloro compounds and chlorine dioxide); and peroxygen bleaching agents ( <i>e.g.</i> , hydrogen peroxide, potassium permanganate, and sodium perborate).

TRI Section	TRI Description	TRI Sub-use Code	TRI Sub-use Code Name	2016 CDR Code	2016 CDR Code Name	2016 CDR Functional Use Definition
3.3.c	Otherwise Use: Ancillary or other use	Z307	Water Treatment	U018	Odor agents	Chemical substances used to control odors, remove odors, mask odors, or impart odors. Examples include benzenoids, terpenes and terpenoids, musk chemicals, aliphatic aldehydes, aliphatic cyanides, and mercaptans.
3.3.c	Otherwise Use: Ancillary or other use	Z307	Water Treatment	U019	Oxidizing/reducing agent	Chemical substances used to alter the valence state of another substance by donating or accepting electrons or by the addition or removal of hydrogen to a substance. Examples of oxidizing agents include nitric acid, perchlorates, hexavalent chromium compounds, and peroxydisulfuric acid salts. Examples of reducing agents include hydrazine, sodium thiosulfate, and coke produced from coal.
3.3.c	Otherwise Use: Ancillary or other use	Z307	Water Treatment	U028	Solid separation agents	Chemical substances used to promote the separation of suspended solids from a liquid. Examples include flotation aids, flocculants, coagulants, dewatering aids, and drainage aids.
3.3.c	Otherwise Use: Ancillary or other use	Z308	Construction Materials			
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U001	Abrasives	Chemical substances used to wear down or polish surfaces by rubbing against the surface. Examples include sandstones, pumice, silex, quartz, silicates, aluminum oxides, and glass.
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U013	Functional fluids (closed systems)	Liquid or gaseous chemical substances used for one or more operational properties in a closed system. Examples include: heat transfer agents ( <i>e.g.</i> , coolants and refrigerants) such as polyalkylene glycols, silicone oils, liquified propane, and carbon dioxide; hydraulic/transmission fluids such as mineral oils, organophosphate esters, silicone, and propylene glycol; and dielectric fluids such as mineral insulating oil and high flash point kerosene. This code does not include fluids used as lubricants.

<b>TRI Section</b>	<b>TRI Description</b>	<b>TRI Sub-use Code</b>	<b>TRI Sub-use Code Name</b>	<b>2016 CDR Code</b>	<b>2016 CDR Code Name</b>	<b>2016 CDR Functional Use Definition</b>
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U014	Functional fluids (open systems)	Liquid or gaseous chemical substances used for one or more operational properties in an open system. Examples include antifreezes and de-icing fluids such as ethylene and propylene glycol, sodium formate, potassium acetate, and, sodium acetate. This code also includes substances incorporated into metal working fluids.
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U018	Odor agents	Chemical substances used to control odors, remove odors, mask odors, or impart odors. Examples include benzenoids, terpenes and terpenoids, musk chemicals, aliphatic aldehydes, aliphatic cyanides, and mercaptans.
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U020	Photosensitive chemicals	Chemical substances used for their ability to alter their physical or chemical structure through absorption of light, resulting in the emission of light, dissociation, discoloration, or other chemical reaction. Examples include sensitizers, fluorescents, photovoltaic agents, ultraviolet absorbers, and ultraviolet stabilizers.
3.3.c	Otherwise Use: Ancillary or other use	Z399	Other	U023	Plating agents and surface treating agents	Chemical substances applied to metal, plastic, or other surfaces to alter physical or chemical properties of the surface. Examples include metal surface treating agents, strippers, etchants, rust and tarnish removers, and descaling agents.

## Appendix D EXPOSURE – PRE-SCREENING ANALYSIS

Pre-screening analysis for the ambient air pathway was completed for both 1-BP and MC in this work. The methodology for this analysis is described in Section 2.1.2.1. All inputs used for all exposure scenarios evaluated are included in Supplemental File *SF\_FLA\_Air Pathway Input Parameters for IIOAC for 1-BP and MC* (Appendix B). Some of the inputs are further discussed below.

The physical parameters of the source type are pre-defined values within IIOAC and are discussed in the IIOAC users guide ([U.S. EPA, 2019c](#)). The only source type parameter that can be varied is the area of a fugitive source. For this work, EPA used 100 m<sup>2</sup> as the area of the fugitive source because even with releases reported to TRI, there was no data available on the actual size of the fugitive source.

**Table\_Apx D-1. Parameters Used for Point and Fugitive Source Type**

Parameter	Stack <sup>a</sup>	Fugitive <sup>b</sup>
Release height (m)	10	3.05
Stack inside diameter (m)	2	N/A
Exit gas velocity (m/s)	5	N/A
Exit gas temperature (K)	300	N/A
Area (m <sup>2</sup> )	N/A	100
<sup>a</sup> Length and width were assumed to be 10 meters.		
<sup>b</sup> N/A indicates parameter is not applicable for that source type.		

**Meteorological Stations:** IIOAC includes 14 pre-defined climate regions (each with a surface station and upper-air station). As discussed in Section 2.1.2.1, where no TRI data or city location was provided for releases, EPA selected two of the 14 climate regions to represent a central tendency (West North Central) and high-end (South [Coastal]) climate region based on a sensitivity analysis of the average concentration and deposition predictions, using 5 years of meteorological data (2011 through 2015) for all source types. A summary of the average air concentration and particle deposition predictions for all 14 climate regions is provided in Table\_Apx D-2.

**Table\_Apx D-2. Average Air Concentrations and Particle Deposition for 14 IIOAC Climate Regions**

Climate Region	Surface Station	Avg. Air Concentration (µg/m <sup>3</sup> )	Avg. Particle Deposition (g/m <sup>2</sup> )	Air Concentration Rank	Particle Deposition Rank
East North Central	Iowa City, IA	3.71	2.66	3	5
Northeast (Coastal)	Camp Springs, MD	3.48	1.75	7	14
Northeast (Inland)	Pittsburgh, PA	1.85	5.58	14	1
Northwest (Coastal)	Everett, WA	3.60	2.14	4	10
Northwest (Inland)	Idaho Falls, ID	2.88	3.64	12	2

Climate Region	Surface Station	Avg. Air Concentration ( $\mu\text{g}/\text{m}^3$ )	Avg. Particle Deposition ( $\text{g}/\text{m}^2$ )	Air Concentration Rank	Particle Deposition Rank
South (Inland)	Topeka, KS	3.46	2.09	8	11
South (Coastal)	Lake Charles, LA	4.51	2.19	1	8
Southeast (Coastal)	New River, NC	3.73	2.50	2	6
Southeast (Inland)	Atlanta, GA	3.08	2.36	10	7
Southwest	Grand Junction, CO	3.14	3.24	9	3
West (Coastal)	Point Mugu, CA	3.05	2.03	11	13
West (Inland)	Las Vegas, NV	2.30	2.75	13	4
West North Central	Sioux Falls, SD	3.49	2.16	6	9
Central	Rockford, IL	3.50	2.06	5	12

24  
25  
26  
27  
28  
29  
30  
31

*Release:* Release data was extracted from the 2019 TRI data set. EPA extracted the maximum total release reported from all TRI reporting facilities for each chemical. EPA also calculated the arithmetic mean of all reported releases across all TRI reporting facilities for each chemical. These values do not include surrogate facilities or EPA estimated releases but were used to represent the maximum and mean releases for purposes of the pre-screening analysis. These releases are summarized in Table\_Apx D-3.

**Table\_Apx D-3. Maximum and Mean Releases by Chemical for Pre-screening Analysis**

Chemical	Number of Days Operating	Maximum Facility Release			Average Facility Release		
		lbs	kg	kg/site-day	lbs	kg	kg/site-day
1-Bromopropane	365	229,135	103,916	285	15,658	7,101	19.46
	260			400			27.31
Methylene Chloride	375	438,116	198,692	544	10,708	4,856	13.30
	260			764			18.68

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

*Exposure Concentrations and Risk Calculations:*

All exposure concentrations for 1-BP for all IIOAC model runs for all exposure scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Pre-Screening Results for 1-BP* (Appendix B). All exposure concentrations for MC for all IIOAC model runs for all exposure scenarios are included in Supplemental File *SF\_FLA\_Air Pathway Pre-Screening Results for MC* (Appendix B).

IIOAC Model runs provided mean (central tendency) and high-end (defined as the 95th percentile) daily-averaged and annual-averaged outdoor air concentrations in micrograms per cubic meter ( $\mu\text{g}/\text{m}^3$ ) at fenceline (100 meters) and community average (100-1000 meters) distances, for each scenario modeled. Exposure concentrations were converted into ppm using the chemical's molecular weight. The highest daily outdoor air concentrations (in ppm), from all the IIOAC model runs, for fenceline and community average distances, respectively, were used to calculate acute non-cancer risks at various

45 PODs. The highest annual outdoor air concentrations (in ppm), from all the IIOAC model runs, for  
46 fenceline and community average distances, respectively, were used to calculate chronic non-cancer and  
47 cancer risks at various PODs. These results are summarized in Table\_Apx D-4. For both 1-BP and MC,  
48 the highest daily and annual average outdoor air concentrations occurred for the following exposure  
49 scenario: Fugitive emissions in a rural setting using the high end meteorological station (South Coastal)  
50 with the maximum release and 365 days of operation (24/7).

51  
52 Risk Findings:

53 Risk Calculations using the highest daily and annual outdoor air concentrations for 1-BP are included in  
54 Supplemental File *SF\_FLA\_Air Pathway Pre-Screening Results for 1-BP* (Appendix B). Risk  
55 calculations using the highest daily and annual outdoor air concentrations for MC are included in  
56 Supplemental File *SF\_FLA\_Air Pathway Pre-Screening Analysis Results for MC* (Appendix B).

57  
58 Based on the data provided in Table\_Apx D-4, acute and chronic non-cancer risks were found at the  
59 fenceline distance of 100 meters for 1-BP for the high-end and central tendency exposure  
60 concentrations. Additionally, cancer risks were found at both fenceline and community average  
61 distances for 1-BP for both the high-end and central tendency exposure concentrations. Neither acute  
62 nor chronic non-cancer risks were found for MC. Cancer risk was found at the fenceline distance of 100  
63 meters for MC for the high-end exposure concentration only.

64  
65 Based on the data provided in Table\_Apx D-4, acute and chronic non-cancer risks were found at the  
66 fenceline distance of 100 meters for 1-BP for the high-end exposure concentration only. Additionally,  
67 cancer risks were found at both fenceline and community average distances for both the high-end and  
68 central tendency exposure concentrations. Non-cancer risks were not found for MC although cancer  
69 risks were found at the fenceline distance of 100 meters for the high-end exposure concentration only.  
70 Based on the results above, we found risks for each of the two chemicals evaluated (1-BP and MC), and  
71 therefore EPA has initiated a full screening level analysis.

1 **Table\_Apx D-4. Exposure Concentrations and Risk Calculations**

Chemical	HIOAC Outputs (Statistics)	Concentration (ppm)				Risks (Inhalation)					
		Fenceline		Community Average		Non-cancer <sup>a b c d</sup>				Cancer <sup>e f</sup>	
		Daily	Annual	Daily	Annual	Acute		Chronic			
						Fenceline	Community Average	Fenceline	Community Average	Fenceline	Community Average
1-BP	HE	9.71E-02	9.71E-02	1.13E-02	1.13E-02	62	531	62	531	5.83E-04	6.78E-05
	CT	8.90E-02	8.90E-02	1.01E-01	1.01E-01	67	597	67	597	5.34E-04	6.03E-05
MC	HE	2.68E-06	2.68E-01	3.12E-02	3.12E-02	648	5569	64	551	1.56E-06	1.81E-07
	CT	6.56E-03	6.56E-03	7.64E-04	7.64E-04	26,507	227,786	2,620	2,2517	3.81E-08	4.43E-09

<sup>a</sup> Used Benchmark MOE of 100 for acute and chronic risks for 1-BP  
<sup>b</sup> Used Benchmark MOE of 30 and 10 for acute and chronic risks, respectively, for MC  
<sup>c</sup> Used End Points (Post-Implantation Loss (F0)) of 6 (per ppm) for acute and chronic risks for 1-BP  
<sup>d</sup> Used End Points of 174 (Decreased Visual Performance) and 17.2 (Vacuolization and Cell Foci) (per ppm) for acute and chronic risks, respectively, for MC  
<sup>e</sup> Used Benchmark MOE of 1.00E-06 for cancer risk  
<sup>f</sup> Used End Points 5.00E-03 (liver) for 1-BP and 5.80E-06 (lung and liver tumors) for MC

2

## Appendix E 1-BP, MC, AND NMP RISK EVALUATION COU TO OES MAPPING

Table\_Apx E-1, Table\_Apx E-2, and Table\_Apx E-3 contain a mapping of the conditions of use (COU) to occupational exposure scenarios (OES) from the 1-BP, MC, and NMP Risk Evaluations, respectively (U.S. EPA, 2020b, c, d). EPA used the OES from the Risk Evaluations, as they are summarized in these tables, for the release estimates in Sections 3.1.3, 3.2.3, and 3.3.3.

**Table\_Apx E-1. 1-BP Risk Evaluation Conditions of Use to OES Mapping**

Conditions of Use from the 1-BP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the 1-BP Risk Evaluation <sup>a</sup>
Life Cycle Stage	Category	Subcategory	
Manufacture	Domestic manufacture	Domestic manufacture	Manufacture
	Import	Import	Import
Processing	Processing as a reactant	Intermediate in all other basic inorganic chemical manufacturing, all other basic organic chemical manufacturing, and pesticide, fertilizer and other agricultural chemical manufacturing	Processing as a Reactant
	Processing – incorporating into formulation, mixture or reaction product	Solvents for cleaning or degreasing in manufacturing of: <ul style="list-style-type: none"> <li>all other chemical product and preparation</li> <li>computer and electronic product</li> <li>electrical equipment, appliance and component</li> <li>soap, cleaning compound and toilet preparation</li> <li>services</li> </ul>	Processing – Incorporation into Formulation, Mixture, or Reaction Product
	Processing – incorporating into articles	Solvents (which become part of product formulation or mixture) in construction	Processing – Incorporation into Articles
Processing	Repackaging	Solvent for cleaning or degreasing in all other basic organic chemical	Repackaging
	Recycling	Recycling	Disposal and Recycling
Distribution in commerce	Distribution	Distribution	Not assessed as a separate operation; exposures/releases from distribution are



Conditions of Use from the 1-BP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the 1-BP Risk Evaluation <sup>a</sup>
Life Cycle Stage	Category	Subcategory	
			considered within each condition of use.
Industrial/ commercial use	Solvent (for cleaning or degreasing)	Batch vapor degreaser (e.g., open-top, closed-loop)	Batch Vapor Degreaser (Open-Top) Batch Vapor Degreaser (Closed-Loop)
		In-line vapor degreaser (e.g., conveyORIZED, web cleaner)	In-line Vapor Degreaser
		Cold cleaner	Cold Cleaner
		Aerosol spray degreaser/cleaner	Aerosol Spray Degreaser/Cleaner
	Adhesives and sealants	Adhesive chemicals - spray adhesive for foam cushion manufacturing and other uses	Adhesive Chemicals (Spray Adhesives)
Industrial/ commercial use Industrial/ commercial use	Cleaning and furniture care products	Dry cleaning solvent	Dry Cleaning
		Spot cleaner, stain remover	Spot Cleaner, Stain Remover
		Liquid cleaner (e.g., coin and scissor cleaner)	Other Uses
		Liquid spray/aerosol cleaner	Other Uses
	Other uses	Arts, crafts and hobby materials – adhesive accelerant	Other Uses
		Automotive care products – engine degreaser, brake cleaner	Aerosol Spray Degreaser/Cleaner
		Anti-adhesive agents – mold cleaning and release product	Other Uses
		Building/construction materials not covered elsewhere – insulation	THERMAX Installation
		Electronic and electronic products and metal products	Other Uses
		Functional fluids (closed systems) – refrigerant	Other Uses
		Functional fluids (open system) – cutting oils	Other Uses
		Other – asphalt extraction	Other Uses

Conditions of Use from the 1-BP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the 1-BP Risk Evaluation <sup>a</sup>
Life Cycle Stage	Category	Subcategory	
		Other – laboratory chemicals	Disposal, Recycling
		Temperature indicator – coatings	
Disposal (Manufacturing, Processing, Use)	Disposal	Municipal waste incinerator	
		Off-site waste transfer	
<sup>a</sup> This table is based on Table 2-2 of the 2020 1-Bromopane Risk Evaluation ( <a href="#">U.S. EPA, 2020b</a> ).			

9  
10

11 Table\_Apx E-2. MC Risk Evaluation Conditions of Use to OES Mapping

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Life Cycle Stage	
Manufacturing	Domestic manufacturing	Manufacturing	Manufacturing
	Import	Import	Repackaging
Processing	Processing as a reactant	Intermediate in industrial gas manufacturing ( <i>e.g.</i> , manufacture of fluorinated gases used as refrigerants)	Processing as a Reactant
		Intermediate for pesticide, fertilizer, and other agricultural chemical manufacturing	
		CBI function for petrochemical manufacturing	
		Intermediate for other chemicals	
	Incorporated into formulation, mixture, or reaction product	Solvents (for cleaning or degreasing), including manufacturing of: <ul style="list-style-type: none"> <li>All other basic organic chemical</li> <li>Soap, cleaning compound and toilet preparation</li> </ul>	Processing – Incorporation into Formulation, Mixture, or Reaction Product
		Solvents (which become part of product formulation or mixture), including manufacturing of: <ul style="list-style-type: none"> <li>All other chemical product and preparation</li> <li>Paints and coatings</li> </ul>	

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Life Cycle Stage	
Processing		Propellants and blowing agents for all other chemical product and preparation manufacturing	Processing – Incorporation into Formulation, Mixture, or Reaction Product
		Propellants and blowing agents for plastics product manufacturing	
		Paint additives and coating additives not described by other codes for CBI industrial sector	
		Laboratory chemicals for all other chemical product and preparation manufacturing	
		Laboratory chemicals for CBI industrial sectors	
		Processing aid, not otherwise listed for petrochemical manufacturing	
		Adhesive and sealant chemicals in adhesive manufacturing	
		Unknown function for oil and gas drilling, extraction, and support activities	
	Repackaging	Solvents (which become part of product formulation or mixture) for all other chemical product and preparation manufacturing	Repackaging
		CBI functions for all other chemical product	

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>	
Life Cycle Stage	Category	Life Cycle Stage		
		and preparation manufacturing		
	Recycling	Recycling	Waste Handling, Disposal, Treatment, and Recycling	
Distribution in commerce	Distribution	Distribution	Repackaging	
Industrial, commercial and consumer uses	Solvents (for cleaning or degreasing)	Batch vapor degreaser (e.g., open-top, closed-loop)	Batch Open-Top Vapor Degreasing	
		In-line vapor degreaser (e.g., conveyORIZED, web cleaner)	ConveyORIZED Vapor Degreasing	
		Cold cleaner	Cold Cleaning	
		Aerosol spray degreaser/cleaner	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)	
	Adhesives and sealants	Single component glues and adhesives and sealants and caulks	Adhesives and Sealants	
	Paints and coatings including paint and coating removers	Paints and coatings use	Paints and Coatings	
		Adhesive/caulk removers	Adhesive and Caulk Removers	
		Paints and coating removers, including furniture refinishers	Paint Remover	
	Industrial, commercial and consumer uses Industrial, commercial and consumer uses	Metal products not covered elsewhere	Degreasers – aerosol and non-aerosol degreasers and cleaners e.g., coil cleaners	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products) Miscellaneous Non-aerosol Industrial and Commercial Uses
			Fabric, textile, and leather products not covered elsewhere	Textile finishing and impregnating/ surface treatment products e.g., water repellent
Automotive care products		Function fluids for air conditioners: refrigerant, treatment, leak sealer	Miscellaneous Non-aerosol Industrial and Commercial Uses	

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Life Cycle Stage	
Industrial, commercial and consumer uses Industrial, commercial and consumer uses		Interior car care – spot remover	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)
	Automotive care products	Degreasers: gasket remover, transmission cleaners, carburetor cleaner, brake quieter/cleaner	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)
	Apparel and footwear care products	Post-market waxes and polishes applied to footwear <i>e.g.</i> , shoe polish	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)
	Laundry and dishwashing products	Spot remover for apparel and textiles	Spot Cleaning
	Lubricants and greases	Liquid and spray lubricants and greases	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products) Miscellaneous Non-aerosol Industrial and Commercial Uses
		Degreasers – aerosol and non-aerosol degreasers and cleaners	
	Building/ construction materials not covered elsewhere	Cold pipe insulation	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)
	Solvents (which become part of product formulation or mixture)	All other chemical product and preparation manufacturing	Processing – Incorporation into Formulation, Mixture, or Reaction Product
	Processing aid not otherwise listed	In multiple manufacturing sectors	Cellulose Triacetate Film Production
	Propellants and blowing agents	Flexible polyurethane foam manufacturing	Flexible Polyurethane Foam Manufacturing
Arts, crafts, and hobby materials	Crafting glue and cement/concrete	Adhesives and Sealants	

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Life Cycle Stage	
	Other Uses	Laboratory chemicals – all other chemical product and preparation manufacturing	Laboratory Use
		Electrical equipment, appliance, and component manufacturing	Miscellaneous Non-aerosol Industrial and Commercial Uses
		Plastic and rubber products	Plastic Product Manufacturing
		Anti-adhesive agent – anti-spatter welding aerosol	Commercial Aerosol Products (Aerosol Degreasing, Aerosol Lubricants, Automotive Care Products)
		Oil and gas drilling, extraction, and support activities	Miscellaneous Non-aerosol Industrial and Commercial Uses
		Toys, playground, and sporting equipment – including novelty articles (toys, gifts, etc.)	Miscellaneous Non-aerosol Industrial and Commercial Uses
		Carbon remover, lithographic printing cleaner, wood floor cleaner, brush cleaner	Lithographic Printing Plate Cleaning
Disposal	Disposal	Industrial pre-treatment	Waste Handling, Disposal, Treatment, and Recycling
		Industrial wastewater treatment	
		Publicly owned treatment works (POTW)	
		Underground injection	
		Municipal landfill	
		Hazardous landfill	
		Other land disposal	
		Municipal waste incinerator	

Conditions of Use from the MC Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the MC Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Life Cycle Stage	
		Hazardous waste incinerator	
		Off-site waste transfer	

<sup>a</sup> This table is based on Table 2-22 of the 2020 Methylene Chloride Risk Evaluation ([U.S. EPA, 2020c](#)).

12



1 **Table\_Apx E-3. NMP Risk Evaluation Conditions of Use to OES Mapping**

<b>Conditions of Use from the NMP Risk Evaluation<sup>a</sup></b>			<b>Occupational Exposure Scenario (OES) from the NMP Risk Evaluation Category<sup>a</sup></b>
<b>Life Cycle Stage</b>	<b>Category</b>	<b>Subcategory</b>	
Manufacturing	Domestic Manufacture	Domestic Manufacture	Manufacturing
	Import	Import	Repackaging
Processing	Processing as a reactant or intermediate	Intermediate in Plastic Material and Resin Manufacturing	Chemical Processing, Excluding Formulation
		Other Non-incorporative Processing	
	Incorporated into formulation, mixture, or reaction product	Adhesives and sealant chemicals in Adhesive Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product
		Anti-adhesive agents in Printing and Related Support Activities	Incorporation into Formulation, Mixture, or Reaction Product
		Paint additives and coating additives not described by other codes in Paint and Coating Manufacturing; and Print Ink Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product
		Processing aids not otherwise listed in Plastic Material and Resin Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product
		Solvents (for cleaning or degreasing) in Non-metallic Mineral Product Manufacturing; Machinery Manufacturing; Plastic Material and Resin Manufacturing; Primary Metal Manufacturing; Soap, Cleaning Compound and Toilet Preparation Manufacturing; Transportation Equipment Manufacturing; All Other Chemical Product and Preparation Manufacturing; Printing and Related Support Activities; Services; Wholesale and Retail Trade	Incorporation into Formulation, Mixture, or Reaction Product
		Surface active agents in Soap, Cleaning Compound and Toilet Preparation Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product
		Plating agents and surface treating agents in Fabricated Metal Product Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product

Conditions of Use from the NMP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the NMP Risk Evaluation Category <sup>a</sup>	
Life Cycle Stage	Category	Subcategory		
Processing		Solvents (which become part of product formulation or mixture) in Electrical Equipment, Appliance and Component Manufacturing; Other Manufacturing; Paint and Coating Manufacturing; Print Ink Manufacturing; Soap, Cleaning Compound and Toilet Preparation Manufacturing; Transportation Equipment Manufacturing; All Other Chemical Product and Preparation Manufacturing; Printing and Related Support Activities; Wholesale and Retail Trade	Incorporation into Formulation, Mixture, or Reaction Product	
		Other uses in Oil and Gas Drilling, Extraction and Support Activities; Plastic Material and Resin Manufacturing; Services	Incorporation into Formulation, Mixture, or Reaction Product	
	Incorporation into articles	Lubricants and lubricant additives in Machinery Manufacturing	Metal Finishing	
		Paint additives and coating additives not described by other codes in Transportation Equipment Manufacturing	Application of Paints, Coatings, Adhesives, and Sealants	
		Solvents (which become part of product formulation or mixture), including in Textiles, Apparel and Leather Manufacturing	Incorporation into Formulation, Mixture, or Reaction Product	
		Other, including in Plastic Product Manufacturing	Chemical Processing, Excluding Formulation	
	Repackaging	Wholesale and Retail Trade	Repackaging	
	Recycling	Recycling	Recycling and Disposal	
	Distribution in Commerce	Distribution	Distribution in Commerce	Repackaging
		Paints and coatings	Paint and coating removers	Removal of Paints, Coatings, Adhesives, and Sealants
Adhesive removers			Removal of Paints, Coatings, Adhesives, and Sealants	

Conditions of Use from the NMP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the NMP Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Subcategory	
Industrial/ Commercial Use		Lacquers, stains, varnishes, primers and floor finishes	Application of Paints, Coatings, Adhesives, and Sealants
		Powder coatings (surface preparation)	Application of Paints, Coatings, Adhesives, and Sealants
	Paint additives and coating additives not described by other codes	Use in Computer and Electronic Product Manufacturing in Electronic Parts Manufacturing	Other Electronics Manufacturing
		Use in Computer and Electronic Product Manufacturing for Use in Semiconductor Manufacturing	Semiconductor Manufacturing
		Use in Construction, Fabricated Metal Product Manufacturing, Machinery Manufacturing, Other Manufacturing, Paint and Coating Manufacturing, Primary Metal Manufacturing, Transportation Equipment Manufacturing, Wholesale and Retail Trade	Application of Paints, Coatings, Adhesives, and Sealants
	Solvents (for cleaning or degreasing)	Use in Electrical Equipment, Appliance and Component Manufacturing	Other Electronics Manufacturing
		Use in Electrical Equipment, Appliance and Component Manufacturing for Use in Semiconductor Manufacturing	Semiconductor Manufacturing
	Ink, toner, and colorant products	Printer ink	Printing and Writing
		Inks in writing equipment	Printing and Writing
	Processing aids, specific to petroleum production	Petrochemical Manufacturing	Chemical Processing, Excluding Formulation
	Other uses	Other uses in Oil and Gas Drilling, Extraction and Support Activities	Chemical Processing, Excluding Formulation
		Functional Fluids (closed systems)	Chemical Processing, Excluding Formulation
	Adhesives and sealants	Adhesives and sealant chemicals including binding agents	Application of Paints, Coatings, Adhesives, and Sealants

Conditions of Use from the NMP Risk Evaluation <sup>a</sup>			Occupational Exposure Scenario (OES) from the NMP Risk Evaluation Category <sup>a</sup>
Life Cycle Stage	Category	Subcategory	
Industrial/ Commercial Use		Single component glues and adhesives, including lubricant adhesives	Application of Paints, Coatings, Adhesives, and Sealants
		Two-component glues and adhesives, including some resins	Application of Paints, Coatings, Adhesives, and Sealants
	Other uses	Soldering materials	Soldering
		Anti-freeze and de-icing products	Commercial Automotive Serving
		Automotive care products	Commercial Automotive Serving
		Lubricants and greases	Commercial Automotive Serving
		Metal products not covered elsewhere	Metal Finishing
		Lubricant and lubricant additives, including hydrophilic coatings	Metal Finishing
		Laboratory chemicals	Laboratory Use
		Lithium ion battery manufacturing	Lithium Ion Cell Manufacturing c
		Cleaning and furniture care products, including wood cleaners, gasket removers	Cleaning
Fertilizer and other agricultural chemical manufacturing – processing aids and solvents	Fertilizer Application		
Disposal	Disposal	Industrial pre-treatment	Recycling and Disposal
		Industrial wastewater treatment	Recycling and Disposal
		Publicly owned treatment works (POTW)	Recycling and Disposal
		Underground injection	Recycling and Disposal
		Landfill (municipal, hazardous, or other land disposal)	Recycling and Disposal
		Emissions to air	Recycling and Disposal
		Incinerators (municipal and hazardous waste)	Recycling and Disposal

<sup>a</sup> This table is based on Table 2-2 of the 2020 n-Methylpyrrolidone Risk Evaluation ([U.S. EPA, 2020d](#)).